


**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2018**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2018

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

**Cumulative Supplement 9
September 2018**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	x
1.7 Cumulative Supplement Legend	xi
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

**CUMULATIVE SUPPLEMENT 9
September 2018**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 38th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the

"@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in

a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

IDT AUSTRALIA LTD
(IDT AUSTRALIA LTD)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

ANI PHARMACEUTICALS INC
(ANI PHARMS INC)

KREMERS URBAN PHARMACEUTICALS INC (KREMERS URBAN PHARMS)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT HOLDINGS INC)	LANNETT CO INC (LANNETT CO INC)
SILARX PHARMACEUTICALS INC (SILARX)	LANNETT CO INC (LANNETT CO INC)
SILARX PHARMACEUTICALS INC (SILARX PHARMS INC)	LANNETT CO INC (LANNETT CO INC)
SAGENT AGILA LLIC (SAGENT AGILA)	MYLAN ASI LLC (MYLAN ASI)
SAGENT AGILA LLC (SAGENT AGILA LLC)	MYLAN ASI LLC (MYLAN ASI)
SAGENT STRIDES LLC (SAGENT STRIDESC)	MYLAN ASI LLC (MYLAN ASI)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharmas NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharmas NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic

Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a

combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2017</u>	<u>MAR 2018</u>	<u>JUN 2018</u>	<u>SEP 2018</u>	<u>DEC 2018</u>
DRUG PRODUCTS	19294	19359	19529	19793	
LISTED SINGLE	2758	2763	2703	2708	
SOURCE	(14.3%)	(14.3%)	(13.8%)	(13.7%)	
MULTISOURCE	16536	16596	16826	17085	
	(85.7%)	(85.7%)	(86.2%)	(86.3%)	
THERAPEUTICALLY	16431	16501	16735	16997	
EQUIVALENT	(85.2%)	(85.2%)	(85.7%)	(85.9%)	
NOT THERAPEUTICALLY	105	95	91	88	
EQUIVALENT	(0.5%)	(0.5%)	(0.5%)	(0.4%)	
EXCEPTIONS ¹	73	72	72	72	
	(0.4%)	(0.4%)	(0.4%)	(0.4%)	
NEW MOLECULAR	25	6	26	23	
ENTITIES APPROVED					
NUMBER OF	1075	1084	1091	1103	
APPLICANTS					

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to

the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

SOLUTION;ORAL						
ABACAVIR SULFATE						
AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/ML	A 077950	001	Mar 14, 2018	Feb NEWA

ABIRATERONE ACETATE

TABLET;ORAL						
YONSA						
+!	SUN PHARMA GLOBAL	125MG	N210308	001	May 22, 2018	May NEWA
ZYTIGA						
+	JANSSEN BIOTECH	250MG	N202379	001	Apr 28, 2011	Feb CHRS
+	!	500MG	N202379	002	Apr 14, 2017	Feb CHRS

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL							
ACEBUTOLOL HYDROCHLORIDE							
AB	!	AMNEAL PHARM	EQ 200MG BASE	A 075047	001	Dec 30, 1999	Jun CHRS
AB	!		EQ 400MG BASE	A 075047	002	Dec 30, 1999	Jun CHRS
SECTRAL							
+	@	PROMIUS PHARMA	EQ 200MG BASE	N018917	001	Dec 28, 1984	Jun DISC
+	@		EQ 400MG BASE	N018917	003	Dec 28, 1984	Jun DISC

ACETAMINOPHEN

SOLUTION;INTRAVENOUS							
ACETAMINOPHEN							
AP		CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jun CDFR
		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015	Jun CDFR
AP		SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Jun CDFR
OFIRMEV							
AP	+!	MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Jun CDFR

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL							
APADAZ							
+		KEMPHARM	325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Feb NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL							
BUTALBITAL AND ACETAMINOPHEN							
		MAYNE PHARMA INC	300MG;50MG	A207313	001	Dec 27, 2017	Mar CAHN
TABLET;ORAL							
BUTALBITAL AND ACETAMINOPHEN							
>A> AA		CNTY LINE PHARMS	300MG;50MG	A207635	001	Jun 05, 2017	Sep CAHN
>D> AA		TEDOR PHARMA INC	300MG;50MG	A207635	001	Jun 05, 2017	Sep CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL							
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
>A> AA		AUROLIFE PHARMA LLC	325MG;50MG;40MG	A204733	001	Sep 26, 2018	Sep NEWA
>D>	!	MAYNE PHARMA INC	325MG;50MG;40MG	A089007	001	Mar 17, 1986	Sep CTEC
>A> AA	!		325MG;50MG;40MG	A089007	001	Mar 17, 1986	Sep CTEC
AA		NUVO PHARMS INC	300MG;50MG;40MG	A207118	001	Oct 28, 2016	Apr CTEC
AA		TEDOR PHARMA INC	300MG;50MG;40MG	A206615	001	Aug 04, 2017	Apr CTEC
TABLET;ORAL							
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
>A> AA		ABHAI LLC	325MG;50MG;40MG	A211106	001	Sep 26, 2018	Sep NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL							
ACETAMINOPHEN AND CODEINE PHOSPHATE							
	@	ACI HEALTHCARE LTD	120MG/5ML;12MG/5ML	A086366	001		Aug CAHN
AA		LANNETT CO INC	120MG/5ML;12MG/5ML	A091238	001	Nov 10, 2011	May CAHN
TABLET;ORAL							
ACETAMINOPHEN AND CODEINE PHOSPHATE							
	@	FOSUN PHARMA	300MG;30MG	A081250	001	Jul 16, 1992	Jan CAHN
	@		300MG;60MG	A081249	001	Jul 16, 1992	Jan CAHN
	@	FRONTIDA BIOPHARM	300MG;15MG	A089673	002	Feb 10, 1988	Aug CAHN
	@		300MG;30MG	A089673	003	Feb 10, 1988	Aug CAHN
	@		300MG;60MG	A089673	001	Feb 10, 1988	Aug CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	GENUS LIFESCIENCES	325MG/15ML;7.5MG/15ML	A040894	001	Jul 19, 2011	Aug CAHN
----	--------------------	-----------------------	---------	-----	--------------	----------

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	AA	AUROLIFE PHARMA LLC	300MG;5MG	A207709	001	Sep 13, 2018	Sep NEWA
>A>	AA		300MG;7.5MG	A207709	002	Sep 13, 2018	Sep NEWA
>A>	AA		300MG;10MG	A207709	003	Sep 13, 2018	Sep NEWA
	AA	EPIC PHARMA LLC	325MG;5MG	A203863	001	Mar 30, 2018	Mar NEWA
	AA		325MG;7.5MG	A203863	002	Mar 30, 2018	Mar NEWA
	AA		325MG;10MG	A203863	003	Mar 30, 2018	Mar NEWA
	AA	PAR PHARM	325MG;5MG	A202935	002	Jun 15, 2016	Jul CAHN
	AA		325MG;7.5MG	A202935	003	Jun 15, 2016	Jul CAHN
	AA		325MG;10MG	A202935	004	Jun 15, 2016	Jul CAHN
	AA	RHODES PHARMS	300MG;5MG	A207808	001	Mar 30, 2018	Mar NEWA
	AA		300MG;7.5MG	A207808	002	Mar 30, 2018	Mar NEWA
	AA		300MG;10MG	A207808	003	Mar 30, 2018	Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

@	SPECGX LLC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006	Jan DISC
---	------------	-------------------	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

@	VINTAGE PHARMS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014	Jan DISC
---	----------------	-------------------	---------	-----	--------------	----------

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ABHAI LLC	325MG;2.5MG	A210644	001	Feb 09, 2018	Jan NEWA
AA		325MG;5MG	A210644	002	Feb 09, 2018	Jan NEWA
AA		325MG;7.5MG	A210644	003	Feb 09, 2018	Jan NEWA
AA		325MG;10MG	A210644	004	Feb 09, 2018	Jan NEWA
AA	ELITE LABS INC	325MG;5MG	A209385	001	Jul 02, 2018	Jun NEWA
AA		325MG;7.5MG	A209385	002	Jul 02, 2018	Jun NEWA
AA		325MG;10MG	A209385	003	Jul 02, 2018	Jun NEWA
AA	EPIC PHARMA LLC	325MG;5MG	A203864	001	Jul 02, 2018	Jun NEWA
AA		325MG;7.5MG	A203864	002	Jul 02, 2018	Jun NEWA
AA		325MG;10MG	A203864	003	Jul 02, 2018	Jun NEWA
AA	WES PHARMA INC	325MG;5MG	A207510	001	Mar 21, 2018	Mar NEWA
AA		325MG;7.5MG	A207510	002	Mar 21, 2018	Mar NEWA
AA		325MG;10MG	A207510	003	Mar 21, 2018	Mar NEWA

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	+! ICU MEDICAL INC	250MG/100ML	N017656	001		Mar CRLD
----	--------------------	-------------	---------	-----	--	----------

SOLUTION/DROPS;OTIC

ACETIC ACID

>A>	AT	ANDA REPOSITORY	2%	A207280	001	Mar 09, 2018	Sep CAHN
	AT	LANNETT CO INC	2%	A040607	001	Feb 24, 2005	May CAHN
>D>	AT	RISING PHARMS	2%	A207280	001	Mar 09, 2018	Sep CAHN
	AT		2%	A207280	001	Mar 09, 2018	Feb NEWA

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

AT	TARO PHARM INDS LTD	2%;1%	A088759	001	Mar 04, 1985	May CAHN
----	---------------------	-------	---------	-----	--------------	----------

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP	ZYDUS PHARMS USA INC	6GM/30ML (200MG/ML)	A208166	001	Jul 20, 2018	Jul NEWA
----	----------------------	---------------------	---------	-----	--------------	----------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB	HERITAGE PHARMS INC	200MG	A074889	001	Oct 31, 1997	Mar CMFD
----	---------------------	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL

ACYCLOVIR

AB	ALEMBIC PHARMS LTD	5%	A209000	001	Apr 06, 2018	Mar NEWA
----	--------------------	----	---------	-----	--------------	----------

TABLET;ORAL

ACYCLOVIR

	@ MYLAN PHARMS INC	400MG	A075211	001	Sep 28, 1998	Jun DISC
	@	800MG	A075211	002	Sep 28, 1998	Jun DISC
AB	YILING PHARM LTD	400MG	A210401	001	Mar 07, 2018	Feb NEWA
AB		800MG	A210401	002	Mar 07, 2018	Feb NEWA

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

	@ FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998	Jun DISC
	@ HIKMA PHARMS	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Jun DISC
	@	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Jun DISC
	ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206535	001	Aug 31, 2018	Aug NEWA
	@	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	Jun DISC
		EQ 1GM BASE/VIAL	A206535	002	Aug 31, 2018	Aug NEWA
	@	EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	Jun DISC

ADAPALENE

SOLUTION;TOPICAL

ADAPALENE

AB	CALL INC	0.1%	A203981	001	Sep 23, 2016	Jul CMFD
	@	0.1%	A203981	001	Sep 23, 2016	Jun DISC
AB		0.1%	A204593	001	Jan 05, 2016	Jul CMFD
	@	0.1%	A204593	001	Jan 05, 2016	Jun DISC

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB	PERRIGO ISRAEL	0.1%;2.5%	A205033	001	Jan 23, 2018	Jan NEWA
AB	TARO	0.1%;2.5%	A206959	001	Jan 24, 2018	Jan NEWA
AB	TOLMAR	0.1%;2.5%	A206164	001	May 23, 2018	May NEWA

ADEFOVIR DIPIVOXIL

TABLET;ORAL

ADEFOVIR DIPIVOXIL

AB	APOTEX INC	10MG	A205459	001	Jul 06, 2018	Jun NEWA
----	------------	------	---------	-----	--------------	----------

ADENOSINE

INJECTABLE;INJECTION

ADENOCARD

	+ @ ASTELLAS	3MG/ML	N019937	002	Oct 30, 1989	May DISC
--	--------------	--------	---------	-----	--------------	----------

ADENOSINE

AP	! AKORN	3MG/ML	A078076	001	Oct 31, 2008	May CHRS
AP	FRESENIUS KABI USA	3MG/ML	A205568	001	Apr 16, 2018	Apr NEWA
AP	GLAND PHARMA LTD	3MG/ML	A206778	001	Feb 16, 2018	Feb NEWA

SOLUTION;INTRAVENOUS

ADENOSCAN

	+ @ ASTELLAS	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Jun CDFR
	+ @	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Jun CDFR

ADENOSINE

AP	AKORN	60MG/20ML (3MG/ML)	A090450	001	Oct 02, 2014	Jun CDFR
AP		90MG/30ML (3MG/ML)	A090450	002	Oct 02, 2014	Jun CDFR
AP	AUROBINDO PHARMA LTD	60MG/20ML (3MG/ML)	A205331	001	Nov 02, 2017	Jun CDFR
AP		90MG/30ML (3MG/ML)	A205331	002	Nov 02, 2017	Jun CDFR
AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Jun CDFR
AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Jun CDFR
AP	FRESENIUS KABI USA	60MG/20ML (3MG/ML)	A077897	001	Nov 27, 2017	Jun CDFR
AP		90MG/30ML (3MG/ML)	A077897	002	Nov 27, 2017	Jun CDFR
AP	HOSPIRA INC	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Jun CDFR
AP		90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Jun CDFR
AP	MYLAN ASI	60MG/20ML (3MG/ML)	A090212	001	Mar 28, 2014	Jun CDFR
AP		90MG/30ML (3MG/ML)	A090212	002	Mar 28, 2014	Jun CDFR
AP	! TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Jun CDFR
AP	!	90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Jun CDFR

ALBENDAZOLE

TABLET;ORAL

ALBENDAZOLE

>A>	AB	CIPLA LTD	200MG	A210434	001	Sep 21, 2018	Sep NEWA
		ALBENZA					
>D>	+	IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996	Sep CFTG

TABLET;ORAL							
ALBENZA							
>A>	AB	+	200MG	N020666	001	Jun 11, 1996	Sep CFTG
<u>ALBUTEROL SULFATE</u>							
SOLUTION; INHALATION							
PROVENTIL							
+	@ SCHERING	EQ 0.083% BASE		N019243	002	Jan 14, 1987	Jun CRLD
+	@	EQ 0.5% BASE		N019243	001	Jan 14, 1987	Jun CRLD
SYRUP;ORAL							
ALBUTEROL SULFATE							
AA	LANNETT CO INC	EQ 2MG BASE/5ML		A078105	001	Dec 27, 2006	May CAHN
TABLET;ORAL							
ALBUTEROL SULFATE							
AB	AMNEAL PHARMS CO	EQ 2MG BASE		A208804	001	May 21, 2018	May NEWA
AB		EQ 4MG BASE		A208804	002	May 21, 2018	May NEWA
AB	APPCO PHARMA LLC	EQ 2MG BASE		A207046	001	Jun 29, 2018	Jun NEWA
AB		EQ 4MG BASE		A207046	002	Jun 29, 2018	Jun NEWA
AB	RISING PHARMS	EQ 2MG BASE		A207046	001	Jun 29, 2018	Aug CAHN
AB		EQ 4MG BASE		A207046	002	Jun 29, 2018	Aug CAHN
	@ YAOPHARMA CO LTD	EQ 2MG BASE		A072151	001	Dec 05, 1989	Jan CAHN
	@	EQ 4MG BASE		A072152	001	Dec 05, 1989	Jan CAHN
TABLET, EXTENDED RELEASE;ORAL							
ALBUTEROL SULFATE							
!	MYLAN	EQ 8MG BASE		A078092	001	Jan 29, 2007	May CTEC
VOSPIRE ER							
@	DAVA PHARMS INC	EQ 8MG BASE		A076130	003	Sep 26, 2002	May DISC
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>							
SOLUTION; INHALATION							
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE							
@	FOSUN PHARMA	EQ 0.083% BASE;0.017%		A076867	001	Dec 21, 2006	Jan CAHN
@	TEVA PHARMS	EQ 0.083% BASE;0.017%		A076724	001	Dec 31, 2007	Aug DISC
<u>ALCOHOL</u>							
SOLUTION; INTRA-ARTERIAL							
ABLYSINOL							
+	BELCHER PHARMS LLC	99% (1ML)		N207987	001	Jun 21, 2018	Jun NEWA
+	!	99% (5ML)		N207987	002	Jun 21, 2018	Jun NEWA
<u>ALENDRONATE SODIUM</u>							
TABLET;ORAL							
ALENDRONATE SODIUM							
AB	HANGZHOU BINJIANG	EQ 5MG BASE		A090258	001	Sep 24, 2009	Jan CAHN
AB		EQ 10MG BASE		A090258	002	Sep 24, 2009	Jan CAHN
AB		EQ 35MG BASE		A090258	003	Sep 24, 2009	Jan CAHN
AB		EQ 70MG BASE		A090258	004	Sep 24, 2009	Jan CAHN
	@ MYLAN	EQ 35MG BASE		A076584	003	Aug 04, 2008	Apr DISC
	@	EQ 70MG BASE		A076584	004	Aug 04, 2008	Apr DISC
AB	NEOPHARMA	EQ 5MG BASE		A079049	003	Aug 04, 2008	Aug CAHN
AB		EQ 10MG BASE		A079049	004	Aug 04, 2008	Aug CAHN
AB		EQ 35MG BASE		A079049	001	Aug 04, 2008	Aug CAHN
AB		EQ 70MG BASE		A079049	002	Aug 04, 2008	Aug CAHN
<u>ALISKIREN HEMIFUMARATE</u>							
CAPSULE, PELLET;ORAL							
TEKTURNA							
+	@ NODEN PHARMA	EQ 37.5MG BASE		N210709	001	Nov 14, 2017	Jun DISC
<u>ALLOPURINOL</u>							
TABLET;ORAL							
ALLOPURINOL							
@	FOSUN PHARMA	100MG		A070268	001	Dec 31, 1985	Jan CAHN
<u>ALOSETRON HYDROCHLORIDE</u>							
TABLET;ORAL							
ALOSETRON HYDROCHLORIDE							
AB	PAR PHARM INC	EQ 0.5MG BASE		A206113	001	Feb 23, 2018	Feb NEWA
AB		EQ 1MG BASE		A206113	002	Feb 23, 2018	Feb NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

+	!	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	Jun	CDFR
+	!		2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003	Jun	CDFR

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB		BRECKENRIDGE PHARM	0.25MG	A207507	001	Jul 09, 2018	Aug	CAHN
AB			0.5MG	A207507	002	Jul 09, 2018	Aug	CAHN
AB			1MG	A207507	003	Jul 09, 2018	Aug	CAHN
AB			2MG	A207507	004	Jul 09, 2018	Aug	CAHN
AB		CENTAUR PHARMS PVT	0.25MG	A207507	001	Jul 09, 2018	Jun	NEWA
AB			0.5MG	A207507	002	Jul 09, 2018	Jun	NEWA
AB			1MG	A207507	003	Jul 09, 2018	Jun	NEWA
AB			2MG	A207507	004	Jul 09, 2018	Jun	NEWA
AB		OXFORD PHARMS	0.25MG	A078491	001	Sep 25, 2008	Jul	CAHN
AB			0.5MG	A078491	002	Sep 25, 2008	Jul	CAHN
AB			1MG	A078491	003	Sep 25, 2008	Jul	CAHN
AB			2MG	A078491	004	Dec 12, 2008	Jul	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

+	@	PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jun	DISC
---	---	----------------------	--------------	---------	-----	--------------	-----	------

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

>A>	AB	GRAVITI PHARMS	100MG	A207570	001	Sep 30, 2016	Sep	CAHN
		@ LANNETT CO INC	100MG	A209221	001	Jun 15, 2017	Jun	DISC
>D>	AB	NEWGEN PHARMS LLC	100MG	A207570	001	Sep 30, 2016	Sep	CAHN

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

>A>	AB	GRAVITI PHARMS	100MG	A207571	001	Jan 31, 2017	Sep	CAHN
	AB	JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018	Jan	NEWA
>D>	AB	NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

+		OSMOTICA PHARM	EQ 129MG BASE	N209410	001	Feb 16, 2018	Feb	NEWA
+			EQ 193MG BASE	N209410	002	Feb 16, 2018	Feb	NEWA
+	!		EQ 258MG BASE	N209410	003	Feb 16, 2018	Feb	NEWA

AMIKACIN SULFATE

SUSPENSION, LIPOSOMAL; INHALATION

ARIKAYCE KIT

>A>	+	INSMED INC	EQ 590MG BASE/8.4ML	N207356	001	Sep 28, 2018	Sep	NEWA
-----	---	------------	---------------------	---------	-----	--------------	-----	------

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

>A>	AB	USPHARMA WINDLAS	5MG	A204180	001	Aug 07, 2015	Sep	CAHN
>D>	AB	WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Sep	CAHN

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@ YAOPHARMA CO LTD	EQ 5MG ANHYDROUS; 50MG	A073357	001	Nov 27, 1991	Jan	CAHN
--	--	--------------------	------------------------	---------	-----	--------------	-----	------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1026ML)	N200656	004	Aug 25, 2014	Jul CDFR
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML)	N200656	005	Aug 25, 2014	Jul CDFR
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML)	N200656	006	Aug 25, 2014	Jul CDFR
+	!	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML)	N200656	007	Aug 25, 2014	Jul CDFR

PERIKABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1440ML)	N200656	001	Aug 25, 2014	Jul CDFR
+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1920ML)	N200656	002	Aug 25, 2014	Jul CDFR
+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jul CDFR

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 8.5% W/ ELECTROLYTES

@	ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986	May DISC
---	-----------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

	ICU MEDICAL INC	8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML	N017673	009	Oct 25, 2002	May NEWA
--	-----------------	---	---------	-----	--------------	----------

AMINOSYN II 8.5% W/ELECTROLYTES

	ICU MEDICAL INC	8.5%;102MG/100ML;492MG/100ML;60MG/100ML;425MG/100ML	N019437	008	Oct 25, 2002	May NEWA
--	-----------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ ELECTROLYTES

@	ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005		May DISC
---	-----------------	--	---------	-----	--	----------

AMINOCAPROIC ACID

SYRUP; ORAL

AMICAR

>D> AA	+	!	CLOVER PHARMS	1.25GM/5ML	N015230	002		Sep CTEC
>A>	+	!		1.25GM/5ML	N015230	002		Sep CTEC
>D>			AMINOCAPROIC ACID					
>D> AA			AKORN	1.25GM/5ML	A074759	001	Sep 02, 1998	Sep DISC
>A>			@	1.25GM/5ML	A074759	001	Sep 02, 1998	Sep DISC

TABLET; ORAL

AMICAR

+	CLOVER PHARMS	500MG	N015197	001			Jul CTEC
	AMINOCAPROIC						
	@ AKORN	500MG	A075602	001	May 24, 2001		Jul DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

	@ AKORN	50MG/ML	A076232	001	Jul 05, 2006		Jun DISC
	NEXTERONE						
+	@ BAXTER HLTHCARE	50MG/ML	N022325	001	Dec 24, 2008		Jun DISC

TABLET;ORAL

CORDARONE

>A>	+	@ WYETH PHARMS	200MG	N018972	001	Dec 24, 1985	Sep CAHN
>D>	+	@ WYETH PHARMS INC	200MG	N018972	001	Dec 24, 1985	Sep CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB		SUN PHARM INDS INC	10MG	A089399	002	Jul 14, 1987	Jan CMFD
AB			25MG	A089399	001	Jul 14, 1987	Jan CMFD
AB			50MG	A089399	003	Jul 14, 1987	Jan CMFD
AB			75MG	A089399	004	Jul 14, 1987	Jan CMFD
AB			100MG	A089399	005	Jul 14, 1987	Jan CMFD
AB			150MG	A089399	006	Jul 14, 1987	Jan CMFD

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	@	FOSUN PHARMA	10MG;2MG	A071062	001	Nov 27, 1987	Jan CAHN
	@		10MG;4MG	A071862	001	Dec 21, 1987	Jan CAHN
	@		25MG;2MG	A071063	001	Nov 27, 1987	Jan CAHN
	@		25MG;4MG	A071064	001	Nov 27, 1987	Jan CAHN
	@		50MG;4MG	A071863	001	Dec 21, 1987	Jan CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB		OXFORD PHARMS	EQ 2.5MG BASE	A078414	001	Apr 07, 2010	Jul CAHN
AB			EQ 5MG BASE	A078414	002	Apr 07, 2010	Jul CAHN
AB			EQ 10MG BASE	A078414	003	Apr 07, 2010	Jul CAHN
AB		SUNSHINE LAKE	EQ 2.5MG BASE	A206524	001	May 04, 2018	Apr NEWA
AB			EQ 5MG BASE	A206524	002	May 04, 2018	Apr NEWA
AB			EQ 10MG BASE	A206524	003	May 04, 2018	Apr NEWA
	@	YAOPHARMA CO LTD	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan CAHN
	@		EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan CAHN
	@		EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan CAHN

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

+		KITOV PHARMS LTD	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	May NEWA
+			EQ 5MG BASE;200MG	N210045	002	May 31, 2018	May NEWA
+	!		EQ 10MG BASE;200MG	N210045	003	May 31, 2018	May NEWA

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB		ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018	Aug NEWA
AB			EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018	Aug NEWA
AB			EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018	Aug NEWA
AB			EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018	Aug NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Feb CAHN
	@	UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014	Jun DISC

AMMONIUM LACTATE

CREAM;TOPICAL

LAC-HYDRIN

	@	SUN PHARM INDS INC	EQ 12% BASE	N020508	001	Aug 29, 1996	Feb CAHN
--	---	--------------------	-------------	---------	-----	--------------	----------

LOTION;TOPICAL

LAC-HYDRIN

+	@	SUN PHARM INDS INC	EQ 12% BASE	N019155	001	Apr 24, 1985	Feb CAHN
---	---	--------------------	-------------	---------	-----	--------------	----------

AMOXAPINETABLET; ORAL
AMOXAPINE

WATSON LABS	25MG	A072691	002	Aug 28, 1992	Mar CMS1
	50MG	A072691	003	Aug 28, 1992	Mar CMS1
	100MG	A072691	004	Aug 28, 1992	Mar CMS1

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLECAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	!	RISING PHARMS	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A206006	001	Oct 07, 2016	Jun CHRS
	@	TEVA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A200218	001	Aug 30, 2013	Jun DISC
		PREVPAC					
	+	@ TAKEDA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	N050757	001	Dec 02, 1997	Jun DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
MYDAYIS

+	!	SHIRE DEV LLC	12.5MG; 12.5MG; 12.5MG; 12.5MG	N022063	004	Jun 20, 2017	May CHRS
---	---	---------------	--------------------------------	---------	-----	--------------	----------

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	NUVO PHARM	1.25MG; 1.25MG; 1.25MG; 1.25MG	A209799	001	Dec 28, 2017	Sep CAHN
>A>	AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A209799	002	Dec 28, 2017	Sep CAHN
>A>	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A209799	003	Dec 28, 2017	Sep CAHN
>A>	AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A209799	004	Dec 28, 2017	Sep CAHN
>A>	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A209799	005	Dec 28, 2017	Sep CAHN
>A>	AB		5MG; 5MG; 5MG; 5MG	A209799	006	Dec 28, 2017	Sep CAHN
>A>	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A209799	007	Dec 28, 2017	Sep CAHN
>D>	AB	SUNRISE PHARM INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A209799	001	Dec 28, 2017	Sep CAHN
>D>	AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A209799	002	Dec 28, 2017	Sep CAHN
>D>	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A209799	003	Dec 28, 2017	Sep CAHN
>D>	AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A209799	004	Dec 28, 2017	Sep CAHN
>D>	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A209799	005	Dec 28, 2017	Sep CAHN
>D>	AB		5MG; 5MG; 5MG; 5MG	A209799	006	Dec 28, 2017	Sep CAHN
>D>	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A209799	007	Dec 28, 2017	Sep CAHN

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

>A>	AA	AMNEAL PHARMS	5MG	A211139	001	Sep 26, 2018	Sep NEWA
>A>	AA		10MG	A211139	002	Sep 26, 2018	Sep NEWA
		EVEKEO					
>D>		ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Sep CTEC
>A>	AA		5MG	A200166	001	Aug 09, 2012	Sep CTEC
>D>	!		10MG	A200166	002	Aug 09, 2012	Sep CTEC
>A>	AA	!	10MG	A200166	002	Aug 09, 2012	Sep CTEC

AMPICILLIN SODIUMINJECTABLE; INJECTION
AMPICILLIN SODIUM

@	AUROBINDO PHARMA	EQ 125MG BASE/VIAL	A065499	001	Aug 17, 2010	Aug DISC
@	ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Mar DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

>D>	AB	DR REDDYS LABS LTD	1MG	A090732	001	Jun 28, 2010	Sep CAHN	
>A>	AB	NEOPHARMA	1MG	A090732	001	Jun 28, 2010	Sep CAHN	
		ARIMIDEX						
AB	+	!	ANI PHARMS INC	1MG	N020541	001	Dec 27, 1995	Jan CAHN

ANGIOTENSIN II ACETATESOLUTION; INTRAVENOUS
GIAPREZA

+	!	LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jun CDFR
+	!		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jun CDFR
+	!	LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jun CAHN

SOLUTION; INTRAVENOUS

GIAPREZA

+ @	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Aug DISC
+	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jun CAHN

SOLUTION; IV (INFUSION)

GIAPREZA

+	LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jan CAIN
+		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jan CAIN

ANIDULAFUNGIN

POWDER; INTRAVENOUS

ERAXIS

+	VICURON	50MG/VIAL	N021632	001	Feb 17, 2006	Jun CDFR
+		100MG/VIAL	N021632	002	Nov 14, 2006	Jun CDFR

APALUTAMIDE

TABLET; ORAL

ERLEADA

+	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb NEWA
---	-----------------	------	---------	-----	--------------	----------

APREPITANT

CAPSULE; ORAL

APREPITANT

AB	GLENMARK PHARMS SA	40MG	A207777	001	Oct 12, 2017	Jan CAHN
AB		80MG	A207777	002	Oct 12, 2017	Jan CAHN
AB		125MG	A207777	003	Oct 12, 2017	Jan CAHN

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	AMNEAL PHARMS CO	250MG/2.5ML (100MG/ML)	A206698	001	Jan 26, 2018	Jan NEWA
----	------------------	------------------------	---------	-----	--------------	----------

INJECTABLE; INTRAVENOUS

ARGATROBAN IN 0.9% SODIUM CHLORIDE

	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014	Aug CDFR
--	-----------------	----------------------	---------	-----	--------------	----------

ARGATROBAN IN SODIUM CHLORIDE

+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	Aug CDFR
AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570	001	May 22, 2017	Aug CDFR
AP	SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	Aug CDFR

SOLUTION; INTRAVENOUS

ARGATROBAN IN DEXTROSE

@	SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011	Jul CDFR
---	--------	----------------------	---------	-----	--------------	----------

ARIPIPRAZOLE

TABLET; ORAL

ARIPIPRAZOLE

>A>	@	MYLAN PHARMS INC	2MG	A206240	001	Sep 19, 2018	Sep DISC
>A>	AB		2MG	A206240	001	Sep 19, 2018	Sep NEWA
>A>	@		5MG	A206240	002	Sep 19, 2018	Sep DISC
>A>	AB		5MG	A206240	002	Sep 19, 2018	Sep NEWA
>A>	@		10MG	A206240	003	Sep 19, 2018	Sep DISC
>A>	AB		10MG	A206240	003	Sep 19, 2018	Sep NEWA
>A>	@		15MG	A206240	004	Sep 19, 2018	Sep DISC
>A>	AB		15MG	A206240	004	Sep 19, 2018	Sep NEWA
>A>	@		20MG	A206240	005	Sep 19, 2018	Sep DISC
>A>	AB		20MG	A206240	005	Sep 19, 2018	Sep NEWA
>A>	@		30MG	A206240	006	Sep 19, 2018	Sep DISC
>A>	AB		30MG	A206240	006	Sep 19, 2018	Sep NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

>D>	@	OTSUKA	10MG	N021729	002	Jun 07, 2006	Sep CRLD
>A>	+	@	10MG	N021729	002	Jun 07, 2006	Sep CRLD
>D>	@		15MG	N021729	003	Jun 07, 2006	Sep CRLD
>A>	+	@	15MG	N021729	003	Jun 07, 2006	Sep CRLD

ARIPIPRAZOLE

AB	SCIEGEN PHARMS INC	10MG	A207240	001	Apr 18, 2018	Apr NEWA
AB		15MG	A207240	002	Apr 18, 2018	Apr NEWA
AB	ZYDUS PHARMS USA INC	10MG	A090165	001	Aug 28, 2018	Aug NEWA
AB		15MG	A090165	002	Aug 28, 2018	Aug NEWA
		20MG	A090165	003	Aug 28, 2018	Aug NEWA
		30MG	A090165	004	Aug 28, 2018	Aug NEWA

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ARISTADA INITIO KIT

+ ALKERMES INC 675MG/2.4ML N209830 001 Jun 29, 2018 Jun NEWA

ARMODAFINIL

TABLET; ORAL
ARMODAFINIL

AB	AUROBINDO PHARMA LTD	50MG	A206069	001	Mar 06, 2018	Feb NEWA
AB		150MG	A206069	002	Mar 06, 2018	Feb NEWA
AB		250MG	A206069	003	Mar 06, 2018	Feb NEWA

ARSENIC TRIOXIDE

INJECTABLE; INJECTION
ARSENIC TRIOXIDE

FRESENIUS KABI USA 1MG/ML A208231 001 Aug 31, 2018 Aug NEWA
TRISENOX

+ @ CEPHALON 1MG/ML N021248 001 Sep 25, 2000 Jul DISC

ASCORBIC ACID

SOLUTION; INTRAVENOUS
ASCOR

+! MCGUFF 25,000MG/50ML (500MG/ML) N209112 001 Oct 02, 2017 Jul CDFR

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS
INFUVITE PEDIATRIC

+! SANDOZ INC 80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL N021265 001 Feb 21, 2001 Aug CDFR

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)
+! SANDOZ INC 80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL N021646 001 Jan 29, 2004 Aug CDFR

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; INTRAVENOUS
M.V.I. PEDIATRIC

+! HOSPIRA 80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.01MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 0.2MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; EQ 1.2MG BASE/VIAL; 0.7MG/VIAL; 7MG/VIAL N018920 001 Sep 21, 2000 Aug CDFR

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; INTRAVENOUS
M.V.I. ADULT

+! HOSPIRA 200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/VIAL N021625 001 Jan 30, 2004 Aug CDFR

M.V.I. ADULT (PHARMACY BULK PACKAGE)
+! HOSPIRA 200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 15MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0.15MG/5ML N021643 001 Feb 18, 2004 Aug CDFR

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL
PLENVU

+! SALIX PHARMS INC 7.54GM; 140GM; 2.2GM; 48.11GM; 5.2GM; 9 N209381 001 May 04, 2018 May NEWA GM

ASENAPINE MALEATE

TABLET;SUBLINGUAL
ASENAPINE MALEATE

AB	SIGMAPHARM LABS LLC	EQ 5MG BASE	A206107	001	Jul 17, 2018	Jul NEWA
AB		EQ 10MG BASE	A206107	002	Jul 17, 2018	Jul NEWA
	SAPHRIS					
AB	+ FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jul CFTG
AB	+!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Jul CFTG

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE
@ FOSUN PHARMA 325MG;50MG;40MG

A086398 002 Apr 06, 1984 Jan CAHN

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL
SYNALGOS-DC
+ @ SUN PHARM INDUSTRIES 356.4MG;30MG;16MG

N011483 004 Sep 06, 1983 Aug DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL
ORPHENGESIC
@ GALT PHARMS 385MG;30MG;25MG
ORPHENGESIC FORTE
@ GALT PHARMS 770MG;60MG;50MG

A075141 001 May 29, 1998 Feb CAHN

A075141 002 May 29, 1998 Feb CAHN

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL
ASPIRIN AND DIPYRIDAMOLE

AB	ANI PHARMS INC	25MG;200MG	A206964	001	Jan 18, 2017	May CAHN
AB	SUN PHARMA GLOBAL	25MG;200MG	A208572	001	Aug 21, 2018	Aug NEWA

ATAZANAVIR SULFATE

CAPSULE;ORAL
ATAZANAVIR SULFATE

AB	AUROBINDO PHARMA LTD	EQ 100MG BASE	A204806	001	Jun 25, 2018	Jun NEWA
AB		EQ 150MG BASE	A204806	002	Jun 25, 2018	Jun NEWA
AB		EQ 200MG BASE	A204806	003	Jun 25, 2018	Jun NEWA
AB		EQ 300MG BASE	A204806	004	Jun 25, 2018	Jun NEWA
AB	CIPLA LTD	EQ 100MG BASE	A200626	001	Aug 09, 2018	Jul NEWA
AB		EQ 150MG BASE	A200626	002	Aug 09, 2018	Jul NEWA
AB		EQ 200MG BASE	A200626	003	Aug 09, 2018	Jul NEWA
AB		EQ 300MG BASE	A200626	004	Aug 09, 2018	Jul NEWA
>A> AB	MYLAN PHARMS INC	EQ 150MG BASE	A208177	001	Sep 24, 2018	Sep NEWA
>A> AB		EQ 200MG BASE	A208177	002	Sep 24, 2018	Sep NEWA
>A> AB		EQ 300MG BASE	A208177	003	Sep 24, 2018	Sep NEWA
AB	TEVA PHARMS USA	EQ 100MG BASE	A091673	001	Apr 22, 2014	Jun CTEC

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL
ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN MALTA	50MG;25MG	A072302	002	May 31, 1990	Jul CMS1
----	---------------	-----------	---------	-----	--------------	----------

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL
ATOMOXETINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	10MG	A090609	001	Feb 23, 2018	Feb NEWA
AB		18MG	A090609	002	Feb 23, 2018	Feb NEWA
AB		25MG	A090609	003	Feb 23, 2018	Feb NEWA
AB		40MG	A090609	004	Feb 23, 2018	Feb NEWA
AB		60MG	A090609	005	Feb 23, 2018	Feb NEWA
AB		80MG	A090609	006	Feb 23, 2018	Feb NEWA
AB		100MG	A090609	007	Feb 23, 2018	Feb NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL
ATORVASTATIN CALCIUM

AB	ACCORD HLTHCARE	EQ 10MG BASE	A207687	001	Mar 30, 2018	Mar NEWA
AB		EQ 20MG BASE	A207687	002	Mar 30, 2018	Mar NEWA
AB		EQ 40MG BASE	A207687	003	Mar 30, 2018	Mar NEWA
AB		EQ 80MG BASE	A207687	004	Mar 30, 2018	Mar NEWA

TABLET;ORAL							
ATORVASTATIN CALCIUM							
AB	GRAVITI PHARMS	EQ 10MG BASE	A209912	001	Jun 18, 2018	Jun	NEWA
AB		EQ 20MG BASE	A209912	002	Jun 18, 2018	Jun	NEWA
AB		EQ 40MG BASE	A209912	003	Jun 18, 2018	Jun	NEWA
AB		EQ 80MG BASE	A209912	004	Jun 18, 2018	Jun	NEWA
<u>ATOVAQUONE</u>							
SUSPENSION;ORAL							
ATOVAQUONE							
	@ APOTEX INC	750MG/5ML	A209750	001	Oct 11, 2017	Jun	DISC
AB	LUPIN LTD	750MG/5ML	A209105	001	Sep 11, 2018	Aug	NEWA
<u>ATROPINE</u>							
SOLUTION;INTRAMUSCULAR							
ATROPINE (AUTOINJECTOR)							
	@ RAFA LABS LTD	EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)	N212319	001	Jul 09, 2018	Jul	NEWA
<u>ATROPINE SULFATE</u>							
SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL							
ATROPINE SULFATE ANSYR PLASTIC SYRINGE							
	+ @ HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Jun	DISC
SOLUTION;IV (INFUSION), INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL							
ATROPINE SULFATE							
	+! FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	Jan	NEWA
SOLUTION/DROPS;OPHTHALMIC							
ISOPTO ATROPINE							
	ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Jul	CMFD
	@	1%	N208151	001	Dec 01, 2016	Apr	DISC
		1%	N208151	001	Dec 01, 2016	Feb	CAHN
<u>ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE</u>							
TABLET;ORAL							
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE							
	@ FOSUN PHARMA	0.025MG;2.5MG	A086173	001		Jan	CAHN
AA	UPSHER-SMITH LABS	0.025MG;2.5MG	A210571	001	Aug 31, 2018	Aug	NEWA
	LONOX						
	@ FOSUN PHARMA	0.025MG;2.5MG	A085311	002		Jan	CAHN
<u>AVATROMBOPAG MALEATE</u>							
TABLET;ORAL							
DOPTELET							
	+! AKARX INC	EQ 20MG BASE	N210238	001	May 21, 2018	May	NEWA
<u>AVIBACTAM SODIUM; CEFTAZIDIME</u>							
POWDER;IV (INFUSION)							
AVYCAZ							
	+! ALLERGAN SALES LLC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Jan	CAHN
<u>AZACITIDINE</u>							
POWDER;INTRAVENOUS, SUBCUTANEOUS							
AZACITIDINE							
AP	ACCORD HLTHCARE	100MG/VIAL	A207475	001	Jul 02, 2018	Jun	NEWA
AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	May	CDFR
AP	CIPLA LTD	100MG/VIAL	A209540	001	May 04, 2018	May	CDFR
AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	May	CDFR
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	May	CDFR
AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017	May	CDFR
AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	May	CDFR
VIDAZA							
AP	+! CELGENE	100MG/VIAL	N050794	001	May 19, 2004	May	CDFR
POWDER;IV (INFUSION), SUBCUTANEOUS							
AZACITIDINE							
AP	CIPLA LTD	100MG/VIAL	A209540	001	May 04, 2018	Apr	NEWA

AZELAIC ACIDAEROSOL, FOAM; TOPICAL
FINACEA

>D>	+	!	BAYER HLTHCARE	15%	N207071	001	Jul 29, 2015	Sep CAHN
>A>	+	!	LEO PHARMA AS	15%	N207071	001	Jul 29, 2015	Sep CAHN
CREAM; TOPICAL AZELEX								
>D>	+	!	ALLERGAN	20%	N020428	001	Sep 13, 1995	Sep CAHN
>A>	+	!	AQUA PHARMS LLC	20%	N020428	001	Sep 13, 1995	Sep CAHN
GEL; TOPICAL FINACEA								
>D>	+	!	BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002	Sep CAHN
>A>	+	!	LEO PHARMA AS	15%	N021470	001	Dec 24, 2002	Sep CAHN

AZITHROMYCINFOR SUSPENSION; ORAL
AZITHROMYCIN

AB			AMNEAL PHARMS LLC	EQ 100MG BASE/5ML	A205666	001	Jul 19, 2018	Jul NEWA
AB				EQ 200MG BASE/5ML	A205666	002	Jul 19, 2018	Jul NEWA
>A>	AB		AUROBINDO PHARMA LTD	EQ 100MG BASE/5ML	A209201	001	Oct 09, 2018	Sep NEWA
>A>	AB			EQ 200MG BASE/5ML	A209201	002	Oct 09, 2018	Sep NEWA
AB			EPIC PHARMA LLC	EQ 100MG BASE/5ML	A207531	001	Apr 09, 2018	Mar NEWA
AB				EQ 200MG BASE/5ML	A207531	002	Apr 09, 2018	Mar NEWA
AB			ZYDUS WORLDWIDE	EQ 100MG BASE/5ML	A211147	001	Jul 31, 2018	Jul NEWA
AB				EQ 200MG BASE/5ML	A211147	002	Jul 31, 2018	Jul NEWA
FOR SUSPENSION, EXTENDED RELEASE; ORAL ZMAX								
	+	@	PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005	Jun DISC
INJECTABLE; INJECTION AZITHROMYCIN								
>A>	AP		HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A203412	001	Oct 09, 2018	Sep NEWA
TABLET; ORAL AZITHROMYCIN								
		@	APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011	Mar DISC
		@		EQ 500MG BASE	A065509	001	Jul 13, 2011	Mar DISC
		@		EQ 600MG BASE	A065508	001	Jul 13, 2011	Mar DISC
AB			AUROBINDO PHARMA LTD	EQ 250MG BASE	A207370	001	Jul 05, 2018	Jul NEWA
AB				EQ 500MG BASE	A207398	001	Jul 05, 2018	Jul NEWA
>A>	AB		CSPC OUYI PHARM CO	EQ 600MG BASE	A207566	001	Sep 24, 2018	Sep NEWA

BACITRACININJECTABLE; INJECTION
BACITRACIN

@	MYLAN ASI	50,000 UNITS/VIAL	A090211	001	May 11, 2010	Jan DISC
@	PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001		Jul DISC

BACLOFENINJECTABLE; INTRATHECAL
BACLOFEN

AP		MYLAN LABS LTD	0.5MG/ML	A209592	001	Mar 21, 2018	Mar NEWA	
AP			1MG/ML	A209594	001	Mar 06, 2018	Feb NEWA	
AP			2MG/ML	A209592	002	Mar 21, 2018	Mar NEWA	
GABLOFEN								
AP	+	!	PIRAMAL CRITICAL	1MG/ML	N022462	004	Jun 22, 2012	Feb CFTG

BARICITINIBTABLET; ORAL
OLUMIANT

+	!	ELI LILLY AND CO	2MG	N207924	001	May 31, 2018	May NEWA
---	---	------------------	-----	---------	-----	--------------	----------

BARIUM SULFATEFOR SUSPENSION; ORAL
E-Z-HD

+!	BRACCO	98%	(334GM/BOT)	N208036	001	Jan 11, 2016	Apr	CPOT
E-Z-PAQUE								
+!	BRACCO	96%	(169GM/BOT)	N208036	002	Apr 07, 2017	Apr	CPOT
PASTE;ORAL								
VARIBAR PUDDING								
	BRACCO	40%		N208844	001	Oct 14, 2016	Jun	CPOT
		40%	(92GM/230ML)	N208844	001	Oct 14, 2016	Jun	CTNA

SUSPENSION;ORAL

LIQUID E-Z-PAQUE

+!	BRACCO	60% (213GM/BOT)	N208143	003	Mar 01, 2017	Apr CPOT
	READI-CAT 2					
+!	BRACCO	2% (9GM/BOT)	N208143	001	Jan 15, 2016	Apr CPOT
	READI-CAT 2 SMOOTHIES					
+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016	Apr CPOT
	TAGITOL V					
+!	BRACCO	40% (8GM/BOT)	N208143	005	Aug 04, 2017	Apr CPOT
	VARIBAR HONEY					
+!	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018	Mar NEWA
	VARIBAR THIN HONEY					
+!	BRACCO	40% (100GM/250ML)	N208143	006	Jan 23, 2018	Jan NEWA

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET;ORAL

DUAVEE

+!	WYETH PHARMS	EQ 20MG BASE;0.45MG	N022247	001	Oct 03, 2013	Aug CAHN
----	--------------	---------------------	---------	-----	--------------	----------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR 40

+	@ TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000	Jun DISC
	QVAR 80					
+	@ TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000	Jun DISC
	QVAR REDIHALER					
+	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017	Jul CMFD
+	@	0.04MG/INH	N207921	001	Aug 03, 2017	Jun DISC
+!		0.04MG/INH	N207921	001	Aug 03, 2017	Jan CHRS
+		0.08MG/INH	N207921	002	Aug 03, 2017	Jul CMFD
+	@	0.08MG/INH	N207921	002	Aug 03, 2017	Jun DISC

BELINOSTAT

POWDER;INTRAVENOUS

BELEODAQ

+!	SPECTRUM PHARMS	500MG/VIAL	N206256	001	Jul 03, 2014	Jun CDFR
----	-----------------	------------	---------	-----	--------------	----------

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB	CASI PHARMS INC	5MG	A076402	001	Feb 11, 2004	Mar CAHN
AB		10MG	A076402	002	Feb 11, 2004	Mar CAHN
AB		20MG	A076402	003	Feb 11, 2004	Mar CAHN
AB		40MG	A076402	004	Feb 11, 2004	Mar CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	MYLAN LABS LTD	25MG/VIAL	A204104	001	Apr 26, 2018	Apr NEWA
AP		100MG/VIAL	A204104	002	Apr 26, 2018	Apr NEWA

SOLUTION;IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018	Jul CHRS
+		100MG/4ML (25MG/ML)	N205580	001	May 15, 2018	May NEWA
	TREANDA					
+	@ CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	May DISC
+	@	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	May DISC

>D> BENZNIDAZOLE

>D> TABLET;ORAL

>D> BENZNIDAZOLE

>D>	+	CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017	Sep DISC
>A>	+	@	12.5MG	N209570	001	Aug 29, 2017	Sep DISC
>D>	+!		100MG	N209570	002	Aug 29, 2017	Sep DISC
>A>	+	@	100MG	N209570	002	Aug 29, 2017	Sep DISC

BENZONATATECAPSULE;ORAL
BENZONATATE

AA	CSPC NBP PHARM CO	100MG	A202765	002	Aug 25, 2017	Mar NEWA
----	-------------------	-------	---------	-----	--------------	----------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEGEL;TOPICAL
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	TARO	3.75%;EQ 1.2% BASE	A208683	001	Jun 05, 2018	May NEWA
AB		5%;EQ 1% BASE	A208776	001	May 25, 2018	May NEWA
AB	TARO PHARMS	5%;1.2%	A206218	001	Dec 15, 2017	May CAHN
	ONEXTON					
AB	+! DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	May CTEC

BENZPHETAMINE HYDROCHLORIDETABLET;ORAL
BENZPHETAMINE HYDROCHLORIDE

>D> AA	MIKART	25MG	A090473	001	Sep 15, 2010	Sep CTEC
>A>		25MG	A090473	001	Sep 15, 2010	Sep CTEC
>D> AA	TEDOR PHARM	25MG	A040747	002	Nov 20, 2015	Sep DISC
>A>	@	25MG	A040747	002	Nov 20, 2015	Sep DISC
>D> AA		50MG	A040747	001	Mar 30, 2007	Sep DISC
>A>	@	50MG	A040747	001	Mar 30, 2007	Sep DISC
AA	TWI PHARMS	50MG	A040578	001	Apr 17, 2006	Jul CAHN

BENZTROPINE MESYLATETABLET;ORAL
BENZTROPINE MESYLATE

@	CHARTWELL RX	1MG	A081265	002	Jan 23, 1992	Aug CMS1
@		2MG	A081265	001	Jan 23, 1992	Jan CAHN

BETAINEFOR SOLUTION;ORAL
CYSTADANE

+!	ORPHAN EUROPE	1GM/SCOOPFUL	N020576	001	Oct 25, 1996	May CAIN
----	---------------	--------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATECREAM, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE

>A> AB	ANDA REPOSITORY	EQ 0.05% BASE	A076603	001	Jan 23, 2004	Sep CAHN
>D> AB	TOLMAR	EQ 0.05% BASE	A076603	001	Jan 23, 2004	Sep CAHN

LOTION;TOPICAL
BETAMETHASONE DIPROPIONATE

AB	HI-TECH PHARMACAL	EQ 0.05% BASE	A209896	001	Feb 06, 2018	Jan NEWA
----	-------------------	---------------	---------	-----	--------------	----------

LOTION, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE

AB	! TARO	EQ 0.05% BASE	A077477	001	May 21, 2007	Aug CHRS
AB	TELIGENT PHARMA INC	EQ 0.05% BASE	A206389	001	Feb 13, 2018	Jan NEWA
	DIPROLENE					
+	@ MERCK SHARP DOHME	EQ 0.05% BASE	N019716	001	Aug 01, 1988	Aug DISC

BETAMETHASONE VALERATELOTION;TOPICAL
BETA-VAL
@ G AND W LABS INC

EQ 0.1% BASE	A070072	001	Jun 27, 1985	Jan DISC
--------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
BETOPTIC

AT	+! SANDOZ INC	EQ 0.5% BASE	N019270	001	Aug 30, 1985	Jan CAHN
----	---------------	--------------	---------	-----	--------------	----------

BEXAROTENECAPSULE;ORAL
BEXAROTENE

AB	AMERIGEN PHARMS LTD	75MG	A209861	001	May 08, 2018	Apr NEWA
AB	AMNEAL PHARMS NY	75MG	A210105	001	Sep 04, 2018	Aug NEWA
AB	UPSHER-SMITH LABS	75MG	A209886	001	Jul 25, 2018	Jul NEWA

BICALUTAMIDETABLET; ORAL
CASODEX

AB	+	ANI PHARMS INC	50MG	N020498	001	Oct 04, 1995	Jan CAHN
----	---	----------------	------	---------	-----	--------------	----------

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATETABLET; ORAL
BIKTARVY

	+	GILEAD SCIENCES INC	EQ 50MG BASE; 200MG; EQ 25MG BASE	N210251	001	Feb 07, 2018	Feb NEWA
--	---	---------------------	-----------------------------------	---------	-----	--------------	----------

BIMATOPROSTSOLUTION/DROPS; TOPICAL
BIMATOPROST

>A>	AT		HI-TECH PHARMACAL	0.03%	A203051	001	Oct 09, 2018	Sep NEWA
-----	----	--	-------------------	-------	---------	-----	--------------	----------

BINIMETINIBTABLET; ORAL
MEKTOVI

	+	ARRAY BIOPHARMA INC	15MG	N210498	001	Jun 27, 2018	Jun NEWA
--	---	---------------------	------	---------	-----	--------------	----------

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDEFOR SOLUTION, TABLET, DELAYED RELEASE; ORAL
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

	@	NOVEL LABS INC	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM; N/A, 5.6GM	A202217	001	Aug 20, 2014	May DISC
--	---	----------------	--	---------	-----	--------------	----------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINECAPSULE; ORAL
PYLERA

	+	ALLERGAN SALES LLC	140MG; 125MG; 125MG	N050786	001	Sep 28, 2006	Jan CAHN
--	---	--------------------	---------------------	---------	-----	--------------	----------

BISOPROLOL FUMARATETABLET; ORAL
BISOPROLOL FUMARATE

AB		CASI PHARMS INC	5MG	A075643	001	Nov 16, 2000	Mar CAHN
----	--	-----------------	-----	---------	-----	--------------	----------

AB			10MG	A075643	002	Nov 16, 2000	Mar CAHN
----	--	--	------	---------	-----	--------------	----------

ZEBETA

	+	@ TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Aug CRLD
--	---	---------------	-----	---------	-----	--------------	----------

	+	@	10MG	N019982	001	Jul 31, 1992	Aug CRLD
--	---	---	------	---------	-----	--------------	----------

BIVALIRUDININJECTABLE; INTRAVENOUS
ANGIOMAX

>A>	AP	+	SANDOZ INC	250MG/VIAL	N020873	001	Dec 15, 2000	Sep CAHN
-----	----	---	------------	------------	---------	-----	--------------	----------

>D>	AP	+	THE MEDICINES CO	250MG/VIAL	N020873	001	Dec 15, 2000	Sep CAHN
-----	----	---	------------------	------------	---------	-----	--------------	----------

BIVALIRUDIN

AP		AUROBINDO PHARMA LTD	250MG/VIAL	A205962	001	Jul 27, 2018	Jul NEWA
----	--	----------------------	------------	---------	-----	--------------	----------

AP		MYLAN INSTITUTIONAL	250MG/VIAL	A202471	001	Jun 01, 2018	May NEWA
----	--	---------------------	------------	---------	-----	--------------	----------

AP		SAGENT PHARMS	250MG/VIAL	A091602	001	Jul 16, 2018	Jul NEWA
----	--	---------------	------------	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

	+	BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017	Jul CDFR
--	---	----------------------	---------------------	---------	-----	--------------	----------

	+		500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017	Jul CDFR
--	---	--	----------------------	---------	-----	--------------	----------

SOLUTION; IV (INFUSION)

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

	+	BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017	Jan CAHN
--	---	----------------------	---------------------	---------	-----	--------------	----------

	+		500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017	Jan CAHN
--	---	--	----------------------	---------	-----	--------------	----------

BLEOMYCIN SULFATEINJECTABLE; INJECTION
BLEOMYCIN SULFATE

AP		HONG KONG	EQ 15 UNITS BASE/VIAL	A205030	001	Apr 20, 2018	Apr NEWA
----	--	-----------	-----------------------	---------	-----	--------------	----------

AP			EQ 30 UNITS BASE/VIAL	A205030	002	Apr 20, 2018	Apr NEWA
----	--	--	-----------------------	---------	-----	--------------	----------

BORTEZOMIBPOWDER; INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB

	+	HOSPIRA INC	2.5MG/VIAL	N209191	001	Jul 12, 2018	Jul NEWA
--	---	-------------	------------	---------	-----	--------------	----------

BRIGATINIBTABLET; ORAL
ALUNBRIG

+	ARIAD	90MG	N208772	002	Apr 28, 2017	Jun CHRS
+	!	180MG	N208772	003	Oct 02, 2017	Jun CHRS

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

@	AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jun DISC
@	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Jun DISC
@	PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jun DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDESYRUP; ORAL
BROMFED-DM

AA	!	WOCKHARDT BIO AG	2MG/5ML; 10MG/5ML; 30MG/5ML	A088811	001	Jun 07, 1985	Apr CAHN
----	---	------------------	-----------------------------	---------	-----	--------------	----------

BUDESONIDECAPSULE; ORAL
BUDESONIDE

AB		RISING PHARMS	3MG	A207367	001	Apr 07, 2017	Aug CAHN
----	--	---------------	-----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL
BUDESONIDE

AB		ACTAVIS LABS FL INC	9MG	A205457	001	Jul 03, 2018	Jun NEWA
----	--	---------------------	-----	---------	-----	--------------	----------

UCERIS

AB	+	!	VALEANT PHARMS INTL	9MG	N203634	001	Jan 14, 2013	Jun CFTG
----	---	---	---------------------	-----	---------	-----	--------------	----------

BUMETANIDEINJECTABLE; INJECTION
BUMETANIDE

AP	!	@	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Apr DISC
		!	WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Apr CHRS

TABLET; ORAL
BUMETANIDE

AB		UPSHER-SMITH LABS	0.5MG	A209916	001	Jan 23, 2018	Jan NEWA
AB			1MG	A209916	002	Jan 23, 2018	Jan NEWA
AB			2MG	A209916	003	Jan 23, 2018	Jan NEWA
AB		ZYDUS PHARMS USA INC	0.5MG	A202900	001	Apr 30, 2018	Apr NEWA
AB			1MG	A202900	002	Apr 30, 2018	Apr NEWA
AB			2MG	A202900	003	Apr 30, 2018	Apr NEWA

BUPIVACAINE HYDROCHLORIDEINJECTABLE; SPINAL
SENSORCAINE

@	FRESENIUS KABI USA	0.75%	A071202	001	Apr 15, 1987	Jun DISC
---	--------------------	-------	---------	-----	--------------	----------

BUPRENORPHINESOLUTION, EXTENDED RELEASE; SUBCUTANEOUS
SUBLOCADE

+	INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 30, 2017	Jul CMS1
+	!	300MG/1.5ML (200MG/ML)	N209819	002	Nov 30, 2017	Jul CMS1

BUPRENORPHINE HYDROCHLORIDEIMPLANT; IMPLANTATION
PROBUPHINE

+	!	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun CAHN
---	---	--------------	----------------------	---------	-----	--------------	----------

TABLET; SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

AB		CASI PHARMS INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	Mar CAHN
AB			EQ 8MG BASE	A090279	002	Jun 10, 2015	Mar CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		DR REDDYS LABS SA	EQ 2MG BASE; EQ 0.5MG BASE	A205299	001	Jun 14, 2018	May NEWA
AB			EQ 4MG BASE; EQ 1MG BASE	A205806	001	Jun 14, 2018	May NEWA
AB			EQ 8MG BASE; EQ 2MG BASE	A205299	002	Jun 14, 2018	May NEWA
AB			EQ 12MG BASE; EQ 3MG BASE	A205806	002	Jun 14, 2018	May NEWA
AB		MYLAN TECHNOLOGIES	EQ 8MG BASE; EQ 2MG BASE	A207607	001	Jun 14, 2018	May NEWA
AB			EQ 12MG BASE; EQ 3MG BASE	A207607	002	Jun 14, 2018	May NEWA

FILM;BUCCAL, SUBLINGUAL
SUBOXONE

AB	+	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	May CFTG
AB	+		EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	May CFTG
AB	+		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	May CFTG
AB	+	!	EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	May CFTG
>A>		FILM;SUBLINGUAL					
>A>		CASSIPA					
>A>	+	TEVA PHARMS USA	EQ 16MG BASE;EQ 4MG BASE	N208042	001	Sep 07, 2018	Sep NEWA

BUPROPION HYDROCHLORIDE

TABLET;ORAL
BUPROPION HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	75MG	A203013	001	Jun 08, 2018	May NEWA
AB			100MG	A203013	002	Jun 08, 2018	May NEWA

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB2		SCIENGEN PHARMS INC	150MG	A206122	001	Aug 17, 2016	Jan CAHN
AB3		YICHANG HUMANWELL	150MG	A210015	001	Jun 14, 2018	Jun NEWA
AB3			300MG	A210015	002	Jun 14, 2018	Jun NEWA
AB3		ZYDUS PHARMS USA INC	150MG	A201567	002	Jul 23, 2018	Jul NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CONTRAVE

+	!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014	Jul CAHN
---	---	------------	----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	5MG	A078246	001	Feb 27, 2009	Feb CAHN
AB			10MG	A078246	002	Feb 27, 2009	Feb CAHN
AB			15MG	A078246	003	Feb 27, 2009	Feb CAHN
AB			30MG	A078246	004	Feb 27, 2009	Feb CAHN
	@	FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002	Jan CAHN
	@		10MG	A075413	002	Mar 19, 2002	Jan CAHN
	@		15MG	A075413	003	Mar 19, 2002	Jan CAHN
AB		INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Apr NEWA
AB			7.5MG	A209696	002	May 03, 2018	Apr NEWA
AB			10MG	A209696	003	May 03, 2018	Apr NEWA
AB			15MG	A209696	004	May 03, 2018	Apr NEWA
AB			30MG	A209696	005	May 03, 2018	Apr NEWA

BUSULFAN

INJECTABLE;INJECTION
BUSULFAN

AP		HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Jul NEWA
AP		MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018	Jul NEWA
>D> AP		SANDOZ INC	6MG/ML	A205106	001	Jul 07, 2017	Sep CMS1
>A> AP			6MG/ML	A205106	001	Sep 21, 2018	Sep CMS1

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION
BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	!	HOSPIRA	1MG/ML	A074626	001	Jan 23, 1997	Mar CHRS
AP	!		2MG/ML	A074626	002	Jan 23, 1997	Mar CHRS
		STADOL					
+	@	APOTHECON	2MG/ML	N017857	004		Mar CRLD
		STADOL PRESERVATIVE FREE					
+	@	APOTHECON	1MG/ML	N017857	001		Mar CRLD
+	@		2MG/ML	N017857	002		Mar CRLD

CABAZITAXEL

SOLUTION;INTRAVENOUS
JEVTANA KIT

+	!	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010	Jul CDFR
---	---	-------------------	----------------------	---------	-----	--------------	----------

CABERGOLINE

TABLET; ORAL						
CABERGOLINE						
AB	@ APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013	Mar DISC
	INGENUS PHARMS LLC	0.5MG	A204735	001	Aug 01, 2018	Jul NEWA

CABOZANTINIB S-MALATE

CAPSULE; ORAL						
COMETRIQ						
+	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012	Jun CHRS
+		EQ 80MG BASE	N203756	002	Nov 29, 2012	Jun CHRS

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL						
MIGERGOT						
!	HZNP	100MG; 2MG	A086557	001	Oct 04, 1983	Aug CAHN

CALCIUM ACETATE

CAPSULE; ORAL						
CALCIUM ACETATE						
AB	LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016	Jun CAHN
TABLET; ORAL						
ELIPHOS						
	@ CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr DISC

CALCIUM CHLORIDE

INJECTABLE; INJECTION						
CALCIUM CHLORIDE 10%						
AP	INTL MEDICATION SYS	100MG/ML	A203477	001	May 09, 2018	Apr NEWA

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION						
BSS PLUS						
+	ALCON	0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N018469	001		Aug CTEC
METHOTREXATE SODIUM						
	@ AKORN	0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N020079	001	Feb 26, 1999	Aug DISC

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION						
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER						
+	@ BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jun DISC
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER						
+	@ BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jun DISC
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER						
+	@ BAXTER HLTHCARE CORP	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jun DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION						
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER						
	@ B BRAUN	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N020000	001	Apr 17, 1992	Aug DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION						
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
+	@ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685	005	Oct 17, 1988	Jan CRLD
+	@	20MG/100ML; 5GM/100ML; 179MG/100ML;	N019685	006	Oct 17, 1988	Jan CRLD

INJECTABLE; INJECTION									
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
600MG/100ML; 310MG/100ML									
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 6	N019685	007	Oct 17, 1988	Jan	CRLD		
00MG/100ML; 310MG/100ML									
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
AP +	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 179MG/100ML; 6	N019685	002	Oct 17, 1988	Jan	CRLD		
00MG/100ML; 310MG/100ML									
+ @		20MG/100ML; 5GM/100ML; 328MG/100ML; 6	N019685	008	Oct 17, 1988	Jan	DISC		
00MG/100ML; 310MG/100ML									
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 6	N019685	003	Oct 17, 1988	Jan	CRLD		
00MG/100ML; 310MG/100ML									
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 6	N019685	004	Oct 17, 1988	Jan	DISC		
00MG/100ML; 310MG/100ML									
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 6	N019685	001	Oct 17, 1988	Jan	CRLD		
00MG/100ML; 310MG/100ML									
<u>CALCIUM GLUCONATE</u>									
SOLUTION; INTRAVENOUS									
CALCIUM GLUCONATE									
+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	May	CDFR		
+!		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	May	CDFR		
+!		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	May	CDFR		
<u>CANDESARTAN CILEXETIL</u>									
TABLET; ORAL									
ATACAND									
AB +	ANI PHARMS INC	4MG	N020838	001	Jun 04, 1998	Jan	CAHN		
AB +		8MG	N020838	002	Jun 04, 1998	Jan	CAHN		
AB +		16MG	N020838	003	Jun 04, 1998	Jan	CAHN		
AB +!		32MG	N020838	004	Jun 04, 1998	Jan	CAHN		
CANDESARTAN CILEXETIL									
@	APOTEX INC	4MG	A202079	001	Jan 10, 2014	Mar	DISC		
@		8MG	A202079	002	Jan 10, 2014	Mar	DISC		
@		16MG	A202079	003	Jan 10, 2014	Mar	DISC		
@		32MG	A202079	004	Jan 10, 2014	Mar	DISC		
AB	MYLAN PHARMS INC	4MG	A078702	001	May 03, 2013	Apr	CAHN		
AB		8MG	A078702	002	May 03, 2013	Apr	CAHN		
AB		16MG	A078702	003	May 03, 2013	Apr	CAHN		
AB		32MG	A078702	004	May 03, 2013	Apr	CAHN		
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE</u>									
TABLET; ORAL									
ATACAND HCT									
AB +	ANI PHARMS INC	16MG; 12.5MG	N021093	001	Sep 05, 2000	Feb	CAHN		
AB +		32MG; 12.5MG	N021093	002	Sep 05, 2000	Feb	CAHN		
AB +!		32MG; 25MG	N021093	003	May 16, 2008	Feb	CAHN		
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE									
@	APOTEX INC	16MG; 12.5MG	A202884	001	Dec 04, 2012	Mar	DISC		
@		32MG; 12.5MG	A202884	002	Dec 04, 2012	Mar	DISC		
@		32MG; 25MG	A202884	003	Jun 03, 2013	Mar	DISC		
AB	PRINSTON INC	16MG; 12.5MG	A207455	001	Apr 11, 2018	Mar	NEWA		
AB		32MG; 12.5MG	A207455	002	Apr 11, 2018	Mar	NEWA		
AB		32MG; 25MG	A207455	003	Apr 11, 2018	Mar	NEWA		
<u>CANGRELOR</u>									
POWDER; INTRAVENOUS									
KENGREAL									
+!	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015	Jul	CDFR		
<u>CAPECITABINE</u>									
TABLET; ORAL									
CAPECITABINE									
AB	EUGIA PHARMA	150MG	A210604	001	Apr 17, 2018	Apr	NEWA		
AB		500MG	A210604	002	Apr 17, 2018	Apr	NEWA		
AB	MSN LABS PVT LTD	150MG	A209365	001	Jul 02, 2018	Jun	NEWA		
AB		500MG	A209365	002	Jul 02, 2018	Jun	NEWA		

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ OXFORD PHARMS	12.5MG	A074418	001	Feb 13, 1996	Jul CAHN
@	25MG	A074418	002	Feb 13, 1996	Jul CAHN
@	50MG	A074418	003	Feb 13, 1996	Jul CAHN
@	100MG	A074418	004	Feb 13, 1996	Jul CAHN
@ YAOPHARMA CO LTD	12.5MG	A074363	001	Nov 09, 1995	Jan CAHN
@	12.5MG	A074519	001	Feb 13, 1996	Jan CAHN
@	25MG	A074363	002	Nov 09, 1995	Jan CAHN
@	25MG	A074519	002	Feb 13, 1996	Jan CAHN
@	50MG	A074363	003	Nov 09, 1995	Jan CAHN
@	50MG	A074519	003	Feb 13, 1996	Jan CAHN
@	100MG	A074363	004	Nov 09, 1995	Jan CAHN
@	100MG	A074519	004	Feb 13, 1996	Jan CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

@ G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Jan DISC
@	25MG;25MG	A074827	002	Dec 29, 1997	Jan DISC
@	50MG;15MG	A074827	004	Dec 29, 1997	Jan DISC
@	50MG;25MG	A074827	003	Dec 29, 1997	Jan DISC
MYLAN	25MG;15MG	A074896	001	Dec 29, 1997	Jan CTEC
!	25MG;25MG	A074896	002	Dec 29, 1997	Jan CTEC
!	50MG;15MG	A074896	004	Dec 29, 1997	Jan CTEC
	50MG;25MG	A074896	003	Dec 29, 1997	Jan CTEC

CARBAMAZEPINE

SOLUTION; INTRAVENOUS

CARNEXIV

+ @ LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jul CDFR
SOLUTION; IV (INFUSION)					
CARNEXIV					
+ @ LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jun DISC

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB	ZYDUS PHARMS USA INC	25MG	A209910	001	May 07, 2018	Apr NEWA
----	----------------------	------	---------	-----	--------------	----------

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

@ CYPRESS PHARM	4MG/5ML	A090418	001	May 04, 2010	Apr DISC
-----------------	---------	---------	-----	--------------	----------

TABLET; ORAL

CARBINOXAMINE MALEATE

@ CYPRESS PHARM	4MG	A090417	001	Aug 23, 2010	Apr DISC
-----------------	-----	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Apr CAHN
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Apr CAHN
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Apr CAHN
	@ MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	May DISC

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+ ONYX THERAP	10MG/VIAL	N202714	003	Jun 07, 2018	Jun NEWA
---------------	-----------	---------	-----	--------------	----------

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

VRAYLAR

+ ALLERGAN SALES LLC	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan CAHN
+	EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan CAHN
+	EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan CAHN
+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan CAHN

CARISOPRODOLCAPSULE;ORAL
SOMA

+ @ MYLAN SPECIALITY LP 250MG

N011792 003

Aug CRLD

TABLET;ORAL

CARISOPRODOL

@ FOSUN PHARMA 350MG

A081025 001 Apr 13, 1989 Jan CAHN

>D> AA INGENUS PHARMS NJ 350MG

A040823 001 Oct 22, 2008 Sep CAHN

>A> AA NOVAST LABS 350MG

A040823 001 Oct 22, 2008 Sep CAHN

CARMUSTINEINJECTABLE;INJECTION
BICNU

AP +! EMCURE PHARMS LTD 100MG/VIAL

N017422 001

Aug CFTG

CARMUSTINE

AP NAVINTA LLC 100MG/VIAL

A210179 001 Sep 11, 2018 Aug NEWA

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB CHARTWELL MOLECULAR 3.125MG

A077474 001 Sep 05, 2007 Mar CAHN

AB 6.25MG

A077474 002 Sep 05, 2007 Mar CAHN

AB 12.5MG

A077474 003 Sep 05, 2007 Mar CAHN

AB 25MG

A077474 004 Sep 05, 2007 Mar CAHN

CARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE;ORAL
CARVEDILOL PHOSPHATE

AB IMPAX LABS INC 10MG

A204717 001 May 07, 2018 Apr NEWA

AB 20MG

A204717 002 May 07, 2018 Apr NEWA

AB 40MG

A204717 003 May 07, 2018 Apr NEWA

AB 80MG

A204717 004 May 07, 2018 Apr NEWA

CASPOFUNGIN ACETATEPOWDER;INTRAVENOUS
CANCIDAS

AP +! MERCK 50MG/VIAL

N021227 001 Jan 26, 2001 May CDFR

AP +! 70MG/VIAL

N021227 002 Jan 26, 2001 May CDFR

CASPOFUNGIN ACETATE

AP CIPLA LTD 50MG/VIAL

A209489 001 Jul 12, 2018 Jul NEWA

AP 70MG/VIAL

A209489 002 Jul 12, 2018 Jul NEWA

AP FRESENIUS KABI USA 50MG/VIAL

N206110 001 Dec 30, 2016 May CDFR

AP 70MG/VIAL

N206110 002 Dec 30, 2016 May CDFR

AP GLAND PHARMA LTD 50MG/VIAL

A207092 001 Sep 29, 2017 May CDFR

AP 70MG/VIAL

A207092 002 Sep 29, 2017 May CDFR

AP MYLAN LABS LTD 50MG/VIAL

A207650 001 Sep 29, 2017 May CDFR

AP 70MG/VIAL

A207650 002 Sep 29, 2017 May CDFR

AP SANDOZ INC 50MG/VIAL

A200833 001 Jun 28, 2018 Jun NEWA

AP 70MG/VIAL

A200833 002 Jun 28, 2018 Jun NEWA

AP XELLIA PHARMS APS 50MG/VIAL

A205923 001 Jul 02, 2018 Jun NEWA

AP 70MG/VIAL

A205923 002 Jul 02, 2018 Jun NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATECAPSULE;ORAL
CEFADROXIL

@ CSPC OUYI PHARM CO EQ 500MG BASE

A205072 001 Jul 28, 2017 Jun DISC

CEFAZOLIN SODIUMINJECTABLE;INJECTION
ANCEF IN PLASTIC CONTAINER

@ BAXTER HLTHCARE EQ 10MG BASE/ML

A063002 001 Mar 28, 1991 Jun DISC

CEFEPIME HYDROCHLORIDEINJECTABLE;INJECTION
CEFEPIME HYDROCHLORIDE

@ FOSUN PHARMA EQ 500MG BASE/VIAL

A090291 001 Dec 21, 2010 Jan CAHN

@ EQ 1GM BASE/VIAL

A090291 002 Dec 21, 2010 Jan CAHN

@ EQ 2GM BASE/VIAL

A090291 003 Dec 21, 2010 Jan CAHN

POWDER;INTRAVENOUS
 CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
 SAMSON MEDCL EQ 100GM BASE

A209408 001 Aug 21, 2018 Aug NEWA

CEFIXIME

CAPSULE;ORAL

>A> CEFIXIME

>A> AB ALKEM LABS LTD 400MG
 SUPRAX

A210574 001 Oct 09, 2018 Sep NEWA

>D> +! LUPIN LTD 400MG

N203195 001 Jun 01, 2012 Sep CFTG

>A> AB +! 400MG

N203195 001 Jun 01, 2012 Sep CFTG

CEFOTAXIME SODIUM

INJECTABLE;INJECTION
 CEFOTAXIME

AP ! HIKMA EQ 500MG BASE/VIAL

A065072 001 Nov 20, 2002 Apr CHRS

AP ! EQ 1GM BASE/VIAL

A065072 002 Nov 20, 2002 Apr CHRS

AP ! EQ 2GM BASE/VIAL

A065072 003 Nov 20, 2002 Apr CHRS

AP ! EQ 10GM BASE/VIAL

A065071 001 Nov 20, 2002 Apr CHRS

CLAFORAN

+ @ US PHARM HOLDINGS EQ 500MG BASE/VIAL

N050547 001 Apr DISC

+ @ EQ 1GM BASE/VIAL

N050547 002 Apr DISC

+ @ EQ 2GM BASE/VIAL

N050547 003 Apr DISC

+ @ EQ 10GM BASE/VIAL

N050547 004 Dec 29, 1983 Apr DISC

CEFOXITIN SODIUM

POWDER;INTRAVENOUS
 CEFOXITIN IN PLASTIC CONTAINER
 SAMSON MEDCL EQ 100GM BASE

A200938 001 Nov 16, 2015 Jul CDFR

CEFPROZIL

TABLET;ORAL
 CEFPROZIL

AB CASI PHARMS INC 250MG

A065235 001 Nov 14, 2005 Mar CAHN

AB 500MG

A065235 002 Nov 14, 2005 Mar CAHN

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS
 TEFLARO

+ ALLERGAN SALES LLC 400MG/VIAL

N200327 001 Oct 29, 2010 Jul CDFR

+! 600MG/VIAL

N200327 002 Oct 29, 2010 Jul CDFR

POWDER;IV (INFUSION)
 TEFLARO

+ ALLERGAN SALES LLC 400MG/VIAL

N200327 001 Oct 29, 2010 Jan CAHN

+! 600MG/VIAL

N200327 002 Oct 29, 2010 Jan CAHN

CEFTAZIDIME

INJECTABLE;INJECTION
 CEFTAZIDIME

@ ACS DOBFAR 500MG/VIAL

A062640 001 Nov 20, 1985 Jun DISC

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION
 FORTAZ IN PLASTIC CONTAINER

+ @ TELIGENT EQ 20MG BASE/ML

N050634 002 Apr 28, 1989 May DISC

+ @ EQ 40MG BASE/ML

N050634 003 Apr 28, 1989 May DISC

CEFTIBUTEN DIHYDRATE

CAPSULE;ORAL
 CEDAX

@ SI PHARMS EQ 400MG BASE

N050685 002 Dec 20, 1995 Jan CAHN

FOR SUSPENSION;ORAL
 CEDAX

+ @ SI PHARMS EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995 Jan CAHN

+ @ EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995 Jan CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUMPOWDER; INTRAVENOUS
ZERBAXA

+!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Jul CDFR
----	-------------------	--------------------------------------	---------	-----	--------------	----------

CEFTRIAXONE SODIUMINJECTABLE; INTRAMUSCULAR, INTRAVENOUS
CEFTRIAXONE

AP	SAGENT PHARMS	EQ 250MG BASE/VIAL	A091049	001	Jun 11, 2018	May NEWA
AP		EQ 500MG BASE/VIAL	A091049	002	Jun 11, 2018	May NEWA
AP		EQ 1GM BASE/VIAL	A091049	003	Jun 11, 2018	May NEWA
AP		EQ 2GM BASE/VIAL	A091049	004	Jun 11, 2018	May NEWA

CEFUROXIME AXETILFOR SUSPENSION; ORAL
CEFTIN

+	@ GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Jul DISC
+	@	EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Jul DISC

TABLET; ORAL
CEFTIN

+	@ GLAXOSMITHKLINE	EQ 125MG BASE	N050605	001	Dec 28, 1987	May DISC
+	@	EQ 250MG BASE	N050605	002	Dec 28, 1987	May DISC
+	@	EQ 500MG BASE	N050605	003	Dec 28, 1987	May DISC

CEFUROXIME AXETIL

	@ FOSUN PHARMA	EQ 250MG BASE	A065126	001	Oct 28, 2003	Jan CAHN
	@	EQ 500MG BASE	A065126	002	Oct 28, 2003	Jan CAHN
AB	! LUPIN	EQ 500MG BASE	A065135	002	Jul 25, 2003	May CHRS

CEFUROXIME SODIUMINJECTABLE; INJECTION
ZINACEF IN PLASTIC CONTAINER

+	@ TELIGENT	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May DISC
---	------------	-----------------	---------	-----	--------------	----------

CELECOXIBCAPSULE; ORAL
CELECOXIB

AB	AMNEAL PHARMS	50MG	A208833	001	May 31, 2018	May NEWA
AB		100MG	A208833	002	May 31, 2018	May NEWA
AB		200MG	A208833	003	May 31, 2018	May NEWA
AB		400MG	A208833	004	May 31, 2018	May NEWA
AB	CSPC OUYI PHARM CO	50MG	A210071	001	Jan 23, 2018	Jan NEWA
AB		100MG	A210071	002	Jan 23, 2018	Jan NEWA
AB		200MG	A210071	003	Jan 23, 2018	Jan NEWA
AB	MICRO LABS	50MG	A204776	001	Apr 30, 2018	Apr NEWA
AB		100MG	A204776	002	Apr 30, 2018	Apr NEWA
AB		200MG	A204776	003	Apr 30, 2018	Apr NEWA
AB		400MG	A204776	004	Apr 30, 2018	Apr NEWA

CETIRIZINE HYDROCHLORIDESYRUP; ORAL
CETIRIZINE HYDROCHLORIDE

>D>	AA	ALLIED	5MG/5ML	A090191	001	Nov 12, 2009	Sep CAHN
>A>	AA	ANDA REPOSITORY	5MG/5ML	A090191	001	Nov 12, 2009	Sep CAHN
	AA	LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	May CAHN
>A>	AA	SAPTALIS PHARMS	5MG/5ML	A090191	001	Nov 12, 2009	Sep CAHN

CEVIMELINE HYDROCHLORIDECAPSULE; ORAL
CEVIMELINE HYDROCHLORIDE
@ APOTEX INC

30MG

A091260	001	Aug 25, 2011	Mar DISC
---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATESOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

>D>	@ APOTEX INC	0.12%	A075561	001	Nov 14, 2000	Sep CAHN
>A>	@ BAJAJ	0.12%	A075561	001	Nov 14, 2000	Sep CAHN

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL
TUXARIN ER

@ SPRIASO LLC 8MG; 54.3MG N206323 001 Jun 22, 2015 Jul CTNA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> AA MAYNE PHARMA INC 4MG/5ML; 5MG/5ML; 60MG/5ML A205657 001 Aug 03, 2015 Sep CMS1

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D> AA MAYNE PHARMA INC 4MG/5ML; 5MG/5ML; 60MG/5ML A205657 001 Aug 03, 2015 Sep CMS1

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

@ LANNETT CO INC EQ 4MG MALEATE/5ML; EQ 20MG N021369 001 Jun 21, 2004 Aug CAHN
BASE/5ML

>D> TUZISTRA XR

>D> +! TRIS PHARMA INC EQ 2.8MG BASE/5ML; EQ 14.7MG N207768 001 Apr 30, 2015 Sep DISC
BASE/5ML

>A> + @ EQ 2.8MG BASE/5ML; EQ 14.7MG N207768 001 Apr 30, 2015 Sep DISC
BASE/5ML

+! EQ 2.8MG BASE/5ML; EQ 14.7MG N207768 001 Apr 30, 2015 Jul CMFD
BASE/5ML

+ @ EQ 2.8MG BASE/5ML; EQ 14.7MG N207768 001 Apr 30, 2015 Jun DISC
BASE/5ML

+! EQ 2.8MG BASE/5ML; EQ 14.7MG N207768 001 Apr 30, 2015 Jun CAHN
BASE/5ML

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB ! NEOS THERAP INC EQ 8MG MALEATE/5ML; EQ 10MG A091671 001 Jun 29, 2012 Apr CHRS
BITARTRATE/5ML

TUSSIONEX PENNKINETIC

+ @ UCB INC EQ 8MG MALEATE/5ML; EQ 10MG N019111 001 Dec 31, 1987 Apr DISC
BITARTRATE/5ML

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SONAZINE

@ FOSUN PHARMA 30MG/ML A080983 004 Jan CAHN

@ 100MG/ML A080983 005 Jan CAHN

SYRUP; ORAL

SONAZINE

@ FOSUN PHARMA 10MG/5ML A083040 001 Jan CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB AMNEAL PHARMS CO 10MG A209755 001 Sep 10, 2018 Aug NEWA

AB 25MG A209755 002 Sep 10, 2018 Aug NEWA

AB 50MG A209755 003 Sep 10, 2018 Aug NEWA

AB 100MG A209755 004 Sep 10, 2018 Aug NEWA

AB 200MG A209755 005 Sep 10, 2018 Aug NEWA

AB USL PHARMA 10MG A083386 001 Aug CTEC

AB ! 25MG A084112 001 Aug CTEC

AB 50MG A084113 001 Aug CTEC

AB ! 100MG A084114 001 Aug CTEC

AB 200MG A084115 001 Aug CTEC

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ ANI PHARMS INC 100MG A088921 001 Apr 12, 1985 Jul DISC

@ 250MG A088922 001 Apr 12, 1985 Jul DISC

MYLAN 100MG A088549 002 Jun 01, 1984 Jul CTEC

! 250MG A088549 001 Jun 01, 1984 Jul CTEC

AB ! 250MG A088549 001 Jun 01, 1984 Jul CHRS

DIABINESE

+ @ PFIZER 100MG N011641 003 Jul DISC

+ @ 250MG N011641 006 Jul DISC

GLUCAMIDE

@ ANI PHARMS INC 250MG A088641 001 Oct 11, 1984 Jul DISC

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	UMEDICA LABS PVT LTD	25MG	A207222	001	May 24, 2018	May NEWA
AB		50MG	A207222	002	May 24, 2018	May NEWA
	THALITONE					
	+ @ CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Apr CRLD

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLORPRES

@ MYLAN

@

@

15MG; 0.1MG

15MG; 0.2MG

15MG; 0.3MG

A071325	003	Feb 09, 1987	Mar DISC
A071325	002	Feb 09, 1987	Mar DISC
A071325	001	Feb 09, 1987	Mar DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	ANI PHARMS INC	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996	Jun CMFD
AB		EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996	Jun CMFD
AB	ZYDUS PHARMS USA INC	EQ 4GM RESIN/SCOOPFUL	A202901	001	Jul 02, 2018	Jun NEWA

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT	TELIGENT PHARMA INC	1%	A209975	001	Apr 05, 2018	Mar NEWA
	SOLUTION; TOPICAL					
	CICLOPIROX					
AT	INGENUS PHARMS LLC	8%	A078124	001	Sep 18, 2007	Jan CAHN

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

! ACS DOBFAR

@ HOSPIRA INC

PRIMAXIN

+ @ MERCK

EQ 250MG BASE/VIAL; 250MG/VIAL

EQ 250MG BASE/VIAL; 250MG/VIAL

EQ 250MG BASE/VIAL; 250MG/VIAL

A090577	001	Dec 21, 2011	Apr CHRS
A090825	001	Nov 16, 2011	Apr DISC
N050587	001	Nov 26, 1985	Apr DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB	CASI PHARMS INC	50MG	A077310	001	Nov 08, 2005	Mar CAHN
AB		100MG	A077021	001	Nov 23, 2004	Mar CAHN
AB	FRONTIDA BIOPHARM	50MG	A077208	002	Mar 29, 2006	Aug CMFD
AB		100MG	A077208	001	Mar 29, 2006	Aug CMFD

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ CHARTWELL MOLECULES

@

@

@ YAOPHARMA CO LTD

@

@

@

200MG

300MG

400MG

200MG

300MG

400MG

800MG

A074329	002	May 17, 1994	Jan CMS1
A074329	003	May 17, 1994	Jan CMS1
A074329	004	May 17, 1994	Jan CMS1
A074100	001	Jan 31, 1995	Jan CAHN
A074100	002	Jan 31, 1995	Jan CAHN
A074100	003	Jan 31, 1995	Jan CAHN
A074100	004	Jan 31, 1995	Jan CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ LANNETT CO INC

EQ 300MG BASE/5ML

A074251	001	Dec 22, 1994	May CAHN
---------	-----	--------------	----------

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 30MG BASE	A206125	001	Mar 08, 2018	Feb NEWA
AB		EQ 60MG BASE	A206125	002	Mar 08, 2018	Feb NEWA
AB		EQ 90MG BASE	A206125	003	Mar 08, 2018	Feb NEWA
AB	CIPLA LTD	EQ 30MG BASE	A208915	001	Mar 08, 2018	Feb NEWA
AB		EQ 60MG BASE	A208915	002	Mar 08, 2018	Feb NEWA
AB		EQ 90MG BASE	A208915	003	Mar 08, 2018	Feb NEWA

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB		PIRAMAL HLTHCARE UK	EQ 30MG BASE	A210207	001	Aug 01, 2018	Jul NEWA
AB			EQ 60MG BASE	A210207	002	Aug 01, 2018	Jul NEWA
AB			EQ 90MG BASE	A210207	003	Aug 01, 2018	Jul NEWA
AB		STRIDES PHARMA	EQ 30MG BASE	A209226	001	Apr 30, 2018	Apr NEWA
AB			EQ 60MG BASE	A209226	002	Apr 30, 2018	Apr NEWA
AB			EQ 90MG BASE	A209226	003	Apr 30, 2018	Apr NEWA
AB		ZYDUS PHARMS USA INC	EQ 30MG BASE	A208971	001	Apr 23, 2018	Apr NEWA
AB			EQ 60MG BASE	A208971	002	Apr 23, 2018	Apr NEWA
AB			EQ 90MG BASE	A208971	003	Apr 23, 2018	Apr NEWA
		SENSIPAR					
AB	+	AMGEN	EQ 30MG BASE	N021688	001	Mar 08, 2004	Feb CFTG
AB	+		EQ 60MG BASE	N021688	002	Mar 08, 2004	Feb CFTG
AB	+		EQ 90MG BASE	N021688	003	Mar 08, 2004	Feb CFTG

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		INFORLIFE	200MG/100ML	A078252	001	Mar 18, 2008	Jan CAHN
AP			400MG/200ML	A078252	002	Mar 18, 2008	Jan CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AT		ALTAIRE PHARMS INC	EQ 0.3% BASE	A204613	001	May 03, 2018	Apr NEWA
>A>	AT	ANDA REPOSITORY	EQ 0.3% BASE	A077689	001	Dec 13, 2006	Sep CAHN
>D>	AT	RISING PHARMS	EQ 0.3% BASE	A077689	001	Dec 13, 2006	Sep CAHN

TABLET;ORAL

CIPRO

+	@	BAYER HLTHCARE	EQ 100MG BASE	N019537	001	Apr 08, 1996	Mar DISC
+	@		EQ 750MG BASE	N019537	004	Oct 22, 1987	Mar DISC
		CIPROFLOXACIN HYDROCHLORIDE					
	@	FOSUN PHARMA	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan CAHN
	@		EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan CAHN
	@		EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan CAHN
	@	MYLAN	EQ 100MG BASE	A075817	001	Jun 25, 2007	Jun DISC
	@		EQ 250MG BASE	A075817	002	Jun 09, 2004	Jun DISC
	@		EQ 750MG BASE	A075817	004	Jun 09, 2004	Jun DISC
AB		YILING PHARM LTD	EQ 250MG BASE	A208921	001	Jun 22, 2018	Jun NEWA
AB			EQ 500MG BASE	A208921	002	Jun 22, 2018	Jun NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

	@	FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007	Jan CAHN
--	---	--------------	-------------------------	---------	-----	--------------	----------

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		HOSPIRA INC	EQ 2MG BASE/ML	A203236	001	Mar 30, 2018	Mar NEWA
AP			EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Mar NEWA
AP			EQ 10MG BASE/ML	A203236	002	Mar 30, 2018	Mar NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+	ALLERGAN SALES LLC	EQ 10MG BASE	N020822	001	Apr 27, 2000	Jan CAHN
AB	+		EQ 20MG BASE	N020822	002	Jul 17, 1998	Jan CAHN
AB	+		EQ 40MG BASE	N020822	003	Jul 17, 1998	Jan CAHN
	@		EQ 60MG BASE	N020822	004	Jul 17, 1998	Jan CAHN

CITALOPRAM HYDROBROMIDE

AB		CHARTWELL MOLECULAR	EQ 10MG BASE	A077044	001	Nov 05, 2004	Mar CAHN
AB			EQ 20MG BASE	A077044	002	Nov 05, 2004	Mar CAHN
AB			EQ 40MG BASE	A077044	003	Nov 05, 2004	Mar CAHN
	@	FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004	Jan CAHN
	@		EQ 10MG BASE	A077040	001	Aug 17, 2005	Jan CAHN
	@		EQ 20MG BASE	A077035	002	Oct 28, 2004	Jan CAHN
	@		EQ 20MG BASE	A077040	002	Aug 17, 2005	Jan CAHN
	@		EQ 40MG BASE	A077035	003	Oct 28, 2004	Jan CAHN
	@		EQ 40MG BASE	A077040	003	Aug 17, 2005	Jan CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

SOLUTION; ORAL

CLENPIQ

+!	FERRING PHARMS INC	12GM/BOT;3.5GM/BOT;10MG/BOT	N209589	001	Nov 28, 2017	Apr	CPOT
----	--------------------	-----------------------------	---------	-----	--------------	-----	------

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

+	@ ABBVIE	125MG/5ML	N050698	001	Dec 23, 1993	Apr	DISC
---	----------	-----------	---------	-----	--------------	-----	------

+	@	250MG/5ML	N050698	002	Dec 23, 1993	Apr	DISC
---	---	-----------	---------	-----	--------------	-----	------

CLARITHROMYCIN

AB	!	SANDOZ	250MG/5ML	A065283	003	Sep 04, 2007	Apr	CHRS
----	---	--------	-----------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB		SUNSHINE LAKE	500MG	A208987	001	Jul 09, 2018	Jun	NEWA
----	--	---------------	-------	---------	-----	--------------	-----	------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

!	TEVA	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	May	CTEC
---	------	-------------------	---------	-----	--------------	-----	------

AA	@	WOCKHARDT BIO AG	EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998	May	DISC
----	---	------------------	-------------------	---------	-----	--------------	-----	------

AA			EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998	May	CAHN
----	--	--	-------------------	---------	-----	--------------	-----	------

TABLET; ORAL

TAVIST

+	@	NOVARTIS	2.68MG	N017661	001		May	CRLD
---	---	----------	--------	---------	-----	--	-----	------

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+	@	CHIESI USA INC	125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013	Jun	DISC
---	---	----------------	------------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>D>	AA	APPCO PHARMA LLC	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	Sep	CAHN
-----	----	------------------	------------------	---------	-----	--------------	-----	------

AA			EQ 75MG BASE/5ML	A207047	001	May 11, 2018	Apr	NEWA
----	--	--	------------------	---------	-----	--------------	-----	------

>A>	AA	HERITAGE PHARMS INC	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	Sep	CAHN
-----	----	---------------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

@	ABBOTT LABS	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001	Mar	CAHN
---	-------------	----------------	---------	-----	--------------	-----	------

@		EQ 12MG BASE/ML	A065027	002	Jun 29, 2001	Mar	CAHN
---	--	-----------------	---------	-----	--------------	-----	------

@		EQ 18MG BASE/ML	A065027	003	Jun 29, 2001	Mar	CAHN
---	--	-----------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT		GLASSHOUSE PHARMS	EQ 1% BASE	A209846	001	Feb 08, 2018	Jan	NEWA
----	--	-------------------	------------	---------	-----	--------------	-----	------

@	WOCKHARDT BIO AG	EQ 1% BASE	A063304	001	Jul 15, 1997	May	DISC
---	------------------	------------	---------	-----	--------------	-----	------

AT			EQ 1% BASE	A063304	001	Jul 15, 1997	May	CAHN
----	--	--	------------	---------	-----	--------------	-----	------

AT		ZYDUS PHARMS USA INC	EQ 1% BASE	A208767	001	Jul 16, 2018	Jul	NEWA
----	--	----------------------	------------	---------	-----	--------------	-----	------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

>A>	AB1	TARO PHARM	0.05%	A208779	001	Oct 04, 2018	Sep	NEWA
-----	-----	------------	-------	---------	-----	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1		CHEMO RESEARCH SL	0.05%	A210034	001	Jun 15, 2018	Jun	NEWA
-----	--	-------------------	-------	---------	-----	--------------	-----	------

AB1		GLENMARK PHARMS	0.05%	A209095	001	May 10, 2018	Apr	NEWA
-----	--	-----------------	-------	---------	-----	--------------	-----	------

AB1		LUPIN LTD	0.05%	A210208	001	Jan 30, 2018	Jan	NEWA
-----	--	-----------	-------	---------	-----	--------------	-----	------

AB1		TELIGENT PHARMA INC	0.05%	A209974	001	Apr 17, 2018	Apr	NEWA
-----	--	---------------------	-------	---------	-----	--------------	-----	------

IMPOYZ

+	!	ENCORE DERMAT	0.025%	N209483	001	Nov 28, 2017	Jan	CAHN
---	---	---------------	--------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB		AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018	Aug	NEWA
----	--	-------------------	-------	---------	-----	--------------	-----	------

AB		CHEMO RESEARCH SL	0.05%	A209701	001	Apr 17, 2018	Apr	NEWA
----	--	-------------------	-------	---------	-----	--------------	-----	------

AB		NOVEL LABS INC	0.05%	A208841	001	May 04, 2018	Apr	NEWA
----	--	----------------	-------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE						
AT	GLENMARK PHARMS LTD	0.05%	A210190	001	Apr 18, 2018	Apr NEWA
SPRAY; TOPICAL						
CLOBETASOL PROPIONATE						
AT	GLENMARK PHARMS	0.05%	A209004	001	Mar 26, 2018	Mar NEWA
AT	LUPIN LTD	0.05%	A208125	001	Mar 26, 2018	Mar NEWA
AT	TARO	0.05%	A208842	001	Mar 26, 2018	Mar NEWA

CLOFARABINE

SOLUTION; INTRAVENOUS

CLOFARABINE

AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	May CDFR
AP	AMNEAL PHARMS CO	20MG/20ML (1MG/ML)	A208857	001	Nov 06, 2017	May CDFR
AP	DR REDDYS LABS LTD	20MG/20ML (1MG/ML)	A205375	001	Nov 06, 2017	May CDFR
>A>	INGENUS PHARMS LLC	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Sep NEWA
AP	MSN LABS PVT LTD	20MG/20ML (1MG/ML)	A209775	001	Dec 06, 2017	May CDFR
AP	MYLAN LABS LTD	20MG/20ML (1MG/ML)	A208860	001	Nov 06, 2017	May CDFR
CLOLAR						
AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	May CDFR

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMID

+ @ SANOFI AVENTIS US		50MG	N016131	002		Jul DISC
CLOMIPHENE CITRATE						
! PAR PHARM		50MG	A075528	001	Aug 30, 1999	Jul CHRS
		50MG	A075528	001	Aug 30, 1999	Jul CTEC

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	X-GEN PHARMS INC	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	May CAHN
AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	May CAHN

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC

@

@ CHARTWELL MOLECULES

@

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

AB1	JUBILANT GENERICS	0.1MG	A210338	001	Jan 29, 2018	Jan NEWA
AB1	MAYNE PHARMA INC	0.1MG	A210680	001	Apr 30, 2018	Apr NEWA

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	PRINSTON INC	EQ 75MG BASE	A206376	001	May 07, 2018	Apr NEWA
AB		EQ 300MG BASE	A206376	002	May 07, 2018	Apr NEWA

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

AUROLIFE PHARMA LLC

@

7.5MG

@

7.5MG

>D>			A072112	002	Aug 11, 2017	Sep DISC
>D>			A072112	002	Aug 11, 2017	Sep DISC
>D>			A072112	003	Aug 11, 2017	Sep DISC
>A>			A072112	003	Aug 11, 2017	Sep DISC

CLOZAPINE

TABLET; ORAL

CLOZAPINE

IVAX SUB TEVA PHARMS

@ MYLAN

TABLET, ORALLY DISINTEGRATING; ORAL

CLOZAPINE

BARR LABS INC

FAZACLO ODT

+ JAZZ PHARMS III

		12.5MG	A074949	003	Jul 31, 2003	Jul CTEC
		12.5MG	A075417	003	Apr 15, 2010	Jul DISC
AB		12.5MG	A090308	003	Apr 09, 2018	Mar NEWA
AB		12.5MG	N021590	004	May 30, 2007	Mar CTEC

COBICISTAT; DARUNAVIR ETHANOLATE; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

SYMITUZA

+	!	JANSSEN PRODS	150MG;EQ 800MG BASE;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018	Jul NEWA
---	---	---------------	---	---------	-----	--------------	----------

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

>D>	AB	INGENUS PHARMS NJ	0.5MG;500MG	A040618	001	May 13, 2008	Sep CAHN
>A>	AB	NOVAST LABS	0.5MG;500MG	A040618	001	May 13, 2008	Sep CAHN

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

COLESEVELAM HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Jul NEWA
AB		3.75GM/PACKET	A202190	002	Jul 16, 2018	Jul NEWA

WELCHOL

AB	+	DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009	Jul CFTG
AB	+	!	3.75GM/PACKET	N022362	002	Oct 02, 2009	Jul CFTG

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

>A>	AB	ALKEM LABS LTD	625MG	A209038	001	Oct 05, 2018	Sep NEWA
>A>	AB	DR REDDYS LABS LTD	625MG	A210889	001	Oct 05, 2018	Sep NEWA
	AB	GLENMARK PHARMS LTD	625MG	A203480	001	May 18, 2018	May NEWA
	AB	IMPAX LABS INC	625MG	A091600	001	May 16, 2018	Apr NEWA

WELCHOL

AB	+	!	DAIICHI SANKYO	625MG	N021176	001	May 26, 2000	Apr CFTG
----	---	---	----------------	-------	---------	-----	--------------	----------

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	NEXUS PHARMS	EQ 150MG BASE/VIAL	A065177	001	Mar 19, 2004	Jun CAHN
----	--------------	--------------------	---------	-----	--------------	----------

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

VAPRISOL

@ CUMBERLAND PHARMS 20MG/4ML (5MG/ML)

N021697	001	Dec 29, 2005	Aug CDFR
---------	-----	--------------	----------

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+	!	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Aug CDFR
---	---	-------------------	-----------------------	---------	-----	--------------	----------

COPANLISIB DIHYDROCHLORIDE

POWDER; INTRAVENOUS

ALIQOPA

+	!	BAYER HEALTHCARE	60MG/VIAL	N209936	001	Sep 14, 2017	Jul CDFR
---	---	------------------	-----------	---------	-----	--------------	----------

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

MYTESI

+	!	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012	Mar CTNA
---	---	-----------------	-------	---------	-----	--------------	----------

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

@ FERA PHARMS LLC 10MG/ML

A075437	001	Apr 21, 2000	Mar CAHN
---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

AT	SANDOZ INC	4%	A075282	001	Jun 16, 1999	Jan CAHN
----	------------	----	---------	-----	--------------	----------

CROTAMITON

CREAM; TOPICAL

EURAX

+	!	SUN PHARM INDS INC	10%	N006927	001		Feb CAHN
---	---	--------------------	-----	---------	-----	--	----------

LOTION; TOPICAL

EURAX

AT	+	!	SUN PHARM INDS INC	10%	N009112	003	Feb CAHN
----	---	---	--------------------	-----	---------	-----	----------

CYCLOBENZAPRINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
AMRIX

AB	+	TEVA PHARMS INTL	15MG	N021777	001	Feb 01, 2007	Jul CFTG
AB	+	!	30MG	N021777	002	Feb 01, 2007	Jul CFTG
CYCLOBENZAPRINE HYDROCHLORIDE							
AB		APOTEX INC	15MG	A206703	001	Jul 24, 2018	Jul NEWA
AB			30MG	A206703	002	Jul 24, 2018	Jul NEWA

CYCLOPENTOLATE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
CYCLOGYL

AT	!	ALCON LABS INC	0.5%	A084109	001		Feb CAHN
AT	!		1%	A084110	001		Feb CAHN
	!		2%	A084108	001		Feb CAHN

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
CYCLOMYDRIL

!	ALCON LABS INC	0.2%;1%	A084300	001		Feb CAHN
---	----------------	---------	---------	-----	--	----------

CYCLOPHOSPHAMIDECAPSULE;ORAL
CYCLOPHOSPHAMIDE

AB		AMERIGEN PHARMS LTD	25MG	A207014	001	Mar 19, 2018	Mar NEWA
AB			50MG	A207014	002	Mar 19, 2018	Mar NEWA
AB		STI PHARMA LLC	25MG	A209872	001	May 07, 2018	Apr NEWA
AB			50MG	A209872	002	May 07, 2018	Apr NEWA
AB	+	WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Mar CFTG
AB	+	!	50MG	N203856	002	Sep 16, 2013	Mar CFTG

INJECTABLE;INJECTION
CYCLOPHOSPHAMIDE

AP		AMNEAL PHARMS CO	500MG/VIAL	A210046	001	May 25, 2018	May NEWA
AP			1GM/VIAL	A210046	002	May 25, 2018	May NEWA
AP			2GM/VIAL	A210046	003	May 25, 2018	May NEWA

CYCLOSPORINECAPSULE;ORAL
CYCLOSPORINE

		IVAX SUB TEVA PHARMS	50MG	A065110	001	Mar 29, 2005	May CTEC
--	--	----------------------	------	---------	-----	--------------	----------

GENGRAF

@	ABBVIE	50MG	A065003	002	May 12, 2000	May DISC
---	--------	------	---------	-----	--------------	----------

SOLUTION;OPHTHALMIC
CEQUA

+	!	SUN PHARMA GLOBAL	0.09%	N210913	001	Aug 14, 2018	Aug NEWA
---	---	-------------------	-------	---------	-----	--------------	----------

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Apr CAHN
>D>	AA	APPCO PHARMA LLC	4MG	A206553	001	Nov 29, 2016	Sep CAHN
	@	FOSUN PHARMA	4MG	A086808	001		Jan CAHN
>D>	AA	INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015	Sep CAHN
	AA	MOUNTAIN	4MG	A040537	001	Sep 30, 2003	Jan CAHN
>A>	AA	NOVAST LABS	4MG	A205087	001	Sep 23, 2015	Sep CAHN
	AA	STRIDES PHARMA	4MG	A209172	001	Apr 11, 2018	Mar NEWA
>A>	AA	TWI PHARMS	4MG	A206553	001	Nov 29, 2016	Sep CAHN

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

AP		HONG KONG	100MG/ML	A205696	001	Jul 17, 2018	Jul NEWA
AP		MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011	Jan CAHN

INJECTABLE, LIPOSOMAL;INJECTION
DEPOCYT

+	@	PACIRA PHARMS INC	10MG/ML	N021041	001	Apr 01, 1999	Aug DISC
---	---	-------------------	---------	---------	-----	--------------	----------

CYTARABINE; DAUNORUBICINPOWDER; INTRAVENOUS
VYXEOS

+	CELATOR PHARMS	100MG; 44MG	N209401	001	Aug 03, 2017	Jul	CDFR
---	----------------	-------------	---------	-----	--------------	-----	------

DACIATASVIR DIHYDROCHLORIDETABLET; ORAL
DAKLINZA

+	BRISTOL-MYERS SQUIBB	EQ 60MG BASE	N206843	002	Jul 24, 2015	Jun	CHRS
+		EQ 90MG BASE	N206843	003	Apr 13, 2016	Jun	CHRS

>A> DACOMITINIB>A> TABLET; ORAL
>A> VIZIMPRO

>A>	+	PFIZER INC	15MG	N211288	001	Sep 27, 2018	Sep	NEWA
>A>	+		30MG	N211288	002	Sep 27, 2018	Sep	NEWA
>A>	+		45MG	N211288	003	Sep 27, 2018	Sep	NEWA

DALBAVANCIN HYDROCHLORIDEPOWDER; INTRAVENOUS
DALVANCE

+	ALLERGAN SALES LLC	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jul	CDFR
---	--------------------	--------------------	---------	-----	--------------	-----	------

DALFAMPRIDINETABLET, EXTENDED RELEASE; ORAL
DALFAMPRIDINE

AB		ACCORD HLTHCARE	10MG	A206863	001	Jul 11, 2018	Jun	NEWA
AB		ALKEM LABS LTD	10MG	A206765	001	Jul 30, 2018	Jul	NEWA

DALFOPRISTIN; QUINUPRISTININJECTABLE; INTRAVENOUS
SYNERCID

+	KING PHARMS	350MG/VIAL; 150MG/VIAL	N050748	001	Sep 21, 1999	Aug	CDFR
@		420MG/VIAL; 180MG/VIAL	N050748	002	Aug 24, 2000	Aug	CDFR

DAPAGLIFLOZINTABLET; ORAL
FARXIGA

+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Mar	CAIN
+		10MG	N202293	002	Jan 08, 2014	Mar	CAIN

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
XIGDUO XR

+	ASTRAZENECA AB	2.5MG; 1GM	N205649	005	Jul 28, 2017	Mar	CAIN
+		5MG; 500MG	N205649	001	Oct 29, 2014	Mar	CAIN
+		5MG; 1GM	N205649	002	Oct 29, 2014	Mar	CAIN
+		10MG; 500MG	N205649	003	Oct 29, 2014	Mar	CAIN
+		10MG; 1GM	N205649	004	Oct 29, 2014	Mar	CAIN

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL
QTERN

+	ASTRAZENECA AB	10MG; EQ 5MG BASE	N209091	001	Feb 27, 2017	Mar	CAIN
---	----------------	-------------------	---------	-----	--------------	-----	------

DAPSONEGEL; TOPICAL
ACZONE

>D>	+	ALLERGAN INC	7.5%	N207154	001	Feb 24, 2016	Sep	CAHN
>A>	+	AQUA PHARMS LLC	7.5%	N207154	001	Feb 24, 2016	Sep	CAHN

DAPTOMYCINPOWDER; INTRAVENOUS
DAPTOMYCIN

AP		FRESENIUS KABI USA	500MG/VIAL	A206077	001	Apr 11, 2018	Mar	NEWA
AP		MYLAN LABS LTD	500MG/VIAL	A205037	001	Jun 05, 2018	May	NEWA
AP		TEVA PHARMS USA	500MG/VIAL	A091039	001	Mar 25, 2016	Feb	CAHN

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

AP	SAGENT PHARMS	50MG/VIAL	A207100	001	Mar 16, 2018	Mar NEWA
----	---------------	-----------	---------	-----	--------------	----------

DEFERIPRONESOLUTION; ORAL
FERRIPROX

+	AOPHARMA INC	80MG/ML	N208030	002	Apr 20, 2018	Apr NEWA
---	--------------	---------	---------	-----	--------------	----------

DEFIBROTIDE SODIUMSOLUTION; INTRAVENOUS
DEFITELIO

+	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Jul CDFR
---	-----------------	-----------------------	---------	-----	--------------	----------

DELAFLXACIN MEGLUMINEPOWDER; INTRAVENOUS
BAXDELA

+	MELINTA	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Jul CDFR
---	---------	--------------------	---------	-----	--------------	----------

DESFLURANELIQUID; INHALATION
DESFLURANE

AN	SHANGHAI HENGRUI	100%	A208234	001	Feb 26, 2018	Feb NEWA
----	------------------	------	---------	-----	--------------	----------

AN	+	BAXTER HLTHCARE	100%	N020118	001	Sep 18, 1992	Feb CFTG
----	---	-----------------	------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

AB	ANI PHARMS INC	10MG	A205153	001	Oct 28, 2016	May CAHN
	@	25MG	A071803	002	Dec 08, 1987	Apr CMS1
AB		25MG	A205153	002	Oct 28, 2016	May CAHN
	@	50MG	A071803	003	Dec 08, 1987	Apr CMS1
AB		50MG	A205153	003	Oct 28, 2016	May CAHN
	@	75MG	A071803	004	Dec 08, 1987	Apr CMS1
AB		75MG	A205153	004	Oct 28, 2016	May CAHN
AB		100MG	A205153	005	Oct 28, 2016	May CAHN
	@	150MG	A071803	005	May 29, 1997	Apr CMS1
AB		150MG	A205153	006	Oct 28, 2016	May CAHN
AB	MOUNTAIN	10MG	A205153	001	Oct 28, 2016	Feb CAHN
AB		25MG	A205153	002	Oct 28, 2016	Feb CAHN
AB		50MG	A205153	003	Oct 28, 2016	Feb CAHN
AB		75MG	A205153	004	Oct 28, 2016	Feb CAHN
AB		100MG	A205153	005	Oct 28, 2016	Feb CAHN
AB		150MG	A205153	006	Oct 28, 2016	Feb CAHN

>D> DESIRUDIN RECOMBINANT

>D> INJECTABLE; SUBCUTANEOUS

>D> IPRIVASK

>D>	+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	Sep DISC
-----	---	----------------------	-----------	---------	-----	--------------	----------

>A>	+	@	15MG/VIAL	N021271	001	Apr 04, 2003	Sep DISC
-----	---	---	-----------	---------	-----	--------------	----------

DESMOPRESSIN ACETATETABLET; SUBLINGUAL
NOC DURNA

+	FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018	Jun NEWA
---	--------------------	----------	---------	-----	--------------	----------

+		0.0553MG	N022517	002	Jun 21, 2018	Jun NEWA
---	--	----------	---------	-----	--------------	----------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

>A>	AB	ACCORD HLTHCARE	0.15MG; 0.03MG	A207067	001	Sep 13, 2018	Sep NEWA
-----	----	-----------------	----------------	---------	-----	--------------	----------

DESONIDEGEL; TOPICAL
DESONATE

>D>	+	BAYER HLTHCARE	0.05%	N021844	001	Oct 20, 2006	Sep CAHN
-----	---	----------------	-------	---------	-----	--------------	----------

>A>	+	LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006	Sep CAHN
-----	---	---------------	-------	---------	-----	--------------	----------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

>A>	AB	ANDA REPOSITORY	0.25%	A205594	001	Jul 02, 2018	Sep CAHN
	AB	GROUPE PARIMA INC	0.25%	A205594	001	Jul 02, 2018	Jun NEWA
>D>	AB	RISING PHARMS	0.25%	A205594	001	Jul 02, 2018	Sep CAHN
	AB		0.25%	A205594	001	Jul 02, 2018	Jul CAHN
>A>	AB	ZYDUS PHARMS USA INC	0.25%	A205620	001	Sep 28, 2018	Sep NEWA

TOPICORT

	AB	! TARO PHARM INDS LTD	0.05%	A073210	001	Nov 30, 1990	May CAHN
	AB	!	0.25%	A073193	001	Nov 30, 1990	May CAHN
		+ @	0.25%	N017856	001		May CAHN

TOPICORT LP

		+ @ TARO PHARM INDS LTD	0.05%	N018309	001		May CAHN
--	--	-------------------------	-------	---------	-----	--	----------

GEL; TOPICAL

DESOXIMETASONE

>A>	AB	ANDA REPOSITORY	0.05%	A204675	001	Aug 12, 2016	Sep CAHN
>D>	AB	RISING PHARMS	0.05%	A204675	001	Aug 12, 2016	Sep CAHN

TOPICORT

	AB	! TARO PHARM INDS LTD	0.05%	A074904	001	Jul 14, 1998	May CAHN
		+ @	0.05%	N018586	001	Mar 29, 1982	May CAHN

OINTMENT; TOPICAL

DESOXIMETASONE

>A>	AB	ANDA REPOSITORY	0.25%	A204272	001	Nov 30, 2016	Sep CAHN
>D>	AB	RISING PHARMS	0.25%	A204272	001	Nov 30, 2016	Sep CAHN

TOPICORT

	AB	+! TARO PHARM INDS LTD	0.05%	N018594	001	Jan 17, 1985	May CAHN
	AB	!	0.25%	A074286	001	Jun 07, 1996	May CAHN
		+ @	0.25%	N018763	001	Sep 30, 1983	May CAHN

SPRAY; TOPICAL

DESOXIMETASONE

AT		LUPIN ATLANTIS	0.25%	A208124	001	Mar 16, 2018	Mar NEWA
----	--	----------------	-------	---------	-----	--------------	----------

TOPICORT

AT		+! TARO PHARMS	0.25%	N204141	001	Apr 11, 2013	May CAHN
----	--	----------------	-------	---------	-----	--------------	----------

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

		+ @ SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Jun DISC
		+ @	EQ 100MG BASE	N205583	002	Jan 28, 2014	Jun DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

>A>	AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	A204003	003	Sep 14, 2018	Sep NEWA
	AB	CASI PHARMS INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Mar CAHN
	AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Mar CAHN
>A>	AB	YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018	Sep NEWA
>A>	AB		EQ 100MG BASE	A210014	002	Oct 01, 2018	Sep NEWA

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA		LANNETT CO INC	0.5MG/5ML	A091188	001	May 11, 2011	May CAHN
----	--	----------------	-----------	---------	-----	--------------	----------

HEXADROL

		@ ASPEN GLOBAL INC	0.5MG/5ML	N012674	001		Feb CAHN
--	--	--------------------	-----------	---------	-----	--	----------

SUSPENSION; INTRAOCULAR

DEXYCU KIT

		+! EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018	Apr CAHN
		+! ICON BIOSCIENCE	9%	N208912	001	Feb 09, 2018	Feb NEWA

TABLET; ORAL

DEXAMETHASONE

BP		FERA PHARMS LLC	0.5MG	A088481	002	Apr 28, 1983	May CMS1
BP			0.75MG	A088481	003	Apr 28, 1983	May CMS1
BP			4MG	A088481	004	Apr 28, 1983	May CMS1
BP			6MG	A088481	001	Nov 28, 1983	Jan CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	AMNEAL PHARMS CO	EQ 4MG PHOSPHATE/ML	A208689	001	Aug 22, 2018	Aug NEWA
AP	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A209192	001	Jul 06, 2018	Jun NEWA
AP	SOMERSET THERAPS LLC	EQ 4MG PHOSPHATE/ML	A207521	001	Jun 08, 2018	May NEWA
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE						
AP	AMNEAL PHARMS CO	EQ 10MG PHOSPHATE/ML	A208690	001	Aug 22, 2018	Aug NEWA
AP	SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A207442	001	Apr 19, 2018	Apr NEWA
HEXADROL						
	+ @ ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML	N014694	002		Feb CAHN
	+ @	EQ 10MG PHOSPHATE/ML	N014694	003		Feb CAHN
	@	EQ 20MG PHOSPHATE/ML	N014694	004		Feb CAHN

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

AA	! WOCKHARDT BIO AG	2MG/5ML	A088251	001	Mar 23, 1984	Jul CTEC
POLMON						
AA	CAPELLON PHARMS LLC	2MG/5ML	A202520	001	Jul 16, 2018	Jul NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	BAXTER HLTHCARE CORP	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A208532	001	Aug 21, 2018	Aug NEWA
AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A208532	002	Aug 21, 2018	Aug NEWA
AP	ZYDUS PHARMS USA INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A206798	001	Feb 27, 2018	Feb NEWA
PRECEDEX						
AP	+! HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013	Aug CFTG
AP	+!	EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013	Aug CFTG

SOLUTION; IV (INFUSION)

DEXMEDETOMIDINE HYDROCHLORIDE

	+ HQ SPCLT PHARMA	EQ 200MG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Jun NEWA
	+	EQ 400MG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Jun NEWA

DESMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ADARE PHARMS INC	5MG	A210279	001	Oct 09, 2018	Sep NEWA
>A>	AB		10MG	A210279	002	Oct 09, 2018	Sep NEWA
>A>	AB		15MG	A210279	003	Oct 09, 2018	Sep NEWA
>A>	AB		20MG	A210279	004	Oct 09, 2018	Sep NEWA
>A>	AB		25MG	A210279	005	Oct 09, 2018	Sep NEWA
>A>	AB		30MG	A210279	006	Oct 09, 2018	Sep NEWA
>A>	AB		35MG	A210279	007	Oct 09, 2018	Sep NEWA
>A>	AB		40MG	A210279	008	Oct 09, 2018	Sep NEWA

TABLET; ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	CEDIPROF INC	5MG	A209211	001	Sep 19, 2018	Sep NEWA
>A>	AB		10MG	A209211	002	Sep 19, 2018	Sep NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Apr CAHN
AA			5MG	A090533	002	Oct 25, 2011	Apr CAHN
			7.5MG	A090533	003	Oct 25, 2011	Apr CAHN
AA			10MG	A090533	004	Oct 25, 2011	Apr CAHN
			15MG	A090533	005	Oct 25, 2011	Apr CAHN
			20MG	A090533	006	Oct 25, 2011	Apr CAHN
			30MG	A090533	007	Oct 25, 2011	Apr CAHN
>A>	AA	NUVO PHARM	5MG	A210059	001	Oct 18, 2017	Sep CAHN
>A>	AA		10MG	A210059	002	Oct 18, 2017	Sep CAHN
>D>	AA	SUNRISE PHARM INC	5MG	A210059	001	Oct 18, 2017	Sep CAHN
>D>	AA		10MG	A210059	002	Oct 18, 2017	Sep CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

@ G AND W LABS INC	15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984	Jan DISC
--------------------	----------------------	---------	-----	--------------	----------

DEXTROSE

INJECTABLE; INJECTION

AP	DEXTROSE 10% IN PLASTIC CONTAINER				
	FRESENIUS KABI USA	10GM/100ML	A209448	001	Jul 16, 2018 Jul NEWA
	DEXTROSE 20% IN PLASTIC CONTAINER				
	+ @ BAXTER HLTHCARE	20GM/100ML	N017521	004	Jun DISC
	+! ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982 Jun CTEC
	DEXTROSE 30% IN PLASTIC CONTAINER				
	+ @ BAXTER HLTHCARE	30GM/100ML	N017521	003	Jun DISC
	+! ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985 Jun CTEC
	DEXTROSE 40% IN PLASTIC CONTAINER				
	+ @ BAXTER HLTHCARE	40GM/100ML	N017521	002	Jun DISC
	+! ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982 Jun CTEC
	DEXTROSE 5% IN PLASTIC CONTAINER				
	+ @ ICU MEDICAL INC	50MG/ML	N019222	001	Jul 13, 1984 Mar DISC
AP	+!	50MG/ML	N019222	001	Jul 13, 1984 Feb CAHN
	DEXTROSE 50% IN PLASTIC CONTAINER				
	+ @ BAXTER HLTHCARE	50GM/100ML	N017521	001	Jun DISC
	DEXTROSE 60% IN PLASTIC CONTAINER				
	+ @ BAXTER HLTHCARE	60GM/100ML	N017521	005	Mar 26, 1982 Jun DISC
	DEXTROSE 70% IN PLASTIC CONTAINER				
AP	+! B BRAUN	70GM/100ML	N019626	005	Feb 18, 2015 Feb NEWA

>D> DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

>D> INJECTABLE; INJECTION

>D> PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>	BAXTER HLTHCARE	5GM/100ML; 32MG/100ML; 128MG/100ML; 2	N017385	001	Sep DISC
		34MG/100ML			
>A>	@	5GM/100ML; 32MG/100ML; 128MG/100ML; 2	N017385	001	Sep DISC
		34MG/100ML			

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	+! ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	009	Jul 05, 1983 Mar CHRS
AP	+!	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	005	Mar 28, 1988 Mar CPOT
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 900MG/100ML	N019308	004	Apr 05, 1985 Mar CTEC
		5GM/100ML; 150MG/100ML; 900MG/100ML	N019308	002	Apr 05, 1985 Mar CTEC
	+ @ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002	Mar 24, 1988 Mar DISC
	+ @	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	004	Mar 24, 1988 Mar DISC
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	+ @ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	006	Mar 28, 1988 Mar DISC
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	+ @ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	006	Mar 24, 1988 Mar DISC
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	+! ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	010	Jul 05, 1983 Mar CHRS
	+ @	5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	007	Mar 28, 1988 Mar DISC
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 900MG/100ML	N019308	003	Apr 05, 1985 Mar CTEC
AP	+! ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	005	Mar 24, 1988 Mar CRLD
	+ @	5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	008	Mar 24, 1988 Mar DISC
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	+! ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	002	Mar CHRS
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 900MG/100ML	N019308	006	Apr 05, 1985 Mar CTEC
	+ @ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	007	Mar 24, 1988 Mar DISC
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	+! ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	003	Mar CHRS
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	+! ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	009	Mar 24, 1988 Mar CRLD
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 450MG/100ML	N018008	004	Mar CTEC
	+ @ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	008	Mar 28, 1988 Mar DISC
	+ @	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	004	Mar 28, 1988 Mar DISC

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 900MG/100ML	N019308	001	Apr 05, 1985	Mar CTEC
+	@	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	001	Mar 24, 1988	Mar DISC
+	@		5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	003	Mar 24, 1988	Mar DISC

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	5GM/100ML; 450MG/100ML	N017607	001		Jan CRLD
----	---	-----------------	------------------------	---------	-----	--	----------

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOGRAFIN-76

+	@	BRACCO	66%; 10%	N010040	001		May DISC
---	---	--------	----------	---------	-----	--	----------

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAPHIN

+	@	BRACCO	52.7%; 26.8%	N011324	002		May DISC
---	---	--------	--------------	---------	-----	--	----------

DIAZEPAM

TABLET; ORAL

DIAZEPAM

	@	DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Apr CMS1
	@		5MG	A070228	003	Sep 26, 1985	Apr CMS1

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

AB	+	ASSERTIO	25MG	N022202	001	Jun 16, 2009	Aug CAHN
----	---	----------	------	---------	-----	--------------	----------

FOR SOLUTION; ORAL

CAMBIA

AB	+	ASSERTIO	50MG	N022165	001	Jun 17, 2009	Aug CAHN
----	---	----------	------	---------	-----	--------------	----------

TABLET; ORAL

DICLOFENAC POTASSIUM

AB		CASI PHARMS INC	50MG	A075229	001	Nov 20, 1998	Mar CAHN
----	--	-----------------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB		CIPLA LTD	1%	A209903	001	Aug 03, 2018	Jul NEWA
>D>	AB	GAGE DEVELOPMENT	3%	A210893	001	Jul 27, 2018	Sep CAHN
AB			3%	A210893	001	Jul 27, 2018	Jul NEWA
>A>	AB	PERRIGO UK FINCO	3%	A210893	001	Jul 27, 2018	Sep CAHN

SOLUTION; INTRAVENOUS

DYLOJECT

+	@	JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)	N022396	001	Dec 23, 2014	Jun DISC
---	---	--------------------	-----------------------	---------	-----	--------------	----------

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT		TWI PHARMS	1.5%	A202393	001	Nov 24, 2014	Jul CAHN
AT		ZYDUS PHARMS USA INC	1.5%	A206411	001	Apr 17, 2018	Apr NEWA

PENNSAID

+	!	HZNP	2%	N204623	001	Jan 16, 2014	Aug CAHN
---	---	------	----	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

>A>	AT	ANDA REPOSITORY	0.1%	A078553	001	Dec 28, 2007	Sep CAHN
>D>	AT	RISING PHARMS	0.1%	A078553	001	Dec 28, 2007	Sep CAHN

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	!	CASI PHARMS INC	25MG	A074376	001	Sep 28, 1995	Mar CAHN
AB	!		50MG	A074376	002	Sep 28, 1995	Mar CAHN
AB	!		75MG	A074394	001	Nov 30, 1995	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

AB	+	ALLERGAN SALES LLC	10MG	N007409	003	Oct 15, 1984	Jan CAHN
----	---	--------------------	------	---------	-----	--------------	----------

DICYCLOMINE HYDROCHLORIDE

>D>		@	HIKMA PHARMS	10MG	A040204	001	Feb 28, 1997	Sep CMFD
>A>	AB		WEST WARD	10MG	A040204	001	Feb 28, 1997	Sep CMFD

INJECTABLE;INJECTION

BENTYL

AP	+	ALLERGAN SALES LLC	10MG/ML	N008370	001	Oct 15, 1984	Jan CAHN
BENTYL PRESERVATIVE FREE							
AP	+	ALLERGAN SALES LLC	10MG/ML	N008370	002	Oct 15, 1984	Jan CAHN
DICYCLOMINE HYDROCHLORIDE							
AP		AKORN INC	10MG/ML	A207084	001	May 04, 2018	Apr NEWA
AP		APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Jun NEWA

TABLET;ORAL

BENTYL

AB	+	ALLERGAN SALES LLC	20MG	N007409	001	Oct 15, 1984	Jan CAHN
----	---	--------------------	------	---------	-----	--------------	----------

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

@	BARR	200MG	A077167	001	Dec 03, 2004	Mar DISC
@		250MG	A077167	002	Dec 03, 2004	Mar DISC
@		400MG	A077167	003	Dec 03, 2004	Mar DISC

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

TENUATE

>D>	AA	+	ACTAVIS LABS UT INC	25MG	N011722	002	Sep CAHN
>A>	AA	+	TEVA BRANDED PHARM	25MG	N011722	002	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

TENUATE DOSPAN

>D>	AB	+	ACTAVIS LABS UT INC	75MG	N012546	001	Sep CAHN
>A>	AB	+	TEVA BRANDED PHARM	75MG	N012546	001	Sep CAHN

DIFLORASONE DIACETATE

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

>D>	AB		RICONPHARMA LLC	0.05%	A207440	001	Feb 27, 2017	Sep CAHN
>A>	AB		RISING PHARMS	0.05%	A207440	001	Feb 27, 2017	Sep CAHN
	AB		TELIGENT PHARMA INC	0.05%	A210753	001	Jun 12, 2018	May NEWA

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

@	SOCORRO	250MG	A073562	001	Nov 27, 1992	Jun CAHN
@		500MG	A073563	001	Nov 27, 1992	Jul CAHN

DIGOXIN

TABLET;ORAL

LANOXIN

+	@	CONCORDIA PHARMS INC	0.1875MG	N020405	003	Sep 30, 1997	May DISC
---	---	----------------------	----------	---------	-----	--------------	----------

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION

DIHYDROERGOTAMINE MESYLATE

AP		SAGENT PHARMS	1MG/ML	A207264	001	Jul 11, 2018	Jun NEWA
----	--	---------------	--------	---------	-----	--------------	----------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB3		PAR PHARM	360MG	A209766	001	May 30, 2018	May NEWA
AB3		TWI PHARMS	120MG	A205231	001	Aug 30, 2018	Aug NEWA
AB3			180MG	A205231	002	Aug 30, 2018	Aug NEWA
AB3			240MG	A205231	003	Aug 30, 2018	Aug NEWA
AB3			300MG	A205231	004	Aug 30, 2018	Aug NEWA
AB3			360MG	A205231	005	Aug 30, 2018	Aug NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

@	FOSUN PHARMA	25MG	A080832	001		Jan CAHN
@		25MG	A080845	002		Jan CAHN
@		50MG	A080832	002		Jan CAHN
@		50MG	A080845	001		Jan CAHN

INJECTABLE;INJECTION

DIPHENYDRAMINE HYDROCHLORIDE

AP	MICRO LABS	50MG/ML	A205723	001	Aug 22, 2018	Aug NEWA
----	------------	---------	---------	-----	--------------	----------

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

AB	APOTEX INC	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008	Apr CAHN
AB		EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008	Apr CAHN
AB		EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008	Apr CAHN

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

	+ @ ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jun DISC
	+ @	80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jun DISC
AP	AMNEAL PHARMS CO	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Jan NEWA
AP		80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Jan NEWA
AP		160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Jan NEWA
AP	CIPLA LTD	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Aug NEWA
AP		80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Aug NEWA
AP		160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Aug NEWA
AP	EAGLE PHARMS	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jun CTEC
		20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jun CDFR
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jun CTEC
		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jun CDFR
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jun CTEC
		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jun CDFR
AP	MYLAN LABS LTD	20MG/2ML (10MG/ML)	A210072	001	Jul 02, 2018	Jun NEWA
AP		80MG/8ML (10MG/ML)	A210848	001	Jul 06, 2018	Jun NEWA

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	MYLAN LABS LTD	160MG/16ML (10MG/ML)	A208859	001	Apr 30, 2018	Apr NEWA
----	----------------	----------------------	---------	-----	--------------	----------

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

AB	APICORE US	0.125MG	A208625	001	Apr 10, 2018	Mar NEWA
AB		0.25MG	A208625	002	Apr 10, 2018	Mar NEWA
AB		0.5MG	A208625	003	Apr 10, 2018	Mar NEWA
AB	BIONPHARMA INC	0.125MG	A208625	001	Apr 10, 2018	May CAHN
AB		0.25MG	A208625	002	Apr 10, 2018	May CAHN
AB		0.5MG	A208625	003	Apr 10, 2018	May CAHN
>A> AB	PAR PHARM INC	0.125MG	A208519	001	Oct 09, 2018	Sep NEWA
>A> AB		0.25MG	A208519	002	Oct 09, 2018	Sep NEWA
>A> AB		0.5MG	A208519	003	Oct 09, 2018	Sep NEWA
AB	SIGMAPHARM LABS LLC	0.125MG	A207746	001	Mar 26, 2018	Mar NEWA
AB		0.25MG	A207746	002	Mar 26, 2018	Mar NEWA
AB		0.5MG	A207746	003	Mar 26, 2018	Mar NEWA
>A> AB	SUN PHARMA GLOBAL	0.125MG	A210466	001	Oct 09, 2018	Sep NEWA
>A> AB		0.25MG	A210466	002	Oct 09, 2018	Sep NEWA
>A> AB		0.5MG	A210466	003	Oct 09, 2018	Sep NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

	@ APOTEX	5MG	A078841	001	Jun 02, 2011	Mar DISC
	@	10MG	A078841	002	Jun 02, 2011	Mar DISC
AB	HISUN PHARM HANGZHOU	23MG	A202410	001	Mar 24, 2017	Aug CAHN
	@ SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr DISC
	@	10MG	A076786	002	Nov 26, 2010	Apr DISC

TABLET, ORALLY DISINTEGRATING;ORAL

ARICEPT ODT

	+ @ EISAI INC	5MG	N021720	001	Oct 18, 2004	Aug DISC
	+ @	10MG	N021720	002	Oct 18, 2004	Aug DISC
	DONEPEZIL HYDROCHLORIDE					
	@ BARR	5MG	A078388	002	Nov 26, 2010	Aug DISC
	@	10MG	A078388	001	Nov 26, 2010	Aug DISC
AB	HISUN PHARM HANGZHOU	5MG	A205269	001	Jul 27, 2018	Jul NEWA
AB		10MG	A205269	002	Jul 27, 2018	Jul NEWA
AB	! SANDOZ	10MG	A091198	002	May 10, 2011	Aug CHRS

TABLET, ORALLY DISINTEGRATING;ORAL
 DONEPEZIL HYDROCHLORIDE
 @ ZYDUS PHARMS USA INC 5MG
 @ 10MG

A090175 001 May 10, 2011 Aug DISC
 A090175 002 May 10, 2011 Aug DISC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
 NAMZARIC

+ ALLERGAN SALES LLC 10MG;7MG
 AB + 10MG;14MG
 + 10MG;21MG
 AB +! 10MG;28MG

N206439 003 Jul 18, 2016 Jun CAHN
 N206439 001 Dec 23, 2014 Jun CAHN
 N206439 004 Jul 18, 2016 Jun CAHN
 N206439 002 Dec 23, 2014 Jun CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
 DOPAMINE HYDROCHLORIDE

AP HIKMA INTL PHARMS 40MG/ML
 AP 80MG/ML
 @ LUITPOLD 160MG/ML

A207707 001 Apr 11, 2018 Mar NEWA
 A207707 002 Apr 11, 2018 Mar NEWA
 A070826 001 Feb 11, 1987 Aug DISC

DORAVIRINE

TABLET;ORAL
 PIFELTRO

+! MSD MERCK CO 100MG

N210806 001 Aug 30, 2018 Aug NEWA

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
 DELSTRIGO

+! MSD MERCK CO 100MG;300MG;300MG

N210807 001 Aug 30, 2018 Aug NEWA

DORIPENEM

>A> INJECTABLE;INTRAVENOUS
 >A> DORIBAX

>A> + @ SHIONOGI INC 250MG/VIAL
 >A> + @ 500MG/VIAL

N022106 002 Oct 05, 2010 Sep CDFR
 N022106 001 Oct 12, 2007 Sep CDFR

>D> INJECTABLE;IV (INFUSION)
 >D> DORIBAX

>D> + @ SHIONOGI INC 250MG/VIAL
 >D> + @ 500MG/VIAL

N022106 002 Oct 05, 2010 Sep CDFR
 N022106 001 Oct 12, 2007 Sep CDFR

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
 DORZOLAMIDE HYDROCHLORIDE

@ TEVA PHARMS EQ 2% BASE
 @ WATSON LABS INC EQ 2% BASE

A078756 001 Dec 04, 2008 Jun DISC
 A202053 001 Sep 11, 2014 May DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
 COSOPT PF

AT +! OAK PHARMS INC EQ 2% BASE;EQ 0.5% BASE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
 AT AUROBINDO PHARMA LTD EQ 2% BASE;EQ 0.5% BASE
 @ WATSON LABS INC EQ 2% BASE;EQ 0.5% BASE

N202667 001 Feb 01, 2012 Jul CFTG
 A207630 001 Jul 24, 2018 Jul NEWA
 A202054 001 Sep 03, 2014 May DISC

DOXAZOSIN MESYLATE

TABLET;ORAL
 DOXAZOSIN MESYLATE

>D> AB APPCO PHARMA LLC EQ 1MG BASE
 AB EQ 1MG BASE
 >D> AB EQ 2MG BASE
 AB EQ 2MG BASE
 >D> AB EQ 4MG BASE
 AB EQ 4MG BASE
 >D> AB EQ 8MG BASE
 AB EQ 8MG BASE
 AB HERITAGE PHARMA EQ 1MG BASE
 AB EQ 2MG BASE
 AB EQ 4MG BASE
 AB EQ 8MG BASE
 >A> AB UPSHER-SMITH LABS EQ 1MG BASE
 >A> AB EQ 2MG BASE
 >A> AB EQ 4MG BASE

A209013 001 Apr 17, 2018 Sep CAHN
 A209013 001 Apr 17, 2018 Apr NEWA
 A209013 002 Apr 17, 2018 Sep CAHN
 A209013 002 Apr 17, 2018 Apr NEWA
 A209013 003 Apr 17, 2018 Sep CAHN
 A209013 003 Apr 17, 2018 Apr NEWA
 A209013 004 Apr 17, 2018 Sep CAHN
 A209013 004 Apr 17, 2018 Apr NEWA
 A205210 001 Feb 13, 2018 Jan NEWA
 A205210 002 Feb 13, 2018 Jan NEWA
 A205210 003 Feb 13, 2018 Jan NEWA
 A205210 004 Feb 13, 2018 Jan NEWA
 A209013 001 Apr 17, 2018 Sep CAHN
 A209013 002 Apr 17, 2018 Sep CAHN
 A209013 003 Apr 17, 2018 Sep CAHN

TABLET;ORAL

DOXAZOSIN MESYLATE

>A>	AB		EQ 8MG BASE	A209013	004	Apr 17, 2018	Sep CAHN
		@ YAOPHARMA CO LTD	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan CAHN
		@	EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan CAHN
		@	EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan CAHN
		@	EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan CAHN

DOXEPIN HYDROCHLORIDE

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

		@ ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jan DISC
		@	EQ 6MG BASE	A201951	002	Jul 26, 2013	Jan DISC
		SILENOR					
	+	PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Jan CTEC
	+	!	EQ 6MG BASE	N022036	002	Mar 17, 2010	Jan CTEC

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

>A>	AB	ANDA REPOSITORY	0.5MCG	A201518	001	Sep 09, 2016	Sep CAHN
>A>	AB		1MCG	A201518	002	Sep 09, 2016	Sep CAHN
>A>	AB		2.5MCG	A201518	003	Sep 09, 2016	Sep CAHN
>D>	AB	RISING PHARMS	0.5MCG	A201518	001	Sep 09, 2016	Sep CAHN
>D>	AB		1MCG	A201518	002	Sep 09, 2016	Sep CAHN
>D>	AB		2.5MCG	A201518	003	Sep 09, 2016	Sep CAHN
		HECTOROL					
	AB	+ SANOFI	0.5MCG	N020862	002	Apr 23, 2004	Aug CAHN
	AB	+	1MCG	N020862	003	Jul 13, 2009	Aug CAHN
	AB	+	2.5MCG	N020862	001	Jun 09, 1999	Aug CAHN
		INJECTABLE;INJECTION					
		DOXERCALCIFEROL					
	AP	+ HOSPIRA INC	4MCG/2ML (2MCG/ML)	N208614	001	Jul 24, 2018	Jul NEWA
		+	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018	Jul NEWA
		HECTOROL					
	AP	+ SANOFI	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Aug CAHN
	AP	+	4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000	Aug CAHN

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

>D>	AP	MYLAN LABS LTD	10MG/VIAL	A200170	001	Oct 28, 2011	Sep DISC
>A>		@	10MG/VIAL	A200170	001	Oct 28, 2011	Sep DISC

DOXYCYCLINE

TABLET;ORAL

DOXYCYCLINE

	AB	SUN PHARM INDS LTD	EQ 150MG BASE	A065356	004	Jul 29, 2010	Jul NEWA
--	----	--------------------	---------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

		+ @ AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	May DISC
--	--	-----------------	--------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

>A>	AB	AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018	Sep NEWA
>A>	AB		EQ 100MG BASE	A211012	002	Sep 24, 2018	Sep NEWA
	AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A210527	001	Jun 13, 2018	May NEWA
	AB		EQ 100MG BASE	A210527	002	Jun 13, 2018	May NEWA
		@ HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005	Jul DISC
	AB	SUN PHARM INDUSTRIES	EQ 50MG BASE	A062676	002	Jul 10, 1986	Jun CMS1
	AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A207774	001	May 31, 2018	May NEWA
	AB		EQ 100MG BASE	A207774	002	May 31, 2018	May NEWA

TABLET;ORAL

DOXYCYCLINE HYCLATE

	CARIBE HOLDINGS	EQ 50MG BASE	A062269	003	Oct 05, 1983	Jul CMS1
>D>	LYMEPAK					
>D>	+! CHARTWELL PHARMA	EQ 100MG BASE	N209844	001	Jun 15, 2018	Sep DISC
>A>	+ @	EQ 100MG BASE	N209844	001	Jun 15, 2018	Sep DISC
	+!	EQ 100MG BASE	N209844	001	Jun 15, 2018	Jun NEWA

TABLET, DELAYED RELEASE;ORAL
DORYX

		+ @ MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr DISC
		DOXYCYCLINE HYCLATE					
AB		ACTAVIS ELIZABETH	EQ 50MG BASE	A090134	003	May 22, 2018	May NEWA
AB			EQ 200MG BASE	A090134	004	May 22, 2018	May NEWA
		@ MYLAN	EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr DISC

DRONABINOL

CAPSULE;ORAL
DRONABINOL

AB		LANNETT CO INC	2.5MG	A201463	001	May 18, 2018	May NEWA
AB			5MG	A201463	002	May 18, 2018	May NEWA
AB			10MG	A201463	003	May 18, 2018	May NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL
DROSPIRENONE AND ETHINYL ESTRADIOL

AB		JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017	Mar CAHN
		LO-ZUMANDIMINE					
AB		AUROBINDO PHARMA LTD	3MG;0.02MG	A209632	001	Feb 27, 2018	Feb NEWA
		TABLET;ORAL-28					
		DROSPIRENONE AND ETHINYL ESTRADIOL					
>A> AB		CYNDEA PHARMA	3MG;0.03MG	A210017	001	Sep 10, 2018	Sep NEWA
>A> AB		JUBILANT CADISTA	3MG;0.03MG	A210017	001	Sep 10, 2018	Sep CAHN
		ZUMANDIMINE					
AB		AUROBINDO PHARMA LTD	3MG;0.03MG	A209407	001	Mar 26, 2018	Mar NEWA

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

AB		LUPIN LTD	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	A205947	001	Jun 13, 2018	May NEWA
----	--	-----------	------------------------------------	---------	-----	--------------	----------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB		BRECKENRIDGE PHARM	EQ 40MG BASE	A203088	004	May 18, 2018	May NEWA
AB		LUPIN LTD	EQ 40MG BASE	A090694	003	Dec 11, 2013	May CTEC
AB		MARKSANS PHARMA	EQ 20MG BASE	A090723	001	Dec 11, 2013	Jul CAHN
AB			EQ 30MG BASE	A090723	002	Dec 11, 2013	Jul CAHN
AB			EQ 60MG BASE	A090723	003	Dec 11, 2013	Jul CAHN

DUTASTERIDE

CAPSULE;ORAL
DUTASTERIDE

>A> AB		BRECKENRIDGE PHARM	0.5MG	A208227	001	Jun 22, 2018	Sep CAHN
>D> AB		HAUPT PHARMA	0.5MG	A207935	001	Oct 13, 2017	Sep CAHN
>A> AB		HERITAGE PHARMS INC	0.5MG	A207935	001	Oct 13, 2017	Sep CAHN
		@ MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	Jun DISC
>D> AB		PHARMACEUTICS	0.5MG	A208227	001	Jun 22, 2018	Sep CAHN
AB			0.5MG	A208227	001	Jun 22, 2018	Jun NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	0.5MG;0.4MG	A207769	001	May 24, 2018	May NEWA
----	--	----------------------	-------------	---------	-----	--------------	----------

>A> DUVELISIB

>A> CAPSULE;ORAL
>A> COPIKTRA

>A>		+ VERASTEM INC	15MG	N211155	001	Sep 24, 2018	Sep NEWA
>A>		+	25MG	N211155	002	Sep 24, 2018	Sep NEWA

ECONAZOLE NITRATE

CREAM;TOPICAL
ECONAZOLE NITRATE

AB		CASI PHARMS INC	1%	A076075	001	Nov 26, 2002	Mar CAHN
AB		MYLAN PHARMS INC	1%	A210364	001	Apr 18, 2018	Apr NEWA

EDARAVONESOLUTION; INTRAVENOUS
RADICAVA

+! MITSUBISHI TANABE 30MG/100ML (0.3MG/ML) N209176 001 May 05, 2017 Jul CDFR

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION
ENLON

>D> ! MYLAN INSTITUTIONAL 10MG/ML A088873 001 Aug 06, 1985 Sep DISC

>A> @ 10MG/ML A088873 001 Aug 06, 1985 Sep DISC

EFAVIRENZTABLET; ORAL
EFAVIRENZ

>A> AB AUROBINDO PHARMA LTD 600MG A077673 001 Sep 21, 2018 Sep NEWA

AB 600MG A205322 001 Aug 30, 2018 Aug NEWA

AB CIPLA LTD 600MG A204766 001 Jun 15, 2018 Jun NEWA

AB HETERO LABS LTD III 600MG A078886 001 Apr 27, 2018 Apr NEWA

AB STRIDES PHARMA 600MG A204869 001 Mar 12, 2018 Feb NEWA

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
ATRIPLA

AB +! GILEAD SCIENCES 600MG; 200MG; 300MG N021937 001 Jul 12, 2006 Aug CFTG

+! 600MG; 200MG; 300MG N021937 001 Jul 12, 2006 Mar CAHN

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB AUROBINDO PHARMA LTD 600MG; 200MG; 300MG A203041 001 Sep 04, 2018 Aug NEWA

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

AUROBINDO PHARMA LTD 600MG; 300MG; 300MG N022343 001 Aug 15, 2018 Aug NEWA

SYMFI

+! MYLAN LABS LTD 600MG; 300MG; 300MG N022142 001 Mar 22, 2018 Mar NEWA

SYMFI LO

+! MYLAN PHARMS INC 400MG; 300MG; 300MG N208255 001 Feb 05, 2018 Feb NEWA

ELAGOLIX SODIUMTABLET; ORAL
ORILISSA

+ ABBVIE INC EQ 150MG BASE N210450 001 Jul 23, 2018 Jul NEWA

+! EQ 200MG BASE N210450 002 Jul 23, 2018 Jul NEWA

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

ELETRIPTAN HYDROBROMIDE

AB AMNEAL PHARMS CO EQ 20MG BASE A206787 001 May 25, 2018 May NEWA

AB EQ 40MG BASE A206787 002 May 25, 2018 May NEWA

ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

PROMACTA

>D> +! NOVARTIS PHARMS CORP EQ 25MG ACID/PACKET N207027 001 Aug 24, 2015 Sep CTNA

PROMACTA KIT

>A> + NOVARTIS PHARMS CORP EQ 12.5MG ACID/PACKET N207027 002 Sep 27, 2018 Sep NEWA

>A> +! EQ 25MG ACID/PACKET N207027 001 Aug 24, 2015 Sep CTNA

EMTRICITABINE

CAPSULE; ORAL

EMTRICITABINE

AB CIPLA LTD 200MG A091168 001 Jul 02, 2018 Jun NEWA

EMTRIVA

AB +! GILEAD 200MG N021500 001 Jul 02, 2003 Jun CFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB AMNEAL PHARMS CO 100MG; 150MG A209721 001 Aug 22, 2018 Aug NEWA

AB 133MG; 200MG A209721 002 Aug 22, 2018 Aug NEWA

AB 167MG; 250MG A209721 003 Aug 22, 2018 Aug NEWA

AB 200MG; 300MG A209721 004 Aug 22, 2018 Aug NEWA

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA LTD	200MG;300MG	A090513	001	Jan 26, 2018	Jan NEWA
AB		MYLAN PHARMS INC	200MG;300MG	A206436	001	Apr 09, 2018	Mar NEWA
TRUVADA							
AB	+	GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Aug CFTG
AB	+		133MG;200MG	N021752	003	Mar 10, 2016	Aug CFTG
AB	+		167MG;250MG	N021752	004	Mar 10, 2016	Aug CFTG

ENCORAFENIB

CAPSULE;ORAL

BRAFTOVI

	+	ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018	Jun NEWA
	+	!	75MG	N210496	002	Jun 27, 2018	Jun NEWA

ENOXAPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

>A>	AP	APOTEX INC	30MG/0.3ML (100MG/ML)	A078990	001	Sep 28, 2018	Sep NEWA
>A>	AP		40MG/0.4ML (100MG/ML)	A078990	002	Sep 28, 2018	Sep NEWA
>A>	AP		60MG/0.6ML (100MG/ML)	A078990	003	Sep 28, 2018	Sep NEWA
>A>	AP		80MG/0.8ML (100MG/ML)	A078990	004	Sep 28, 2018	Sep NEWA
>A>	AP		100MG/ML (100MG/ML)	A078990	005	Sep 28, 2018	Sep NEWA
>A>	AP		120MG/0.8ML (150MG/ML)	A078990	006	Sep 28, 2018	Sep NEWA
>A>	AP		150MG/ML (150MG/ML)	A078990	007	Sep 28, 2018	Sep NEWA

ENTACAPONE

TABLET;ORAL

ENTACAPONE

>A>	AB	SUNSHINE LAKE	200MG	A206669	001	Oct 03, 2018	Sep NEWA
-----	----	---------------	-------	---------	-----	--------------	----------

ENTECAVIR

TABLET;ORAL

ENTECAVIR

AB		BRECKENRIDGE PHARM	0.5MG	A208721	001	Mar 15, 2018	Apr NEWA
AB			1MG	A208721	002	Mar 15, 2018	Apr NEWA
AB		CASI PHARMS INC	0.5MG	A206672	001	May 11, 2017	Mar CAHN
AB			1MG	A206672	002	May 11, 2017	Mar CAHN

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

CORPHEDRA

AP		PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Apr CDFR
----	--	----------------------	-------------------	---------	-----	--------------	----------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT		CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Mar CAHN
----	--	-----------------	-------	---------	-----	--------------	----------

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

ADRENALIN

BX	+	IMPAX	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Aug CAHN
BX	+		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Aug CAHN
EPINEPHRINE (AUTOINJECTOR)							
AB		TEVA PHARMS USA	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Jul NEWA
AB			0.3MG/DELIVERY	A090589	001	Aug 16, 2018	Jul NEWA
EPIPEN							
AB	+	MYLAN SPECIALITY LP	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	Jul CFTG
EPIPEN JR.							
AB	+	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul CFTG
TWINJECT 0.15							
	@	IMPAX	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Aug CAHN
TWINJECT 0.3							
	@	IMPAX	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Aug CAHN
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS							
ADRENALIN							
AP	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jun CFTG
EPINEPHRINE							
AP		LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Jun NEWA

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
SYMJEPI

>A>	+	ADAMIS PHARMS CORP	0.15MG/0.3ML (0.15MG/0.3ML)	N207534	002	Sep 27, 2018	Sep NEWA
		SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS					
		EPINEPHRINE					
	+	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Apr CRLD

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
@ EASTMAN KODAK 0.01MG/ML;2%
@ 0.02MG/ML;2%

A040057 002 Feb 26, 1993 Mar DISC
A040057 001 Feb 26, 1993 Mar DISC

EPIRUBICIN HYDROCHLORIDE

>D>		INJECTABLE;IV (INFUSION)					
>D>		EPIRUBICIN HYDROCHLORIDE					
>D>		@ HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006	Sep CDFR
>D>		@	200MG/VIAL	N050807	002	Sep 15, 2006	Sep CDFR
>A>		POWDER;INTRAVENOUS					
>A>		EPIRUBICIN HYDROCHLORIDE					
>A>		@ HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006	Sep CDFR
>A>		@	200MG/VIAL	N050807	002	Sep 15, 2006	Sep CDFR

EPLERENONE

TABLET;ORAL
EPLERENONE

>A>	AB	BRECKENRIDGE PHARM	25MG	A208283	001	Sep 14, 2018	Sep NEWA
>A>	AB		50MG	A208283	002	Sep 14, 2018	Sep NEWA

EPROSARTAN MESYLATE

TABLET;ORAL
EPROSARTAN MESYLATE

AB	!	MYLAN PHARMS INC	EQ 600MG BASE	A202012	002	Nov 16, 2011	Mar CHRS
		TEVETEN					
	+	@ ABBVIE	EQ 400MG BASE	N020738	005	Dec 22, 1997	Mar DISC
	+	@	EQ 600MG BASE	N020738	006	May 27, 1999	Mar DISC

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP		MYLAN LABS LTD	2MG/ML	A203258	001	Jul 20, 2018	Jul NEWA
AP			75MG/100ML	A203258	002	Jul 20, 2018	Jul NEWA
AP		SAGENT PHARMS	2MG/ML	A204693	001	Mar 07, 2018	Feb NEWA
AP			75MG/100ML	A204693	002	Mar 07, 2018	Feb NEWA

ERAVACYCLINE DIHYDROCHLORIDE

POWDER;INTRAVENOUS
XERAVA

+	!	TETRAPHASE PHARMS	EQ 50MG BASE/VIAL	N211109	001	Aug 27, 2018	Aug NEWA
---	---	-------------------	-------------------	---------	-----	--------------	----------

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, IV (INFUSION)
ERTAPENEM SODIUM

AP		ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A208790	001	Apr 16, 2018	Apr NEWA
AP		AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A209133	001	Jun 25, 2018	Jun NEWA
		INVANZ					
AP	+	MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Apr CFTG

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL
STEGLUJAN

+		MERCK SHARP DOHME	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017	Jan CMS1
+	!		15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017	Jan CMS1

ERYTHROMYCIN

SOLUTION;TOPICAL
ERYTHRA-DERM

>A>		@ ANDA REPOSITORY	2%	A062687	001	Feb 05, 1988	Sep CAHN
>D>		@ SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Sep CAHN

TABLET;ORAL

ERYTHROMYCIN

AB	AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018	Feb NEWA
AB		500MG	A209720	002	Mar 09, 2018	Feb NEWA
AB	ARBOR PHARMS LLC	250MG	A061621	001		Feb CTEC
AB	!	500MG	A061621	002		Feb CTEC

TABLET, COATED PARTICLES;ORAL

PCE

+	@ ARBOR PHARMS LLC	333MG	N050611	001	Sep 09, 1986	Jun DISC
+	@	500MG	N050611	002	Aug 22, 1990	Jun DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCIN

@ HOSPIRA

EQ 1GM BASE/VIAL

A062638 002 Oct 31, 1986 Jul DISC

ESCITALOPRAM OXALATE

SOLUTION;ORAL

LEXAPRO

AA	+! ALLERGAN SALES LLC	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan CAHN
----	-----------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

ESCITALOPRAM OXALATE

>A>	AB	PHARM ASSOC	EQ 5MG BASE	A077512	001	Sep 12, 2012	Sep CAHN
>A>	AB		EQ 10MG BASE	A077512	002	Sep 12, 2012	Sep CAHN
>A>	AB		EQ 20MG BASE	A077512	003	Sep 12, 2012	Sep CAHN
>D>	AB	STI PHARMA LLC	EQ 5MG BASE	A077512	001	Sep 12, 2012	Sep CAHN
>D>	AB		EQ 10MG BASE	A077512	002	Sep 12, 2012	Sep CAHN
>D>	AB		EQ 20MG BASE	A077512	003	Sep 12, 2012	Sep CAHN

LEXAPRO

AB	+	ALLERGAN SALES LLC	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan CAHN
AB	+		EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan CAHN
AB	+!		EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP	MYLAN LABS LTD	10MG/ML	A206608	001	Jun 08, 2018	May NEWA
AP		20MG/ML	A206608	002	Jun 08, 2018	May NEWA
AP	SAGENT PHARMS	10MG/ML	A207107	001	Jun 08, 2018	May NEWA
AP		20MG/ML	A207107	002	Jun 08, 2018	May NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB	HEC PHARM	EQ 20MG BASE	A207265	002	May 18, 2018	Aug CAHN
AB		EQ 40MG BASE	A207265	001	May 18, 2018	Aug CAHN
AB	HEC PHARM CO LTD	EQ 20MG BASE	A207265	002	May 18, 2018	May NEWA
AB		EQ 40MG BASE	A207265	001	May 18, 2018	May NEWA
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A209735	001	Apr 30, 2018	Apr NEWA
AB		EQ 40MG BASE	A209735	002	Apr 30, 2018	Apr NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

VIMOVO

	+	HORIZON	EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Aug CTEC
AB	+		EQ 20MG BASE;375MG	N022511	002	Apr 30, 2010	Aug CAHN
	+	!	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Aug CTEC
AB	+	!	EQ 20MG BASE;500MG	N022511	001	Apr 30, 2010	Aug CAHN

ESTRADIOL

CREAM;VAGINAL

ESTRADIOL

AB	ALVOGEN PINE BROOK	0.01%	A209767	001	Mar 05, 2018	Feb NEWA
AB	PERRIGO UK FINCO	0.01%	A210194	001	Jan 22, 2018	Jan NEWA
AB	TEVA PHARMS USA	0.01%	A210488	001	Mar 30, 2018	Mar NEWA

FILM, EXTENDED RELEASE;TRANSDERMAL

ESTRADIOL

AB	MYLAN TECHNOLOGIES	0.025MG/24HR	A206685	001	Aug 15, 2018	Jul NEWA
AB		0.0375MG/24HR	A206685	002	Aug 15, 2018	Jul NEWA
AB		0.05MG/24HR	A206685	003	Aug 15, 2018	Jul NEWA
AB		0.075MG/24HR	A206685	004	Aug 15, 2018	Jul NEWA
AB		0.1MG/24HR	A206685	005	Aug 15, 2018	Jul NEWA

FILM, EXTENDED RELEASE;TRANSDERMAL
MINIVELLE

AB	+	NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014	Jul CFTG
AB	+		0.0375MG/24HR	N203752	001	Oct 29, 2012	Jul CFTG
AB	+		0.05MG/24HR	N203752	003	Oct 29, 2012	Jul CFTG
AB	+		0.075MG/24HR	N203752	002	Oct 29, 2012	Jul CFTG
AB	+	!	0.1MG/24HR	N203752	004	Oct 29, 2012	Jul CFTG

GEL;TRANSDERMAL
DIVIGEL

+	VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jul CPOT
INSERT;VAGINAL						
IMVEXXY						
+	THERAPEUTICSMD INC	0.004MG	N208564	001	May 29, 2018	May NEWA
+	!	0.01MG	N208564	002	May 29, 2018	May NEWA

TABLET;VAGINAL
ESTRADIOL

>A> AB		GLENMARK PHARMS LTD	10MCG	A210264	001	Sep 14, 2018	Sep NEWA
--------	--	---------------------	-------	---------	-----	--------------	----------

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL
FEMRING

+	MILLICENT	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	May CAHN
+	!	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	May CAHN

ESTRADIOL HEMIHYDRATE

EMULSION;TOPICAL
ESTRASORB

+	@ EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun DISC
---	-------------------	-------	---------	-----	--------------	----------

ESTRADIOL VALERATE

INJECTABLE;INJECTION
ESTRADIOL VALERATE

@	FOSUN PHARMA	10MG/ML	A040628	001	Oct 04, 2007	Jan CAHN
@		20MG/ML	A040628	002	Oct 04, 2007	Jan CAHN
@		40MG/ML	A040628	003	Oct 04, 2007	Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB		ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Feb NEWA
----	--	-----------------	-----------	---------	-----	--------------	----------

ESTROGENS, CONJUGATED

CREAM;TOPICAL, VAGINAL
PREMARIN

+	!	WYETH PHARMS	0.625MG/GM	N020216	001		Jun CAHN
---	---	--------------	------------	---------	-----	--	----------

INJECTABLE;INJECTION
PREMARIN

+	!	WYETH PHARMS	25MG/VIAL	N010402	001		Jun CAHN
---	---	--------------	-----------	---------	-----	--	----------

TABLET;ORAL

PREMARIN

+	WYETH PHARMS	0.3MG	N004782	003		Jun CAHN
+		0.45MG	N004782	006	Jul 16, 2003	Jun CAHN
+	!	0.625MG	N004782	004		Jun CAHN
+	!	0.9MG	N004782	005	Jan 26, 1984	Jun CAHN
+	!	1.25MG	N004782	001		Jun CAHN
@		2.5MG	N004782	002		Jun CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28

PREMPHASE 14/14

+	!	WYETH PHARMS	0.625MG,0.625MG;N/A,5MG	N020527	002	Nov 17, 1995	Jun CAHN
---	---	--------------	-------------------------	---------	-----	--------------	----------

PREMPRO

+	!	WYETH PHARMS	0.3MG;1.5MG	N020527	005	Jun 04, 2003	Jun CAHN
+	!		0.45MG;1.5MG	N020527	004	Mar 12, 2003	Jun CAHN
+	!		0.625MG;2.5MG	N020527	001	Nov 17, 1995	Jun CAHN
+	!		0.625MG;5MG	N020527	003	Jan 09, 1998	Jun CAHN

ETEPLIRSENSOLUTION; INTRAVENOUS
EXONDYS 51

+	!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016	Jul CDFR
+	!		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016	Jul CDFR

ETHACRYNIC ACIDTABLET; ORAL
ETHACRYNIC ACID

AB		ALVOGEN	25MG	A205709	001	Jul 24, 2018	Jul NEWA
AB		AMNEAL PHARMS CO	25MG	A208805	001	May 08, 2018	Apr NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATETABLET; ORAL-28
MALMOREDE

AB		NOVAST LABS	0.05MG; 1MG	A209547	001	Jul 25, 2018	Jul NEWA
----	--	-------------	-------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; LEVONORGESTRELTABLET; ORAL
BALCOLTRA

		AVION PHARMS	0.02MG; 0.1MG	N208612	001	Jan 09, 2018	Feb CAHN
		NEUVOSYN LABS LLC	0.02MG; 0.1MG	N208612	001	Jan 09, 2018	Jan NEWA
		ICLEVIA					
AB		AUROBINDO PHARMA LTD	0.03MG; 0.15MG	A206850	001	Jun 29, 2018	Jun NEWA
		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL					
AB		LABS LEON FARMA	0.02MG, 0.1MG; 0.01MG, N/A	A205131	001	Dec 14, 2017	Apr CPOT
AB		LUPIN LTD	0.02MG, 0.1MG; 0.01MG, N/A	A091674	001	Oct 26, 2011	Apr CPOT
AB		MAYNE PHARMA	0.02MG, 0.1MG; 0.01MG, N/A	A200407	001	Oct 25, 2011	Apr CPOT
AB		MYLAN LABS LTD	0.02MG, 0.1MG; 0.01MG, N/A	A200493	001	Jun 17, 2015	Apr CPOT
		LO SIMPESE					
AB		AUROBINDO PHARMA LTD	0.02MG, 0.1MG; 0.01MG, N/A	A206852	001	Apr 28, 2017	Apr CPOT
		LOSEASONIQUE					
AB		TEVA BRANDED PHARM	0.02MG, 0.1MG; 0.01MG, N/A	N022262	001	Oct 24, 2008	Apr CPOT
		TABLET; ORAL-21					
		ALESSE					
	+	@ WYETH PHARMS	0.02MG; 0.1MG	N020683	001	Mar 27, 1997	May CAHN
		TRIPHASIL-21					
	+	@ WYETH PHARMS	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	N019192	001	Nov 01, 1984	May CAHN
		TABLET; ORAL-28					
		ALESSE					
	+	@ WYETH PHARMS	0.02MG; 0.1MG	N020683	002	Mar 27, 1997	May CAHN
		LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB		MYLAN LABS LTD	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202970	001	Mar 23, 2018	Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONETABLET; ORAL-28
BALZIVA-28

AB	!	BARR	0.035MG; 0.4MG	A076238	001	Apr 22, 2004	Aug CHRS
		MODICON 28					
	+	@ JANSSSEN PHARMS	0.035MG; 0.5MG	N017735	001		Feb DISC
		NORETHINDRONE AND ETHINYL ESTRADIOL					
		@ MYLAN LABS LTD	0.035MG; 0.4MG	A200897	001	May 11, 2015	Aug DISC
		WERA					
AB	!	NOVAST LABS LTD	0.035MG; 0.5MG	A091204	001	Mar 27, 2012	Feb CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATETABLET; ORAL
LO LOESTRIN FE

	+	!	APIL	0.01MG, 0.01MG; 1MG, N/A	N022501	001	Oct 21, 2010	Apr CTEC
			NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
		@	MYLAN LABS LTD	0.01MG, 0.01MG; 1MG, N/A	A205049	001	May 31, 2016	Apr DISC
			NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
>D>	AB		APOTEX INC	0.02MG; 1MG	A208639	001	Mar 21, 2018	Sep DISC
>A>		@		0.02MG; 1MG	A208639	001	Mar 21, 2018	Sep DISC
	AB			0.02MG; 1MG	A208639	001	Mar 21, 2018	Mar NEWA
			TABLET; ORAL-28					
			HAILEY 1.5/30					
AB			GLENMARK PHARMS	0.03MG; 1.5MG	A209297	001	Jun 05, 2018	May NEWA

TABLET;ORAL-28

	HAILEY FE 1.5/30								
AB	GLENMARK PHARMS	0.03MG;1.5MG	A209031	001	Jun 05, 2018	May	NEWA		
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL								
AB	MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Jun	NEWA		
	TABLET, CHEWABLE;ORAL								
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE								
AB	CHEMO RESEARCH SL	0.02MG;1MG	A209609	001	Jul 16, 2018	Jul	NEWA		
	TABLET, CHEWABLE, TABLET;ORAL								
	LO MINASTRIN FE								
	+ @ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan	DISC		

ETHINYL ESTRADIOL; NORGESTIMATE

>D>	TABLET;ORAL								
>D>	NORGESTIMATE AND ETHINYL ESTRADIOL								
>D> AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494	001	Jun 17, 2011	Sep	CDFR		
>A>	TABLET;ORAL-28								
>A>	NORGESTIMATE AND ETHINYL ESTRADIOL								
>A> AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494	001	Jun 17, 2011	Sep	CDFR		

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

	RING;VAGINAL								
	ANNOVERA								
>D>	+! POPULATION COUNCIL	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Sep	CAHN		
	+!	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Aug	NEWA		
>A>	+! THERAPEUTICSMD INC	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Sep	CAHN		

ETHIONAMIDETABLET;ORAL
TRECATOR

	+! WYETH PHARMS	250MG	N013026	002		May	CAHN		
--	-----------------	-------	---------	-----	--	-----	------	--	--

ETODOLACTABLET;ORAL
ETODOLAC

AB	AMNEAL PHARMS CO	400MG	A208834	001	Jun 07, 2018	May	NEWA		
AB		500MG	A208834	002	Jun 07, 2018	May	NEWA		

EVEROLIMUSTABLET;ORAL
EVEROLIMUS

AB	WEST-WARD PHARMS INT	0.25MG	A206133	001	Apr 12, 2018	Apr	NEWA		
AB		0.5MG	A206133	002	Apr 12, 2018	Apr	NEWA		
AB		0.75MG	A206133	003	Apr 12, 2018	Apr	NEWA		
	ZORTRESS								
AB	+ NOVARTIS	0.25MG	N021560	001	Apr 20, 2010	Apr	CFTG		
AB	+	0.5MG	N021560	002	Apr 20, 2010	Apr	CFTG		
AB	+!	0.75MG	N021560	003	Apr 20, 2010	Apr	CFTG		

EXEMESTANETABLET;ORAL
EXEMESTANE

AB	CIPLA LTD	25MG	A210323	001	Apr 27, 2018	Apr	NEWA		
>A> AB	ZYDUS PHARMS USA INC	25MG	A202602	001	Oct 03, 2018	Sep	NEWA		

EZETIMIBE; SIMVASTATINTABLET;ORAL
EZETIMIBE AND SIMVASTATIN

AB	ANI PHARMS INC	10MG;10MG	A201890	001	Apr 26, 2017	May	CAHN		
AB		10MG;20MG	A201890	002	Apr 26, 2017	May	CAHN		
AB		10MG;40MG	A201890	003	Apr 26, 2017	May	CAHN		
AB		10MG;80MG	A201890	004	Apr 26, 2017	May	CAHN		

FAMOTIDINETABLET;ORAL
FAMOTIDINE

	@ PLD ACQUISITIONS	20MG	A075302	001	Apr 16, 2001	Feb	CAHN		
	@	40MG	A075302	002	Apr 16, 2001	Feb	CAHN		

FAMOTIDINE; IBUPROFENTABLET; ORAL
DUEXIS

+! HORIZON

26.6MG; 800MG

N022519 001 Apr 23, 2011 Aug CAHN

FELBAMATETABLET; ORAL
FELBAMATE

AB ANI PHARMS INC

400MG

A202284 001 Nov 04, 2015 May CAHN

AB 600MG

A202284 002 Nov 04, 2015 May CAHN

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB AJANTA PHARMA LTD

67MG

A210705 001 Sep 10, 2018 Aug NEWA

AB 134MG

A210705 002 Sep 10, 2018 Aug NEWA

AB 200MG

A210705 003 Sep 10, 2018 Aug NEWA

AB AMERIGEN PHARMS LTD

67MG

A209504 001 Apr 30, 2018 Apr NEWA

AB 134MG

A209504 002 Apr 30, 2018 Apr NEWA

AB 200MG

A209504 003 Apr 30, 2018 Apr NEWA

AB TORRENT PHARMS LTD

67MG

A210782 001 Jun 26, 2018 Jun NEWA

AB 134MG

A210782 002 Jun 26, 2018 Jun NEWA

AB 200MG

A210782 003 Jun 26, 2018 Jun NEWA

TABLET; ORAL

FENOFIBRATE

AB AJANTA PHARMA LTD

54MG

A210138 001 Jul 23, 2018 Jul NEWA

AB 160MG

A210138 002 Jul 23, 2018 Jul NEWA

AB AMNEAL PHARMS LLC

48MG

A209951 001 Feb 09, 2018 Jan NEWA

AB 54MG

A209950 001 Mar 19, 2018 Mar NEWA

AB 145MG

A209951 002 Feb 09, 2018 Jan NEWA

AB 160MG

A209950 002 Mar 19, 2018 Mar NEWA

AB GRAVITI PHARMS

54MG

A210606 001 Aug 17, 2018 Aug NEWA

AB 160MG

A210606 002 Aug 17, 2018 Aug NEWA

AB PRINSTON INC

48MG

A211080 001 Aug 28, 2018 Aug NEWA

AB 145MG

A211080 002 Aug 28, 2018 Aug NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+ XSPIRE PHARMA

EQ 200MG BASE

N017604 003

Jun CHRS

+!

EQ 400MG BASE

N017604 004 Jul 21, 2009 Jun CHRS

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-37

+ JANSSEN PHARMS

37.5MCG/HR

N019813 006 Jan 24, 2018 Jan NEWA

FENTANYL-100

>D> AB ACTAVIS LABS UT INC

100MCG/HR

A076709 004 Aug 20, 2007 Sep DISC

>A> @ 100MCG/HR

A076709 004 Aug 20, 2007 Sep DISC

FENTANYL-25

>D> AB ACTAVIS LABS UT INC

25MCG/HR

A076709 001 Aug 20, 2007 Sep DISC

>A> @ 25MCG/HR

A076709 001 Aug 20, 2007 Sep DISC

FENTANYL-50

>D> AB ACTAVIS LABS UT INC

50MCG/HR

A076709 002 Aug 20, 2007 Sep DISC

>A> @ 50MCG/HR

A076709 002 Aug 20, 2007 Sep DISC

FENTANYL-75

>D> AB ACTAVIS LABS UT INC

75MCG/HR

A076709 003 Aug 20, 2007 Sep DISC

>A> @ 75MCG/HR

A076709 003 Aug 20, 2007 Sep DISC

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

@ PAR PHARM

EQ 0.2MG BASE

A077312 001 Oct 30, 2009 Jun DISC

@

EQ 0.4MG BASE

A077312 002 Oct 30, 2009 Jun DISC

@

EQ 0.6MG BASE

A077312 003 Oct 30, 2009 Jun DISC

@

EQ 0.8MG BASE

A077312 004 Oct 30, 2009 Jun DISC

@

EQ 1.2MG BASE

A077312 005 Oct 30, 2009 Jun DISC

@

EQ 1.6MG BASE

A077312 006 Oct 30, 2009 Jun DISC

FENTANYL HYDROCHLORIDESYSTEM; IONTOPHORESIS, TRANSDERMAL
IONSYS

+ @ THE MEDICINES CO EQ 40MCG BASE/ACTIVATION N021338 001 May 22, 2006 Jun DISC

FERRIC PYROPHOSPHATE CITRATESOLUTION; INTRAVENOUS
TRIFERIC

+! ROCKWELL MEDICAL INC 27.2MG IRON/5ML (5.44MG IRON/ML) N206317 001 Jan 23, 2015 Jul CDFR

+ @ 272MG IRON/50ML (5.44MG IRON/ML) N206317 002 Sep 04, 2015 Jul CDFR

SOLUTION; IV (INFUSION)
TRIFERIC

+ @ ROCKWELL MEDICAL INC 272MG IRON/50ML (5.44MG IRON/ML) N206317 002 Sep 04, 2015 May DISC

FEXOFENADINE HYDROCHLORIDESUSPENSION; ORAL
ALLEGRA

+ @ SANOFI AVENTIS US 30MG/5ML N021963 001 Oct 16, 2006 May DISC

FEXOFENADINE HYDROCHLORIDE

@ ACTAVIS MID ATLANTIC 30MG/5ML A201311 001 Jul 25, 2012 Aug DISC

! 30MG/5ML A201311 001 Jul 25, 2012 May CHRS

FINAFLOXACINSUSPENSION/DROPS; OTIC
XTORO

+! MERLION PHARMS GMBH 0.3% N206307 001 Dec 17, 2014 Jul CAHN

FINASTERIDETABLET; ORAL
FINASTERIDE

@ MYLAN PHARMS INC 1MG A078161 001 Nov 05, 2013 Jul DISC

FINGOLIMOD HYDROCHLORIDECAPSULE; ORAL
GILENYA

+ NOVARTIS EQ 0.25MG BASE N022527 002 May 11, 2018 May NEWA

+! EQ 0.5MG BASE N022527 001 Sep 21, 2010 May CAIN

FISH OIL TRIGLYCERIDESEMULSION; INTRAVENOUS
OMEGAVEN

+! FRESENIUS KABI USA 5GM/50ML (0.1GM/ML) N210589 001 Jul 27, 2018 Jul NEWA

+! 10GM/100ML (0.1GM/ML) N210589 002 Jul 27, 2018 Jul NEWA

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OILEMULSION; INTRAVENOUS
SMOFLIPID 20%

+! FRESENIUS KABI USA 3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (1000ML) N207648 004 Aug 10, 2018 Aug NEWA

FLOXURIDINEINJECTABLE; INJECTION
FLOXURIDINE

AP LUITPOLD 500MG/VIAL A203008 001 Nov 22, 2017 Jul CAHN

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ! INFORLIFE 200MG/100ML (2MG/ML) A079104 001 Jul 30, 2009 Jan CAHN

AP ! 400MG/200ML (2MG/ML) A079104 002 Jul 30, 2009 Jan CAHN

FLUCYTOSINECAPSULE; ORAL
FLUCYTOSINE

AB RECIPHARM 250MG A207536 001 Jun 18, 2018 Jun NEWA

AB 500MG A207536 002 Jun 18, 2018 Jun NEWA

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION
FLUDARABINE PHOSPHATE

AP	AREVA PHARMS	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	Jul CAHN
----	--------------	--------------------	---------	-----	--------------	----------

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

	+ @ FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005	May DISC
	@ MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015	May DISC
AP	! PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011	May CHRS

FLUNISOLIDE

SPRAY, METERED;NASAL
FLUNISOLIDE

	@ APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun DISC
--	--------------	---------------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL
FLUOCINOLONE ACETONIDE

	@ G AND W LABS	0.025%	A089525	001	Jul 26, 1988	Jan DISC
--	----------------	--------	---------	-----	--------------	----------

OIL/DROPS;OTIC
FLAC

AT	PATRIN PHARMA INC	0.01%	A210736	001	Apr 11, 2018	Mar NEWA
----	-------------------	-------	---------	-----	--------------	----------

SOLUTION;TOPICAL
FLUOCINOLONE ACETONIDE
@ G AND W LABS INC

0.01%	A207441	001	Sep 28, 2016	Jan DISC
-------	---------	-----	--------------	----------

FLUOCINONIDE

CREAM;TOPICAL
FLUOCINONIDE

AB1	AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018	Aug NEWA
AB		0.1%	A211111	001	Jun 04, 2018	May NEWA

FLUOCINONIDE EMULSIFIED BASE

AB2	! TARO PHARM INDS LTD	0.05%	A072494	001	Jan 19, 1989	May CAHN
-----	-----------------------	-------	---------	-----	--------------	----------

GEL;TOPICAL
FLUOCINONIDE

AB	TELIGENT PHARMA INC	0.05%	A209030	001	Jun 19, 2018	Jun NEWA
----	---------------------	-------	---------	-----	--------------	----------

OINTMENT;TOPICAL
FLUOCINONIDE

>A> AB	TELIGENT PHARMA INC	0.05%	A207680	001	Sep 28, 2018	Sep NEWA
--------	---------------------	-------	---------	-----	--------------	----------

SOLUTION;TOPICAL
FLUOCINONIDE

AT	GLASSHOUSE PHARMS	0.05%	A209118	001	Apr 23, 2018	Apr NEWA
AT	MACLEODS PHARMS LTD	0.05%	A209283	001	Apr 23, 2018	Apr NEWA
AT	ZYDUS PHARMS USA INC	0.05%	A208948	001	Jul 17, 2018	Jul NEWA

FLUORESCCEIN SODIUM

INJECTABLE;INTRAVENOUS
FLUORESCITE

AP	+! ALCON LABS INC	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Feb CAHN
----	-------------------	--------------------------------------	---------	-----	--------------	----------

FLUOROURACIL

CREAM;TOPICAL
FLUOROURACIL

AB	MAYNE PHARMA	5%	A077524	001	Apr 11, 2008	Jul CAHN
----	--------------	----	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL
FLUOXETINE HYDROCHLORIDE

AB1	MARKSANS PHARMA	EQ 10MG BASE	A075465	001	Jan 29, 2002	Jul CAHN
AB1		EQ 20MG BASE	A075465	002	Jan 29, 2002	Jul CAHN
AB		EQ 40MG BASE	A075465	003	Aug 02, 2001	Jul CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	EQ 10MG BASE	A076006	001	Jan 30, 2002	Apr CAHN
AB		EQ 20MG BASE	A076006	002	Apr 23, 2018	Apr NEWA
AB		EQ 20MG BASE	A076006	002	Apr 23, 2018	Apr CAHN
	@ FOSUN PHARMA	EQ 10MG BASE	A076024	001	Jan 29, 2002	Jan CAHN

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
FLUPHENAZINE DECANOATE

AO MYLAN LABS LTD 25MG/ML A075918 001 Aug 17, 2001 Jun CMFD

FLURANDRENOLIDE

TAPE; TOPICAL
CORDRAN

>D> +! ALLERGAN SALES LLC 0.004MG/SQ CM N016455 001 Sep CAHN
>A> +! AQUA PHARMS LLC 0.004MG/SQ CM N016455 001 Sep CAHN

FLUTAMIDE

CAPSULE; ORAL
FLUTAMIDE

@ YAOPHARMA CO LTD 125MG A075818 001 Sep 18, 2001 Jan CAHN

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS
VIZAMYL

+ @ GE HEALTHCARE 40.5mCi/10ML (4.05mCi/ML) N203137 001 Oct 25, 2013 Jun DISC

FLUTICASONE FUROATE

POWDER; INHALATION
ARNUITY ELLIPTA

+! GLAXOSMITHKLINE 0.05MG/INH N205625 003 May 17, 2018 May NEWA

FLUTICASONE PROPIONATE

CREAM; TOPICAL

FLUTICASONE PROPIONATE

>A> AB ANDA REPOSITORY 0.05% A076633 001 May 14, 2004 Sep CAHN
>D> AB TOLMAR 0.05% A076633 001 May 14, 2004 Sep CAHN

OINTMENT; TOPICAL

CUTIVATE

>D> AB +! FOUGERA PHARMS 0.005% N019957 001 Dec 14, 1990 Sep DISC
>A> + @ 0.005% N019957 001 Dec 14, 1990 Sep DISC

FLUTICASONE PROPIONATE

>D> AB FOUGERA PHARMS 0.005% A076300 001 May 14, 2004 Sep DISC
>A> @ 0.005% A076300 001 May 14, 2004 Sep DISC
>D> AB PERRIGO NEW YORK 0.005% A076668 001 May 14, 2004 Sep CHRS
>A> AB ! 0.005% A076668 001 May 14, 2004 Sep CHRS

SPRAY, METERED; NASAL
FLONASE

+ @ GLAXOSMITHKLINE 0.05MG/SPRAY N020121 001 Oct 19, 1994 Jul CAHN

XHANCE

+! OPTINOSE US INC 0.093MG N209022 001 Sep 18, 2017 Jan CMS1

FOLIC ACID

TABLET; ORAL

FOLIC ACID

>D> AA AIPING PHARM INC 1MG A091145 001 Jul 12, 2013 Sep CAHN
>A> AA ANBISON LAB 1MG A091145 001 Jul 12, 2013 Sep CAHN
AA CHARTWELL MOLECULAR 1MG A090035 001 Jun 09, 2009 Jun CAHN

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

FONDAPARINUX SODIUM

AP JIANGSU HENGRUI MED 2.5MG/0.5ML A206812 001 May 15, 2018 Apr NEWA
AP 5MG/0.4ML A206812 002 May 15, 2018 Apr NEWA
AP 7.5MG/0.6ML A206812 003 May 15, 2018 Apr NEWA
AP 10MG/0.8ML A206812 004 May 15, 2018 Apr NEWA

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL
MONUROL

+! ZAMBON SPA EQ 3GM BASE/PACKET N050717 001 Dec 19, 1996 Aug CDFR

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010	Jan CAHN
AB	!	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan CAHN

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER; INTRAVENOUS

AKYNZEO

+	!	HEL SINN HLTHCARE	EQ 235MG BASE;EQ 0.25MG BASE	N210493	001	Apr 19, 2018	Apr NEWA
---	---	-------------------	------------------------------	---------	-----	--------------	----------

FOSTAMATINIB DISODIUM

TABLET; ORAL

TAVALLISSE

+		RIGEL PHARMS INC	EQ 100MG BASE	N209299	001	Apr 17, 2018	Apr NEWA
+	!		EQ 150MG BASE	N209299	002	Apr 17, 2018	Apr NEWA

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB		ACI HEALTHCARE LTD	100MG	A206943	001	May 14, 2018	Apr NEWA
AB			300MG	A206943	002	May 14, 2018	Apr NEWA
AB			400MG	A206943	003	May 14, 2018	Apr NEWA

TABLET; ORAL

GABAPENTIN

AB		LUPIN LTD	600MG	A209306	001	Aug 24, 2018	Aug NEWA
AB			800MG	A209306	002	Aug 24, 2018	Aug NEWA

GRALISE

BX	+	!	ASSERTIO	300MG	N022544	001	Jan 28, 2011	Aug CAHN
BX	+	!		600MG	N022544	002	Jan 28, 2011	Aug CAHN

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+	@	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Aug DISC
+	@		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Aug DISC
+	@		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Aug DISC
+	@		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Aug DISC
+	@		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Aug DISC
		OPTIMARK IN PLASTIC CONTAINER					
+	@	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Aug DISC
+	@		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Aug DISC
+	@		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Aug DISC
+	@		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Aug DISC

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

@	MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jun DISC
@		EQ 16MG BASE	A090900	002	Jan 24, 2011	Jun DISC
@		EQ 24MG BASE	A090900	003	Jan 24, 2011	Jun DISC

GANCICLOVIR

>A> SOLUTION; INTRAVENOUS

>A> GANCICLOVIR

>A>	+	!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Sep CDFR
-----	---	---	----------------------	----------------------	---------	-----	--------------	----------

>D> SOLUTION; IV (INFUSION)

>D> GANCICLOVIR

>D>	+	!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Sep CDFR
-----	---	---	----------------------	----------------------	---------	-----	--------------	----------

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

AT		MICRO LABS	0.5%	A206446	001	Jun 08, 2018	May NEWA
AT		MYLAN PHARMS INC	0.5%	A206446	001	Jun 08, 2018	Aug CAHN

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP	SAGENT PHARMS	200MG/5.26ML (38MG/ML)	A209077	001	Jul 20, 2018	Jul NEWA
AP		1GM/26.3ML (38MG/ML)	A209077	002	Jul 20, 2018	Jul NEWA
AP		2GM/52.6ML (38MG/ML)	A209077	003	Jul 20, 2018	Jul NEWA

>A> SOLUTION; INTRAVENOUS

>A> GEMCITABINE HYDROCHLORIDE

>A>	+	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017	Sep CDFR
>A>	+		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017	Sep CDFR
>A>	+		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017	Sep CDFR
>A>	+		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017	Sep CDFR

INFUGEM

+	SUN PHARM INDS INC	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018	Jul NEWA
+		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018	Jul NEWA
+		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018	Jul NEWA
+		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018	Jul NEWA
+		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018	Jul NEWA
+		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018	Jul NEWA
+		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018	Jul NEWA
+		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018	Jul NEWA
+		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018	Jul NEWA
+		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018	Jul NEWA
+	SUN PHARM INDS LTD	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018	Aug CAHN
+		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018	Aug CAHN
+		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018	Aug CAHN
+		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018	Aug CAHN
+		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018	Aug CAHN
+		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018	Aug CAHN
+		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018	Aug CAHN
+		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018	Aug CAHN
+		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018	Aug CAHN
+		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018	Aug CAHN

>D> SOLUTION; IV (INFUSION)

>D> GEMCITABINE HYDROCHLORIDE

>D>	+	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017	Sep CDFR
>D>	+		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017	Sep CDFR
>D>	+		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017	Sep CDFR
>D>	+		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017	Sep CDFR

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

	@ YAOPHARMA CO LTD	600MG	A074615	001	Sep 29, 1995	Jan CAHN
AB	ZYDUS PHARMS USA INC	600MG	A204189	001	Aug 28, 2018	Aug NEWA

GENTAMICIN SULFATE

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT	G AND W LABS INC	EQ 0.1% BASE	A064054	001	Apr 29, 1994	Jan CMFD
----	------------------	--------------	---------	-----	--------------	----------

GLATIRAMER ACETATEINJECTABLE;SUBCUTANEOUS
GLATOPIA

AP	SANDOZ INC	40MG/ML	A206921	001	Feb 12, 2018	Jan NEWA
----	------------	---------	---------	-----	--------------	----------

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

@	TEVA PHARMS USA	1MG;4MG
@		2MG;4MG
@		2MG;8MG
@		4MG;4MG
@		4MG;8MG

A078709	001	Apr 01, 2016	Jul DISC
A078709	002	Apr 01, 2016	Jul DISC
A078709	004	Apr 01, 2016	Jul DISC
A078709	003	Apr 01, 2016	Jul DISC
A078709	005	Apr 01, 2016	Jul DISC

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

@	OXFORD PHARMS	5MG
@		10MG

A074378	001	Nov 28, 1994	Jul CAHN
A074378	002	Nov 28, 1994	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB	ZYDUS PHARMS USA INC	2.5MG
AB		5MG
AB		10MG

A203499	001	Jul 16, 2018	Jul NEWA
A203499	002	Jul 16, 2018	Jul NEWA
A203499	003	Jul 16, 2018	Jul NEWA

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

+! LILLY 1MG/VIAL

N020928	001	Sep 11, 1998	Apr CAIN
---------	-----	--------------	----------

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION

GLUCAGEN

+! NOVO NORDISK EQ 1MG BASE/VIAL

N020918	001	Jun 22, 1998	Apr CAIN
---------	-----	--------------	----------

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

@	YAOPHARMA CO LTD	1.5MG
@		3MG

A075174	001	Jun 22, 1998	Jan CAHN
A075174	002	Jun 22, 1998	Jan CAHN

GLYCINE

SOLUTION;IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT	+! BAXTER HLTHCARE	1.5GM/100ML
----	--------------------	-------------

N017865	001		Mar CRLD
---------	-----	--	----------

GLYCOPYRROLATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

EXELA PHARMA SCS LLC	0.2MG/ML (0.2MG/ML)
	0.4MG/2ML (0.2MG/ML)

N210997	001	Jul 11, 2018	Jul NEWA
N210997	002	Jul 11, 2018	Jul NEWA

TABLET;ORAL

GLYCOPYRROLATE

>A> AA	ANDA REPOSITORY	1MG
--------	-----------------	-----

A040821	001	Dec 29, 2008	Sep CAHN
---------	-----	--------------	----------

>A> AA		2MG
--------	--	-----

A040821	002	Dec 29, 2008	Sep CAHN
---------	-----	--------------	----------

AA	OXFORD PHARMS	1MG
----	---------------	-----

A090020	001	Oct 19, 2011	Jul CAHN
---------	-----	--------------	----------

AA		2MG
----	--	-----

A090020	002	Oct 19, 2011	Jul CAHN
---------	-----	--------------	----------

AA	! PAR PHARM	1MG
----	-------------	-----

A040653	001	Aug 31, 2006	May CHRS
---------	-----	--------------	----------

AA	!	2MG
----	---	-----

A040653	002	Aug 31, 2006	May CHRS
---------	-----	--------------	----------

@	RENATA	1MG
---	--------	-----

A040568	001	Dec 22, 2004	Apr CAHN
---------	-----	--------------	----------

@		2MG
---	--	-----

A040568	002	Dec 22, 2004	Apr CAHN
---------	-----	--------------	----------

>D> AA	RISING PHARMS	1MG
--------	---------------	-----

A040821	001	Dec 29, 2008	Sep CAHN
---------	-----	--------------	----------

>D> AA		2MG
--------	--	-----

A040821	002	Dec 29, 2008	Sep CAHN
---------	-----	--------------	----------

ROBINUL

+	@ CASPER PHARMA LLC	1MG
---	---------------------	-----

N012827	001		May DISC
---------	-----	--	----------

ROBINUL FORTE

+	@ CASPER PHARMA LLC	2MG
---	---------------------	-----

N012827	002		May DISC
---------	-----	--	----------

GLYCOPYRRONIUM TOSYLATECLOTH; TOPICAL
QBREXZA

+! DERMIRA INC EQ 2.4% BASE N210361 001 Jun 28, 2018 Jun NEWA

GRANISETRON HYDROCHLORIDEINJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

>D> AP BIONPHARMA INC EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078863 001 Jun 30, 2008 Sep CAHN

>D> AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078880 001 Jun 30, 2008 Sep CAHN

>A> AP BLUEPHARMA EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) A078863 001 Jun 30, 2008 Sep CAHN

>A> AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML) A078880 001 Jun 30, 2008 Sep CAHN

@ TEVA PHARMS USA EQ 1MG BASE/ML (EQ 1MG BASE/ML) A077963 001 Jan 03, 2008 Feb DISC

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

>D> AP BIONPHARMA INC EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078863 002 Jun 30, 2008 Sep CAHN

>A> AP BLUEPHARMA EQ 1MG BASE/ML (EQ 1MG BASE/ML) A078863 002 Jun 30, 2008 Sep CAHN

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB CHARTWELL MOLECULAR EQ 1MG BASE A078037 001 Feb 27, 2008 Mar CAHN

GRISEOFULVIN, ULTRAMICROSIZED

TABLET; ORAL

GRISEOFULVIN, ULTRAMICROSIZED

AB MOUNTAIN 125MG A204371 001 Jan 09, 2014 Jan CAHN

AB 250MG A204371 002 Jan 09, 2014 Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

FLOWTUSS

@ BKK PHARMS 200MG/5ML; 2.5MG/5ML N022424 001 May 14, 2015 Aug DISC

200MG/5ML; 2.5MG/5ML N022424 001 May 14, 2015 May CAHN

OBREDON

>D> + @ SOVEREIGN PHARMS 200MG/5ML; 2.5MG/5ML N205474 001 Nov 14, 2014 Sep CMFD

>A> +! 200MG/5ML; 2.5MG/5ML N205474 001 Nov 14, 2014 Sep CMFD

TABLET; ORAL

HYDROCODONE BITARTRATE AND GUAIFENESIN

+! ECI PHARMS LLC 400MG; 5MG N208085 001 Apr 25, 2018 Apr NEWA

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+ @ BKK PHARMS 200MG/5ML; 2.5MG/5ML; 30MG/5ML N022279 001 May 14, 2015 Aug DISC

+! 200MG/5ML; 2.5MG/5ML; 30MG/5ML N022279 001 May 14, 2015 May CAHN

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

@ YAOPHARMA CO LTD EQ 4MG BASE A074517 001 Sep 30, 1998 Jan CAHN

@ EQ 8MG BASE A074517 002 Sep 30, 1998 Jan CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB ! MYLAN EQ 1MG BASE A074796 001 Jan 27, 1997 Jun CHRS

AB ! EQ 2MG BASE A074796 002 Jan 27, 1997 Jun CHRS

TENEX

+ @ PROMIUS PHARMA EQ 1MG BASE N019032 001 Oct 27, 1986 Jun DISC

+ @ EQ 2MG BASE N019032 002 Nov 07, 1988 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB APOTEX INC EQ 1MG BASE A205430 001 Jul 25, 2018 Jul NEWA

AB EQ 2MG BASE A205430 002 Jul 25, 2018 Jul NEWA

AB EQ 3MG BASE A205430 003 Jul 25, 2018 Jul NEWA

AB EQ 4MG BASE A205430 004 Jul 25, 2018 Jul NEWA

HALCINONIDECREAM;TOPICAL
HALOG

+! SUN PHARM INDS INC 0.1% N017556 001 Feb CAHN

HALOBETASOL PROPIONATEAEROSOL, FOAM;TOPICAL
HALOBETASOL PROPIONATE

+! THERAPS INC 0.05% N210566 001 May 24, 2018 May NEWA

CREAM;TOPICAL
ULTRAVATE

AB + SUN PHARM INDS INC 0.05% N019967 001 Dec 27, 1990 Feb CAHN

OINTMENT;TOPICAL
HALOBETASOL PROPIONATE

AB TELIGENT PHARMA INC 0.05% A209978 001 Mar 20, 2018 Mar NEWA

ULTRAVATE

AB + SUN PHARM INDS INC 0.05% N019968 001 Dec 17, 1990 Feb CAHN

HALOPERIDOL DECANOATEINJECTABLE;INJECTION
HALOPERIDOL DECANOATE

AO SOMERSET THERAPS LLC EQ 50MG BASE/ML A209101 001 Jul 03, 2018 Jun NEWA

AO EQ 100MG BASE/ML A209101 002 Jul 03, 2018 Jun NEWA

HALOPERIDOL LACTATEINJECTABLE;INJECTION
HALOPERIDOL

@ FOSUN PHARMA EQ 5MG BASE/ML A076464 001 Sep 29, 2004 Jan CAHN

HEPARIN SODIUMINJECTABLE;INJECTION
HEPARIN SODIUM

AP CASI PHARMS INC 5,000 UNITS/ML A091659 001 Jun 08, 2011 Mar CAHN

+ @ WEST-WARD PHARMS INT 1,000 UNITS/ML N017007 001 Aug CRLD

+ @ 2,500 UNITS/ML N017007 007 Aug CRLD

+ @ 5,000 UNITS/ML N017007 002 Aug CRLD

+ @ 5,000 UNITS/0.5ML N017007 010 Aug CRLD

+ @ 7,500 UNITS/ML N017007 003 Aug CRLD

+ @ 10,000 UNITS/ML N017007 004 Aug CRLD

+ @ 15,000 UNITS/ML N017007 005 Aug CRLD

+ @ 20,000 UNITS/ML N017007 006 Aug CRLD

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AP HOSPIRA 200 UNITS/100ML N018916 010 Jun 23, 1989 Sep CRLD

>A> AP +! 200 UNITS/100ML N018916 010 Jun 23, 1989 Sep CHRS

>A> AP + 200 UNITS/100ML N018916 010 Jun 23, 1989 Sep CRLD

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AP HOSPIRA 200 UNITS/100ML N018916 011 Jun 23, 1989 Sep CRLD

>A> AP +! 200 UNITS/100ML N018916 011 Jun 23, 1989 Sep CHRS

>A> AP + 200 UNITS/100ML N018916 011 Jun 23, 1989 Sep CRLD

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYCODAN

+ @ GENUS LIFESCIENCES 1.5MG/5ML;5MG/5ML N005213 002 Jul 26, 1988 Aug CAHN

TABLET;ORAL

HYCODAN

+ @ GENUS LIFESCIENCES 1.5MG;5MG N005213 001 Jul 26, 1988 Aug CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA APPCO PHARMA LLC 10MG A209251 001 Jul 09, 2018 Jun NEWA

AA 25MG A209251 002 Jul 09, 2018 Jun NEWA

AA 50MG A209251 003 Jul 09, 2018 Jun NEWA

AA 100MG A209251 004 Jul 09, 2018 Jun NEWA

AA SCIEGEN PHARMS INC 10MG A205236 001 May 26, 2017 Feb CAHN

AA 25MG A205236 002 May 26, 2017 Feb CAHN

AA 50MG A205236 003 May 26, 2017 Feb CAHN

AA 100MG A205236 004 May 26, 2017 Feb CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL						
HYDROCHLOROTHIAZIDE						
	@ APOTEX	12.5MG	A078389	001	May 16, 2008	Mar DISC
TABLET; ORAL						
HYDROCHLOROTHIAZIDE						
	@ APOTEX	25MG	A040774	001	Oct 03, 2007	Mar DISC
	@	50MG	A040774	002	Oct 03, 2007	Mar DISC
	@ DAVA PHARMS INC	100MG	A087060	001		Jul CAHN
AB	OXFORD PHARMS	25MG	A087059	001		Jul CAHN
AB		50MG	A087068	001		Jul CAHN
AB	SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014	Jan CAHN
AB		50MG	A203018	002	Jul 23, 2014	Jan CAHN
	@ YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982	Jan CAHN
	@	50MG	A084912	001		Jan CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL						
IRBESARTAN AND HYDROCHLOROTHIAZIDE						
	@ ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016	Aug DISC
	@	12.5MG;300MG	A203036	002	Jan 15, 2016	Aug DISC
	@	25MG;300MG	A203036	003	Jan 15, 2016	Aug DISC
AB	HISUN PHARM HANGZHOU	12.5MG;150MG	A207896	001	Oct 14, 2016	Aug CAHN
AB		12.5MG;300MG	A207896	002	Oct 14, 2016	Aug CAHN
	@ MYLAN PHARMS INC	12.5MG;150MG	A077969	001	Sep 27, 2012	Jun DISC
	@	12.5MG;300MG	A077969	002	Sep 27, 2012	Jun DISC
	@	25MG;300MG	A077969	003	Jul 20, 2016	Jun DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL						
LISINAPRIL AND HYDROCHLOROTHIAZIDE						
	@ APOTEX INC	12.5MG;10MG	A076674	001	Oct 05, 2004	Apr DISC
	@	12.5MG;20MG	A076674	002	Oct 05, 2004	Apr DISC
	@	25MG;20MG	A076674	003	Oct 05, 2004	Apr DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL						
HYZAAR						
	+ @ MERCK SHARP DOHME	12.5MG;50MG	N020387	001	Apr 28, 1995	Apr DISC
	+ @	25MG;100MG	N020387	002	Nov 10, 1998	Apr DISC
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE						
	@ APOTEX	12.5MG;50MG	A090150	001	Oct 06, 2010	Mar DISC
	@	12.5MG;100MG	A090150	002	Aug 11, 2010	Mar DISC
	@	25MG;100MG	A090150	003	Oct 06, 2010	Mar DISC
AB	! AUROBINDO PHARMA	25MG;100MG	A091629	003	Jan 06, 2010	Apr CHRS

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL						
METHYLDOPA AND HYDROCHLOROTHIAZIDE						
	@ YAOPHARMA CO LTD	15MG;250MG	A070182	001	Jan 15, 1986	Jan CAHN
	@	25MG;250MG	A070183	001	Jan 15, 1986	Jan CAHN
	@	30MG;500MG	A070543	001	Jan 15, 1986	Jan CAHN
	@	50MG;500MG	A070544	001	Jan 15, 1986	Jan CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL						
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
	@ YAOPHARMA CO LTD	25MG;40MG	A071060	001	Aug 26, 1987	Jan CAHN
	@	25MG;80MG	A071061	001	Aug 26, 1987	Jan CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL						
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE						
	@ YAOPHARMA CO LTD	25MG;25MG	A086881	001		Jan CAHN

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL						
TRIAMTERENE AND HYDROCHLOROTHIAZIDE						
AB	! CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Mar CAHN

TABLET; ORAL							
TRIAMTERENE AND HYDROCHLOROTHIAZIDE							
AB	ZYDUS PHARMS USA INC	25MG; 37.5MG	A208360	001	Jun 29, 2018	Jun	NEWA
AB		50MG; 75MG	A208360	002	Jun 29, 2018	Jun	NEWA
<u>HYDROCHLOROTHIAZIDE; VALSARTAN</u>							
TABLET; ORAL							
VALSARTAN AND HYDROCHLOROTHIAZIDE							
	@ APOTEX INC	12.5MG; 80MG	A203026	001	Mar 21, 2013	Mar	DISC
	@	12.5MG; 160MG	A203026	002	Mar 21, 2013	Mar	DISC
	@	12.5MG; 320MG	A203026	003	Mar 21, 2013	Mar	DISC
	@	25MG; 160MG	A203026	004	Mar 21, 2013	Mar	DISC
	@	25MG; 320MG	A203026	005	Mar 21, 2013	Mar	DISC
	@ WATSON LABS TEVA	12.5MG; 80MG	A091519	001	Mar 21, 2013	Aug	DISC
	@	12.5MG; 160MG	A091519	002	Mar 21, 2013	Aug	DISC
	@	12.5MG; 320MG	A091519	003	Mar 21, 2013	Aug	DISC
	@	25MG; 160MG	A091519	004	Mar 21, 2013	Aug	DISC
	@	25MG; 320MG	A091519	005	Mar 21, 2013	Aug	DISC
<u>HYDROCORTISONE</u>							
CREAM; TOPICAL							
HYDROCORTISONE							
AT	LANNETT CO INC	2.5%	A040503	001	Mar 12, 2004	May	CAHN
	@ TARO PHARM INDS LTD	1%	A086155	001		May	CAHN
AT		2.5%	A088799	001	Nov 09, 1984	May	CAHN
AT		2.5%	A088799	001	Nov 09, 1984	May	CAHN
AT	TELIGENT PHARMA INC	2.5%	A203810	001	Jul 23, 2018	Jul	NEWA
LOTION; TOPICAL							
HYDROCORTISONE							
AT	LANNETT CO INC	2.5%	A040417	001	Jul 30, 2003	May	CAHN
AT	TELIGENT PHARMA INC	2.5%	A203804	001	Jul 27, 2018	Jul	NEWA
<u>HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE</u>							
AEROSOL, METERED; TOPICAL							
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%							
	@ GENUS LIFESCIENCES	1%; 1%	A089440	001	May 17, 1988	Aug	CAHN
<u>HYDROCORTISONE BUTYRATE</u>							
LOTION; TOPICAL							
HYDROCORTISONE BUTYRATE							
AB	LUPIN LTD	0.1%	A210209	001	Aug 17, 2018	Aug	NEWA
<u>HYDROCORTISONE VALERATE</u>							
CREAM; TOPICAL							
WESTCORT							
	+ @ SUN PHARM INDS INC	0.2%	N017950	001		Mar	CAHN
OINTMENT; TOPICAL							
WESTCORT							
	+ @ SUN PHARM INDS INC	0.2%	N018726	001	Aug 08, 1983	Feb	CAHN
<u>HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>							
SOLUTION/DROPS; OTIC							
CORTISPORIN							
	+ @ MONARCH PHARMS	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N050479	001		Aug	DISC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE							
	@ AMRING PHARMS	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A065216	001	Oct 31, 2005	Aug	DISC
AT	! BAUSCH AND LOMB	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A064053	001	Dec 29, 1995	Aug	CHRS
<u>HYDROMORPHONE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
DILAUDID							
	+ @ FRESENIUS KABI USA	4MG/ML	N019034	005	Apr 30, 2009	Aug	DISC
DILAUDID-HP							
	+ @ FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Aug	DISC
HYDROMORPHONE HYDROCHLORIDE							
AP	EUROHLTH INTL SARL	2MG/ML	A202159	001	Apr 27, 2018	Apr	NEWA
TABLET; ORAL							
HYDROMORPHONE HYDROCHLORIDE							
AB	ASCENT PHARMS INC	2MG	A210506	001	Jan 17, 2018	Jan	NEWA

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		4MG	A210506	002	Jan 17, 2018	Jan NEWA
AB		8MG	A210506	003	Jan 17, 2018	Jan NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB	ALKALOIDA ZRT	200MG	A201691	001	May 08, 2018	Apr NEWA
AB	AMNEAL PHARMS CO	200MG	A210577	001	May 15, 2018	Apr NEWA
>D> AB	APPCO PHARMA LLC	200MG	A210441	001	May 01, 2018	Sep CAHN
AB		200MG	A210441	001	May 01, 2018	Apr NEWA
AB	LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Jun NEWA
>A> AB	TWI PHARMS	200MG	A210441	001	May 01, 2018	Sep CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

AP	LUITPOLD	250MG/ML (250MG/ML)	A210723	001	Jun 21, 2018	Jun NEWA
	MAKENA PRESERVATIVE FREE					
AP	+! AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Jun CFTG
	SOLUTION;SUBCUTANEOUS					
	MAKENA (AUTOINJECTOR)					
	+! AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Feb NEWA

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDROXYZINE HYDROCHLORIDE

@	FRESENIUS KABI USA	25MG/ML	A087329	001		Aug DISC
@		50MG/ML	A087329	002		Aug DISC
!	LUITPOLD	25MG/ML	A087408	001		Aug CHRS
		25MG/ML	A087408	001		Aug CTEC
!		50MG/ML	A087408	002		Aug CHRS
		50MG/ML	A087408	002		Aug CTEC

TABLET;ORAL

ATARAX

+	@ PFIZER	10MG	N010392	001		Feb CRLD
+	@	25MG	N010392	004		Feb CRLD
+	@	50MG	N010392	006		Feb CRLD
+	@	100MG	N010392	005		Feb CRLD

IBRUTINIB

TABLET;ORAL

IMBRUVICA

+	PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018	Feb NEWA
+		280MG	N210563	002	Feb 16, 2018	Feb NEWA
+		420MG	N210563	003	Feb 16, 2018	Feb NEWA
+	!	560MG	N210563	004	Feb 16, 2018	Feb NEWA

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	Feb NEWA
----------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

>D> AB	AIPING PHARM INC	400MG	A202413	001	Nov 23, 2016	Sep CAHN
>D> AB		600MG	A202413	002	Nov 23, 2016	Sep CAHN
>D> AB		800MG	A202413	003	Nov 23, 2016	Sep CAHN
AB	HEC PHARM	400MG	A204062	001	Sep 10, 2018	Aug NEWA
AB		600MG	A204062	002	Sep 10, 2018	Aug NEWA
AB		800MG	A204062	003	Sep 10, 2018	Aug NEWA
>A> AB	SHANDONG XINHUA	400MG	A202413	001	Nov 23, 2016	Sep CAHN
>A> AB		600MG	A202413	002	Nov 23, 2016	Sep CAHN
>A> AB		800MG	A202413	003	Nov 23, 2016	Sep CAHN

IBUPROFEN LYSINE

INJECTABLE;INTRAVENOUS

IBUPROFEN LYSINE

>D> AP	EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Sep CAHN
>A> AP	X-GEN PHARMS INC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Sep CAHN

IBUTILIDE FUMARATE

INJECTABLE;INJECTION
IBUTILIDE FUMARATE

@ MYLAN INSTITUTIONAL 0.1MG/ML A090924 001 Jan 11, 2010 Jan DISC

IFOSFAMIDE

INJECTABLE;INJECTION
IFOSFAMIDE

>D> AP FRESENIUS KABI USA 1GM/20ML (50MG/ML) A090181 001 Sep 22, 2009 Sep DISC
>A> @ 1GM/20ML (50MG/ML) A090181 001 Sep 22, 2009 Sep DISC
>D> AP 3GM/60ML (50MG/ML) A090181 002 Sep 22, 2009 Sep DISC
>A> @ 3GM/60ML (50MG/ML) A090181 002 Sep 22, 2009 Sep DISC

IMATINIB MESYLATE

TABLET;ORAL
IMATINIB MESYLATE

AB DR REDDYS LABS LTD EQ 100MG BASE A206547 001 Aug 13, 2018 Jul NEWA
AB EQ 400MG BASE A206547 002 Aug 13, 2018 Jul NEWA
AB WEST-WARD PHARMS INT EQ 100MG BASE A207586 001 Jul 13, 2018 Jul NEWA
AB EQ 400MG BASE A207586 002 Jul 13, 2018 Jul NEWA

IMIQUIMOD

CREAM;TOPICAL
IMIQUIMOD

>A> AB ANDA REPOSITORY 5% A091044 001 Feb 28, 2011 Sep CAHN
@ G AND W LABS INC 5% A200481 001 Apr 18, 2011 Jan DISC
@ STRIDES PHARMA 5% A202002 001 Jun 24, 2014 Jun DISC
>D> AB TOLMAR 5% A091044 001 Feb 28, 2011 Sep CAHN

INDAPAMIDE

TABLET;ORAL
INDAPAMIDE

@ YAOPHARMA CO LTD 1.25MG A074594 001 May 23, 1996 Jan CAHN
@ 2.5MG A074594 002 May 23, 1996 Jan CAHN

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

>A> @ BWXT ITG 1mCi/ML A202586 001 Jul 25, 2018 Sep CAHN
>D> AP +! GE HEALTHCARE 1mCi/ML N019044 001 Dec 24, 1985 Sep CTEC
>A> +! 1mCi/ML N019044 001 Dec 24, 1985 Sep CTEC
AP +! 1mCi/ML N019044 001 Dec 24, 1985 Jul CFTG
>D> AP NORDION INC 1mCi/ML A202586 001 Jul 25, 2018 Sep DISC
>A> @ 1mCi/ML A202586 001 Jul 25, 2018 Sep DISC
AP 1mCi/ML A202586 001 Jul 25, 2018 Jul NEWA

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS
NOVOLOG FLEXTOUCH

+ @ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N020986 005 Oct 31, 2013 Jun DISC

INSULIN GLARGINE RECOMBINANT

SOLUTION;SUBCUTANEOUS
TOUJEO MAX SOLOSTAR

+! SANOFI US SERVICES 900 UNITS/3ML (300 UNITS/ML) N206538 002 Mar 26, 2018 Mar NEWA
TOUJEO SOLOSTAR
+! SANOFI US SERVICES 450 UNITS/1.5ML (300 UNITS/ML) N206538 001 Feb 25, 2015 Mar CPOT

INSULIN GLULISINE RECOMBINANT

INJECTABLE;IV (INFUSION), SUBCUTANEOUS
APIDRA

>D> +! SANOFI AVENTIS US 300 UNITS/3ML (100 UNITS/ML) N021629 002 Dec 20, 2005 Sep DISC
>A> + @ 300 UNITS/3ML (100 UNITS/ML) N021629 002 Dec 20, 2005 Sep DISC

IOBENGUANE I-131

SOLUTION;INTRAVENOUS
AZEDRA

+! PROGENICS PHARMS INC 15mCi/ML N209607 001 Jul 30, 2018 Jul NEWA

IOHEXOL

SOLUTION; INJECTION, ORAL, RECTAL
OMNIPAQUE 240

@ GE HEALTHCARE 51.8%

N020608 001 Oct 24, 1995 May DISC

SOLUTION; ORAL
OMNIPAQUE 12

+! GE HEALTHCARE 2.6%

N018956 009 Apr 17, 2018 Jun NEWA

OMNIPAQUE 9

+! GE HEALTHCARE 1.9%

N018956 008 Apr 17, 2018 Jun NEWA

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION
CONRAY 30

+ @ LIEBEL-FLARSHEIM 30%

N016983 001 Aug DISC

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

AB ! WEST-WARD PHARMS INT 0.021MG/SPRAY

A076664 001 Nov 05, 2003 Jan CHRS

AB ! 0.042MG/SPRAY

A076598 001 Nov 05, 2003 Jan CHRS

IRBESARTAN

TABLET; ORAL
IRBESARTAN

AB AMNEAL PHARMS 75MG

A204740 001 Apr 17, 2018 Apr NEWA

AB 150MG

A204740 002 Apr 17, 2018 Apr NEWA

AB 300MG

A204740 003 Apr 17, 2018 Apr NEWA

@ APOTEX INC 75MG

A200832 001 Oct 15, 2012 Mar DISC

@ 150MG

A200832 002 Oct 15, 2012 Mar DISC

@ 300MG

A200832 003 Oct 15, 2012 Mar DISC

AB CHARTWELL MOLECULAR 75MG

A077205 001 Nov 14, 2012 Apr CAHN

AB 150MG

A077205 002 Nov 14, 2012 Apr CAHN

AB 300MG

A077205 003 Nov 14, 2012 Apr CAHN

AB HISUN PHARM HANGZHOU 75MG

A206194 001 Jun 14, 2016 Aug CAHN

AB 150MG

A206194 002 Jun 14, 2016 Aug CAHN

AB 300MG

A206194 003 Jun 14, 2016 Aug CAHN

AB NEOPHARMA 75MG

A203161 001 Sep 27, 2012 Aug CAHN

AB 150MG

A203161 002 Sep 27, 2012 Aug CAHN

AB 300MG

A203161 003 Sep 27, 2012 Aug CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

AP NEOPHARMA 40MG/2ML (20MG/ML)

A078953 001 Apr 15, 2010 Aug CAHN

AP 100MG/5ML (20MG/ML)

A078953 002 Apr 15, 2010 Aug CAHN

>A> INJECTABLE, LIPOSOMAL; INTRAVENOUS

>A> ONIVYDE

>A> +! IPSEN INC EQ 43MG BASE/10ML (EQ 4.3MG
BASE/ML)

N207793 001 Oct 22, 2015 Sep CDJR

>D> INJECTABLE, LIPOSOMAL; IV (INFUSION)

>D> ONIVYDE

>D> +! IPSEN INC EQ 43MG BASE/10ML (EQ 4.3MG
BASE/ML)

N207793 001 Oct 22, 2015 Sep CDJR

ISAVUCONAZONIUM SULFATE

>A> POWDER; INTRAVENOUS

>A> CRESEMBA

>A> +! ASTELLAS 372MG

N207501 001 Mar 06, 2015 Sep CDJR

>D> POWDER; IV (INFUSION)

>D> CRESEMBA

>D> +! ASTELLAS 372MG

N207501 001 Mar 06, 2015 Sep CDJR

ISOFLURANE

LIQUID; INHALATION
ISOFLURANE

>D> AN HOSPIRA 99.9%

A074097 001 Jan 25, 1993 Sep DISC

>A> @ 99.9%

A074097 001 Jan 25, 1993 Sep DISC

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION					
ISOPROTERENOL HYDROCHLORIDE					
AP	AMPHASTAR PHARMS INC	0.2MG/ML	A210106	001	Jun 18, 2018 Jun NEWA
ISOPROTERENOL HYDROCHLORIDE					
AP	CIPLA LTD	0.2MG/ML	A210322	001	Jun 12, 2018 May NEWA

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL					
ISOSORBIDE MONONITRATE					
	@ ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017 Apr DISC
	@	60MG	A209684	002	Oct 24, 2017 Apr DISC
	@	120MG	A209684	003	Oct 24, 2017 Apr DISC
AB	DEXCEL LTD	120MG	A210822	001	Aug 29, 2018 Aug NEWA

ITRACONAZOLE

CAPSULE; ORAL					
ITRACONAZOLE					
AB	TORRENT PHARMS LTD	100MG	A209460	001	Aug 24, 2018 Aug NEWA
SOLUTION; ORAL					
ITRACONAZOLE					
AA	AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015 Aug CMFD
SPORANOX					
AA	+! JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997 Aug CTEC

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET, TABLET; ORAL					
SYMDEKO (COPACKAGED)					
	+! VERTEX PHARMS INC	150MG, N/A; 150MG, 100MG	N210491	001	Feb 12, 2018 Feb NEWA

IVACAFTOR; LUMACAFTOR

GRANULE; ORAL					
ORKAMBI					
	+ VERTEX PHARMS INC	125MG/PACKET; 100MG/PACKET	N211358	001	Aug 07, 2018 Aug NEWA
	+!	188MG/PACKET; 150MG/PACKET	N211358	002	Aug 07, 2018 Aug NEWA

IVOSIDENIB

TABLET; ORAL					
TIBSOVO					
	+! AGIOS PHARMS INC	250MG	N211192	001	Jul 20, 2018 Jul NEWA

IXABEPILONE

>A>	INJECTABLE; INTRAVENOUS				
>A>	IXEMPRA KIT				
>A>	+! R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007 Sep CDFR
>A>	+!	45MG/VIAL	N022065	002	Oct 16, 2007 Sep CDFR
>D>	INJECTABLE; IV (INFUSION)				
>D>	IXEMPRA KIT				
>D>	+! R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007 Sep CDFR
>D>	+!	45MG/VIAL	N022065	002	Oct 16, 2007 Sep CDFR

KANAMYCIN SULFATE

INJECTABLE; INJECTION					
KANAMYCIN SULFATE					
	@ FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002 Jun DISC
	@	EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002 Jun DISC

KETOCONAZOLE

TABLET; ORAL					
KETOCONAZOLE					
AB	STRIDES PHARMA	200MG	A210457	001	Jun 18, 2018 Jun NEWA

KETOPROFEN

CAPSULE; ORAL					
KETOPROFEN					
	@ MYLAN	50MG	A074035	002	Dec 31, 1996 Jun DISC
	@	75MG	A074035	003	Dec 31, 1996 Jun DISC
CAPSULE, EXTENDED RELEASE; ORAL					
KETOPROFEN					
	@ ACTAVIS LABS FL INC	100MG	A075270	002	Mar 24, 1999 Jun DISC

CAPSULE, EXTENDED RELEASE;ORAL
KETOPROFEN

@	150MG	A075270	003	Mar 24, 1999	Jun DISC
@	200MG	A075270	001	Mar 24, 1999	Jun DISC
@ MYLAN	100MG	A075679	003	Feb 20, 2002	Jun DISC
@	150MG	A075679	002	Feb 20, 2002	Jun DISC
!	200MG	A075679	001	Feb 20, 2002	Jun CTEC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE					
AP	CYCLE PHARMS LTD	15MG/ML	A209900	002	Jul 25, 2018 Jul NEWA
SOLUTION/DROPS;OPHTHALMIC					
KETOROLAC TROMETHAMINE					
AT	SANDOZ INC	0.4%	A078721	001	Nov 05, 2009 Jan CAHN
TABLET;ORAL					
KETOROLAC TROMETHAMINE					
AB	CYCLE PHARMS LTD	10MG	A210616	001	Aug 16, 2018 Aug NEWA

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE					
@ AKORN INC	5MG/ML	A075524	001	Nov 29, 1999	Aug DISC
TABLET;ORAL					
LABETALOL HYDROCHLORIDE					
AB	APPCO PHARMA LLC	100MG	A209603	001	Jun 20, 2018 Jun NEWA
AB		200MG	A209603	002	Jun 20, 2018 Jun NEWA
AB		300MG	A209603	003	Jun 20, 2018 Jun NEWA
AB	TWI PHARMS	100MG	A209603	001	Jun 20, 2018 Aug CAHN
AB		200MG	A209603	002	Jun 20, 2018 Aug CAHN
AB		300MG	A209603	003	Jun 20, 2018 Aug CAHN

LACTULOSE

SOLUTION;ORAL

LACTULOSE					
AA	BIO-PHARM INC	10GM/15ML	A207786	001	Jun 11, 2018 May NEWA
AA	LANNETT CO INC	10GM/15ML	A075993	001	Jul 26, 2001 May CAHN

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE					
>D> AB	APPCO PHARMA LLC	150MG	A206974	001	Nov 21, 2016 Sep CAHN
>D> AB		300MG	A206974	002	Nov 21, 2016 Sep CAHN
>A> AB	ARISE PHARMS	150MG	A206974	001	Nov 21, 2016 Sep CAHN
>A> AB		300MG	A206974	002	Nov 21, 2016 Sep CAHN
AB	STRIDES PHARMA	150MG	A090457	001	Apr 19, 2018 Apr NEWA
AB		300MG	A090457	002	Apr 19, 2018 Apr NEWA

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE					
+	@ MICRO LABS	150MG;200MG;300MG	N205626	001	Aug 13, 2018 Aug NEWA

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

CIMDUO					
+	! MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018 Feb NEWA
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE					
@ AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	Jul DISC
	300MG;300MG	N022344	001	May 15, 2018	May NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE					
AB	CIPLA LTD	150MG;300MG	A077411	001	Sep 07, 2018 Aug NEWA
AB	MACLEODS PHARMS LTD	150MG;300MG	A090679	001	Aug 29, 2018 Aug NEWA
@ PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Jun DISC
AB	SHANGHAI DESANO	150MG;300MG	A206375	001	Apr 10, 2018 Mar NEWA

LATANOPROST

>A>	EMULSION;OPHTHALMIC						
>A>	XELPROS						
>A>	+! SUN PHARMA GLOBAL	0.005%	N206185	001	Sep 12, 2018	Sep	NEWA

LEFLUNOMIDE

	TABLET;ORAL						
	LEFLUNOMIDE						
	@ FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Jan	CAHN
	@	20MG	A077087	002	Sep 13, 2005	Jan	CAHN

LETERMOVIR

>A>	SOLUTION;INTRAVENOUS						
>A>	PREVYMIS						
>A>	+! MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017	Sep	CDFR
>A>	+!	480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017	Sep	CDFR
>D>	SOLUTION;IV (INFUSION)						
>D>	PREVYMIS						
>D>	+! MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017	Sep	CDFR
>D>	+!	480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017	Sep	CDFR

LETROZOLE

	TABLET;ORAL						
	LETROZOLE						
	@ MYLAN	2.5MG	A078190	001	Dec 24, 2008	Jun	DISC

LEUCOVORIN CALCIUM

	INJECTABLE;INJECTION						
	LEUCOVORIN CALCIUM						
	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Mar	NEWA
	LEUCOVORIN CALCIUM						
AP	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Jul	NEWA
	LEUCOVORIN CALCIUM PRESERVATIVE FREE						
AP	! WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Jul	CTEC

LEUPROLIDE ACETATE

	FOR SUSPENSION;INTRAMUSCULAR						
	LUTRATE DEPOT KIT						
	+! GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	Aug	NEWA
	INJECTABLE;INJECTION						
	LUPRON						
	+ @ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Feb	CRLD
	LUPRON DEPOT						
	+ ABBVIE ENDOCRINE INC	22.5MG/VIAL	N020517	001	Dec 22, 1995	Jun	CHRS
	+!	45MG/VIAL	N020517	003	Jun 17, 2011	Jun	CHRS

LEVETIRACETAM

	INJECTABLE;IV (INFUSION)						
	LEVETIRACETAM						
AP	AKORN	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Apr	NEWA
AP	HAINAN POLY PHARM	500MG/5ML (100MG/ML)	A209781	001	Mar 20, 2018	Mar	NEWA
	SOLUTION;ORAL						
	LEVETIRACETAM						
AA	ACI HEALTHCARE LTD	100MG/ML	A078582	001	Jan 15, 2009	May	CAHN
AA	LANNETT CO INC	100MG/ML	A090079	001	Apr 11, 2012	May	CAHN
	TABLET;ORAL						
	LEVETIRACETAM						
	@ FOSUN PHARMA	250MG	A077324	001	Jan 15, 2009	Jan	CAHN
	@	500MG	A077324	002	Jan 15, 2009	Jan	CAHN
	@	750MG	A077324	003	Jan 15, 2009	Jan	CAHN
	@	1GM	A077324	004	Jan 15, 2009	Jan	CAHN
AB	OXFORD PHARMS	250MG	A077319	001	Mar 20, 2009	Jul	CAHN
AB		500MG	A077319	002	Mar 20, 2009	Jul	CAHN
AB		750MG	A077319	003	Mar 20, 2009	Jul	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	LEVETIRACETAM						
	@ VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Jun	DISC
	@	750MG	A091291	002	Sep 12, 2011	Jun	DISC

LEVOCARNITINE

TABLET; ORAL

LEVOCARNITINE

>A>	AB	ANDA REPOSITORY	330MG	A076858	001	Sep 20, 2004	Sep CAHN
>D>	AB	RISING PHARMS	330MG	A076858	001	Sep 20, 2004	Sep CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

		@ FOSUN PHARMA	5MG	A090486	001	Mar 26, 2013	Jan CAHN
AB		NEOPHARMA	5MG	A204323	001	Dec 20, 2016	Aug CAHN

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

		+ @ JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Feb DISC
		+ @	EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Feb DISC

LEVOFLOXACIN

AP	!	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Mar CHRS
AP	!		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Mar CHRS
		@ EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Mar DISC
		@	EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Mar DISC
		@ MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun DISC
		@	EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun DISC
		@ ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	Feb DISC
		@	EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	Feb DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!	INFORLIFE	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Jan CAHN
AP	!		EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Jan CAHN
AP	!		EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jan CAHN

SOLUTION; ORAL

LEVOFLOXACIN

AA	!	HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	May CTEC
AA		LANNETT CO INC	250MG/10ML	A205222	001	May 25, 2018	May NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

>A>	AT	!	ANDA REPOSITORY	0.5%	A077700	001	Dec 20, 2010	Sep CAHN
>D>	AT	!	RISING PHARMS	0.5%	A077700	001	Dec 20, 2010	Sep CAHN

TABLET; ORAL

LEVAQUIN

		+ @ JANSSEN PHARMS	250MG	N020634	001	Dec 20, 1996	Feb DISC
		+ @	500MG	N020634	002	Dec 20, 1996	Feb DISC
		+ @	750MG	N020634	003	Sep 08, 2000	Feb DISC

LEVOFLOXACIN

AB	!	AUROBINDO PHARMA LTD	750MG	A201043	003	Jun 20, 2011	Feb CHRS
----	---	----------------------	-------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

FUSILEV

AP	+	!	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	May CDFR
			LEVOLEUCOVORIN CALCIUM					
AP			ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	May CDFR
		+	!	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May CDFR
AP			AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	May CDFR
AP			WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	May CDFR

SOLUTION; INTRAVENOUS

FUSILEV

		+ @ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	May CDFR
		+ @	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	May CDFR

LEVOLEUCOVORIN CALCIUM

AP			AMNEAL PHARMS CO	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A207548	001	Sep 08, 2017	May CDFR
>A>	AP		GLAND PHARMA LTD	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210892	001	Sep 14, 2018	Sep NEWA
>A>	AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210892	002	Sep 14, 2018	Sep NEWA
AP			INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	May CDFR
AP				EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	May CDFR

SOLUTION; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

AP	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	May CDFR
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	May CDFR
AP	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	May CDFR
AP	!	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	May CDFR

SOLUTION; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP	INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018	Apr NEWA
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018	Apr NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMA

+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CAHN
+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CAHN
+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CAHN
+	!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

SENTYNL THERAPS INC

1MG	A074278	002	Jun 18, 2018	Jun NEWA
3MG	A074278	003	Jun 18, 2018	Jun NEWA

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

+	INSTITUT BIOCHIMIQUE	0.15MG	N021924	007	Oct 13, 2006	May CHRS
+	!	0.200MG	N021924	012	Apr 25, 2017	May CHRS

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	PIRAMAL CRITICAL	100MCG/VIAL	A206163	001	Jun 29, 2016	Jan CAHN
AP		500MCG/VIAL	A206163	002	Jun 29, 2016	Jan CAHN

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

EUTHYROX

>A>						
>A>	@ MERCK KGAA	0.025MG	N021292	001	May 31, 2002	Sep CTNA
>A>	@	0.05MG	N021292	002	May 31, 2002	Sep CTNA
>A>	@	0.075MG	N021292	003	May 31, 2002	Sep CTNA
>A>	@	0.088MG	N021292	004	May 31, 2002	Sep CTNA
>A>	@	0.1MG	N021292	005	May 31, 2002	Sep CTNA
>A>	@	0.112MG	N021292	006	May 31, 2002	Sep CTNA
>A>	@	0.125MG	N021292	007	May 31, 2002	Sep CTNA
>A>	@	0.137MG	N021292	008	May 31, 2002	Sep CTNA
>A>	@	0.15MG	N021292	009	May 31, 2002	Sep CTNA
>A>	@	0.175MG	N021292	010	May 31, 2002	Sep CTNA
>A>	@	0.2MG	N021292	011	May 31, 2002	Sep CTNA
>A>	@	0.3MG	N021292	012	May 31, 2002	Sep CTNA
>A>	@ PROVELL	0.025MG	N021292	001	May 31, 2002	Sep CAHN
>A>	@	0.05MG	N021292	002	May 31, 2002	Sep CAHN
>A>	@	0.075MG	N021292	003	May 31, 2002	Sep CAHN
>A>	@	0.088MG	N021292	004	May 31, 2002	Sep CAHN
>A>	@	0.1MG	N021292	005	May 31, 2002	Sep CAHN
>A>	@	0.112MG	N021292	006	May 31, 2002	Sep CAHN
>A>	@	0.125MG	N021292	007	May 31, 2002	Sep CAHN
>A>	@	0.137MG	N021292	008	May 31, 2002	Sep CAHN
>A>	@	0.15MG	N021292	009	May 31, 2002	Sep CAHN
>A>	@	0.175MG	N021292	010	May 31, 2002	Sep CAHN
>A>	@	0.2MG	N021292	011	May 31, 2002	Sep CAHN
>A>	@	0.3MG	N021292	012	May 31, 2002	Sep CAHN

NOVOTHYROX

>D>	@ MERCK KGAA	0.025MG	N021292	001	May 31, 2002	Sep CTNA
>D>	@	0.05MG	N021292	002	May 31, 2002	Sep CTNA
>D>	@	0.075MG	N021292	003	May 31, 2002	Sep CTNA
>D>	@	0.088MG	N021292	004	May 31, 2002	Sep CTNA

TABLET;ORAL
NOVOTHYROX

>D>	@	0.1MG	N021292	005	May 31, 2002	Sep CTNA
>D>	@	0.112MG	N021292	006	May 31, 2002	Sep CTNA
>D>	@	0.125MG	N021292	007	May 31, 2002	Sep CTNA
>D>	@	0.137MG	N021292	008	May 31, 2002	Sep CTNA
>D>	@	0.15MG	N021292	009	May 31, 2002	Sep CTNA
>D>	@	0.175MG	N021292	010	May 31, 2002	Sep CTNA
>D>	@	0.2MG	N021292	011	May 31, 2002	Sep CTNA
>D>	@	0.3MG	N021292	012	May 31, 2002	Sep CTNA

LIDOCAINE

OINTMENT;TOPICAL
LIDOCAINE

AT	TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018	Jan NEWA
	PATCH;TOPICAL					
	ZTLIDO					
+	SCILEX PHARMS INC	1.8%	N207962	001	Feb 28, 2018	Feb NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

	LIDOCAINE HYDROCHLORIDE					
AP	B BRAUN MEDICAL INC	1%	A208474	001	Aug 03, 2018	Jul NEWA
AP	SPECTRA MDCL DEVICES	1%	A208017	001	Apr 18, 2018	Apr NEWA
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
@	INTL MEDICATION	20%	N017702	001		Jun DISC

JELLY;TOPICAL

	ANESTACON					
>D>	@ BIONPHARMA INC	2%	A080429	001		Sep CAHN
>A>	@ BLUEPHARMA	2%	A080429	001		Sep CAHN
	LIDOCAINE HYDROCHLORIDE					
@	WATSON LABS INC	2%	A040837	001	Mar 23, 2011	Aug DISC

SOLUTION;ORAL

	LIDOCAINE HYDROCHLORIDE VISCOUS					
AT	! LANNETT CO INC	2%	A040708	001	Feb 27, 2007	May CAHN
	SOLUTION;TOPICAL					
	LIDOCAINE HYDROCHLORIDE					
AT	LANNETT CO INC	4%	A040710	001	Feb 27, 2007	May CAHN

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

	LIDOCAINE AND PRILOCAINE					
AB	TELIGENT PHARMA INC	2.5%;2.5%	A205887	001	Jun 29, 2018	Jun NEWA

LINACLOTIDE

CAPSULE;ORAL

	LINZESS					
+	ALLERGAN SALES LLC	72MCG	N202811	003	Jan 25, 2017	Jan CAHN
+		145MCG	N202811	001	Aug 30, 2012	Jan CAHN
+	!	290MCG	N202811	002	Aug 30, 2012	Jan CAHN

LINDANE

LOTION;TOPICAL

	LINDANE					
!	OLTA PHARMS	1%	A087313	001		Jun CHRS
		1%	A087313	001		Jun CTEC
@	WOCKHARDT	1%	A088190	001	Aug 16, 1984	Jun DISC

LINEZOLID

SOLUTION;INTRAVENOUS

	LINEZOLID					
AP	AUROBINDO PHARMA LTD	600MG/300ML (2MG/ML)	A206917	001	Aug 04, 2016	May CDFR
AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)	A204764	001	Mar 15, 2016	May CDFR
AP	HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	May CDFR
AP	HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A207001	001	Jul 07, 2017	May CDFR
AP		600MG/300ML (2MG/ML)	A207001	002	Jul 07, 2017	May CDFR
AP	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	May CDFR
AP		600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	May CDFR
AP	NANG KUANG PHARM CO	200MG/100ML (2MG/ML)	A207354	001	Dec 20, 2016	May CDFR
AP		600MG/300ML (2MG/ML)	A207354	002	Dec 20, 2016	May CDFR
AP	SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	May CDFR
AP		600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	May CDFR

SOLUTION; INTRAVENOUS

LINEZOLID

AP	SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015	May CDFR
AP		600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015	May CDFR
AP	TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	May CDFR
	LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+! HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015	May CDFR
	ZYVOX					
AP	+ PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	May CDFR
	+ @	400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	Jul DISC
	+	400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	May CDFR
AP	+!	600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000	May CDFR

>D> LIOTRIX (T4;T3)

>D> TABLET; ORAL

>D> THYROLAR-0.25

>D>	+ ALLERGAN SALES LLC	0.0125MG;0.0031MG	N016807	001		Sep DISC
>A>	+ @	0.0125MG;0.0031MG	N016807	001		Sep DISC
	+	0.0125MG;0.0031MG	N016807	001		Apr CAHN

>D> THYROLAR-0.5

>D>	+ ALLERGAN SALES LLC	0.025MG;0.0063MG	N016807	005		Sep DISC
>A>	+ @	0.025MG;0.0063MG	N016807	005		Sep DISC
	+	0.025MG;0.0063MG	N016807	005		Apr CAHN

>D> THYROLAR-1

>D>	+ ALLERGAN SALES LLC	0.05MG;0.0125MG	N016807	004		Sep DISC
>A>	+ @	0.05MG;0.0125MG	N016807	004		Sep DISC
	+	0.05MG;0.0125MG	N016807	004		Apr CAHN

>D> THYROLAR-2

>D>	+ ALLERGAN SALES LLC	0.1MG;0.025MG	N016807	002		Sep DISC
>A>	+ @	0.1MG;0.025MG	N016807	002		Sep DISC
	+	0.1MG;0.025MG	N016807	002		Apr CAHN

>D> THYROLAR-3

>D>	+! ALLERGAN SALES LLC	0.15MG;0.0375MG	N016807	003		Sep DISC
>A>	+ @	0.15MG;0.0375MG	N016807	003		Sep DISC
	+!	0.15MG;0.0375MG	N016807	003		Apr CAHN

THYROLAR-5

@ ALLERGAN SALES LLC	0.25MG;0.0625MG	N016807	006		Apr CAHN
----------------------	-----------------	---------	-----	--	----------

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	CASI PHARMS INC	2.5MG	A075994	001	Jul 01, 2002	Mar CAHN
AB		5MG	A075994	002	Jul 01, 2002	Mar CAHN
AB		10MG	A075994	003	Jul 01, 2002	Mar CAHN
AB		20MG	A075994	004	Jul 01, 2002	Mar CAHN
AB		30MG	A075994	005	Jul 01, 2002	Mar CAHN
AB		40MG	A075994	006	Jul 01, 2002	Mar CAHN

LOFEXIDINE HYDROCHLORIDE

TABLET; ORAL

LUCEMYRA

+!	US WORLDMEDS LLC	EQ 0.18MG BASE	N209229	001	May 16, 2018	May NEWA
----	------------------	----------------	---------	-----	--------------	----------

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

+ @	CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Jun DISC
-----	---------------	-----	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

+ @	J AND J CONSUMER INC	2MG	N017694	001		Jun CRLD
	LOPERAMIDE HYDROCHLORIDE					
@	YAOPHARMA CO LTD	2MG	A072993	001	Aug 28, 1992	Jan CAHN

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

>A> AA	ANDA REPOSITORY	2MG/ML	A079244	001	Apr 28, 2009	Sep CAHN
>D> AA	SAPTALIS PHARMS	2MG/ML	A079244	001	Apr 28, 2009	Sep CAHN

TABLET;ORAL

LORAZEPAM

	@ ANDA REPOSITORY	0.5MG	A072555	002	Mar 29, 1991	May CMS1
	@	1MG	A072555	003	Mar 29, 1991	May CMS1
	@ MYLAN	0.5MG	A071591	002	Oct 13, 1987	Jan CMS1
	@	1MG	A071591	003	Oct 13, 1987	Jan CMS1
AB	OXFORD PHARMS	0.5MG	A077754	001	May 10, 2006	Jul CAHN
AB		1MG	A077754	002	May 10, 2006	Jul CAHN
AB		2MG	A077754	003	May 10, 2006	Jul CAHN
	@ SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	May DISC
	@	1MG	A076045	002	Aug 29, 2001	May DISC
	@	2MG	A076045	003	Aug 29, 2001	May DISC

LOSARTAN POTASSIUM

TABLET;ORAL

COZAAR

	+ @ MERCK SHARP DOHME	25MG	N020386	001	Apr 14, 1995	Apr DISC
	+ @	50MG	N020386	002	Apr 14, 1995	Apr DISC
	LOSARTAN POTASSIUM					
	@ APOTEX CORP	25MG	A090790	001	Oct 06, 2010	Mar DISC
	@	50MG	A090790	002	Oct 06, 2010	Mar DISC
	@	100MG	A090790	003	Oct 06, 2010	Mar DISC

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS;OPHTHALMIC

INVELTYS

	+! KALA PHARMS INC	1%	N210565	001	Aug 22, 2018	Aug NEWA
--	--------------------	----	---------	-----	--------------	----------

LUSUTROMBOPAG

TABLET;ORAL

MULPLETA

	+! SHIONOGI INC	3MG	N210923	001	Jul 31, 2018	Jul NEWA
--	-----------------	-----	---------	-----	--------------	----------

LUTETIUM DOTATATE LU-177

>A>	SOLUTION;INTRAVENOUS					
>A>	LUTATHERA					
>A>	+! AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Sep CDJR
>D>	SOLUTION;IV (INFUSION)					
>D>	LUTATHERA					
>D>	+! AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Sep CDJR
	+!	10mCi/ML	N208700	001	Jan 26, 2018	Jan NEWA

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

	+! STRONGBRIDGE IRELAND	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017	May CMS1
	+!	EQ 60MG BASE/POUCH	N205598	001	Dec 21, 2017	Jan CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

	+! BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	001		Apr CRLD
--	--------------------	---	---------	-----	--	----------

PLASMA-LYTE A IN PLASTIC CONTAINER

	+! BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	Apr CRLD
--	--------------------	---	---------	-----	--------------	----------

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MYLAN LABS LTD	1GM/100ML	A209932	001	Sep 10, 2018	Aug NEWA
	MAGNESIUM SULFATE IN PLASTIC CONTAINER					
>A> AP	MYLAN LABS LTD	2GM/50ML (40MG/ML)	A209911	001	Sep 14, 2018	Sep NEWA
>A> AP		4GM/100ML (40MG/ML)	A209911	002	Sep 14, 2018	Sep NEWA

MALATHION

LOTION;TOPICAL

OVIDE

AT	+! TARO PHARM INDS LTD	0.5%	N018613	001	Aug 02, 1982	May CAHN
----	------------------------	------	---------	-----	--------------	----------

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

+!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Mar	CRLD
----	---------	-----------------------	---------	-----	--------------	-----	------

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316	001		Mar	CRLD
----	-----------------	-------------------------	---------	-----	--	-----	------

MAZINDOL

TABLET;ORAL

SANOREX

+	@	HEXIM	1MG	N017247	001		Jul	CAHN
+	@		2MG	N017247	002		Jul	CAHN

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

VERMOX

+	@	JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Feb	DISC
---	---	----------------	-------	---------	-----	--------------	-----	------

MECHLORETHAMINE HYDROCHLORIDE

GEL;TOPICAL

VALCHLOR

+!	HELSINN	EQ 0.016% BASE	N202317	001	Aug 23, 2013	Aug	CAHN
----	---------	----------------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

>A>	@	ANDA REPOSITORY	12.5MG	A040179	001	Jan 30, 1997	Sep	CAHN
>A>	@		25MG	A040179	002	Jan 30, 1997	Sep	CAHN
>D>	@	RISING PHARMS	12.5MG	A040179	001	Jan 30, 1997	Sep	CAHN
>D>	@		25MG	A040179	002	Jan 30, 1997	Sep	CAHN

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLOFENAMATE SODIUM

@	FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan	CAHN
@		EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan	CAHN

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

>D>	AB	BELCHER PHARMS INC	250MG	A091608	001	Jun 02, 2014	Sep	CAHN
	AB		250MG	A091608	001	Jun 02, 2014	Jul	CAHN
>A>	AB	BELCHER PHARMS LLC	250MG	A091608	001	Jun 02, 2014	Sep	CAHN
	AB	MICRO LABS	250MG	A090562	001	Nov 19, 2010	Feb	CAHN

MELOXICAM

TABLET;ORAL

MELOXICAM

@	MYLAN	7.5MG	A077923	001	Jul 19, 2006	Jun	DISC
@		15MG	A077923	002	Jul 19, 2006	Jun	DISC

MEMANTINE HYDROCHLORIDE

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA		APOTEX INC	2MG/ML	A209955	001	Feb 09, 2018	Jan	NEWA	
AA	!	BIO-PHARM INC	2MG/ML	A205446	001	Dec 07, 2015	Apr	CHRS	
		NAMENDA							
	+	@	ALLERGAN SALES LLC	2MG/ML	N021627	001	Apr 18, 2005	Apr	DISC
AA	+	!		2MG/ML	N021627	001	Apr 18, 2005	Jan	CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		APOTEX INC	5MG	A090244	001	Jul 11, 2018	Jun	NEWA
AB			10MG	A090244	002	Jul 11, 2018	Jun	NEWA
AB		CSPC OUYI PHARM CO	5MG	A209527	001	May 07, 2018	Apr	NEWA
AB			10MG	A209527	002	May 07, 2018	Apr	NEWA
		NAMENDA						
AB	+	ALLERGAN SALES LLC	5MG	N021487	001	Oct 16, 2003	Jan	CAHN
AB	+	!	10MG	N021487	002	Oct 16, 2003	Jan	CAHN

MEROPENEM

INJECTABLE; INJECTION
MEROPENEM

AP	ACS DOBFAR SPA	500MG/VIAL	A204139	001	Jun 09, 2016	Apr CAHN
AP		1GM/VIAL	A204139	002	Jun 09, 2016	Apr CAHN
>A>	POWDER; INTRAVENOUS					
>A>	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER					
>A>	B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Sep CDHR
>A>		1GM/VIAL	N202106	002	Apr 30, 2015	Sep CDHR
>D>	POWDER; IV (INFUSION)					
>D>	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER					
>D>	B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Sep CDHR
>D>		1GM/VIAL	N202106	002	Apr 30, 2015	Sep CDHR

MEROPENEM; VABORBACTAM

>A>	POWDER; INTRAVENOUS					
>A>	VABOMERE					
>A>	+! REMPEX PHARMS	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017	Sep CDHR
>D>	POWDER; IV (INFUSION)					
>D>	VABOMERE					
>D>	+! REMPEX PHARMS	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017	Sep CDHR
	+!	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017	Jan CAHN

MESALAMINE

ENEMA; RECTAL
MESALAMINE

	@ G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004	Jan DISC
	SUPPOSITORY; RECTAL					
	CANASA					
	@ ALLERGAN SALES LLC	500MG	N021252	001	Jan 05, 2001	Jan CAHN
AB	+!	1GM	N021252	002	Nov 05, 2004	Jan CAHN
	TABLET, DELAYED RELEASE; ORAL					
	MESALAMINE					
AB	ACTAVIS LABS FL	1.2GM	A203817	001	Mar 23, 2018	Mar NEWA

MESNA

INJECTABLE; INTRAVENOUS
MESNA

	@ MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012	Jan DISC
--	-----------------------	----------	---------	-----	--------------	----------

METARAMINOL BITARTRATE

INJECTABLE; INJECTION
METARAMINOL BITARTRATE

	@ FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001		Feb DISC
--	----------------------	-----------------	---------	-----	--	----------

METAXALONE

TABLET; ORAL
METAXALONE

>A> AB	APCO PHARMA LLC	800MG	A208774	001	Sep 24, 2018	Sep NEWA
	MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Jan CAHN
>A> AB	RISING PHARMS	800MG	A208774	001	Sep 24, 2018	Sep CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

AB	LAURUS LABS LTD	500MG	A209882	001	Aug 27, 2018	Aug NEWA
AB		850MG	A209882	002	Aug 27, 2018	Aug NEWA
AB		1GM	A209882	003	Aug 27, 2018	Aug NEWA
	@ PROVIDENT PHARM	500MG	A077853	001	Jul 28, 2006	Jun DISC
	@	850MG	A077853	002	Jul 28, 2006	Jun DISC
	@	1GM	A077853	003	Jul 28, 2006	Jun DISC
	@ SANDOZ	500MG	A075985	001	Jan 25, 2002	Mar DISC
	@	850MG	A075985	002	Jan 25, 2002	Mar DISC
	@	1GM	A075985	003	Jan 25, 2002	Mar DISC
	TABLET, EXTENDED RELEASE; ORAL					
	METFORMIN HYDROCHLORIDE					
AB1	ALIGNSCIENCE PHARMA	500MG	A209303	001	Mar 19, 2018	Mar NEWA
AB1	GRANULES INDIA LTD	500MG	A209313	001	Mar 16, 2018	Mar NEWA
AB		750MG	A209313	002	Mar 16, 2018	Mar NEWA
AB1	PRINSTON INC	500MG	A208880	001	Sep 10, 2018	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL
METFORMIN HYDROCHLORIDE

AB		750MG	A208880	002	Sep 10, 2018	Aug NEWA
>A> AB1	YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018	Sep NEWA
>A> AB		750MG	A211052	002	Sep 24, 2018	Sep NEWA

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL
REPAGLINIDE AND METFORMIN HYDROCHLORIDE

@ LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015	May DISC
@	500MG;2MG	A200624	002	Jul 15, 2015	May DISC

METHADONE HYDROCHLORIDE

TABLET;ORAL
METHADONE HYDROCHLORIDE

AA	ELITE LABS INC	5MG	A210484	001	Aug 02, 2018	Jul NEWA
AA		10MG	A210484	002	Aug 02, 2018	Jul NEWA
AA	SUN PHARM INDUSTRIES	5MG	A208305	001	Mar 30, 2018	Mar NEWA
AA		10MG	A208305	002	Mar 30, 2018	Mar NEWA

METHAZOLAMIDE

TABLET;ORAL
METHAZOLAMIDE

>A> AB	MICRO LABS	25MG	A207438	001	Oct 05, 2018	Sep NEWA
>A> AB		50MG	A207438	002	Oct 05, 2018	Sep NEWA

METHIMAZOLE

TABLET;ORAL
METHIMAZOLE

>A> AB	ANDA REPOSITORY	5MG	A202068	001	Mar 07, 2012	Sep CAHN
>A> AB		10MG	A202068	002	Mar 07, 2012	Sep CAHN
AB	CASI PHARMS INC	5MG	A040411	001	Mar 27, 2001	Mar CAHN
AB		10MG	A040411	002	Mar 27, 2001	Mar CAHN
>D> AB	RISING PHARMS	5MG	A202068	001	Mar 07, 2012	Sep CAHN
>D> AB		10MG	A202068	002	Mar 07, 2012	Sep CAHN

METHOCARBAMOL

SOLUTION;IM-IV
METHOCARBAMOL

AP	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	A209331	001	Apr 17, 2018	Apr NEWA
----	--------------------	---------------------	---------	-----	--------------	----------

TABLET;ORAL
METHOCARBAMOL

AA	ALLIED PHARMA INC	500MG	A203550	001	Feb 08, 2017	Feb CAHN
AA		750MG	A203550	002	Feb 08, 2017	Feb CAHN
AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	May CAHN
AA		750MG	A203550	002	Feb 08, 2017	May CAHN
	@ FOSUN PHARMA	500MG	A084616	001		Jan CAHN
	@	750MG	A084615	001		Jan CAHN
AA	GRANULES INDIA LTD	500MG	A209312	001	May 07, 2018	Apr NEWA
AA		750MG	A209312	002	May 07, 2018	Apr NEWA
AA	OXFORD PHARMS	500MG	A040489	001	Jan 29, 2003	Jul CAHN
AA		750MG	A040489	002	Jan 29, 2003	Jul CAHN

METHOTREXATE

SOLUTION;SUBCUTANEOUS
RASUVO

+	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr CHRS
+		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr CHRS
+		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr CHRS
+		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr CHRS
+		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr CHRS
+		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr CHRS
+		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr CHRS
+		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr CHRS
+		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr CHRS

METHOTREXATE SODIUM

INJECTABLE;INJECTION
METHOTREXATE SODIUM

@ FRESENIUS KABI USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040263	002	Feb 26, 1999	Aug DISC
----------------------	--------------------------------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	SAGENT PHARMS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A203407	001	Aug 09, 2018	Jul NEWA
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A203407	002	Aug 09, 2018	Jul NEWA
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A203407	003	Aug 09, 2018	Jul NEWA

METHSUXIMIDE

CAPSULE;ORAL

CELONTIN

	+ @ PARKE DAVIS	150MG	N010596	007		Jun DISC
--	-----------------	-------	---------	-----	--	----------

METHYCLOTHIAZIDE

TABLET;ORAL

METHYCLOTHIAZIDE

@ YAOPHARMA CO LTD

@

2.5MG
5MG

A089835 001 Aug 18, 1988 Jan CAHN
A089837 001 Aug 18, 1988 Jan CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

@ YAOPHARMA CO LTD

@

@

125MG
250MG
500MG

A071700 001 Mar 02, 1988 Jan CAHN
N018934 001 Jun 29, 1984 Jan CAHN
N018934 002 Jun 29, 1984 Jan CAHN

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB	AMNEAL PHARMS	0.2MG
AB	GRANULES PHARMS	0.2MG
AB	! NOVEL LABS INC	0.2MG

A211483 001 Sep 10, 2018 Aug NEWA
A210424 001 May 15, 2018 Apr NEWA
A091577 001 May 02, 2011 Apr CTEC

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

JORNAY PM

	+ IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018	Aug NEWA
	+	40MG	N209311	002	Aug 08, 2018	Aug NEWA
	+	60MG	N209311	003	Aug 08, 2018	Aug NEWA
	+	80MG	N209311	004	Aug 08, 2018	Aug NEWA
	+	100MG	N209311	005	Aug 08, 2018	Aug NEWA

METADATE CD

AB2	+ LANNETT CO INC	10MG	N021259	003	May 27, 2003	Mar CAHN
AB2	+	20MG	N021259	001	Apr 03, 2001	Mar CAHN
AB2	+	30MG	N021259	002	Jun 19, 2003	Mar CAHN
AB2	+	40MG	N021259	004	Feb 19, 2006	Mar CAHN
AB2	+	50MG	N021259	005	Feb 19, 2006	Mar CAHN
AB2	++	60MG	N021259	006	Feb 19, 2006	Mar CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB1	MAYNE PHARMA	10MG	A200886	001	Feb 26, 2018	Feb NEWA
-----	--------------	------	---------	-----	--------------	----------

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018	Apr NEWA
----	---------------------	--------	---------	-----	--------------	----------

QUILLIVANT XR

AB	++ NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Apr CFTG
----	--------------------	--------	---------	-----	--------------	----------

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A> AA	WES PHARMA INC	5MG/5ML	A210139	001	Oct 03, 2018	Sep NEWA
>A> AA		10MG/5ML	A210139	002	Oct 03, 2018	Sep NEWA

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	BIONPHARMA INC	5MG	A209753	001	Mar 02, 2018	Feb NEWA
AB		10MG	A209753	002	Mar 02, 2018	Feb NEWA
AB		20MG	A209753	003	Mar 02, 2018	Feb NEWA
AB	LANNETT CO INC	5MG	A086429	001		Mar CAHN
AB		10MG	A085799	001		Mar CAHN
AB		20MG	A086428	001		Mar CAHN
AB	MOUNTAIN	5MG	A091159	001	Mar 12, 2014	Jan CAHN
AB		10MG	A091159	002	Mar 12, 2014	Jan CAHN
AB		20MG	A091159	003	Mar 12, 2014	Jan CAHN
AB	OXFORD PHARMS	5MG	A202892	001	Sep 23, 2014	Jul CAHN
AB		10MG	A202892	002	Sep 23, 2014	Jul CAHN
AB		20MG	A202892	003	Sep 23, 2014	Jul CAHN

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ANDA REPOSITORY	2.5MG	A205756	001	Nov 07, 2016	Sep CAHN
>A>	AB		5MG	A205756	002	Nov 07, 2016	Sep CAHN
>A>	AB		10MG	A205756	003	Nov 07, 2016	Sep CAHN
>A>	AB	RISING PHARMS	2.5MG	A205756	001	Nov 07, 2016	Sep CAHN
>A>	AB		5MG	A205756	002	Nov 07, 2016	Sep CAHN
>A>	AB		10MG	A205756	003	Nov 07, 2016	Sep CAHN
>D>	AB	TEDOR PHARMA INC	2.5MG	A205756	001	Nov 07, 2016	Sep CAHN
>D>	AB		5MG	A205756	002	Nov 07, 2016	Sep CAHN
>D>	AB		10MG	A205756	003	Nov 07, 2016	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

		@ LANNETT CO INC	10MG	A040306	001	Oct 20, 1999	Mar CAHN
AB	!		20MG	A089601	001	Jun 01, 1988	Mar CAHN
		METHYLIN ER					
>D>	AB	! SPECGX LLC	20MG	A075629	002	May 09, 2000	Sep CHRS
>A>	AB		20MG	A075629	002	May 09, 2000	Sep CHRS
	AB	!	20MG	A075629	002	May 09, 2000	Aug CHRS

METHYLPHENIDATE HYDROCHLORIDE

AB		ACTAVIS LABS FL	54MG	A076655	001	Mar 21, 2018	Mar NEWA
AB		AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jan NEWA
AB			27MG	A207515	002	Feb 01, 2018	Jan NEWA
AB			36MG	A207515	003	Feb 01, 2018	Jan NEWA
AB			54MG	A207515	004	Feb 01, 2018	Jan NEWA
AB		ANI PHARMS INC	18MG	A208607	001	Jul 14, 2017	May CAHN
AB			27MG	A208607	002	Jul 14, 2017	May CAHN
AB			36MG	A208607	003	Jul 14, 2017	May CAHN
AB			54MG	A208607	004	Jul 14, 2017	May CAHN
AB		MOUNTAIN	18MG	A208607	001	Jul 14, 2017	Jan CAHN
AB			27MG	A208607	002	Jul 14, 2017	Jan CAHN
AB			36MG	A208607	003	Jul 14, 2017	Jan CAHN
AB			54MG	A208607	004	Jul 14, 2017	Jan CAHN
	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Jan CHRS
		RITALIN-SR					
+		@ NOVARTIS	20MG	N018029	001	Mar 30, 1982	Aug DISC
		TABLET, EXTENDED RELEASE, CHEWABLE;ORAL					
		QUILLICHEW ER					
+		NEXTWAVE PHARMS	20MG	N207960	001	Dec 04, 2015	Aug CAHN
+			30MG	N207960	002	Dec 04, 2015	Aug CAHN
+	!		40MG	N207960	003	Dec 04, 2015	Aug CAHN

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

AB		TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr NEWA
AB		ZYDUS PHARMS USA INC	4MG	A206751	001	Apr 23, 2018	Apr NEWA
AB			8MG	A206751	002	Apr 23, 2018	Apr NEWA
AB			16MG	A206751	003	Apr 23, 2018	Apr NEWA
AB			32MG	A206751	004	Apr 23, 2018	Apr NEWA

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

AB	+	! PHARMACIA AND UPJOHN	20MG/ML	N011757	002		Jun CFTG
		METHYLPREDNISOLONE ACETATE					
AB		SAGENT PHARMS	20MG/ML	A201835	001	Jun 27, 2018	Jun NEWA
AB			40MG/ML	A201835	002	Jun 27, 2018	Jun NEWA
AB			80MG/ML	A201835	003	Jun 27, 2018	Jun NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ YAOPHARMA CO LTD EQ 5MG BASE
 @ EQ 10MG BASE
 @ EQ 10MG BASE

A074478	001	Oct 05, 1995	Jan CAHN
A072215	001	Jan 30, 1990	Jan CAHN
A074478	002	Oct 05, 1995	Jan CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

NOVEL LABS INC EQ 5MG BASE
 ! EQ 10MG BASE
 METOZOLV ODT
 + @ SALIX PHARMS EQ 5MG BASE

A202191	001	Aug 15, 2014	Aug CTEC
A202191	002	Aug 15, 2014	Aug CHRS
N022246	001	Sep 04, 2009	Aug DISC

METOLAZONE

TABLET; ORAL							
MYKROX							
	@ LANNETT CO INC	0.5MG	N019532	001	Oct 30, 1987	Apr	CAHN
ZAROXOLYN							
AB	+ LANNETT CO INC	2.5MG	N017386	001		Mar	CAHN
AB	+!	5MG	N017386	002		Mar	CAHN
AB	+!	10MG	N017386	003		Mar	CAHN

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE; ORAL							
KAPSPARGO SPRINKLE							
+	SPII	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018	Jun	CTNA
+		EQ 25MG TARTRATE	N210428	001	Jan 26, 2018	Jan	NEWA
+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018	Jun	CTNA
+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018	Jan	NEWA
+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018	Jun	CTNA
+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018	Jan	NEWA
+	!	EQ 200MG TARTRATE	N210428	004	Jan 26, 2018	Jun	CTNA
+	!	EQ 200MG TARTRATE	N210428	004	Jan 26, 2018	Jan	NEWA
TABLET, EXTENDED RELEASE; ORAL							
METOPROLOL SUCCINATE							
AB	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Mar	CMS1
AB	NOVAST LABS	EQ 25MG TARTRATE	A204106	001	Feb 06, 2018	Jan	NEWA
AB		EQ 50MG TARTRATE	A204106	002	Feb 06, 2018	Jan	NEWA
AB		EQ 100MG TARTRATE	A204106	003	Feb 06, 2018	Jan	NEWA
AB		EQ 200MG TARTRATE	A204106	004	Feb 06, 2018	Jan	NEWA
AB	ZYDUS PHARMS USA INC	EQ 25MG TARTRATE	A203894	001	Mar 23, 2018	Mar	NEWA
AB		EQ 50MG TARTRATE	A203894	002	Mar 23, 2018	Mar	NEWA
AB		EQ 100MG TARTRATE	A203894	003	Mar 23, 2018	Mar	NEWA
AB		EQ 200MG TARTRATE	A203894	004	Mar 23, 2018	Mar	NEWA

METOPROLOL TARTRATE

TABLET; ORAL							
METOPROLOL TARTRATE							
	@ RENATA	50MG	A074453	001	Apr 27, 1995	Jan	CAHN
	@	100MG	A074453	002	Apr 27, 1995	Jan	CAHN
	@ YAOPHARMA CO LTD	50MG	A073288	001	Mar 25, 1994	Jan	CAHN
	@	100MG	A073289	001	Mar 25, 1994	Jan	CAHN

METRONIDAZOLE

TABLET; ORAL							
METRONIDAZOLE							
>D>	AB	APPCO PHARMA LLC	250MG	A205245	001	Sep 23, 2015	Sep CAHN
>D>	AB		500MG	A205245	002	Sep 23, 2015	Sep CAHN
		@ FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982	Jan CAHN
		@	250MG	N018740	001	Oct 22, 1982	Jan CAHN
		@	500MG	N018620	002	Jun 02, 1983	Jan CAHN
		@	500MG	N018740	002	Oct 22, 1982	Jan CAHN
>A>	AB	HERITAGE PHARMS INC	250MG	A205245	001	Sep 23, 2015	Sep CAHN
>A>	AB		500MG	A205245	002	Sep 23, 2015	Sep CAHN
	AB	STRIDES VIVIMED	250MG	A070040	001	Jan 29, 1985	Jul CAHN
TABLET, EXTENDED RELEASE; ORAL							
FLAGYL ER							
+	@ GD SEARLE LLC	750MG	N020868	001	Nov 26, 1997	May	DISC
METRONIDAZOLE							
	@ ALEMBIC PHARMS LTD	750MG	A090222	001	May 05, 2010	May	DISC

METYRAPONE

CAPSULE; ORAL							
METOPIRONE							
+	! LABORATORIE HRA	250MG	N012911	002	Aug 09, 1996	Jun	CAHN
TABLET; ORAL							
METOPIRONE							
	@ LABORATORIE HRA	250MG	N012911	001		Jun	CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXITIL

+ @ BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985	Jul CRLD
+ @	200MG	N018873	003	Dec 30, 1985	Jul CRLD
+ @	250MG	N018873	004	Dec 30, 1985	Jul CRLD

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MYCAMINE

+! ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May CDFR
+!	EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May CDFR

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

@ AKORN INC

EQ 5MG BASE/ML

A075481 001 Jun 30, 2000 Aug DISC

SOLUTION;INTRAMUSCULAR

SEIZALAM

>A>

>A>	+! MERIDIAN MEDCL TECHN	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018	Sep NEWA
-----	-------------------------	------------------------------------	---------	-----	--------------	----------

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB APOTEX INC

2.5MG

A077746 001 Sep 12, 2006 Feb CTEC

AB

5MG

A077746 002 Sep 12, 2006 Feb CTEC

AB

10MG

A077746 003 Sep 12, 2006 Feb CTEC

AB

CASI PHARMS INC

2.5MG

A076514 001 Sep 11, 2003 Mar CAHN

AB

5MG

A076514 002 Sep 11, 2003 Mar CAHN

AB

10MG

A076514 003 Jul 02, 2004 Mar CAHN

MIGALASTAT HYDROCHLORIDE

CAPSULE;ORAL

GALAFOLD

+! AMICUS THERAPS US	EQ 123MG BASE	N208623	001	Aug 10, 2018	Aug NEWA
----------------------	---------------	---------	-----	--------------	----------

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

AB AMERIGEN PHARMS LTD

100MG

A208342 001 Apr 17, 2018 Apr NEWA

ZAVESCA

AB

+! ACTELION PHARMS LTD

100MG

N021348 001 Jul 31, 2003 Apr CFTG

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

@ USPHARMA WINDLAS

12.5MG

A205071 001 Jan 27, 2016 Mar CAHN

@

25MG

A205071 002 Jan 27, 2016 Mar CAHN

@

50MG

A205071 003 Jan 27, 2016 Mar CAHN

@

100MG

A205071 004 Jan 27, 2016 Mar CAHN

MINOCYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION

MINOCIN

+! REMPEX PHARMS	EQ 100MG BASE/VIAL	N050444	001		Jan CAHN
------------------	--------------------	---------	-----	--	----------

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB ALKEM LABS LTD

EQ 65MG BASE

A204453 006 Mar 16, 2018 Mar NEWA

AB

EQ 115MG BASE

A204453 007 Mar 16, 2018 Mar NEWA

>A>

AB AUROBINDO PHARMA LTD

EQ 65MG BASE

A202261 002 Sep 28, 2018 Sep NEWA

>A>

AB

EQ 115MG BASE

A202261 004 Sep 28, 2018 Sep NEWA

AB

BARR LABS INC

EQ 65MG BASE

A065485 004 May 18, 2012 Jan CMFD

AB

EQ 115MG BASE

A065485 005 May 18, 2012 Jan CMFD

MINOLIRA

>D>

DR REDDYS LABS LTD

EQ 105MG BASE

N209269 001 May 08, 2017 Sep CAHN

>D>

EQ 135MG BASE

N209269 002 May 08, 2017 Sep CAHN

>A>

EPI HLTH

EQ 105MG BASE

N209269 001 May 08, 2017 Sep CAHN

>A>

EQ 135MG BASE

N209269 002 May 08, 2017 Sep CAHN

SOLODYN

AB + MEDICIS

EQ 65MG BASE

N050808 004 Jul 23, 2009 Mar CTEC

AB

+!

EQ 115MG BASE

N050808 005 Jul 23, 2009 Mar CTEC

MINOXIDIL

TABLET;ORAL							
MINOXIDIL							
AB	SUN PHARM INDUSTRIES	2.5MG	A072709	002	Dec 14, 1995	Jun	CMS1

MI POMERSEN SODIUM

SOLUTION;SUBCUTANEOUS
KYNAMRO

+	@ KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun	DISC
---	----------------------	---------------------	---------	-----	--------------	-----	------

MIRTAZAPINE

TABLET;ORAL
REMERON

+	@ ORGANON USA INC	45MG	N020415	003	Mar 17, 1997	Jul	DISC
---	-------------------	------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

@	ACTAVIS LABS FL INC	15MG	A076307	001	Dec 17, 2003	Jun	DISC
@		30MG	A076307	002	Dec 17, 2003	Jun	DISC
@		45MG	A076307	003	Feb 28, 2006	Jun	DISC

MITOMYCIN

INJECTABLE;INJECTION
MITOMYCIN

@	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	May	DISC
@		20MG/VIAL	A064117	002	Apr 19, 1995	May	DISC
@		40MG/VIAL	A064117	003	Jun 02, 1999	May	CMS1

MITOTANE

TABLET;ORAL
LYSODREN

+	! LABORATOIRE HRA	500MG	N016885	001		Jul	CAHN
---	-------------------	-------	---------	-----	--	-----	------

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS
MIVACRON

+	@ ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jun	DISC
+	@	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jun	DISC

MODAFINIL

TABLET;ORAL
MODAFINIL

>D>	AB	APPCO PHARMA LLC	100MG	A207196	001	Aug 16, 2017	Sep	CAHN
>D>	AB		200MG	A207196	002	Aug 16, 2017	Sep	CAHN
>A>	AB	HERITAGE PHARMS INC	100MG	A207196	001	Aug 16, 2017	Sep	CAHN
>A>	AB		200MG	A207196	002	Aug 16, 2017	Sep	CAHN

MOMETASONE FUROATE

CREAM;TOPICAL
MOMETASONE FUROATE

>A>	AB	ANDA REPOSITORY	0.1%	A076591	001	Apr 18, 2007	Sep	CAHN
>D>	AB	TOLMAR	0.1%	A076591	001	Apr 18, 2007	Sep	CAHN

LOTION;TOPICAL

MOMETASONE FUROATE

>A>	AB	ANDA REPOSITORY	0.1%	A076499	001	Nov 21, 2007	Sep	CAHN
>D>	AB	TOLMAR	0.1%	A076499	001	Nov 21, 2007	Sep	CAHN

OINTMENT;TOPICAL

MOMETASONE FUROATE

>A>	AB	ANDA REPOSITORY	0.1%	A076481	001	Nov 14, 2003	Sep	CAHN
>D>	AB	TOLMAR	0.1%	A076481	001	Nov 14, 2003	Sep	CAHN
	AB	TORRENT PHARMS LTD	0.1%	A207899	001	Jul 13, 2018	Jul	NEWA

MONTELUKAST SODIUM

GRANULE;ORAL
MONTELUKAST SODIUM

AB	TORRENT PHARMS LLC	EQ 4MG BASE/PACKET	A210431	001	Jul 31, 2018	Jul	NEWA
----	--------------------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL

MONTELUKAST SODIUM

@	APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012	Mar	DISC
---	-------------	--------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE;ORAL
MONTELUKAST SODIUM

	@ APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012	Mar DISC
	@	EQ 5MG BASE	A201508	002	Aug 03, 2012	Mar DISC
AB	UNICHEM LABS LTD	EQ 4MG BASE	A208621	001	Jul 02, 2018	Jun NEWA
AB		EQ 5MG BASE	A208621	002	Jul 02, 2018	Jun NEWA

MORPHINE SULFATE

INJECTABLE;INJECTION
INFUMORPH

AP	+! WEST-WARD PHARMS INT	10MG/ML	N018565	003	Jul 19, 1991	Jul CFTG
AP	+!	25MG/ML	N018565	004	Jul 19, 1991	Jul CFTG
	MITIGO					
AP	PIRAMAL CRITICAL	10MG/ML	A204393	001	Jul 16, 2018	Jul NEWA
AP		25MG/ML	A204393	002	Jul 16, 2018	Jul NEWA

SOLUTION;ORAL

MORPHINE SULFATE

AA	ANI PHARMS INC	10MG/5ML	A205509	001	Apr 17, 2018	Apr NEWA
AA		20MG/5ML	A205509	002	Apr 17, 2018	Apr NEWA
AA		100MG/5ML	A205509	003	Apr 17, 2018	Apr NEWA
AA	LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015	May CAHN
AA		20MG/5ML	A202310	001	Oct 30, 2015	May CAHN
>D>	@	100MG/5ML	N201517	001	Jun 23, 2011	Sep CMFD
>A>		100MG/5ML	N201517	001	Jun 23, 2011	Sep CMFD
	@	100MG/5ML	N201517	001	Jun 23, 2011	Aug DISC
AA	NOSTRUM LABS INC	100MG/5ML	A201011	003	Oct 06, 2016	Jul CMS1

TABLET, EXTENDED RELEASE;ORAL

>D>	ARYMO ER					
>D>	+ EGALET	15MG	N208603	001	Jan 09, 2017	Sep DISC
>A>	+ @	15MG	N208603	001	Jan 09, 2017	Sep DISC
>D>	+ @	30MG	N208603	002	Jan 09, 2017	Sep DISC
>A>	+ @	30MG	N208603	002	Jan 09, 2017	Sep DISC
>D>	+ @	60MG	N208603	003	Jan 09, 2017	Sep DISC
>A>	+ @	60MG	N208603	003	Jan 09, 2017	Sep DISC

MORPHINE SULFATE

>D> AB	EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016	Sep DISC
>A>	@	15MG	A091357	001	Jun 23, 2016	Sep DISC
>D> AB		30MG	A091357	002	Jun 23, 2016	Sep DISC
>A>	@	30MG	A091357	002	Jun 23, 2016	Sep DISC
>D> AB		60MG	A091357	003	Jun 23, 2016	Sep DISC
>A>	@	60MG	A091357	003	Jun 23, 2016	Sep DISC
>D> AB		100MG	A091357	004	Jun 23, 2016	Sep DISC
>A>	@	100MG	A091357	004	Jun 23, 2016	Sep DISC
>D> AB		200MG	A091357	005	Jun 23, 2016	Sep DISC
>A>	@	200MG	A091357	005	Jun 23, 2016	Sep DISC

MOXIDECTIN

TABLET;ORAL
MOXIDECTIN

+!	MDGH	2MG	N210867	001	Jun 13, 2018	Jun NEWA
----	------	-----	---------	-----	--------------	----------

MOXIFLOXACIN HYDROCHLORIDE

>A>	SOLUTION;INTRAVENOUS					
>A>	AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
>A>	+ @ BAYER HLTHCARE	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Sep CDFR
>A>	MOXIFLOXACIN HYDROCHLORIDE					
>A>	+! FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Sep CDFR
>A>	MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
>A>	! MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Sep CDFR
>D>	SOLUTION;IV (INFUSION)					
>D>	AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
>D>	+ @ BAYER HLTHCARE	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Sep CDFR
>D>	MOXIFLOXACIN HYDROCHLORIDE					
>D>	+! FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Sep CDFR
>D>	MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
>D>	! MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017	Sep CDFR
	TABLET;ORAL					
	MOXIFLOXACIN HYDROCHLORIDE					
>A> AB	SUNSHINE LAKE	EQ 400MG BASE	A206295	001	Sep 28, 2018	Sep NEWA

MUPIROICIN CALCIUM

CREAM; TOPICAL

BACTROBAN

+ @ GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Apr DISC
---------------------	------------	---------	-----	--------------	----------

MUPIROICIN

! GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	Apr CHRS
-----------------------	------------	---------	-----	--------------	----------

OINTMENT; NASAL

BACTROBAN

+ @ GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995	May DISC
---------------------	------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

@ APOTEX CORP	250MG	A090419	001	Apr 22, 2009	Mar DISC
---------------	-------	---------	-----	--------------	----------

TABLET; ORAL

MYCOPHENOLATE MOFETIL

@ APOTEX	500MG	A090499	001	Apr 22, 2009	Mar DISC
----------	-------	---------	-----	--------------	----------

AB	OXFORD PHARMS	500MG	A090606	001	Jul 16, 2010	Jul CAHN
----	---------------	-------	---------	-----	--------------	----------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	CASI PHARMS INC	500MG	A075280	001	Feb 25, 2002	Mar CAHN
----	-----------------	-------	---------	-----	--------------	----------

AB		750MG	A075280	002	Feb 25, 2002	Mar CAHN
----	--	-------	---------	-----	--------------	----------

NADOLOL

TABLET; ORAL

NADOLOL

AB	BEXIMCO PHARMS USA	20MG	A210955	001	Jul 23, 2018	Jul NEWA
----	--------------------	------	---------	-----	--------------	----------

AB		40MG	A210955	002	Jul 23, 2018	Jul NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A210955	003	Jul 23, 2018	Jul NEWA
----	--	------	---------	-----	--------------	----------

>A> AB	NOVAST LABS	20MG	A210786	001	Jun 01, 2018	Sep CAHN
--------	-------------	------	---------	-----	--------------	----------

>A> AB		40MG	A210786	002	Jun 01, 2018	Sep CAHN
--------	--	------	---------	-----	--------------	----------

>A> AB		80MG	A210786	003	Jun 01, 2018	Sep CAHN
--------	--	------	---------	-----	--------------	----------

>D> AB	RICONPHARMA LLC	20MG	A210786	001	Jun 01, 2018	Sep CAHN
--------	-----------------	------	---------	-----	--------------	----------

AB		20MG	A210786	001	Jun 01, 2018	May NEWA
----	--	------	---------	-----	--------------	----------

>D> AB		40MG	A210786	002	Jun 01, 2018	Sep CAHN
--------	--	------	---------	-----	--------------	----------

AB		40MG	A210786	002	Jun 01, 2018	May NEWA
----	--	------	---------	-----	--------------	----------

>D> AB		80MG	A210786	003	Jun 01, 2018	Sep CAHN
--------	--	------	---------	-----	--------------	----------

AB		80MG	A210786	003	Jun 01, 2018	May NEWA
----	--	------	---------	-----	--------------	----------

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

! TARO	1%	A205975	001	Sep 08, 2016	Apr CHRS
--------	----	---------	-----	--------------	----------

! TARO PHARMS	1%	A205975	001	Sep 08, 2016	May CAHN
---------------	----	---------	-----	--------------	----------

AB		2%	A206901	001	Jan 06, 2016	Jun CAHN
----	--	----	---------	-----	--------------	----------

NAFTIN

+ @ SEBELA IRELAND LTD	1%	N019599	001	Feb 29, 1988	Apr DISC
------------------------	----	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE

SPRAY, METERED; NASAL

NARCAN

+ @ ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Apr DISC
-----------	-----------	---------	-----	--------------	----------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

@ FOSUN PHARMA	50MG	A075434	001	Mar 08, 2000	Jan CAHN
----------------	------	---------	-----	--------------	----------

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

@ AKORN INC	0.1%	A083590	001		Jun DISC
-------------	------	---------	-----	--	----------

NAPROXEN

TABLET; ORAL

NAPROSYN

+ @ ATNAHS PHARMA US	250MG	N017581	002		Aug	DISC
+ @	375MG	N017581	003		Aug	DISC

NAPROXEN

@ FOSUN PHARMA	250MG	A074140	001	Dec 21, 1993	Jan	CAHN
@	375MG	A074140	002	Dec 21, 1993	Jan	CAHN
@	500MG	A074140	003	Dec 21, 1993	Jan	CAHN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

@ FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998	Jan	CAHN
@	500MG	A075061	002	Feb 18, 1998	Jan	CAHN

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

+ @ ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Aug	DISC
----------------------	---------------	---------	-----	--	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

AB	AUROBINDO PHARMA LTD	500MG;EQ 85MG BASE	A207457	001	Feb 15, 2018	Feb	NEWA
AB	MYLAN PHARMS INC	500MG;EQ 85MG BASE	A090872	001	Sep 04, 2018	Aug	NEWA
AB	SUN PHARMA GLOBAL	500MG;EQ 85MG BASE	A202803	001	Jul 20, 2018	Jul	NEWA
	TREXIMET						
	+ @ PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun	DISC
AB	+!	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Feb	CFTG

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

	@ APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Mar	DISC
	@	EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Mar	DISC
AB	CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Mar	CAHN
AB		EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Mar	CAHN

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB	INDICUS PHARMA	60MG	A205544	001	Jun 18, 2018	Jun	NEWA
AB		120MG	A205544	002	Jun 18, 2018	Jun	NEWA
AB	WILSHIRE PHARMS INC	60MG	A205544	001	Jun 18, 2018	Jun	CAHN
AB		120MG	A205544	002	Jun 18, 2018	Jun	CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

AB	+ ALLERGAN SALES LLC	EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Feb	CFTG
	+	EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Jan	CAHN
AB	+	EQ 5MG BASE	N021742	003	Dec 17, 2007	Feb	CFTG
	+	EQ 5MG BASE	N021742	003	Dec 17, 2007	Jan	CAHN
AB	+	EQ 10MG BASE	N021742	004	Dec 17, 2007	Feb	CFTG
	+	EQ 10MG BASE	N021742	004	Dec 17, 2007	Jan	CAHN
AB	+!	EQ 20MG BASE	N021742	005	Oct 08, 2008	Feb	CFTG
	+!	EQ 20MG BASE	N021742	005	Oct 08, 2008	Jan	CAHN

NEBIVOLOL HYDROCHLORIDE

	@ TORRENT PHARMS LTD	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Mar	DISC
AB		EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Feb	NEWA
	@	EQ 5MG BASE	A203966	002	Mar 02, 2018	Mar	DISC
AB		EQ 5MG BASE	A203966	002	Mar 02, 2018	Feb	NEWA
	@	EQ 10MG BASE	A203966	003	Mar 02, 2018	Mar	DISC
AB		EQ 10MG BASE	A203966	003	Mar 02, 2018	Feb	NEWA
	@	EQ 20MG BASE	A203966	004	Mar 02, 2018	Mar	DISC
AB		EQ 20MG BASE	A203966	004	Mar 02, 2018	Feb	NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

BYVALSON

+!	ALLERGAN SALES LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	Jan CAHN
----	--------------------	------------------	---------	-----	--------------	----------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@	FOSUN PHARMA	50MG	A076302	001	Sep 16, 2003	Jan CAHN
@		100MG	A076302	002	Sep 16, 2003	Jan CAHN
@		150MG	A076302	003	Sep 16, 2003	Jan CAHN
@		200MG	A076302	004	Sep 16, 2003	Jan CAHN
@		250MG	A076302	005	Sep 16, 2003	Jan CAHN

NELARABINE

>A>	INJECTABLE; INTRAVENOUS					
>A>	ARRANON					
>A>	+!	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005
>D>	INJECTABLE; IV (INFUSION)					Sep CDFR
>D>	ARRANON					
>D>	+!	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005
						Sep CDFR

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

AP	+!	AVADEL LEGACY	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Feb CAHN
AP	+!		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Feb CAHN

NEOSTIGMINE METHYLSULFATE

AP		AMNEAL PHARMS CO	5MG/10ML (0.5MG/ML)	A210051	001	Jun 15, 2018	Jun NEWA
AP			10MG/10ML (1MG/ML)	A210051	002	Jun 15, 2018	Jun NEWA
AP		DR REDDYS LABS LTD	5MG/10ML (0.5MG/ML)	A209135	001	Jul 10, 2018	Jun NEWA
AP			10MG/10ML (1MG/ML)	A209135	002	Jul 10, 2018	Jun NEWA
AP		LUITPOLD	5MG/10ML (0.5MG/ML)	A209182	001	May 04, 2018	Apr NEWA
AP			10MG/10ML (1MG/ML)	A209182	002	May 04, 2018	Apr NEWA
AP		RENAISSANCE SSA LLC	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Aug NEWA
AP			10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Aug NEWA
>A>		NEOSTIGMINE METHYLSULFATE PFS					
>A>		FRESENIUS KABI USA	3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018	Sep NEWA

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

@ APOTEX INC 200MG

A203021	001	May 22, 2012	Mar DISC
---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

@ APOTEX INC 400MG

A205258	001	Apr 03, 2014	Jan DISC
---------	-----	--------------	----------

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB		AUROBINDO PHARMA LTD	500MG	A209236	001	Feb 01, 2018	Jan NEWA
AB			750MG	A209236	002	Feb 01, 2018	Jan NEWA
AB			1GM	A209236	003	Feb 01, 2018	Jan NEWA
AB		JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Apr NEWA
AB			750MG	A209156	002	May 14, 2018	Apr NEWA
AB			1GM	A209156	003	May 14, 2018	Apr NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARDENE

+	@	CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	May DISC
---	---	----------------	----------------------	---------	-----	--------------	----------

NICARDIPINE HYDROCHLORIDE

		EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	May CTEC
	@	LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	May DISC
	@	MYLAN INSTITUTIONAL	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	May DISC
	@	NAVINTA LLC	25MG/10ML (2.5MG/ML)	A090125	001	Nov 17, 2009	May DISC
	@	SUN PHARMA GLOBAL	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	May DISC
	@	WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	May DISC
	@	WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	May DISC

INJECTABLE;INTRAVENOUS

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+ @ CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Mar DISC
--------------------	-----------------------	---------	-----	--------------	----------

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB1	ZYDUS PHARMS USA INC	30MG	A210184	001	Jun 29, 2018	Jun NEWA
AB1		60MG	A210184	002	Jun 29, 2018	Jun NEWA
AB1		90MG	A210184	003	Jun 29, 2018	Jun NEWA

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

TASIGNA

+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Jun CAIN
+		EQ 150MG BASE	N022068	002	Jun 17, 2010	Jun CAIN
+	!	EQ 200MG BASE	N022068	001	Oct 29, 2007	Jun CAIN

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE;ORAL

TASIGNA

+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Mar NEWA
---	----------	--------------	---------	-----	--------------	----------

NITRIC OXIDE

GAS;INHALATION

INOMAX

>D>	+	!	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Sep CFTG
>A>	AA	+	!	800PPM	N020845	003	Dec 23, 1999	Sep CFTG
>A>			NOXIVENT					
>A>			PRAXAIR DISTRIBUTION	100PPM	A207141	001	Oct 02, 2018	Sep NEWA
>A>	AA			800PPM	A207141	002	Oct 02, 2018	Sep NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB	NOVEL LABS INC	50MG	A203233	001	Jul 09, 2018	Jun NEWA
AB		100MG	A203233	002	Jul 09, 2018	Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	SUNNY PHARMTECH INC	75MG;25MG	A208516	001	May 24, 2018	May NEWA
----	---------------------	-----------	---------	-----	--------------	----------

NITROGLYCERIN

INJECTABLE;INJECTION

NITROGLYCERIN IN DEXTROSE 5%

@	HOSPIRA	10MG/100ML	A071846	001	Aug 31, 1990	Jun DISC
@		20MG/100ML	A071847	001	Aug 31, 1990	Jun DISC
@		40MG/100ML	A071848	001	Aug 31, 1990	Jun DISC

OINTMENT;INTRA-ANAL

RECTIV

+	!	ALLERGAN SALES LLC	0.4%	N021359	001	Jun 21, 2011	Jan CAHN
---	---	--------------------	------	---------	-----	--------------	----------

TABLET;SUBLINGUAL

NITROGLYCERIN

AB	GLENMARK PHARMS SA	0.3MG	A206391	001	Sep 19, 2017	Jan CAHN
AB		0.4MG	A206391	002	Sep 19, 2017	Jan CAHN
AB		0.6MG	A206391	003	Sep 19, 2017	Jan CAHN
AB	SIGMAPHARM LABS LLC	0.3MG	A207745	001	May 07, 2018	Apr NEWA
AB		0.4MG	A207745	002	May 07, 2018	Apr NEWA
AB		0.6MG	A207745	003	May 07, 2018	Apr NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

>A>	AP	MYLAN LABS LTD	EQ 1MG BASE/ML	A211242	001	Oct 04, 2018	Sep NEWA
-----	----	----------------	----------------	---------	-----	--------------	----------

NORETHINDRONE ACETATE

TABLET; ORAL					
AYGESTIN					
	+ @ DURAMED RES	5MG	N018405	001	Apr 21, 1982 May DISC
NORETHINDRONE ACETATE					
AB	! BARR	5MG	A075951	001	May 25, 2001 May CHRS

NORGESTREL

TABLET; ORAL					
OPILL					
	+ LABORATOIRE HRA	0.075MG	N017031	001	Aug CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL					
NORTRIPTYLINE HYDROCHLORIDE					
AB	MAYNE PHARMA	EQ 10MG BASE	A073556	002	Mar 30, 1992 Mar CMS1
AB		EQ 25MG BASE	A073556	003	Mar 30, 1992 Mar CMS1
AB		EQ 50MG BASE	A073556	004	Mar 30, 1992 Mar CMS1

NYSTATIN

OINTMENT; TOPICAL					
NYSTATIN					
	@ G AND W LABS INC	100,000 UNITS/GM	A209114	001	Oct 06, 2017 Jan DISC
AT	LYNE	100,000 UNITS/GM	A209082	001	May 21, 2018 May NEWA
AT	ZYDUS PHARMS USA INC	100,000 UNITS/GM	A207767	001	May 25, 2018 May NEWA
POWDER; TOPICAL					
NYSTATIN					
AT	EPIC PHARMA LLC	100,000 UNITS/GM	A210532	001	Apr 30, 2018 Apr NEWA
SUSPENSION; ORAL					
NYSTATIN					
	@ G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982 Jan DISC
AA	LANNETT CO INC	100,000 UNITS/ML	A065148	001	Jun 28, 2005 May CAHN
	@ SOCORRO	100,000 UNITS/ML	A062832	001	Dec 27, 1991 Jun CAHN
TABLET; VAGINAL					
NYSTATIN					
	@ ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985 Jun DISC

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL					
NYSTATIN AND TRIAMCINOLONE ACETONIDE					
AT	AMNEAL PHARMS LLC	100,000 UNITS/GM; 0.1%	A209990	001	Feb 15, 2018 Feb NEWA
AT	LUPIN LTD	100,000 UNITS/GM; 0.1%	A208205	001	May 31, 2018 May NEWA
OINTMENT; TOPICAL					
NYSTATIN AND TRIAMCINOLONE ACETONIDE					
>D> AT	RICONPHARMA LLC	100,000 UNITS/GM; 0.1%	A206785	001	Dec 29, 2016 Sep CAHN
>A> AT	RISING PHARMS	100,000 UNITS/GM; 0.1%	A206785	001	Dec 29, 2016 Sep CAHN
AT	STRIDES PHARMA	100,000 UNITS/GM; 0.1%	A210077	001	Jan 29, 2018 Jan NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION					
OCTREOTIDE ACETATE					
AP	USV NORTH AMERICA	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018 Aug NEWA
AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018 Aug NEWA

OLANZAPINE

TABLET; ORAL					
OLANZAPINE					
>A> AB	JIANGSU HANSO PHARM	2.5MG	A209399	001	Sep 24, 2018 Sep NEWA
>A> AB		5MG	A209399	002	Sep 24, 2018 Sep NEWA
>A> AB		10MG	A209399	003	Sep 24, 2018 Sep NEWA
AB	ZYDUS PHARMS USA INC	2.5MG	A090459	001	Jul 16, 2018 Jul NEWA
AB		5MG	A090459	002	Jul 16, 2018 Jul NEWA
AB		7.5MG	A090459	003	Jul 16, 2018 Jul NEWA
AB		10MG	A090459	004	Jul 16, 2018 Jul NEWA
AB		15MG	A090459	005	Jul 16, 2018 Jul NEWA
AB		20MG	A090459	006	Jul 16, 2018 Jul NEWA
TABLET, ORALLY DISINTEGRATING; ORAL					
OLANZAPINE					
AB	HEC PHARM	5MG	A208146	001	Jul 02, 2018 Jul CAHN
AB		10MG	A208146	002	Jul 02, 2018 Jul CAHN
AB		15MG	A208146	003	Jul 02, 2018 Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB		20MG	A208146	004	Jul 02, 2018	Jul CAHN
AB	HEC PHARM CO LTD	5MG	A208146	001	Jul 02, 2018	Jun NEWA
AB		10MG	A208146	002	Jul 02, 2018	Jun NEWA
AB		15MG	A208146	003	Jul 02, 2018	Jun NEWA
AB		20MG	A208146	004	Jul 02, 2018	Jun NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL
OLMESARTAN MEDOXOMIL

AB	SCIEGEN PHARMS INC	5MG	A208130	001	Jun 29, 2018	Jun NEWA
AB		20MG	A208130	002	Jun 29, 2018	Jun NEWA
AB		40MG	A208130	003	Jun 29, 2018	Jun NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	MICRO LABS LTD INDIA	EQ 0.1% BASE	A204392	001	Mar 21, 2018	Mar NEWA
AT	MYLAN PHARMS INC	EQ 0.1% BASE	A204392	001	Mar 21, 2018	May CAHN

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL
EPANOVA

	+ @ ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	Jun DISC
--	------------------------	---	---------	-----	--------------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	MYLAN PHARMS INC	10MG	A205070	001	Jun 29, 2018	Jun NEWA
AB		20MG	A205070	002	Jun 29, 2018	Jun NEWA
AB		40MG	A205070	003	Jun 29, 2018	Jun NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

AB	ZYDUS PHARMS USA INC	20MG;1.1GM	A203290	001	May 25, 2018	May NEWA
AB		40MG;1.1GM	A203290	002	May 25, 2018	May NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

	@ CHARTWELL MOLECULES	4MG	A077406	003	Dec 26, 2006	Mar CMS1
	@	8MG	A077406	004	Dec 26, 2006	Mar CMS1

ONDANSETRON HYDROCHLORIDE

TABLET;ORAL
ONDANSETRON HYDROCHLORIDE

AB	CASI PHARMS INC	EQ 4MG BASE	A077517	001	Jun 25, 2007	Mar CAHN
AB		EQ 8MG BASE	A077517	002	Jun 25, 2007	Mar CAHN
AB		EQ 24MG BASE	A077517	003	Jun 25, 2007	Mar CAHN

ORITAVANCIN DIPHOSPHATE

>A>	POWDER;INTRAVENOUS					
>A>	ORBACTIV					
>A>	+! MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Sep CDFR
	POWDER;IV (INFUSION)					
	ORBACTIV					
	+! MELINTA	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Jan CAHN
>D>	+! MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Sep CDFR
	+!	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Mar CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL
ORPHENADRINE CITRATE

>A>	AB	ANDA REPOSITORY	100MG	A040249	001	Jan 29, 1999	Sep CAHN
>D>	AB	TEDOR PHARMA INC	100MG	A040249	001	Jan 29, 1999	Sep CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	HETERO LABS LTD III	EQ 30MG BASE	A209438	001	Feb 23, 2018	Feb NEWA
AB		EQ 45MG BASE	A209438	002	Feb 23, 2018	Feb NEWA
AB		EQ 75MG BASE	A209438	003	Feb 23, 2018	Feb NEWA
AB	STRIDES PHARMA	EQ 30MG BASE	A209421	001	Jun 08, 2018	May NEWA
AB		EQ 45MG BASE	A209421	002	Jun 08, 2018	May NEWA
AB		EQ 75MG BASE	A209421	003	Jun 08, 2018	May NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	AMNEAL PHARMS NY	EQ 6MG BASE/ML	A210186	001	Feb 27, 2018	Aug NEWA
AB	LUPIN ATLANTIS	EQ 6MG BASE/ML	A208347	001	Feb 20, 2018	Feb NEWA

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

AP	! SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Jun CHRS
AP	!	EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Jun CHRS
AP	!	EQ 10GM BASE/VIAL	A091245	001	Mar 30, 2012	Jun CHRS
	@ SANDOZ	EQ 1GM BASE/VIAL	A061490	003		May DISC
	@	EQ 2GM BASE/VIAL	A061490	004		May DISC
	@	EQ 10GM BASE/VIAL	A061490	006	May 09, 1991	May DISC

POWDER;INTRAVENOUS

OXACILLIN SODIUM

@ SANDOZ

@

EQ 1GM BASE/VIAL

EQ 2GM BASE/VIAL

A062737 001 Dec 23, 1986 May DISC

A062737 002 Dec 23, 1986 May DISC

OXALIPLATIN

INJECTABLE;IV (INFUSION)

OXALIPLATIN

AP	ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb NEWA
AP		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb NEWA
AP	EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Apr CAHN
AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Apr CAHN

OXANDROLONE

TABLET;ORAL

OXANDRIN

>D>						
>D>	AB	+ GEMINI LABS LLC	2.5MG	N013718	001	Sep DISC
>A>		+ @	2.5MG	N013718	001	Sep DISC
>D>	AB	+!	10MG	N013718	002	Nov 05, 2001 Sep DISC
>A>		+ @	10MG	N013718	002	Nov 05, 2001 Sep DISC

OXANDROLONE

>D>	AB	PAR PHARM	10MG	A077827	002	Jun 22, 2007 Sep CHRS
>A>	AB	!	10MG	A077827	002	Jun 22, 2007 Sep CHRS

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB	TARO PHARMS	EQ 1% BASE	A205076	001	Mar 07, 2016	May CAHN
----	-------------	------------	---------	-----	--------------	----------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

CHOLEDYL SA

@ WARNER CHILCOTT LLC

400MG

A087863 001 May 24, 1983 Aug DISC

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

AB	+! ALLERGAN SALES LLC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	May CFTG
		OXYBUTYNIN CHLORIDE				

AB	PAR PHARM INC	10% (100MG/PACKET)	A207329	001	May 31, 2018	May NEWA
----	---------------	--------------------	---------	-----	--------------	----------

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA	LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004	May CAHN
----	----------------	---------	---------	-----	--------------	----------

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB	TULEX PHARMS INC	5MG	A210125	001	Sep 06, 2018	Aug NEWA
----	------------------	-----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
DITROPAN XL

AB	+	JANSSEN PHARMS	5MG	N020897	001	Dec 16, 1998	Jun CMFD
	+	@	5MG	N020897	001	Dec 16, 1998	Feb DISC
AB	+		10MG	N020897	002	Dec 16, 1998	Jun CMFD
	+	@	10MG	N020897	002	Dec 16, 1998	Feb DISC
		OXYBUTYNIN CHLORIDE					
AB	!	MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Feb CHRS

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

AB	+	GENUS LIFESCIENCES	5MG	N200534	001	Oct 20, 2010	Apr CAHN
----	---	--------------------	-----	---------	-----	--------------	----------

SOLUTION;ORAL

		OXYCODONE HYDROCHLORIDE					
AA	+	GENUS LIFESCIENCES	5MG/5ML	N200535	002	Aug 22, 2013	Apr CAHN
AA	+	!	100MG/5ML	N200535	001	Oct 20, 2010	Apr CAHN
AA		SPECGX LLC	5MG/5ML	A210758	001	Apr 30, 2018	Apr NEWA
AA			100MG/5ML	A210758	002	Apr 30, 2018	Apr NEWA

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

>D>	AB	KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Sep CAHN
>D>	AB		10MG	A207119	002	Apr 12, 2016	Sep CAHN
>D>	AB		15MG	A207119	003	Apr 12, 2016	Sep CAHN
>D>	AB		20MG	A207119	004	Apr 12, 2016	Sep CAHN
>D>	AB		30MG	A207119	005	Apr 12, 2016	Sep CAHN
>A>	AB	NUVO PHARM	5MG	A207119	001	Apr 12, 2016	Sep CAHN
>A>	AB		10MG	A207119	002	Apr 12, 2016	Sep CAHN
>A>	AB		15MG	A207119	003	Apr 12, 2016	Sep CAHN
>A>	AB		20MG	A207119	004	Apr 12, 2016	Sep CAHN
>A>	AB		30MG	A207119	005	Apr 12, 2016	Sep CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	5MG	A210175	001	Feb 02, 2018	Jan NEWA
AB			10MG	A210175	002	Feb 02, 2018	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

!		IMPAX LABS	40MG	A079087	007	Jun 14, 2010	Jun CHRS
---	--	------------	------	---------	-----	--------------	----------

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

@		CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	N061015	001		Jul DISC
!			EQ 5MG BASE/GM;10,000 UNITS/GM	N061015	001		Feb CMS2

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP		SAGENT PHARMS	10USP UNITS/ML (10USP UNITS/ML)	A091676	001	Jul 13, 2018	Jul NEWA
AP			100USP UNITS/10ML (10USP UNITS/ML)	A091676	002	Jul 13, 2018	Jul NEWA

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

AP		ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	Aug NEWA
----	--	-----------------	--------	---------	-----	--------------	----------

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

AB		SUN PHARMA GLOBAL	1.5mg	A205618	001	Apr 06, 2018	Mar NEWA
AB			3MG	A205618	002	Apr 06, 2018	Mar NEWA
AB			6MG	A205618	003	Apr 06, 2018	Mar NEWA
AB			9MG	A205618	004	Apr 06, 2018	Mar NEWA

PALONOSETRON HYDROCHLORIDEINJECTABLE; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

>A>	AP	CIPLA LTD	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206396	001	Sep 19, 2018	Sep NEWA
>A>	AP	FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206801	001	Sep 19, 2018	Sep NEWA
>A>	AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206802	001	Sep 19, 2018	Sep NEWA
>A>	AP	HOSPIRA INC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A207005	001	Sep 19, 2018	Sep NEWA
>A>	AP		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018	Sep NEWA
>A>	AP	MYLAN INSTITUTIONAL	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A206416	001	Sep 19, 2018	Sep NEWA
>A>	AP	QILU PHARM CO LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018	Sep NEWA
>A>	AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A205648	001	Sep 19, 2018	Sep NEWA
>A>	AP	SAGENT PHARMS	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204289	001	Sep 19, 2018	Sep NEWA
>A>	AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A205870	001	Sep 19, 2018	Sep NEWA
	AP	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Mar NEWA
	AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Mar 23, 2018	Mar NEWA
>A>	AP	VIRTUS PHARM	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A209287	001	Sep 19, 2018	Sep NEWA

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)CAPSULE, DELAYED RELEASE; ORAL
PANCREAZE

+	JANSSEN PHARMS	24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Mar CPOT
+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Mar CPOT
+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Mar CPOT
+		98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Mar CPOT
+	VIVUS INC	10,850USP UNITS; 2,600USP UNITS; 6,200USP UNITS	N022523	005	Mar 07, 2014	Jun CAHN
+		24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Jun CAHN
+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Jun CAHN
+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Jun CAHN
+		98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Jun CAHN

PANTOPRAZOLE SODIUMFOR SUSPENSION, DELAYED RELEASE; ORAL
PROTONIX

+	WYETH PHARMS	EQ 40MG BASE	N022020	001	Nov 14, 2007	Jul CAHN
		INJECTABLE; IV (INFUSION)				
		PANTOPRAZOLE SODIUM				
AP	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Apr NEWA
		PROTONIX IV				
AP	WYETH PHARMS	EQ 40MG BASE/VIAL	N020988	001	Mar 22, 2001	Jul CAHN
		TABLET, DELAYED RELEASE; ORAL				
		PANTOPRAZOLE SODIUM				
	@ SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr DISC
	@	EQ 40MG BASE	A200794	002	May 02, 2012	Apr DISC
		PROTONIX				
AB	WYETH PHARMS	EQ 20MG BASE	N020987	002	Jun 12, 2001	Jul CAHN
AB	+	EQ 40MG BASE	N020987	001	Feb 02, 2000	Jul CAHN

PARICALCITOLCAPSULE; ORAL
PARICALCITOL

AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Jun CAHN
AB		2MCG	A206710	002	Feb 24, 2016	Jun CAHN
AB		4MCG	A206710	003	Feb 24, 2016	Jun CAHN

SOLUTION; INTRAVENOUS
PARICALCITOL

>A> AP	AUROBINDO PHARMA LTD	0.002MG/ML (0.002MG/ML)	A205982	001	Oct 09, 2018	Sep NEWA
>A> AP		0.005MG/ML (0.005MG/ML)	A205982	002	Oct 09, 2018	Sep NEWA
>A> AP		0.01MG/2ML (0.005MG/ML)	A205982	003	Oct 09, 2018	Sep NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PAROXETINE HYDROCHLORIDE

AB	SCIECURE PHARMA INC	EQ 12.5MG BASE	A209293	001	Jun 12, 2018	May NEWA
AB		EQ 25MG BASE	A209293	002	Jun 12, 2018	May NEWA
AB		EQ 37.5MG BASE	A209293	003	Jun 12, 2018	May NEWA

PASIREOTIDE PAMOATE

FOR SUSPENSION; INTRAMUSCULAR
SIGNIFOR LAR KIT

+	NOVARTIS PHARMS CORP	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Jun NEWA
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Jun CDFR
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Jun NEWA
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Jun CDFR
+	!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Jun CDFR

POWDER; INTRAMUSCULAR
SIGNIFOR LAR KIT

+	NOVARTIS PHARMS CORP	EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Jun CTNA
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Jun CTNA
+	!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Jun CTNA

PATISIRAN SODIUM

SOLUTION; INTRAVENOUS
ONPATRO

+	!	ALNYLAM PHARMS INC	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N210922	001	Aug 10, 2018	Aug NEWA
---	---	--------------------	-----------------------------------	---------	-----	--------------	----------

PEGADEMASE BOVINE

INJECTABLE; INJECTION
ADAGEN

+	!	LEADIANT BIOSCI INC	250 UNITS/ML	N019818	001	Mar 21, 1990	Jun CAHN
---	---	---------------------	--------------	---------	-----	--------------	----------

PEMETREXED DISODIUM

POWDER; INTRAVENOUS
ALIMTA

+	!	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007	Jun CDFR
+	!		EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004	Jun CDFR

PEMOLINE

TABLET; ORAL
PEMOLINE

@	FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999	Jan CAHN
@		37.5MG	A075286	002	Jun 30, 1999	Jan CAHN
@		75MG	A075286	003	Jun 30, 1999	Jan CAHN

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION
BICILLIN L-A

+	@	KING PHARMS LLC	300,000 UNITS/ML	N050141	003		Jun DISC
		PERMAPEN					
	@	CASPER PHARMA LLC	600,000 UNITS/ML	N060014	001		Jul DISC
BC			600,000 UNITS/ML	N060014	001		Feb CMS2

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION
BICILLIN C-R

+	@	KING PHARMS LLC	150,000 UNITS/ML; 150,000 UNITS/ML	N050138	002		Jun DISC
---	---	-----------------	------------------------------------	---------	-----	--	----------

PENTAZOCINE LACTATE

INJECTABLE; INJECTION
TALWIN

+	@	HOSPIRA	EQ 30MG BASE/ML	N016194	001		Jun DISC
---	---	---------	-----------------	---------	-----	--	----------

PERAMIVIRSOLUTION; INTRAVENOUS
RAPIVAB

+! BIOCRYST 200MG/20ML (10MG/ML)

N206426 001 Dec 19, 2014 Jun CDFR

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE

@ APOTEX

2MG

A090463 001 Aug 30, 2010 Jan DISC

@

4MG

A090463 002 Aug 30, 2010 Jan DISC

@

8MG

A090463 003 Aug 30, 2010 Jan DISC

AB AUROBINDO PHARMA

2MG

A079070 001 Nov 10, 2009 Mar CHRS

AB

4MG

A079070 002 Nov 10, 2009 Mar CHRS

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENDIMETRAZINE TARTRATE

@ VIRTUS PHARMS

35MG

A085695 001

May CAHN

CAPSULE, EXTENDED RELEASE; ORAL

PHENDIMETRAZINE TARTRATE

@ VIRTUS PHARMS

105MG

A087378 001

May CAHN

+!

105MG

N018074 001

Mar CAHN

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

@ VIRTUS PHARMS

35MG

A085497 001

May CAHN

AA

35MG

A085588 001

Mar CAHN

@

35MG

A086365 001

May CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

@ ELITE LABS INC

15MG

A040460 001 Jan 14, 2003 Jan CAHN

>D> AA

KEN LIFESCIENCE

15MG

A205019 001 Dec 05, 2014 Sep CAHN

>D> AA

30MG

A205019 002 Dec 05, 2014 Sep CAHN

>D> AA

37.5MG

A205017 001 Sep 25, 2014 Sep CAHN

>A> AA

NUVO PHARM

15MG

A205019 001 Dec 05, 2014 Sep CAHN

>A> AA

30MG

A205019 002 Dec 05, 2014 Sep CAHN

>A> AA

37.5MG

A205017 001 Sep 25, 2014 Sep CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

>D> AA

INGENUS PHARMS NJ

37.5MG

A091451 001 Sep 21, 2012 Sep CAHN

>D> AA

KEN LIFESCIENCE

37.5MG

A205008 001 Sep 25, 2014 Sep CAHN

>A> AA

NOVAST LABS

37.5MG

A091451 001 Sep 21, 2012 Sep CAHN

>A> AA

NUVO PHARM

37.5MG

A205008 001 Sep 25, 2014 Sep CAHN

PHENYL BUTAZONE

CAPSULE; ORAL

PHENYL BUTAZONE

@ FOSUN PHARMA

100MG

A087774 001 Jun 16, 1982 Jan CAHN

TABLET; ORAL

PHENYL BUTAZONE

@ FOSUN PHARMA

100MG

A084339 001

Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP AMNEAL PHARMS CO

10MG/ML (10MG/ML)

A211079 001 Jul 05, 2018 Jun NEWA

AP 50MG/5ML (10MG/ML)

A211078 001 Jul 19, 2018 Jul NEWA

AP 100MG/10ML (10MG/ML)

A211078 002 Jul 19, 2018 Jul NEWA

AP CIPLA LTD 10MG/ML (10MG/ML)

A210334 001 Apr 27, 2018 Jun CDFR

AP 100MG/10ML (10MG/ML)

A210333 002 Apr 27, 2018 Jun CDFR

AP +! WEST WARD PHARM CORP 10MG/ML (10MG/ML)

N203826 001 Dec 20, 2012 Jun CDFR

PHENYLEPHRINE HYDROCHLORIDE

AP CIPLA LTD 50MG/5ML (10MG/ML)

A210333 001 Apr 27, 2018 Jun CDFR

VAZCULEP

AP + AVADEL LEGACY 10MG/ML (10MG/ML)

N204300 001 Jun 27, 2014 Jun CTEC

AP + 10MG/ML (10MG/ML)

N204300 001 Jun 27, 2014 Jun CDFR

AP + 50MG/5ML (10MG/ML)

N204300 002 Jun 27, 2014 Jun CDFR

AP +! 100MG/10ML (10MG/ML)

N204300 003 Jun 27, 2014 Jun CDFR

SOLUTION;IV (INFUSION)

PHENYLEPHRINE HYDROCHLORIDE

AP	CIPLA LTD	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Apr NEWA
AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Apr NEWA
AP	+! WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Apr CFTG
PHENYLEPHRINE HYDROCHLORIDE						
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Apr NEWA
VAZCULEP						
AP	+ AVADEL LEGACY	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Apr CFTG
AP	+!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Apr CFTG

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	! VINTAGE	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Jan CHRS
PROMETH VC PLAIN						
	@ G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jan DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

AB	WOCKHARDT BIO AG	125MG/5ML	A040420	001	Apr 19, 2002	Jan CAHN
----	------------------	-----------	---------	-----	--------------	----------

PHYTONADIONE

TABLET;ORAL

MEPHYTON

AB	+! VALEANT PHARMS	5MG	N010104	003		Apr CFTG
PHYTONADIONE						
AB	AMNEAL PHARMS CO	5MG	A209373	001	May 11, 2018	Apr NEWA

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

NUPLAZID

	+! ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018	Jun NEWA
TABLET;ORAL						
		NUPLAZID				
	+! ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018	Jun NEWA

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	NEOPHARMA	EQ 15MG BASE	A078383	001	Mar 12, 2013	Aug CAHN
AB		EQ 30MG BASE	A078383	002	Mar 12, 2013	Aug CAHN
AB		EQ 45MG BASE	A078383	003	Mar 12, 2013	Aug CAHN
AB	PRINSTON INC	EQ 15MG BASE	A207806	001	Apr 17, 2018	Apr NEWA
AB		EQ 30MG BASE	A207806	002	Apr 17, 2018	Apr NEWA
AB		EQ 45MG BASE	A207806	003	Apr 17, 2018	Apr NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	APOLLO PHARMS INC	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Aug NEWA
AP	FRESENIUS KABI	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A203719	001	May 18, 2018	May NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A203719	002	May 18, 2018	May NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A203719	003	May 18, 2018	May NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A203720	001	May 11, 2018	Apr NEWA
AP	FRESENIUS KABI USA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018	Apr NEWA
AP	QILU TIANHE	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A204959	001	Aug 10, 2018	Jul NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A204959	002	Aug 10, 2018	Jul NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A204959	003	Aug 10, 2018	Jul NEWA
AP	SANDOZ INC	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A203557	001	Oct 29, 2014	Apr CDFFR
AP	WOCKHARDT BIO AG	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan CPOT

INJECTABLE; INJECTION

ZOSYN

AP	+	WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993	Aug CAHN
AP	+		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993	Aug CAHN
AP	+		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993	Aug CAHN
AP	+		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993	Aug CAHN
ZOSYN IN PLASTIC CONTAINER							
	+	WYETH PHARMS	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998	Aug CAHN
	+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998	Aug CAHN
	+		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998	Aug CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

>A>	AB	BRECKENRIDGE PHARM	10MG	A208991	001	Feb 21, 2018	Sep CAHN
>A>	AB		20MG	A208991	002	Feb 21, 2018	Sep CAHN
>D>	AB	LABORATORIOS CINFA	10MG	A208991	001	Feb 21, 2018	Sep CAHN
	AB		10MG	A208991	001	Feb 21, 2018	Feb NEWA
>D>	AB		20MG	A208991	002	Feb 21, 2018	Sep CAHN
	AB		20MG	A208991	002	Feb 21, 2018	Feb NEWA
	AB	MICRO LABS	10MG	A206152	001	Dec 29, 2017	Feb CRLD
	AB		20MG	A206152	002	Dec 29, 2017	Feb CRLD
	AB	STRIDES PHARMA	10MG	A210347	001	Jan 26, 2018	Jan NEWA
	AB		20MG	A210347	002	Jan 26, 2018	Jan NEWA
	AB	ZYDUS PHARMS USA INC	10MG	A205585	001	Jul 17, 2018	Jul NEWA
	AB		20MG	A205585	002	Jul 17, 2018	Jul NEWA

PLAZOMICIN SULFATE

SOLUTION; INTRAVENOUS

ZEMDRI

	+	ACHAOGEN INC	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	Jun NEWA
--	---	--------------	---	---------	-----	--------------	----------

POLIDOCANOL

SOLUTION; INTRAVENOUS

VARITHENA

	+	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Jan CDJR
--	---	-----------	-------------------------	---------	-----	--------------	----------

POSACONAZOLE

SOLUTION; INTRAVENOUS

NOXAFIL

	+	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	Aug CDJR
--	---	-------------------	------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

	+	@ NESHER PHARMS	8MEQ	N018238	001		Apr DISC
--	---	-----------------	------	---------	-----	--	----------

MICRO-K 10

	+	@ NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Apr DISC
--	---	-----------------	-------	---------	-----	--------------	----------

SOLUTION; ORAL

POTASSIUM CHLORIDE

AA		AMNEAL PHARMS LLC	20MEQ/15ML	A210041	001	Jul 19, 2018	Jul NEWA
AA			40MEQ/15ML	A210041	002	Jul 19, 2018	Jul NEWA
AA		APOTEX INC	20MEQ/15ML	A211067	001	Aug 08, 2018	Jul NEWA
AA			40MEQ/15ML	A211067	002	Aug 08, 2018	Jul NEWA
AA	+	GENUS LIFESCIENCES	20MEQ/15ML	N206814	001	Dec 22, 2014	Jul CFTG
AA	+		40MEQ/15ML	N206814	002	Dec 22, 2014	Jul CFTG
AA		NOVEL LABS INC	20MEQ/15ML	A209786	001	Aug 29, 2018	Aug NEWA
AA			40MEQ/15ML	A209786	002	Aug 29, 2018	Aug NEWA

TABLET, EXTENDED RELEASE; ORAL

K-TAB

AB3	+	ABBVIE	10MEQ	N018279	001		Jan CTEC
-----	---	--------	-------	---------	-----	--	----------

AB2	+		20MEQ	N018279	003	Nov 25, 2013	Jan CTEC
-----	---	--	-------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

AB3		PADDOK LLC	10MEQ	A209688	001	Jan 12, 2018	Jan NEWA
AB2			20MEQ	A209688	002	Jan 12, 2018	Jan NEWA
AB2		STRIDES PHARMA	8MEQ	A210733	001	Aug 31, 2018	Aug NEWA
AB2			10MEQ	A210733	002	Aug 31, 2018	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB2	YICHANG HUMANWELL	8MEQ	A209314	001	Jun 22, 2018	Jun NEWA
AB2		10MEQ	A209314	002	Jun 22, 2018	Jun NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%

+ @ BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648	003		Jun DISC
---------------------	-------------------------	---------	-----	--	----------

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CITRATE

AB	MOUNTAIN	5MEQ	A077440	001	Jun 09, 2006	Jan CAHN
AB		10MEQ	A077440	002	Jun 09, 2006	Jan CAHN
AB	TEVA PHARMS USA INC	5MEQ	A209758	001	Mar 05, 2018	Feb NEWA
AB		10MEQ	A209758	002	Mar 05, 2018	Feb NEWA
AB		15MEQ	A209758	003	Mar 05, 2018	Feb NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>A> AB	CSPC OUYI PHARM CO	0.25MG	A211088	001	Oct 03, 2018	Sep NEWA
>A> AB		0.5MG	A211088	002	Oct 03, 2018	Sep NEWA
>A> AB		0.75MG	A211088	003	Oct 03, 2018	Sep NEWA
>A> AB		1MG	A211088	004	Oct 03, 2018	Sep NEWA
>A> AB		1.5MG	A211088	005	Oct 03, 2018	Sep NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

AB	ACCORD HLTHCARE	EQ 5MG BASE	A205987	001	Feb 02, 2018	Jan NEWA
AB		EQ 10MG BASE	A205987	002	Feb 02, 2018	Jan NEWA
AB	AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Jun NEWA
AB		EQ 10MG BASE	A205913	002	Jun 19, 2018	Jun NEWA
AB	USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Jan CAHN
AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Jan CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

>D> AB	APPCO PHARMA LLC	10MG	A209869	001	Apr 13, 2018	Sep CAHN
AB		10MG	A209869	001	Apr 13, 2018	Apr NEWA
>D> AB		20MG	A209869	002	Apr 13, 2018	Sep CAHN
AB		20MG	A209869	002	Apr 13, 2018	Apr NEWA
>D> AB		40MG	A209869	003	Apr 13, 2018	Sep CAHN
AB		40MG	A209869	003	Apr 13, 2018	Apr NEWA
>D> AB		80MG	A209869	004	Apr 13, 2018	Sep CAHN
AB		80MG	A209869	004	Apr 13, 2018	Apr NEWA
>A> AB	UPSHER-SMITH LABS	10MG	A209869	001	Apr 13, 2018	Sep CAHN
>A> AB		20MG	A209869	002	Apr 13, 2018	Sep CAHN
>A> AB		40MG	A209869	003	Apr 13, 2018	Sep CAHN
>A> AB		80MG	A209869	004	Apr 13, 2018	Sep CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

>A> AB	NOVITIUM PHARMA	EQ 1MG BASE	A210971	001	Oct 03, 2018	Sep NEWA
>A> AB		EQ 2MG BASE	A210971	002	Oct 03, 2018	Sep NEWA
>A> AB		EQ 5MG BASE	A210971	003	Oct 03, 2018	Sep NEWA

PREDNISOLONE

SYRUP;ORAL

PREDNISOLONE

AA	LANNETT CO INC	15MG/5ML	A040775	001	Sep 21, 2007	May CAHN
----	----------------	----------	---------	-----	--------------	----------

TABLET;ORAL

PREDNISOLONE

@ FOSUN PHARMA	5MG	A080339	001		Jan CAHN
----------------	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL						
PREDNISOLONE SODIUM PHOSPHATE						
AA	!	WOCKHARDT BIO AG	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004 Jan CAHN
SOLUTION/DROPS;OPHTHALMIC						
PREDNISOLONE SODIUM PHOSPHATE						
	@	BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994 Apr CAHN

PREDNISONE

TABLET;ORAL						
PREDNISONE						
	@	HIKMA PHARMS	2.5MG	A040538	001	Jan 08, 2004 May DISC

PREGABALIN

TABLET, EXTENDED RELEASE;ORAL						
LYRICA CR						
+	PF PRISM CV	82.5MG	N209501	001	Oct 11, 2017	Aug CAHN
+		165MG	N209501	002	Oct 11, 2017	Aug CAHN
+	!	330MG	N209501	003	Oct 11, 2017	Aug CAHN

PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION						
CITANEST PLAIN DENTAL						
+	@	DENTSPLY PHARM	4%	N021382	001	May CRLD

PRIMAQUINE PHOSPHATE

TABLET;ORAL						
PRIMAQUINE PHOSPHATE						
>D>	AB	INGENUS PHARMS NJ	EQ 15MG BASE	A206043	001	Jun 23, 2016 Sep CAHN
>A>	AB	NOVAST LABS	EQ 15MG BASE	A206043	001	Jun 23, 2016 Sep CAHN

PRIMIDONE

TABLET;ORAL						
PRIMIDONE						
AB		OXFORD PHARMS	50MG	A040586	001	Feb 24, 2005 Jul CAHN
AB			250MG	A040586	002	Feb 24, 2005 Jul CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL						
PROPAFENONE HYDROCHLORIDE						
AB		INDICUS PHARMA	225MG	A205956	001	Jul 02, 2018 Jun NEWA
AB			325MG	A205956	002	Jul 02, 2018 Jun NEWA
AB			425MG	A205956	003	Jul 02, 2018 Jun NEWA
AB		WILSHIRE PHARMS INC	225MG	A205956	001	Jul 02, 2018 Jul CAHN
AB			325MG	A205956	002	Jul 02, 2018 Jul CAHN
AB			425MG	A205956	003	Jul 02, 2018 Jul CAHN
TABLET;ORAL						
PROPAFENONE HYDROCHLORIDE						
AB	!	VINTAGE PHARMS	300MG	A075938	003	Oct 17, 2002 Jul CHRS
RYTHMOL						
+	@	GLAXOSMITHKLINE LLC	150MG	N019151	001	Nov 27, 1989 Jul DISC
+	@		225MG	N019151	003	Nov 20, 1992 Jul DISC
+	@		300MG	N019151	002	Nov 27, 1989 Jul DISC

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC						
ALCAINE						
	@	ALCON LABS INC	0.5%	A080027	001	May DISC
AT	!		0.5%	A080027	001	Feb CAHN
PROPARACAINE HYDROCHLORIDE						
AT	!	AKORN INC	0.5%	A040277	001	Mar 16, 2000 May CHRS

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL						
PROPRANOLOL HYDROCHLORIDE						
	@	MYLAN	60MG	A078022	001	Feb 15, 2007 Jun DISC
	@		80MG	A078022	002	Feb 15, 2007 Jun DISC
	@		120MG	A078022	003	Feb 15, 2007 Jun DISC
	@		160MG	A078022	004	Feb 15, 2007 Jun DISC

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

+ @ BAXTER HLTHCARE CORP	1MG/ML	N016419	001		Jul	DISC
@ FOSUN PHARMA	1MG/ML	A076400	001	Feb 26, 2003	Jan	CAHN
! HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008	Jul	CHRS

TABLET; ORAL

INDERAL

>A>	+ @ WYETH PHARMS	10MG	N016418	001		Sep	CAHN
>A>	+ @	20MG	N016418	003		Sep	CAHN
>A>	+ @	40MG	N016418	002		Sep	CAHN
>A>	+ @	60MG	N016418	009	Oct 18, 1982	Sep	CAHN
>A>	+ @	80MG	N016418	004		Sep	CAHN
>A>	+ @	90MG	N016418	010	Oct 18, 1982	Sep	CAHN
>D>	+ @ WYETH PHARMS INC	10MG	N016418	001		Sep	CAHN
>D>	+ @	20MG	N016418	003		Sep	CAHN
>D>	+ @	40MG	N016418	002		Sep	CAHN
>D>	+ @	60MG	N016418	009	Oct 18, 1982	Sep	CAHN
>D>	+ @	80MG	N016418	004		Sep	CAHN
>D>	+ @	90MG	N016418	010	Oct 18, 1982	Sep	CAHN

PROPRANOLOL HYDROCHLORIDE

AB	IMPAX LABS INC	20MG	A071972	002	Apr 06, 1988	May	CMS1
AB		40MG	A071972	003	Apr 06, 1988	May	CMS1
AB		60MG	A071976	002	May 13, 1986	May	CMS1
AB	WATSON LABS	60MG	A070178	002	Apr 23, 2018	Jul	NEWA
	@ YAOPHARMA CO LTD	10MG	A070663	001	Jun 13, 1986	Jan	CAHN
	@	20MG	A070664	001	Jun 13, 1986	Jan	CAHN
	@	40MG	A070665	001	Jun 13, 1986	Jan	CAHN
	@	60MG	A070666	001	Oct 10, 1986	Jan	CAHN
	@	80MG	A070667	001	Jun 13, 1986	Jan	CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

CORPHED

@ FOSUN PHARMA	60MG; 2.5MG	A088602	001	Apr 11, 1985	Jan	CAHN
----------------	-------------	---------	-----	--------------	-----	------

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

>A> AB	APNAR PHARMA LP	60MG	A211181	001	Jul 20, 2018	Sep	CAHN
>D> AB	INVATECH PHARMA	60MG	A211181	001	Jul 20, 2018	Sep	CAHN
AB		60MG	A211181	001	Jul 20, 2018	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

PYRIDOSTIGMINE BROMIDE

>A> AB	ANDA REPOSITORY	180MG	A205464	001	Aug 15, 2017	Sep	CAHN
>D> AB	KINEDEXE UK	180MG	A205464	001	Aug 15, 2017	Sep	CAHN
>A> AB	RISING PHARMS	180MG	A205464	001	Aug 15, 2017	Sep	CAHN

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+! VYERA PHARMS LLC	25MG	N008578	001		Jan	CAHN
---------------------	------	---------	-----	--	-----	------

QUAZEPAM

TABLET; ORAL

DORAL

@ GALT PHARMS	7.5MG	N018708	003	Feb 26, 1987	Feb	CAHN
+!	15MG	N018708	001	Dec 27, 1985	Feb	CAHN

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

>A> AB	ALIGNSCIENCE PHARMA	EQ 150MG BASE	A209497	001	Sep 28, 2018	Sep	NEWA
>A> AB		EQ 200MG BASE	A209497	002	Sep 28, 2018	Sep	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@ SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr	DISC
@	EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr	DISC
@	EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr	DISC
@	EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr	DISC
@ YAOPHARMA CO LTD	EQ 5MG BASE	A076803	001	Mar 02, 2005	Jan	CAHN

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@ EQ 10MG BASE
 @ EQ 20MG BASE
 @ EQ 40MG BASE

A076803 002 Mar 02, 2005 Jan CAHN
 A076803 003 Mar 02, 2005 Jan CAHN
 A076803 004 Mar 02, 2005 Jan CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

@ G AND W LABS INC 300MG

A040045 001 Jun 30, 1994 Jan DISC

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

>A> AB NOVAST LABS 324MG
 >D> AB RICONPHARMA LLC 324MG

A204372 001 Jul 22, 2015 Sep CAHN
 A204372 001 Jul 22, 2015 Sep CAHN

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

ACIPHEX SPRINKLE

+ CERECOR INC 5MG
 +! 10MG

N204736 001 Mar 26, 2013 Feb CAHN
 N204736 002 Mar 26, 2013 Feb CAHN

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

AB ALKEM LABS LTD 20MG

A208644 001 Apr 24, 2018 Apr NEWA

RALTEGRAVIR POTASSIUM

TABLET;ORAL

ISENTRESS HD

+! MERCK SHARP DOHME EQ 600MG BASE

N022145 002 May 26, 2017 May CHRS

RAMELTEON

TABLET;ORAL

RAMELTEON

AB DR REDDYS LABS SA 8MG

A091693 001 Jul 26, 2013 Mar CAHN

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB CHARTWELL MOLECULAR 1.25MG
 AB 2.5MG
 AB 5MG
 AB 10MG
 @ WATSON LABS 5MG
 @ YAOPHARMA CO LTD 1.25MG
 @ 2.5MG
 @ 5MG
 @ 10MG

A078745 001 Jun 18, 2008 Jun CAHN
 A078745 002 Jun 18, 2008 Jun CAHN
 A078745 003 Jun 18, 2008 Jun CAHN
 A078745 004 Jun 18, 2008 Jun CAHN
 A076549 003 Oct 24, 2005 Mar DISC
 A077514 001 Jun 18, 2008 Jan CAHN
 A077514 002 Jun 18, 2008 Jan CAHN
 A077514 003 Jun 18, 2008 Jan CAHN
 A077514 004 Jun 18, 2008 Jan CAHN

TABLET;ORAL

RAMIPRIL

@ APOTEX INC 1.25MG
 @ 2.5MG
 @ 5MG
 @ 10MG

A091069 001 Dec 02, 2015 May DISC
 A091069 002 Dec 02, 2015 May DISC
 A091069 003 Dec 02, 2015 May DISC
 A091069 004 Dec 02, 2015 May DISC

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

>A> AB AJANTA PHARMA LTD EQ 150MG BASE
 >A> AB EQ 300MG BASE
 AB AUROBINDO PHARMA LTD EQ 150MG BASE
 AB EQ 300MG BASE

A209859 001 Sep 27, 2018 Sep NEWA
 A209859 002 Sep 27, 2018 Sep NEWA
 A211058 001 Jul 16, 2018 Jul NEWA
 A211058 002 Jul 16, 2018 Jul NEWA

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

>A> AA ANDA REPOSITORY EQ 15MG BASE/ML
 AA LANNETT CO INC EQ 15MG BASE/ML
 AA ! PHARM ASSOC EQ 15MG BASE/ML
 >D> AA TOLMAR EQ 15MG BASE/ML
 ZANTAC
 + @ GLAXO GRP LTD EQ 15MG BASE/ML

A090054 001 Nov 15, 2010 Sep CAHN
 A078890 001 Jul 01, 2010 May CAHN
 A077405 001 Sep 21, 2007 Jul CHRS
 A090054 001 Nov 15, 2010 Sep CAHN
 N019675 001 Dec 30, 1988 Jul DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB	!	AMNEAL PHARMS NY	EQ 300MG BASE	A077824	002	Oct 13, 2006	Jul CHRS
AB		VIVIMED GLOBAL	EQ 150MG BASE	A210010	001	Aug 01, 2018	Jul NEWA
AB			EQ 300MG BASE	A210010	002	Aug 01, 2018	Jul NEWA
		ZANTAC 150					
	+	@ GLAXO GRP LTD	EQ 150MG BASE	N018703	001	Jun 09, 1983	Apr DISC
		ZANTAC 300					
	+	@ GLAXO GRP LTD	EQ 300MG BASE	N018703	002	Dec 09, 1985	Jul DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

	@	APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013	Mar DISC
	@		EQ 1MG BASE	A201950	002	Sep 12, 2013	Mar DISC
AB		SANDOZ INC	EQ 0.5MG BASE	A201892	001	Jul 27, 2018	Jul NEWA
AB			EQ 1MG BASE	A201892	002	Jul 27, 2018	Jul NEWA

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

REMIFENTANIL HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 1MG BASE/VIAL	A206223	001	Jan 16, 2018	Jan NEWA
AP			EQ 2MG BASE/VIAL	A206223	002	Jan 16, 2018	Jan NEWA
AP			EQ 5MG BASE/VIAL	A206223	003	Jan 16, 2018	Jan NEWA
		ULTIVA					
AP	+	MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630	001	Jul 12, 1996	Jan CFTG
AP	+		EQ 2MG BASE/VIAL	N020630	002	Jul 12, 1996	Jan CFTG
AP	+	!	EQ 5MG BASE/VIAL	N020630	003	Jul 12, 1996	Jan CFTG

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB		CASI PHARMS INC	0.5MG	A078555	001	Nov 22, 2013	Mar CAHN
AB			1MG	A078555	002	Jan 22, 2014	Mar CAHN
AB			2MG	A078555	003	Jan 22, 2014	Mar CAHN

RIBAVIRIN

CAPSULE;ORAL

RIBAVIRIN

AB		CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Mar CAHN
		TABLET;ORAL					
		COPEGUS					
	@	ROCHE	200MG	N021511	001	Dec 03, 2002	Apr DISC

RILUZOLE

>A>		SUSPENSION;ORAL					
>A>		TIGLUTIK KIT					
>A>	+	! ITALFARMACO SPA	50MG/10ML	N209080	001	Sep 05, 2018	Sep NEWA

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

AB		IMPAX LABS INC	35MG	A205066	001	Jun 29, 2018	Jun NEWA
AB		ZYDUS PHARMS USA INC	35MG	A203822	001	Sep 11, 2018	Aug NEWA

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

PERSERIS KIT

	+	INDIVIOR INC	90MG	N210655	001	Jul 27, 2018	Jul NEWA
	+	!	120MG	N210655	002	Jul 27, 2018	Jul NEWA

SOLUTION;ORAL

RISPERIDONE

>A>	AA	AUROBINDO PHARMA LTD	1MG/ML	A078452	001	Sep 04, 2009	Sep CAHN
	AA	LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	May CAHN
>D>	AA	LIFESTAR PHARMA	1MG/ML	A078452	001	Sep 04, 2009	Sep CAHN

TABLET;ORAL

RISPERIDONE

AB		CHARTWELL MOLECULAR	0.25MG	A077543	001	May 18, 2011	Mar CAHN
AB			0.5MG	A077543	002	May 18, 2011	Mar CAHN
AB			1MG	A077543	003	May 18, 2011	Mar CAHN
AB			2MG	A077543	004	May 18, 2011	Mar CAHN
AB			3MG	A077543	005	May 18, 2011	Mar CAHN

TABLET;ORAL
RISPERIDONE

AB		4MG	A077543	006	May 18, 2011	Mar CAHN
AB	RENATA	0.25MG	A078707	001	Dec 29, 2008	Jan CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Jan CAHN
AB		1MG	A078707	003	Dec 29, 2008	Jan CAHN
AB		2MG	A078707	004	Dec 29, 2008	Jan CAHN
AB		3MG	A078707	005	Dec 29, 2008	Jan CAHN
AB		4MG	A078707	006	Dec 29, 2008	Jan CAHN

RITONAVIR

CAPSULE;ORAL
NORVIR

	+ @ ABBVIE	100MG	N020945	001	Jun 29, 1999	Apr DISC
--	------------	-------	---------	-----	--------------	----------

TABLET;ORAL
RITONAVIR

>A>	AB	AMNEAL PHARMS LLC	100MG	A208890	001	Sep 17, 2018	Sep NEWA
>A>	AB	AUROBINDO PHARMA LTD	100MG	A206614	001	Sep 17, 2018	Sep NEWA
>A>	AB	HETERO LABS LTD III	100MG	A204587	001	Sep 17, 2018	Sep NEWA

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

AB	MYLAN TECHNOLOGIES	4.6MG/24HR	A205622	001	Jun 20, 2018	Jun NEWA
AB		9.5MG/24HR	A205622	002	Jun 20, 2018	Jun NEWA
AB		13.3MG/24HR	A205622	003	Jun 20, 2018	Jun NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL
MAXALT

	+ @ MERCK	EQ 5MG BASE	N020864	001	Jun 29, 1998	Apr DISC
	RIZATRIPTAN BENZOATE					
	@ APOTEX INC	EQ 5MG BASE	A202244	001	Dec 31, 2012	Mar DISC
	@	EQ 10MG BASE	A202244	002	Dec 31, 2012	Mar DISC

TABLET, ORALLY DISINTEGRATING;ORAL
MAXALT-MLT

	+ @ MERCK	EQ 5MG BASE	N020865	001	Jun 29, 1998	Apr DISC
	RIZATRIPTAN BENZOATE					
	@ APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013	Mar DISC
	@	EQ 10MG BASE	A202477	002	Jul 01, 2013	Mar DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	GLAND CHEMS PVT	50MG/5ML (10MG/ML)	A205656	001	Apr 04, 2018	Mar NEWA
AP		100MG/10ML (10MG/ML)	A205656	002	Apr 04, 2018	Mar NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A205656	001	Apr 04, 2018	Apr CAHN
AP		100MG/10ML (10MG/ML)	A205656	002	Apr 04, 2018	Apr CAHN

ROFLUMILAST

TABLET;ORAL
DALIRESP

	+ ASTRAZENECA PHARMS	250MCG	N022522	002	Jan 23, 2018	Jan NEWA
>D>	+	500MCG	N022522	001	Feb 28, 2011	Sep CTEC
>A>	AB	500MCG	N022522	001	Feb 28, 2011	Sep CTEC
	+	500MCG	N022522	001	Feb 28, 2011	Aug CTEC
AB	+	500MCG	N022522	001	Feb 28, 2011	Jul CFTG

ROFLUMILAST

>A>	AB	BRECKENRIDGE PHARM	500MCG	A208236	001	Oct 03, 2018	Sep NEWA
		@ MYLAN PHARMS INC	500MCG	A208257	001	Jul 13, 2018	Aug DISC
	AB		500MCG	A208257	001	Jul 13, 2018	Jul NEWA
	AB	TORRENT PHARMS LTD	500MCG	A208272	001	Aug 06, 2018	Jul NEWA

ROLAPITANT HYDROCHLORIDE

EMULSION;INTRAVENOUS
VARUBI

	+ @ TERSERA THERAPS LLC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017	Aug CDFR
--	-------------------------	---	---------	-----	--------------	----------

EMULSION;IV (INFUSION)
VARUBI

	+ @ TERSERA THERAPS LLC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017	Jul CAHN
--	-------------------------	---	---------	-----	--------------	----------

EMULSION; IV (INFUSION)

VARUBI

+ @ TESARO INC	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399	001	Oct 25, 2017	Jun DISC
----------------	---	---------	-----	--------------	----------

TABLET; ORAL

VARUBI

+! TERSERA THERAPS LLC	EQ 90MG BASE	N206500	001	Sep 01, 2015	Jul CAHN
------------------------	--------------	---------	-----	--------------	----------

ROMIDEPSIN

POWDER; INTRAVENOUS

ISTODAX

+! CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009	Aug CDFR
------------	-----------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

@ G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Jan DISC
@	EQ 0.5MG BASE	A077460	002	May 05, 2008	Jan DISC
@	EQ 1MG BASE	A077460	003	May 05, 2008	Jan DISC
@	EQ 2MG BASE	A077460	004	May 05, 2008	Jan DISC
@	EQ 3MG BASE	A077460	005	May 05, 2008	Jan DISC
@	EQ 4MG BASE	A077460	006	May 05, 2008	Jan DISC
@	EQ 5MG BASE	A077460	007	May 19, 2008	Jan DISC

TABLET, EXTENDED RELEASE; ORAL

ROPINIROLE HYDROCHLORIDE

>D> AB	MYLAN PHARMS INC	EQ 2MG BASE	A200462	001	Oct 15, 2012	Sep DISC
>A>	@	EQ 2MG BASE	A200462	001	Oct 15, 2012	Sep DISC
>D> AB		EQ 4MG BASE	A200462	003	Oct 15, 2012	Sep DISC
>A>	@	EQ 4MG BASE	A200462	003	Oct 15, 2012	Sep DISC
>D> AB		EQ 6MG BASE	A200462	004	Oct 15, 2012	Sep DISC
>A>	@	EQ 6MG BASE	A200462	004	Oct 15, 2012	Sep DISC
>D> AB		EQ 8MG BASE	A200462	005	Oct 15, 2012	Sep DISC
>A>	@	EQ 8MG BASE	A200462	005	Oct 15, 2012	Sep DISC
>D> AB		EQ 12MG BASE	A200462	006	Oct 15, 2012	Sep DISC
>A>	@	EQ 12MG BASE	A200462	006	Oct 15, 2012	Sep DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

NAROPIN

AP	+ FRESENIUS KABI USA	400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar CTEC
AP	+	500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	May CTEC
AP	+	1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	May CTEC

ROPIVACAINE HYDROCHLORIDE

AP	AKORN	200MG/100ML (2MG/ML)	A204636	001	Mar 16, 2018	Mar NEWA
AP		400MG/200ML (2MG/ML)	A204636	002	Mar 16, 2018	Mar NEWA
AP	INFORLIFE	200MG/100ML (2MG/ML)	A206166	001	Jun 11, 2018	May NEWA
AP		400MG/200ML (2MG/ML)	A206166	002	Jun 11, 2018	May NEWA
AP		500MG/100ML (5MG/ML)	A206166	003	Jun 11, 2018	May NEWA
AP		1GM/200ML (5MG/ML)	A206166	004	Jun 11, 2018	May NEWA
AP	SOMERSET THERAPS LLC	20MG/10ML (2MG/ML)	A207636	001	Jun 15, 2018	Jun NEWA
AP		40MG/20ML (2MG/ML)	A207636	002	Jun 15, 2018	Jun NEWA
AP		100MG/20ML (5MG/ML)	A207636	003	Jun 15, 2018	Jun NEWA
AP		100MG/10ML (10MG/ML)	A207636	006	Jun 15, 2018	Jun NEWA
AP		150MG/30ML (5MG/ML)	A207636	004	Jun 15, 2018	Jun NEWA
AP		150MG/20ML (7.5MG/ML)	A207636	005	Jun 15, 2018	Jun NEWA
AP		200MG/20ML (10MG/ML)	A207636	007	Jun 15, 2018	Jun NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

+ SB PHARMC	EQ 2MG BASE	N021071	002	May 25, 1999	Jul CTEC
+	EQ 4MG BASE	N021071	003	May 25, 1999	Jul CTEC
+ @	EQ 8MG BASE	N021071	004	May 25, 1999	Jul DISC

ROSIGLITAZONE MALEATE

@ TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013	Jul DISC
@	EQ 4MG BASE	A076747	002	Jan 25, 2013	Jul DISC
@	EQ 8MG BASE	A076747	003	Jan 25, 2013	Jul DISC

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

AB	ALLIED	5MG	A079168	001	Jul 19, 2016	Aug CAHN
AB		10MG	A079168	002	Jul 19, 2016	Aug CAHN
AB		20MG	A079168	003	Jul 19, 2016	Aug CAHN
AB		40MG	A079168	004	Jul 19, 2016	Aug CAHN

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

>D> ELDEPRYL

>D> AB	+! SOMERSET	5MG	N020647	001	May 15, 1996	Sep DISC
>A>	+ @	5MG	N020647	001	May 15, 1996	Sep DISC

SELEGILINE HYDROCHLORIDE

>D> AB	APOTEX	5MG	A075321	001	Dec 04, 1998	Sep CHRS
>A> AB	!	5MG	A075321	001	Dec 04, 1998	Sep CHRS

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

AT	! PERRIGO NEW YORK	2.5%	A089996	001	Jan 10, 1991	Jul CHRS
	SELSUN					
	+ @ CHATTEM	2.5%	N007936	001		Jul DISC

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@ ACI HEALTHCARE LTD EQ 20MG BASE/ML

A076934 001 Jun 30, 2006 May CAHN

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@	CHARTWELL MOLECULAR	EQ 25MG BASE	A077162	001	Feb 06, 2007	Mar CAHN
@		EQ 50MG BASE	A077162	002	Feb 06, 2007	Mar CAHN
@		EQ 100MG BASE	A077162	003	Feb 06, 2007	Mar CAHN
@	FOSUN PHARMA	EQ 25MG BASE	A077713	001	Feb 06, 2007	Jan CAHN
@		EQ 50MG BASE	A077713	002	Feb 06, 2007	Jan CAHN
@		EQ 100MG BASE	A077713	003	Feb 06, 2007	Jan CAHN

SEVELAMER CARBONATE

TABLET; ORAL

RENVELA

AB	+! SANOFI	800MG	N022127	001	Oct 19, 2007	Aug CAHN
	SEVELAMER CARBONATE					
AB	SANDOZ INC	800MG	A200959	001	Mar 20, 2018	Mar NEWA

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

AB	AJANTA PHARMA LTD	EQ 20MG BASE	A210394	001	May 04, 2018	Apr NEWA
AB	AMNEAL PHARMS NY	EQ 25MG BASE	A202023	001	Jun 27, 2018	Jun NEWA
AB		EQ 50MG BASE	A202023	002	Jun 27, 2018	Jun NEWA
AB		EQ 100MG BASE	A202023	003	Jun 27, 2018	Jun NEWA
	@ APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012	Mar DISC
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A203962	001	Jun 11, 2018	May NEWA
AB		EQ 50MG BASE	A203962	002	Jun 11, 2018	May NEWA
AB		EQ 100MG BASE	A203962	003	Jun 11, 2018	May NEWA
AB	HETERO LABS LTD V	EQ 25MG BASE	A202659	001	Jun 11, 2018	May NEWA
AB		EQ 50MG BASE	A202659	002	Jun 11, 2018	May NEWA
AB		EQ 100MG BASE	A202659	003	Jun 11, 2018	May NEWA
AB	RUBICON RES PVT LTD	EQ 25MG BASE	A204882	001	Jun 11, 2018	May NEWA
AB		EQ 50MG BASE	A204882	002	Jun 11, 2018	May NEWA
AB		EQ 100MG BASE	A204882	003	Jun 11, 2018	May NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A091448	001	Jun 11, 2018	May NEWA
AB		EQ 50MG BASE	A091448	002	Jun 11, 2018	May NEWA
AB		EQ 100MG BASE	A091448	003	Jun 11, 2018	May NEWA

SILVER SULFADIAZINE

CREAM; TOPICAL

SSD AF

@	DR REDDYS LA	1%	N018578	003	Jul 11, 1990	Jun DISC
---	--------------	----	---------	-----	--------------	----------

SIMEPREVIR SODIUMCAPSULE;ORAL
OLYSIO

+ @ JANSSEN PRODS EQ 150MG BASE N205123 001 Nov 22, 2013 May DISC

SIMVASTATINTABLET;ORAL
SIMVASTATIN

@ HISUN PHARM	10MG	A206557	001	Nov 13, 2017	May DISC
@	20MG	A206557	002	Nov 13, 2017	May DISC
@	40MG	A206557	003	Nov 13, 2017	May DISC
@	80MG	A206557	004	Nov 13, 2017	May DISC
@ HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Aug CAHN
@	20MG	A206557	002	Nov 13, 2017	Aug CAHN
@	40MG	A206557	003	Nov 13, 2017	Aug CAHN
@	80MG	A206557	004	Nov 13, 2017	Aug CAHN
@ YAOPHARMA CO LTD	5MG	A077766	001	Dec 20, 2006	Jan CAHN
@	10MG	A077766	002	Dec 20, 2006	Jan CAHN
@	20MG	A077766	003	Dec 20, 2006	Jan CAHN
@	40MG	A077766	004	Dec 20, 2006	Jan CAHN
@	80MG	A077766	005	Dec 20, 2006	Jan CAHN

SINECATECHINSOINTMENT;TOPICAL
VEREGEN

+! FOUGERA PHARMS INC 15% N021902 001 Oct 31, 2006 Jan CAHN

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION;INTRAVENOUS
AMMONUL

AP	+! MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	May CDFR
	SODIUM PHENYLACETATE AND SODIUM BENZOATE					
AP	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	May CDFR
AP	MAIA PHARMS INC	10%;10% (5GM/50ML;5GM/50ML)	A208521	001	May 08, 2017	May CDFR
AP	NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	May CDFR

SODIUM BICARBONATEINJECTABLE;INJECTION
SODIUM BICARBONATE

@ HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Mar DISC
@	0.5MEQ/ML	A202981	001	Mar 04, 2016	Mar DISC

SODIUM CHLORIDEINJECTABLE;INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	450MG/100ML	A208122	001	Jul 23, 2018	Jul NEWA
	SODIUM CHLORIDE 0.9%					
	+ @ MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Jun CRLD
	+ @	22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Jun CRLD
	+ @	27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Jun CRLD
	+ @	45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Jun CRLD
	+ @	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012	Jun CRLD
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+ @ ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Apr DISC
AP	+! @ MEDEFIL INC	9MG/ML (9MG/ML)	N019217	001	Jul 13, 1984	Feb CAHN
			N202832	001	Jan 06, 2012	Jun CRLD
	SOLUTION;IRRIGATION					
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AT	+! B BRAUN	900MG/100ML	N016733	001		Mar CRLD

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP	SOFIE	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN
	@ UNIV TX MD ANDERSON	10-200mCi/ML	A203247	001	Dec 23, 2013	Jun DISC

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

+ @ MALLINKRODT NUCLEAR	0.8-100mCi	N016517	001		Jun	DISC
-------------------------	------------	---------	-----	--	-----	------

SOLUTION;ORAL

SODIUM IODIDE I 131

+ @ MALLINKRODT NUCLEAR	3.5-150mCi/VIAL	N016515	001		Jun	DISC
-------------------------	-----------------	---------	-----	--	-----	------

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

AP	APICORE US	25MG/ML	A209584	001	Aug 10, 2018	Jul	NEWA
AP	CIPLA LTD	25MG/ML	A210855	001	Jul 16, 2018	Jul	NEWA
AP	MEDICURE	25MG/ML	A209584	001	Aug 10, 2018	Aug	CAHN
AP	MYLAN LABS LTD	25MG/ML	A210763	001	Apr 17, 2018	Apr	NEWA
AP	RENAISSANCE SSA LLC	25MG/ML	A209834	001	Jun 26, 2018	Jun	NEWA
AP	SOMERSET THERAPS LLC	25MG/ML	A210882	001	Aug 17, 2018	Aug	NEWA

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+	EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017	Aug	CDFR
+		20MG/100ML (0.2MG/ML)	N209387	003	Jul 13, 2018	Jul	NEWA
+		50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Aug	CDFR

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	APNAR PHARMA LP	454GM/BOT	A206815	001	Feb 18, 2016	Mar	CAHN
----	-----------------	-----------	---------	-----	--------------	-----	------

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION;ORAL

LOKELMA

+	ASTRAZENECA PHARMS	5GM/PACKET	N207078	001	May 18, 2018	May	NEWA
+		10GM/PACKET	N207078	002	May 18, 2018	May	NEWA

SOMATROPIN

INJECTABLE;INJECTION

BIO-TROPIN

@ FERRING

4.8MG/VIAL

N019774	001	May 25, 1995	Feb	CAIN
---------	-----	--------------	-----	------

ZOMACTON

BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Feb	CAIN
	+		10MG/VIAL	N019774	003	Mar 07, 2012	Feb	CAIN

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

GENOTROPIN PRESERVATIVE FREE

+	@ PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280	004	Aug 24, 1995	Jun	DISC
---	------------------------	------------	---------	-----	--------------	-----	------

NUTROPIN AQ PEN

+	@ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002	Jun	DISC
---	-------------	-------------------	---------	-----	--------------	-----	------

+	@	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun	DISC
---	---	--------------------	---------	-----	--------------	-----	------

VALTROPIN

@ LG CHEM LTD

5MG/VIAL

N021905	001	Apr 19, 2007	Jun	DISC
---------	-----	--------------	-----	------

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

AB1	OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003	Jul	CAHN
AB1		120MG	A075563	002	Nov 07, 2003	Jul	CAHN
AB1		160MG	A075563	003	Nov 07, 2003	Jul	CAHN
AB1		240MG	A075563	004	Nov 07, 2003	Jul	CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB	CASI PHARMS INC	25MG	A086809	001		Mar	CAHN
AB	OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006	Jul	CAHN
AB		50MG	A040750	002	Aug 29, 2006	Jul	CAHN
AB		100MG	A040750	003	Aug 29, 2006	Jul	CAHN
AB	ZYDUS PHARMS USA INC	25MG	A205936	001	Jul 18, 2018	Jul	NEWA
AB		50MG	A205936	002	Jul 18, 2018	Jul	NEWA
AB		100MG	A205936	003	Jul 18, 2018	Jul	NEWA

STANOZOLOLTABLET; ORAL
WINSTROL

+ @ LUNDBECK INC 2MG N012885 001 May 14, 1984 Aug CRLD

STERILE WATER FOR IRRIGATIONLIQUID; IRRIGATION
STERILE WATER IN PLASTIC CONTAINER

AT + B BRAUN 100% N016734 001 Mar CRLD

STIRIPENTOLCAPSULE; ORAL
DIACOMIT

+ BIOCODEX SA 250MG N206709 001 Aug 20, 2018 Aug NEWA

+! 500MG N206709 002 Aug 20, 2018 Aug NEWA

FOR SUSPENSION; ORAL
DIACOMIT

+ BIOCODEX SA 250MG/PACKET N207223 001 Aug 20, 2018 Aug NEWA

+! 500MG/PACKET N207223 002 Aug 20, 2018 Aug NEWA

SUCCINYLCHOLINE CHLORIDEINJECTABLE; INJECTION
SUCCINYLCHOLINE CHLORIDE

AP RENAISSANCE SSA LLC 20MG/ML A210231 001 Jun 04, 2018 May NEWA

AP ZYDUS PHARMS USA INC 20MG/ML A209467 001 May 04, 2018 Apr NEWA

SUCRALFATESUSPENSION; ORAL
CARAFATE

+! ALLERGAN SALES LLC 1GM/10ML N019183 001 Dec 16, 1993 Jan CAHN

TABLET; ORAL
CARAFATE

AB +! ALLERGAN SALES LLC 1GM N018333 001 Jan CAHN

SUCRALFATE

@ MYLAN IRELAND LTD 1GM A074415 001 Jun 08, 1998 Jul DISC

SULFADIAZINETABLET; ORAL
SULFADIAZINE

+ @ LILLY 500MG N004122 002 Aug CRLD

SULFAMETHOXAZOLE; TRIMETHOPRIMSUSPENSION; ORAL
BACTRIM

+ @ SUN PHARM INDUSTRIES 200MG/5ML; 40MG/5ML N017560 001 Jul CRLD

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB LANNETT CO INC 200MG/5ML; 40MG/5ML A077785 001 Jan 24, 2007 May CAHN

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ FOSUN PHARMA 400MG; 80MG A070889 001 Nov 13, 1986 Jan CAHN

@ 400MG; 80MG N018598 003 May 19, 1982 Jan CAHN

@ 800MG; 160MG A070890 001 Nov 13, 1986 Jan CAHN

@ SUN PHARM INDUSTRIES 400MG; 80MG A071017 002 Aug 25, 1986 Apr CMS1

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

@ FOSUN PHARMA 800MG; 160MG N018598 004 May 19, 1982 Jan CAHN

SULINDACTABLET; ORAL
SULINDAC

@ FOSUN PHARMA 150MG A072712 001 Aug 30, 1991 Jan CAHN

@ 200MG A072713 001 Aug 30, 1991 Jan CAHN

SUMATRIPTAN SUCCINATEINJECTABLE; SUBCUTANEOUS
SUMAVEL DOSEPRO

+ @ ENDO VENTURES LTD EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) N022239 002 Nov 26, 2013 Mar DISC

+ @ EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) N022239 001 Jul 15, 2009 Mar DISC

SOLUTION;SUBCUTANEOUS								
ZEMBRACE SYMTOUCH								
>D>	DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Sep	CRLD	
>A>	+	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Sep	CRLD	
TABLET;ORAL								
SUMATRIPTAN SUCCINATE								
	@ FOSUN PHARMA	EQ 25MG BASE	A076976	001	Aug 10, 2009	Jan	CAHN	
	@	EQ 50MG BASE	A076976	002	Aug 10, 2009	Jan	CAHN	
	@	EQ 100MG BASE	A076976	003	Aug 10, 2009	Jan	CAHN	
<u>TACROLIMUS</u>								
FOR SUSPENSION;ORAL								
PROGRAF								
+	ASTELLAS	EQ 0.2MG BASE/PACKET	N210115	001	May 24, 2018	May	NEWA	
+	!	EQ 1MG BASE/PACKET	N210115	002	May 24, 2018	May	NEWA	
OINTMENT;TOPICAL								
TACROLIMUS								
AB	GLENMARK PHARMS LTD	0.1%	A210393	001	Apr 16, 2018	Apr	NEWA	
<u>TADALAFIL</u>								
TABLET;ORAL								
ADCIRCA								
AB2	+	ELI LILLY CO	20MG	N022332	001	May 22, 2009	Aug	CTEC
AB	+	!	20MG	N022332	001	May 22, 2009	Jul	CFTG
CIALIS								
AB	+	LILLY	2.5MG	N021368	004	Jan 07, 2008	May	CFTG
AB	+		5MG	N021368	001	Nov 21, 2003	May	CFTG
AB	+		10MG	N021368	002	Nov 21, 2003	May	CFTG
AB1	+	!	20MG	N021368	003	Nov 21, 2003	Aug	CTEC
AB	+	!	20MG	N021368	003	Nov 21, 2003	May	CFTG
TADALAFIL								
AB2	MYLAN PHARMS INC	20MG	A200630	001	Aug 03, 2018	Aug	CTEC	
AB		20MG	A200630	001	Aug 03, 2018	Jul	NEWA	
AB	TEVA PHARMS USA	2.5MG	A090141	001	May 22, 2018	May	NEWA	
AB		5MG	A090141	002	May 22, 2018	May	NEWA	
AB		10MG	A090141	003	May 22, 2018	May	NEWA	
AB1		20MG	A090141	004	May 22, 2018	Aug	CTEC	
AB		20MG	A090141	004	May 22, 2018	May	NEWA	
<u>TAFENOQUINE SUCCINATE</u>								
TABLET;ORAL								
ARAKODA								
+	60 DEGREES PHARMS	EQ 100MG BASE	N210607	001	Aug 08, 2018	Aug	NEWA	
KRINTAFEL								
+	GLAXOSMITHKLINE	EQ 150MG BASE	N210795	001	Jul 20, 2018	Jul	NEWA	
<u>TALC</u>								
AEROSOL;INTRAPLEURAL								
SCLEROSOL								
+	LYMOL MEDCL	4GM/SPRAY	N020587	001	Dec 24, 1997	Mar	CPOT	
<u>TALIGLUCERASE ALFA</u>								
POWDER;INTRAVENOUS								
ELELYSO								
+	PFIZER	200 UNITS/VIAL	N022458	001	May 01, 2012	Aug	CDFR	
<u>TAMOXIFEN CITRATE</u>								
SOLUTION;ORAL								
SOLTAMOX								
	MIDATECH PHARMA US	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Mar	CPOT	
<u>TAPENTADOL HYDROCHLORIDE</u>								
SOLUTION;ORAL								
NUCYNTA								
+	@ DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May	DISC	
TABLET;ORAL								
NUCYNTA								
>A>	+	DEPO NF	EQ 50MG BASE	N022304	001	Nov 20, 2008	Sep	CAHN
>A>	+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Sep	CAHN
>A>	+	!	EQ 100MG BASE	N022304	003	Nov 20, 2008	Sep	CAHN

TABLET;ORAL
NUCYNTA

>D>	+	DEPOMED INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	Sep CAHN
>D>	+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Sep CAHN
>D>	+	!	EQ 100MG BASE	N022304	003	Nov 20, 2008	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL
NUCYNTA ER

>A>	+	DEPO NF	EQ 50MG BASE	N200533	001	Aug 25, 2011	Sep CAHN
>A>	+		EQ 100MG BASE	N200533	002	Aug 25, 2011	Sep CAHN
>A>	+		EQ 150MG BASE	N200533	003	Aug 25, 2011	Sep CAHN
>A>	+		EQ 200MG BASE	N200533	004	Aug 25, 2011	Sep CAHN
>A>	+	!	EQ 250MG BASE	N200533	005	Aug 25, 2011	Sep CAHN
>D>	+	DEPOMED INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	Sep CAHN
>D>	+		EQ 100MG BASE	N200533	002	Aug 25, 2011	Sep CAHN
>D>	+		EQ 150MG BASE	N200533	003	Aug 25, 2011	Sep CAHN
>D>	+		EQ 200MG BASE	N200533	004	Aug 25, 2011	Sep CAHN
>D>	+	!	EQ 250MG BASE	N200533	005	Aug 25, 2011	Sep CAHN

TAZAROTENE

CREAM;TOPICAL
TAZAROTENE

AB		TARO PHARMS	0.1%	A208258	001	Apr 03, 2017	May CAHN
----	--	-------------	------	---------	-----	--------------	----------

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE;INJECTION
PULMOLITE

	+	@ JUBILANT DRAXIMAGE	N/A	N017776	001		Feb DISC
--	---	----------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION
CIS-MDP

		PHARMALUCENCE	N/A	N018124	001		Jan CTEC
--	--	---------------	-----	---------	-----	--	----------

MDP-BRACCO

	@	CARDINAL HEALTH 414	N/A	N018107	001		Jan DISC
--	---	---------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION
DTPA

	+	!	JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Jan CAHN
--	---	---	--------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC
RADIOGENIX SYSTEM

	+	NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018	Feb NEWA
--	---	-------------------	----------------------	---------	-----	--------------	----------

TECOVIRIMAT

CAPSULE;ORAL
TPOXX

	+	!	SIGA TECHNOLOGIES	200MG	N208627	001	Jul 13, 2018	Jul NEWA
--	---	---	-------------------	-------	---------	-----	--------------	----------

TEDIZOLID PHOSPHATE

POWDER;INTRAVENOUS
SIVEXTRO

	+	!	CUBIST PHARMS LLC	200MG/VIAL	N205436	001	Jun 20, 2014	Aug CDFR
--	---	---	-------------------	------------	---------	-----	--------------	----------

TELAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS
VIBATIV

	+	@	THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Aug CDFR
	+	!		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	Aug CDFR

TELMISARTAN

TABLET;ORAL
TELMISARTAN

	@	WATSON LABS	40MG	A078710	002	Jan 08, 2014	Jul DISC
--	---	-------------	------	---------	-----	--------------	----------

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB	APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jun	NEWA
AB		20MG	A204159	002	Jul 05, 2018	Jun	NEWA
AB		100MG	A204159	003	Jul 05, 2018	Jun	NEWA
AB		140MG	A204159	004	Jul 05, 2018	Jun	NEWA
AB		180MG	A204159	005	Jul 05, 2018	Jun	NEWA
AB		250MG	A204159	006	Jul 05, 2018	Jun	NEWA
	@ MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Apr	DISC
	@	20MG	A205227	002	Jun 29, 2016	Apr	DISC
	@	100MG	A205227	003	Jun 29, 2016	Mar	DISC
	@	140MG	A205227	004	Jun 29, 2016	Mar	DISC
	@	180MG	A205227	005	Jun 29, 2016	Mar	DISC
	@	250MG	A205227	006	Jun 29, 2016	Mar	DISC

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TEMSIROLIMUS

AP	ACCORD HLTHCARE	25MG/ML (25MG/ML)	A203153	001	Jul 30, 2018	Jul	NEWA
	TORISEL						
AP	+! PF PRISM CV	25MG/ML (25MG/ML)	N022088	001	May 30, 2007	Jul	CFTG

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB	APOTEX INC	300MG	A206481	001	Jul 26, 2018	Jul	NEWA
AB	AUROBINDO PHARMA LTD	150MG	A090647	001	Jan 26, 2018	Jan	NEWA
AB		200MG	A090647	002	Jan 26, 2018	Jan	NEWA
AB		250MG	A090647	003	Jan 26, 2018	Jan	NEWA
AB		300MG	A090647	004	Jan 26, 2018	Jan	NEWA
AB	CIPLA LTD	300MG	A078800	001	Jan 26, 2018	Jan	NEWA
AB	HETERO LABS LTD III	300MG	A090636	001	Jan 26, 2018	Jan	NEWA
AB	LAURUS LABS PVT	300MG	A209550	001	Feb 26, 2018	Feb	NEWA
AB	MACLEODS PHARMS LTD	300MG	A203232	001	Jan 26, 2018	Jan	NEWA
AB	STRIDES PHARMA	300MG	A090742	001	Jan 26, 2018	Jan	NEWA
AB	TEVA PHARMS USA	150MG	A091612	002	Jan 26, 2018	Jan	NEWA
AB		200MG	A091612	003	Jan 26, 2018	Jan	NEWA
AB		250MG	A091612	004	Jan 26, 2018	Jan	NEWA
	VIREAD						
AB	+ GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012	Jan	CFTG
AB	+	200MG	N021356	003	Jan 18, 2012	Jan	CFTG
AB	+	250MG	N021356	004	Jan 18, 2012	Jan	CFTG

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 7

	+ @ JANSSEN PHARMS	0.4%	N019579	001	Dec 31, 1987	Feb	DISC
	TERCONAZOLE						
AB	! TARO	0.4%	A076043	001	Jan 19, 2005	Feb	CHRS
	SUPPOSITORY; VAGINAL						
	TERAZOL 3						
	+ @ JANSSEN PHARMS	80MG	N019641	001	May 24, 1988	Feb	DISC
	TERCONAZOLE						
AB	! PERRIGO NEW YORK	80MG	A077149	001	Mar 17, 2006	Feb	CHRS

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

AB	+ SANOFI AVENTIS US	7MG	N202992	001	Sep 12, 2012	Jul	CFTG
AB	+!	14MG	N202992	002	Sep 12, 2012	Jul	CFTG
	TERIFLUNOMIDE						
>A> AB	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Sep	NEWA
>A> AB		14MG	A209613	002	Sep 28, 2018	Sep	NEWA
AB	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Aug	NEWA
AB		14MG	A209700	002	Sep 04, 2018	Aug	NEWA
AB	WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018	Jul	NEWA
AB		14MG	A209549	002	Jul 27, 2018	Jul	NEWA

TESTOSTERONESOLUTION, METERED; TRANSDERMAL
TESTOSTERONE

AT	CIPLA LTD	30MG/1.5ML ACTUATION	A209533	001	Jan 29, 2018	Jan NEWA
----	-----------	----------------------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATEINJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

AO	CIPLA LTD	100MG/ML	A210362	001	Jun 19, 2018	Jun NEWA
AO		200MG/ML	A210362	002	Jun 19, 2018	Jun NEWA

TESTOSTERONE ENANTHATEINJECTABLE; INJECTION
DELATESTRYL

	+ @ ENDO PHARMS	200MG/ML	N009165	003		Jun DISC
	TESTOSTERONE ENANTHATE					
	@ MYLAN INSTITUTIONAL	200MG/ML	A040647	001	Oct 05, 2009	Jun DISC
AO	NEXUS PHARMS	200MG/ML	A040575	001	Jun 14, 2006	Aug CMFD
	@	200MG/ML	A040575	001	Jun 14, 2006	Jul DISC
AO		200MG/ML	A040575	001	Jun 14, 2006	Jun CAHN
AO	! WATSON PHARMS INC	200MG/ML	A085598	001		Jun CHRS

SOLUTION; SUBCUTANEOUS

>A>	XYOSTED (AUTOINJECTOR)					
>A>	+ @ ANTARES PHARMA INC	50MG/0.5ML (50MG/0.5ML)	N209863	001	Sep 28, 2018	Sep NEWA
>A>	+ @	75MG/0.5ML (75MG/0.5ML)	N209863	002	Sep 28, 2018	Sep NEWA
>A>	+ @	100MG/0.5ML (100MG/0.5ML)	N209863	003	Sep 28, 2018	Sep NEWA

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

AB	LUPIN LTD	12.5MG	A210544	001	Apr 20, 2018	Apr NEWA
AB		25MG	A210544	002	Apr 20, 2018	Apr NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

	+! ALCON LABS	0.5%	N208135	001	Feb 29, 2016	Mar CAHN
--	---------------	------	---------	-----	--------------	----------

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

>D>	AB	+ HERITAGE PHARMA	250MG	N050278	003	Sep CAHN
>D>	AB	+!	500MG	N050278	001	Sep CAHN
>A>	AB	+ HERITAGE PHARMS INC	250MG	N050278	003	Sep CAHN
>A>	AB	+!	500MG	N050278	001	Sep CAHN

TETRACYCLINE HYDROCHLORIDE

>A>	AB	AMNEAL PHARMS NY	250MG	A210674	001	Sep 18, 2018	Sep NEWA
>A>	AB		500MG	A210674	002	Sep 18, 2018	Sep NEWA

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

	+! B BRAUN	40MG/100ML	N019826	001	Aug 14, 1992	Jun CTEC
--	------------	------------	---------	-----	--------------	----------

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

	+! B BRAUN	160MG/100ML	N019826	003	Aug 14, 1992	Jun CTEC
--	------------	-------------	---------	-----	--------------	----------

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

	+! B BRAUN	320MG/100ML	N019826	006	Aug 14, 1992	Jun CTEC
--	------------	-------------	---------	-----	--------------	----------

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+ @ HOSPIRA INC	4MG/ML	N019211	007	Dec 14, 1984	Jun DISC
	+ @	40MG/100ML	N019211	001	Dec 14, 1984	Jun DISC
	+ @	160MG/100ML	N019211	003	Dec 14, 1984	Jun DISC
	+ @	320MG/100ML	N019211	006	Jan 20, 1988	Jun DISC

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

AB	NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Jan CTEC
AB		200MG	A087400	004	Feb 21, 1985	Jan CTEC

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

@	FOSUN PHARMA	10MG	A088131	001	Aug 30, 1983	Jan CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan CAHN

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

AP	DR REDDYS LABS LTD	15MG/VIAL	A210337	001	May 04, 2018	Apr NEWA
AP	JIANGSU HENGRUI MED	15MG/VIAL	A209150	001	May 04, 2018	Apr NEWA
AP	! WEST-WARD PHARMS INT	15MG/VIAL	A075547	001	Apr 02, 2001	Apr CTEC
POWDER; INTRAVENOUS						
TEPADINA						
+	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Aug CDFR
+		100MG/VIAL	N208264	002	Jan 26, 2017	Aug CDFR

THIOTHIXENE

CAPSULE; ORAL

NAVANE

+	@	PFIZER	1MG	N016584	001	Jan CRLD
+	@		2MG	N016584	002	Jan CRLD
+	@		5MG	N016584	003	Jan CRLD
+	@		10MG	N016584	004	Jan CRLD
+	@		20MG	N016584	005	Jan CRLD

TICAGRELOR

TABLET; ORAL

BRILINTA

AB	+	ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Aug CFTG
AB	+		90MG	N022433	001	Jul 20, 2011	Aug CFTG
TICAGRELOR							
AB		WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Aug NEWA
AB			90MG	A208390	002	Sep 04, 2018	Aug NEWA

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

@	YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999	Jan CAHN
@		250MG	A075326	001	Aug 20, 1999	Jan CAHN

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jun CDFR
AP	AMNEAL PHARMS LLC	50MG/VIAL	N211158	001	Aug 02, 2018	Aug NEWA
AP	FRESENIUS KABI USA	50MG/VIAL	N205645	001	Dec 01, 2016	Jun CDFR
AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Jun CDFR
TYGACIL						
AP	+! PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Jun CDFR
POWDER; IV (INFUSION)						
TIGECYCLINE						
	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jan NEWA

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOPTIC

AT	+	ATON	EQ 0.25% BASE	N018086	001	Jan CMFD
AT1	+		EQ 0.5% BASE	N018086	002	Jan CMFD

TABLET; ORAL

TIMOLOL MALEATE

@	YAOPHARMA CO LTD	5MG	A072550	001	Apr 13, 1989	Jan CAHN
@		10MG	A072551	001	Apr 13, 1989	Jan CAHN
@		20MG	A072552	001	Apr 13, 1989	Jan CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	CASI PHARMS INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Mar CAHN
AB		EQ 4MG BASE	A076280	002	Jun 27, 2002	Mar CAHN
AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb NEWA
AB		EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb NEWA

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

AN	DR REDDYS LABS INTL	300MG/5ML	A207080	001	Jul 09, 2018	Jun NEWA
AN	DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Jul CAHN

TOFACITINIB CITRATE

TABLET; ORAL

XELJANZ

+	PF PRISM CV	EQ 10MG BASE	N203214	002	May 30, 2018	May NEWA
---	-------------	--------------	---------	-----	--------------	----------

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@ YAOPHARMA CO LTD

100MG

A071633 001 Dec 09, 1987 Jan CAHN

@

250MG

A070289 001 Mar 13, 1986 Jan CAHN

@

500MG

A070290 001 Mar 13, 1986 Jan CAHN

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

@ YAOPHARMA CO LTD

500MG

A086574 001 Jan CAHN

TOLCAPONE

TABLET; ORAL

TOLCAPONE

AB	INGENUS PHARMS LLC	100MG	A208937	001	Aug 07, 2018	Jul NEWA
----	--------------------	-------	---------	-----	--------------	----------

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

@ FOSUN PHARMA

EQ 400MG BASE

A073462 001 Apr 30, 1992 Jan CAHN

TABLET; ORAL

TOLMETIN SODIUM

@ FOSUN PHARMA

EQ 200MG BASE

A073588 001 Jul 31, 1992 Jan CAHN

@

EQ 600MG BASE

A074002 001 Sep 27, 1993 Jan CAHN

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

@ APOTEX CORP

1MG

A200164 001 Sep 25, 2012 Mar DISC

@

2MG

A200164 002 Sep 25, 2012 Mar DISC

TOLVAPTAN

TABLET; ORAL

JYNARQUE

+	OTSUKA PHARM CO LTD	15MG	N204441	001	Apr 23, 2018	Apr NEWA
+		30MG	N204441	002	Apr 23, 2018	Apr NEWA
+		45MG	N204441	003	Apr 23, 2018	Apr NEWA
+		60MG	N204441	004	Apr 23, 2018	Apr NEWA
+		90MG	N204441	005	Apr 23, 2018	Apr NEWA

TOPIRAMATE

CAPSULE; ORAL

TOPIRAMATE

@ FOSUN PHARMA

15MG

A079206 001 Oct 14, 2009 Jan CAHN

@

25MG

A079206 002 Oct 14, 2009 Jan CAHN

TRABECTEDINPOWDER; INTRAVENOUS
YONDELIS

+! JANSSEN PRODS 1MG/VIAL N207953 001 Oct 23, 2015 Aug CDFR

TRAMADOL HYDROCHLORIDETABLET; ORAL
TRAMADOL HYDROCHLORIDE
@ FOSUN PHARMA

50MG

A075968 001 Jun 25, 2002 Jan CAHN

TRANDOLAPRILTABLET; ORAL
MAVIK

+ @ ABBVIE	1MG	N020528	001	Apr 26, 1996	Mar DISC
+ @	2MG	N020528	002	Apr 26, 1996	Mar DISC
+ @	4MG	N020528	003	Apr 26, 1996	Mar DISC

TRANDOLAPRIL

AB	!	LUPIN	4MG	A077522	003	Jun 12, 2007	Mar CHRS
	@	WATSON LABS	1MG	A077805	001	Jun 12, 2007	May DISC
	@		2MG	A077805	002	Jun 12, 2007	May DISC
	@		4MG	A077805	003	Jun 12, 2007	May DISC

TRANEXAMIC ACIDINJECTABLE; INJECTION
TRANEXAMIC ACID

AP ACIC PHARMS 100MG/ML A202436 001 Feb 11, 2014 May CAHN

TRANLYCYPROMINE SULFATETABLET; ORAL
TRANLYCYPROMINE SULFATE

>A>	AB	CNTY LINE PHARMS	EQ 10MG BASE	A206856	001	Apr 17, 2018	Sep CAHN
>D>	AB	KINEDEXE UK	EQ 10MG BASE	A206856	001	Apr 17, 2018	Sep CAHN
	AB		EQ 10MG BASE	A206856	001	Apr 17, 2018	Apr NEWA

TRAZODONE HYDROCHLORIDETABLET; ORAL
TRAZODONE HYDROCHLORIDE

	@	FOSUN PHARMA	100MG	A072483	001	Apr 30, 1990	Jan CAHN
AB		OXFORD PHARMS	50MG	A072192	001	Feb 02, 1989	Jul CAHN
AB			100MG	A072193	001	Feb 02, 1989	Jul CAHN

TREPROSTINILSOLUTION; INTRAVENOUS, SUBCUTANEOUS
REMODULIN

	UNITED THERAP	20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018	Jul NEWA
		50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018	Jul NEWA
		100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018	Jul NEWA
		200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018	Jul NEWA

TRETINOINLOTION; TOPICAL
ALTRENO

+! DOW PHARM 0.05% N209353 001 Aug 23, 2018 Aug NEWA

TRIAMCINOLONE ACETONIDECREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

AT		LANNETT CO INC	0.025%	A040671	001	Jun 09, 2006	May CAHN
AT			0.1%	A040671	002	Jun 09, 2006	May CAHN
AT		MACLEODS PHARMS LTD	0.025%	A209535	001	May 18, 2018	May NEWA
AT			0.1%	A209535	002	May 18, 2018	May NEWA
AT			0.5%	A209535	003	May 18, 2018	May NEWA
AT		PERRIGO NEW YORK	0.025%	A086413	002		Mar CMS1
AT			0.1%	A086413	003		Mar CMS1
AT		TARO PHARM INDS LTD	0.1%	A040039	001	Nov 26, 1997	May CAHN

INJECTABLE; INJECTION
KENALOG-40

>D>	AP	+!	APOTHECON	40MG/ML	N014901	001	Sep CTEC
>A>	AB	+!		40MG/ML	N014901	001	Sep CTEC

		INJECTABLE; INJECTION					
		TRIAMCINOLONE ACETONIDE					
>D>	AP	AMNEAL PHARMS CO	40MG/ML	A207550	001	Dec 11, 2017	Sep CTEC
>A>	AB		40MG/ML	A207550	001	Dec 11, 2017	Sep CTEC
		LOTION; TOPICAL					
		TRIAMCINOLONE ACETONIDE					
	AT	LANNETT CO INC	0.1%	A040672	002	Dec 13, 2006	May CAHN
		OINTMENT; TOPICAL					
		TRIAMCINOLONE ACETONIDE					
	AT	! PERRIGO NEW YORK	0.025%	A087385	002		Jun CMS1
	AT	!	0.1%	A087385	003		Jun CMS1
	AT	TARO PHARM INDS LTD	0.1%	A040037	001	Sep 30, 1994	May CAHN
		SPRAY; TOPICAL					
		KENALOG					
	AT	+! SUN PHARM INDS INC	0.147MG/GM	N012104	001		Feb CAHN
		TRIAMCINOLONE ACETONIDE					
>D>	AT	RICONPHARMA LLC	0.147MG/GM	A206786	001	Sep 08, 2017	Sep CAHN
>A>	AT	RISING PHARMS	0.147MG/GM	A206786	001	Sep 08, 2017	Sep CAHN

TRIENTINE HYDROCHLORIDE

		CAPSULE; ORAL					
		SYPRINE					
	AB	+! ATON	250MG	N019194	001	Nov 08, 1985	Jan CFTG
		TRIENTINE HYDROCHLORIDE					
	AB	WATSON LABS TEVA	250MG	A207567	001	Feb 07, 2018	Jan NEWA

TRIFLUOPERAZINE HYDROCHLORIDE

		CONCENTRATE; ORAL					
		TRIFLUOPERAZINE HYDROCHLORIDE					
		@ FOSUN PHARMA	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982	Jan CAHN

TROPICAMIDE

		SOLUTION/DROPS; OPHTHALMIC					
		TROPICAMIDE					
	AT	BAUSCH AND LOMB	0.5%	A040067	001	Jul 27, 1994	Apr CAHN

UROFOLLITROPIN

		INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS					
		BRAVELLE					
		+ @ FERRING	75 IU/VIAL	N021289	001	May 06, 2002	Jun DISC

URSODIOL

		CAPSULE; ORAL					
		URSODIOL					
	AB	ABHAI LLC	300MG	A210707	001	May 17, 2018	May NEWA
		TABLET; ORAL					
		URSO 250					
	AB	+ ALLERGAN SALES LLC	250MG	N020675	001	Dec 10, 1997	Apr CAHN
		URSO FORTE					
	AB	+! ALLERGAN SALES LLC	500MG	N020675	002	Jul 21, 2004	Apr CAHN

VALACYCLOVIR HYDROCHLORIDE

		TABLET; ORAL					
		VALACYCLOVIR HYDROCHLORIDE					
	AB	TIME-CAP LABS INC	EQ 500MG BASE	A079012	001	May 24, 2010	Aug CAHN
	AB		EQ 1GM BASE	A079012	002	May 24, 2010	Aug CAHN

VALBENAZINE TOSYLATE

		CAPSULE; ORAL					
		INGREZZA					
		+! NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017	Jun CPOT
		+	EQ 80MG BASE	N209241	002	Oct 04, 2017	Jun CPOT

VALPROIC ACID

		SYRUP; ORAL					
		VALPROIC ACID					
	AA	LANNETT CO INC	250MG/5ML	A077960	001	Oct 13, 2006	May CAHN

VALSARTAN

SOLUTION;ORAL

PREXXARTAN

+ @ CARMEL BIOSCIENCES	20MG/5ML	N209139	001	Dec 19, 2017	Jun DISC
+ @	80MG/20ML	N209139	002	Dec 19, 2017	Jun DISC

TABLET;ORAL

VALSARTAN

AB	SQUARE PHARMS LTD	40MG	A205347	001	Apr 09, 2018	Mar NEWA
AB		80MG	A205347	002	Apr 09, 2018	Mar NEWA
AB		160MG	A205347	003	Apr 09, 2018	Mar NEWA
AB		320MG	A205347	004	Apr 09, 2018	Mar NEWA
AB	UNICHEM LABS LTD	40MG	A209261	001	May 04, 2018	Apr NEWA
AB		80MG	A209261	002	May 04, 2018	Apr NEWA
AB		160MG	A209261	003	May 04, 2018	Apr NEWA
AB		320MG	A209261	004	May 04, 2018	Apr NEWA
	@ WATSON LABS INC	40MG	A090642	001	Jan 05, 2015	Aug DISC
	@	80MG	A090642	002	Jan 05, 2015	Aug DISC
	@	160MG	A090642	003	Jan 05, 2015	Aug DISC
	@	320MG	A090642	004	Jan 05, 2015	Aug DISC

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

@ FRESENIUS KABI USA	EQ 125MG BASE	A065453	001	Jun 18, 2012	Feb DISC
@	EQ 250MG BASE	A065453	002	Jun 18, 2012	Feb DISC

FOR SOLUTION;ORAL

FIRVANQ KIT

+! RXMTM THERAPS LLC	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Jan NEWA
+!	EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Jan NEWA

INJECTABLE;INJECTION

VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+! BAXTER HLTHCARE	EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Apr NEWA
--------------------	-------------------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

>A> AP	HIKMA PHARMS	EQ 750MG BASE/VIAL	A206616	001	Oct 03, 2018	Sep NEWA
>A> AP		EQ 750MG BASE/VIAL	A206616	001	Oct 03, 2018	Sep CAHN

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+! MYLAN LABS LTD	EQ 250MG BASE/VIAL	N209481	001	Jul 10, 2018	Jul NEWA
+!	EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018	Jul NEWA
+!	EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018	Jul NEWA
+!	EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018	Jul NEWA

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRA

+ @ BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003	Apr DISC
--------------------	-------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

+! BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Jul CMFD
+ @	10MG	N200179	001	Jun 17, 2010	Apr DISC

VARENICLINE TARTRATE

TABLET;ORAL

CHANTIX

+ PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Feb CAHN
+!	EQ 1MG BASE	N021928	002	May 10, 2006	Feb CAHN

VELAGLUCERASE ALFA

INJECTABLE;INTRAVENOUS

VPRIV

SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575	001	Feb 26, 2010	Jul CDFR
---------------------	----------------	---------	-----	--------------	----------

POWDER;INTRAVENOUS

VPRIV

@ SHIRE HUMAN GENETIC	200 UNITS/VIAL	N022575	002	Feb 26, 2010	Jul CDFR
-----------------------	----------------	---------	-----	--------------	----------

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
EFFEXOR XR

AB	+	WYETH PHARMS	EQ 37.5MG BASE	N020699	001	Oct 20, 1997	Jul CAHN
AB	+		EQ 75MG BASE	N020699	002	Oct 20, 1997	Jul CAHN
	@		EQ 100MG BASE	N020699	003	Oct 20, 1997	Jul CAHN
AB	+	!	EQ 150MG BASE	N020699	004	Oct 20, 1997	Jul CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

@	FOSUN PHARMA	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan CAHN
@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan CAHN
@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan CAHN
@		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan CAHN
@		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan CAHN

VERAPAMIL HYDROCHLORIDESOLUTION;INTRAVENOUS
VERAPAMIL HYDROCHLORIDE

AP		AMNEAL PHARMS CO	5MG/2ML (2.5MG/ML)	A210994	001	Jul 13, 2018	Jul NEWA
AP			10MG/4ML (2.5MG/ML)	A210994	002	Jul 13, 2018	Jul NEWA
AP		EXELA PHARMA SCS LLC	10MG/4ML (2.5MG/ML)	N018925	002	Apr 05, 2018	May NEWA
AP	!	HOSPIRA	5MG/2ML (2.5MG/ML)	A070738	001	May 06, 1987	Jan CPOT
AP		SOMERSET THERAPS LLC	5MG/2ML (2.5MG/ML)	A211015	001	Jun 18, 2018	Jun NEWA
AP			5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018	Jun NEWA
AP			10MG/4ML (2.5MG/ML)	A211015	002	Jun 18, 2018	Jun NEWA
AP			10MG/4ML (2.5MG/ML)	A211035	002	Jun 18, 2018	Jun NEWA

TABLET;ORAL

ISOPTIN

+	@	MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr CRLD
+	@		80MG	N018593	001	Mar 08, 1982	Apr CRLD
+	@		120MG	N018593	002	Mar 08, 1982	Apr CRLD

VERAPAMIL HYDROCHLORIDE

@	YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992	Jan CAHN
@		80MG	A071423	001	May 24, 1988	Jan CAHN
@		120MG	A071424	001	May 25, 1988	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

@	APOTEX CORP	120MG	A200878	001	Apr 20, 2012	Mar DISC
@		180MG	A200878	002	Apr 20, 2012	Mar DISC
@		240MG	A200878	003	Apr 20, 2012	Mar DISC

VIGABATRINFOR SOLUTION;ORAL
VIGABATRIN

AA		AMNEAL PHARMS	500MG/PACKET	A210155	001	Mar 13, 2018	Feb NEWA
AA		TEVA PHARMS USA	500MG/PACKET	A209824	001	Apr 23, 2018	Apr NEWA
		VIGADRONE					
AA		AUCTA PHARMS	500MG/PACKET	A210196	001	Jun 21, 2018	Jun NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

+	!	ALLERGAN SALES LLC	10MG	N022567	001	Jan 21, 2011	Jan CAHN
+			20MG	N022567	002	Jan 21, 2011	Jan CAHN
+			40MG	N022567	003	Jan 21, 2011	Jan CAHN

VINBLASTINE SULFATE

INJECTABLE;INJECTION

VELBAN

+	@	LILLY	10MG/VIAL	N012665	001		Apr CRLD
---	---	-------	-----------	---------	-----	--	----------

VITAMIN A PALMITATE

INJECTABLE;INJECTION

AQUASOL A

+	!	CASPER PHARMA LLC	EQ 50,000 UNITS BASE/ML	N006823	001		Jul CAHN
---	---	-------------------	-------------------------	---------	-----	--	----------

VORICONAZOLE

INJECTABLE;IV (INFUSION)
VORICONAZOLE

AP	ZYDUS PHARMS USA INC	200MG/VIAL	A208983	001	Jul 16, 2018	Jul NEWA
	TABLET;ORAL					
	VORICONAZOLE					
AB	RISING PHARMS	50MG	A206762	001	May 24, 2016	Aug CAHN
AB		200MG	A206762	002	May 24, 2016	Aug CAHN

WARFARIN SODIUM

TABLET;ORAL
WARFARIN SODIUM

	@ YAOPHARMA CO LTD	1MG	A040196	001	Sep 30, 1997	Jan CAHN
	@	2MG	A040196	002	Sep 30, 1997	Jan CAHN
	@	2.5MG	A040196	003	Sep 30, 1997	Jan CAHN
	@	3MG	A040196	008	Jul 26, 2000	Jan CAHN
	@	4MG	A040196	004	Sep 30, 1997	Jan CAHN
	@	5MG	A040196	005	Sep 30, 1997	Jan CAHN
	@	6MG	A040196	009	Jul 26, 2000	Jan CAHN
	@	7.5MG	A040196	006	Sep 30, 1997	Jan CAHN
	@	10MG	A040196	007	Sep 30, 1997	Jan CAHN

ZICONOTIDE ACETATE

INJECTABLE;INTRATHECAL
PRIALT

>D>	+!	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Sep CAHN
>D>	@		200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Sep CAHN
>D>	+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Sep CAHN
>D>	+!		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Sep CAHN
>A>	+!	TERSERA THERAPS LLC	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Sep CAHN
>A>	@		200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Sep CAHN
>A>	+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Sep CAHN
>A>	+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Sep CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL
ZIPRASIDONE HYDROCHLORIDE

	@ MYLAN PHARMS INC	EQ 20MG BASE	A202395	001	Oct 10, 2013	Mar DISC
	@	EQ 40MG BASE	A202395	002	Oct 10, 2013	Mar DISC
	@	EQ 60MG BASE	A202395	003	Oct 10, 2013	Mar DISC
	@	EQ 80MG BASE	A202395	004	Oct 10, 2013	Jul DISC

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)
ZOLEDRONIC

AP	GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Jun NEWA
	ZOLEDRONIC ACID					
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jan CAHN
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Jan CAHN

ZOLMITRIPTAN

TABLET;ORAL
ZOLMITRIPTAN

	@ APOTEX INC	2.5MG	A202078	001	May 14, 2013	Mar DISC
	@	5MG	A202078	002	May 14, 2013	Mar DISC
>D> AB	APPCO PHARMA LLC	2.5MG	A206973	001	Jun 30, 2017	Sep CAHN
>D> AB		5MG	A206973	002	Jun 30, 2017	Sep CAHN
	@ MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Jul DISC
	@	5MG	A203186	002	May 14, 2013	Jul DISC
>A> AB	TWI PHARMS	2.5MG	A206973	001	Jun 30, 2017	Sep CAHN
>A> AB		5MG	A206973	002	Jun 30, 2017	Sep CAHN
AB	ZYDUS PHARMS USA INC	2.5MG	A203019	001	Jul 11, 2018	Jun NEWA
AB		5MG	A203019	002	Jul 11, 2018	Jun NEWA
	TABLET, ORALLY DISINTEGRATING;ORAL					
	ZOLMITRIPTAN					
	@ APOTEX INC	2.5MG	A202476	001	May 14, 2013	Mar DISC
	@	5MG	A202476	002	May 14, 2013	Mar DISC

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@ SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr DISC
@	10MG	A078055	002	Apr 23, 2007	Apr DISC

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

+ @ SUNOVION PHARMS INC	50MG	N020789	002	Aug 22, 2003	Jul DISC
-------------------------	------	---------	-----	--------------	----------

ZONISAMIDE

@ AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Feb CAHN
------------------------	------	---------	-----	--------------	----------

@	50MG	A077645	003	Sep 29, 2006	Feb CAHN
---	------	---------	-----	--------------	----------

@	100MG	A077645	001	Dec 22, 2005	Feb CAHN
---	-------	---------	-----	--------------	----------

>D> AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Sep CAHN
--------	----------------	------	---------	-----	--------------	----------

>D> AB		50MG	A077813	002	Aug 16, 2006	Sep CAHN
--------	--	------	---------	-----	--------------	----------

>D> AB		100MG	A077813	003	Aug 16, 2006	Sep CAHN
--------	--	-------	---------	-----	--------------	----------

>A> AB	BLUEPHARMA	25MG	A077813	001	Aug 16, 2006	Sep CAHN
--------	------------	------	---------	-----	--------------	----------

>A> AB		50MG	A077813	002	Aug 16, 2006	Sep CAHN
--------	--	------	---------	-----	--------------	----------

>A> AB		100MG	A077813	003	Aug 16, 2006	Sep CAHN
--------	--	-------	---------	-----	--------------	----------

ACETAMINOPHEN

SUPPOSITORY;RECTAL
 ACEPHEN

@ G AND W LABS 325MG
 @ 650MG

N018060 003 Dec 18, 1986 Jan DISC
 N018060 002 Jan DISC

ACETAMINOPHEN

+ TARO PHARM INDS LTD 120MG
 + 325MG
 +! 650MG

N018337 003 Sep 12, 1983 May CAHN
 N018337 002 May CAHN
 N018337 001 May CAHN

INFANTS' FEVERALL

+ TARO PHARM INDS LTD 80MG

N018337 004 Aug 26, 1992 May CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

HERITAGE PHARMA 650MG

A207035 001 May 31, 2018 May NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL
 GAVISCON

+ @ SANOFI AVENTIS US 160MG;40MG

N018685 002 Dec 09, 1983 May DISC

ASPIRIN

CAPSULE;ORAL

VAZALORE

+! PLX PHARMA 325MG

N203697 001 Jan 14, 2013 Aug CTNA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

BUTENAFINE HYDROCHLORIDE

TARO PHARMS 1%

A205181 001 Nov 16, 2017 May CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA LTD 10MG

A209107 001 Jul 20, 2018 Jul NEWA

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA LTD 10MG

A209107 002 Jul 20, 2018 Jul NEWA

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D> ALLIED 5MG/5ML

A091327 001 Oct 17, 2011 Sep CAHN

>A> APNAR PHARMA LP 5MG/5ML

A091327 001 Oct 17, 2011 Sep CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D> ALLIED 5MG/5ML

A091327 002 Oct 17, 2011 Sep CAHN

>A> APNAR PHARMA LP 5MG/5ML

A091327 002 Oct 17, 2011 Sep CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>D> JUBILANT CADISTA 5MG

A078933 001 Jun 15, 2010 Sep CAHN

>D> 10MG

A078933 002 Jun 15, 2010 Sep CAHN

>A> MARKSANS PHARMA 5MG

A078933 001 Jun 15, 2010 Sep CAHN

>A> 10MG

A078933 002 Jun 15, 2010 Sep CAHN

PLD ACQUISITIONS 5MG

A077946 001 Dec 27, 2007 Feb CAHN

10MG

A077946 002 Dec 27, 2007 Feb CAHN

CETIRIZINE HYDROCHLORIDE HIVES

>D> JUBILANT CADISTA 5MG

A078933 003 Jun 15, 2010 Sep CAHN

>D> 10MG

A078933 004 Jun 15, 2010 Sep CAHN

>A> MARKSANS PHARMA 5MG

A078933 003 Jun 15, 2010 Sep CAHN

>A> 10MG

A078933 004 Jun 15, 2010 Sep CAHN

! UNIQUE PHARM LABS 10MG

A077829 002 Aug 26, 2009 Aug CHRS

ZYRTEC ALLERGY

+ @ J AND J CONSUMER INC 5MG

N019835 003 Nov 16, 2007 Aug DISC

ZYRTEC HIVES RELIEF

+ @ J AND J CONSUMER INC 5MG

N019835 005 Nov 16, 2007 Aug DISC

+ @ 10MG

N019835 006 Nov 16, 2007 Aug DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

PLD ACQUISITIONS 5MG;120MG

A077991 001 Mar 05, 2008 Feb CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOLSOLUTION; TOPICAL
SOLUPREP

+!	3M HEALTH CARE	2%;70%	N208288	001	Aug 08, 2018	Aug	NEWA
----	----------------	--------	---------	-----	--------------	-----	------

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+!	BECTON DICKINSON CO	2%;70% (1ML)	N020832	008	Oct 23, 2008	Feb	NEWA
----	---------------------	--------------	---------	-----	--------------	-----	------

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

!	L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995	Jul	CHRS
@	PLD ACQUISITIONS LLC	1.34MG	A073458	001	Oct 31, 1993	Jul	DISC
		1.34MG	A073458	001	Oct 31, 1993	Jan	CAHN

TAVIST-1

+	@ GLAXOSMITHKLINE CONS	1.34MG	N020925	001	Aug 21, 1992	Jul	DISC
---	------------------------	--------	---------	-----	--------------	-----	------

CLOTTRIMAZOLE

CREAM; VAGINAL

MYCELEX-7

@	BAYER HEALTHCARE LLC	1%	N018230	002	Dec 26, 1991	Mar	DISC
---	----------------------	----	---------	-----	--------------	-----	------

CREAM, TABLET; TOPICAL, VAGINAL

MYCELEX-7 COMBINATION PACK

@	BAYER HEALTHCARE LLC	1%,100MG	N020389	002	Jun 23, 1994	Feb	DISC
---	----------------------	----------	---------	-----	--------------	-----	------

TABLET; VAGINAL

MYCELEX-7

@	BAYER HEALTHCARE LLC	100MG	N018182	002	Dec 26, 1991	Mar	DISC
---	----------------------	-------	---------	-----	--------------	-----	------

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

@	AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Jun	DISC
---	-------------	-----------	---------	-----	--------------	-----	------

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

	PERRIGO R AND D	30MG;600MG	A207602	002	Mar 05, 2018	Apr	NEWA
		60MG;1.2MG	A207602	001	Mar 05, 2018	Apr	NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

	DR REDDYS LABS LTD	EQ 20MG BASE	A207673	001	May 15, 2018	Apr	NEWA
--	--------------------	--------------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

>D>	+	@ SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Sep	CMFD
-----	---	---------------------	----------	---------	-----	--------------	-----	------

>A>	+		30MG/5ML	N201373	001	Jan 24, 2011	Sep	CMFD
-----	---	--	----------	---------	-----	--------------	-----	------

	+	@	30MG/5ML	N201373	001	Jan 24, 2011	Jul	DISC
--	---	---	----------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+	@ SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jul	DISC
---	---------------------	----------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

!	ACTAVIS MID ATLANTIC	30MG/5ML	A203330	001	Nov 18, 2014	Jul	CHRS
---	----------------------	----------	---------	-----	--------------	-----	------

@	TARO PHARM	30MG/5ML	A208123	001	Nov 09, 2017	Jul	DISC
---	------------	----------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

!	ACTAVIS MID ATLANTIC	30MG/5ML	A203330	002	Nov 18, 2014	Jul	CHRS
---	----------------------	----------	---------	-----	--------------	-----	------

@	TARO PHARM	30MG/5ML	A208123	002	Nov 09, 2017	Jul	DISC
---	------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

ALLEGRA HIVES

+	@ SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jun	DISC
---	---------------------	------	---------	-----	--------------	-----	------

+	@	180MG	N020872	009	Jan 24, 2011	Jun	DISC
---	---	-------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA ALLERGY

+	@ SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jun	DISC
---	---------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+	@ SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jun	DISC
---	---------------------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

	UNIQUE PHARM LABS	180MG	A210137	001	Aug 13, 2018	Jul	NEWA
--	-------------------	-------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL
CHILDREN'S ALLEGRA ALLERGY

+ @ SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jul DISC
CHILDREN'S ALLEGRA HIVES					
+ @ SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jul DISC
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY					
@ DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013	Jul DISC
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
@ DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013	Jul DISC

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN

AMNEAL PHARMS	600MG	A207342	001	Jul 11, 2018	Jun NEWA
	1.2GM	A207342	002	Jul 11, 2018	Jun NEWA
GUARDIAN DRUG	600MG	A209215	001	Sep 06, 2017	Aug CAHN
	1.2GM	A209215	002	Sep 06, 2017	Aug CAHN
OHM LABS INC	600MG	A209254	001	Jul 16, 2018	Jul NEWA
	1.2GM	A209254	002	Jul 16, 2018	Jul NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A207753	001	Jun 29, 2018	Jun NEWA
STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469	001	Mar 28, 2018	Mar NEWA

SUSPENSION;ORAL

IBUPROFEN

AUROBINDO PHARMA LTD	100MG/5ML	A209179	001	Apr 17, 2018	Apr NEWA
GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018	Aug NEWA

SUSPENSION/DROPS;ORAL

IBUPROFEN

>A>	GUARDIAN DRUG	40MG/ML	A210755	001	Sep 26, 2018	Sep NEWA
-----	---------------	---------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

>D>	AIPING PHARM INC	200MG	A206990	001	Aug 21, 2018	Sep CAHN
		200MG	A206990	001	Aug 21, 2018	Aug NEWA
>D>		200MG	A207095	001	May 05, 2017	Sep CAHN
	DR REDDYS LABS INC	200MG	A076117	001	Nov 20, 2001	Jul CPOT
>D>	LNK	100MG	A076741	001	Jun 17, 2004	Sep DISC
>A>	@	100MG	A076741	001	Jun 17, 2004	Sep DISC
	@ P AND L DEV LLC	200MG	A070733	001	Sep 19, 1986	Jan CAHN
>A>	SHANDONG XINHUA	200MG	A206990	001	Aug 21, 2018	Sep CAHN
>A>		200MG	A207095	001	May 05, 2017	Sep CAHN
	STRIDES PHARMA	200MG	A206989	001	Jun 29, 2018	Jun NEWA

TABLET, CHEWABLE;ORAL

CHILDREN'S MOTRIN

+ @ J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996	Jul DISC
IBUPROFEN					
@ PERRIGO	50MG	A076359	001	Jan 16, 2004	Jul DISC
!	100MG	A076359	002	Jan 16, 2004	Jul CHRS
JUNIOR STRENGTH MOTRIN					
+ @ J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996	Jul DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

DR REDDYS LABS LTD	5MG	A210375	001	Jan 19, 2018	Jan NEWA
--------------------	-----	---------	-----	--------------	----------

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>A>	AMNEAL PHARMS	1.5MG	A204044	001	Jul 03, 2018	Sep CAHN
>A>	APOTEX INC	1.5MG	A205329	001	Sep 18, 2018	Sep NEWA
>D>	HAUPT PHARMA	1.5MG	A204044	001	Jul 03, 2018	Sep CAHN
		1.5MG	A204044	001	Jul 03, 2018	Jun NEWA

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

>D>	ALLIED	1MG/5ML	A073079	001	Apr 30, 1992	Sep DISC
>A>	@	1MG/5ML	A073079	001	Apr 30, 1992	Sep DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

PERRIGO R AND D 2MG;125MG

A209837 001 Sep 05, 2018 Aug NEWA

LORATADINE

SYRUP;ORAL

LORATADINE

AUROBINDO PHARMA LTD 1MG/ML

A208931 001 Jun 29, 2018 Jun NEWA

TABLET;ORAL

LORATADINE

AUROBINDO PHARMA LTD 10MG

A208314 001 Apr 16, 2018 Apr NEWA

PLD ACQUISITIONS LLC 10MG

A075209 001 Jan 21, 2003 Jan CAHN

TABLET, CHEWABLE;ORAL

LORATADINE

SUN PHARMA GLOBAL 5MG

A210088 001 Apr 16, 2018 Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

AUROBINDO PHARMA LTD 10MG

A208477 001 Apr 11, 2018 Mar NEWA

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

TARO PHARMS 2%

A074444 001 Jan 13, 1997 May CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

@ G AND W LABS 2%,100MG

A076585 001 Mar 26, 2004 Jan DISC

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

PURACAP PHARM LLC EQ 200MG BASE

A208363 001 Mar 15, 2018 Jun NEWA

TABLET;ORAL

NAPROXEN SODIUM

@ PLD ACQUISITIONS LLC EQ 200MG BASE

A074646 001 Jan 13, 1997 Jan CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

THRIVE

@ GLAXOSMITHKLINE CONS	EQ 4MG BASE	A077656	001	Jun 19, 2007	Aug DISC
	EQ 4MG BASE	A077656	001	Jun 19, 2007	Feb CAHN

TROCHE/LOZENGE;ORAL

NICORETTE

+ GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330	001	Oct 31, 2002	Feb CTNA
+!	EQ 4MG BASE	N021330	002	Oct 31, 2002	Feb CTNA

NICOTINE POLACRILEX

WATSON LABS INC EQ 2MG BASE

A209206 001 Jun 26, 2018 Jun NEWA

EQ 4MG BASE

A209206 002 Jun 26, 2018 Jun NEWA

WATSON LABS TEVA EQ 2MG BASE

A209519 001 Jul 02, 2018 Jun NEWA

EQ 4MG BASE

A209519 002 Jul 02, 2018 Jun NEWA

OMEPRazole MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRazole MAGNESIUM

SPIL EQ 20MG BASE

A210593 001 Jul 20, 2018 Jul NEWA

TABLET, DELAYED RELEASE;ORAL

OMEPRazole MAGNESIUM

AUROBINDO PHARMA LTD EQ 20MG BASE

A206877 001 Jun 06, 2018 May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

ZYDUS PHARMS USA INC 20MG;1.1GM

A203345 001 Mar 16, 2018 Mar NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

APNAR PHARMA LP 17GM/SCOOPFUL

A202071 001 Dec 28, 2012 Mar CAHN

AUROBINDO PHARMA LTD 17GM/SCOOPFUL

A209017 001 Apr 09, 2018 Mar NEWA

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

AFRINOL

+ @ SCHERING PLOUGH 120MG

N018191 001 Jul DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

GRANULES INDIA LTD EQ 150MG BASE

A210243 001 Aug 20, 2018 Aug NEWA

EQ 150MG BASE

A210243 002 Aug 20, 2018 Aug NEWA

VIVIMED GLOBAL EQ 75MG BASE

A209160 001 Mar 05, 2018 Feb NEWA

EQ 150MG BASE

A209161 001 Feb 22, 2018 Feb NEWA

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021124 001 Mar 17, 2000 Feb CAHN

SPRAY;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER 2018

NO SEPTEMBER 2018 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2018 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Dec 15, 2029	DS DP U-1981		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	8822438	Aug 24, 2027	U-1579		I-765	Feb 07, 2021
	8822438	Aug 24, 2027	U-1580			
	8822438	Aug 24, 2027	U-2235			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579		I-765	Feb 07, 2021
	8822438	Aug 24, 2027	U-1580			
	8822438	Aug 24, 2027	U-2235			
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308 001	9889144	Mar 17, 2034	DP			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	7459554	Nov 24, 2026	DS		ODE-175	Oct 31, 2024
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9399012	Sep 11, 2031	U-2261			
	9399012	Sep 11, 2031	U-2262			
	9399012*PED	Mar 11, 2032				
	9610265	Nov 13, 2028	U-2263			
	9610265*PED	May 13, 2029				
	9987238	Nov 13, 2028	U-2261			
	9987238*PED	May 13, 2029				
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	RE46417	Feb 10, 2025	DS DP U-1263			
<u>AFATINIB DIMALEATE - GILOTREF</u>						
N 201292 001	10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	10004743	Jul 05, 2030	DP		I-763	Jan 12, 2021
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	9861771	Oct 11, 2020	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10022510	May 18, 2031	DP			
<u>ALCOHOL - ABLYSINOL</u>						
N 207987 001					ODE-192	Jun 21, 2025
<u>ALCOHOL - ABLYSINOL</u>						
N 207987 002					ODE-192	Jun 21, 2025
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	9956205	Dec 28, 2031	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	9956205	Dec 28, 2031	U-2104			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	9867791	Dec 02, 2030	U-2106		I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	9867791	Dec 02, 2030	U-2106		I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001					I-766	Mar 09, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001					NC	May 31, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	002				NC	May 31, 2021
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	003				NC	May 31, 2021
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 208147	001 >A>	10086087	Mar 15, 2027	DP		
<u>AMPHETAMINE SULFATE - AMPHETAMINE SULFATE</u>						
A 211139	001				>A> CGT	Mar 26, 2019
<u>AMPHETAMINE SULFATE - AMPHETAMINE SULFATE</u>						
A 211139	002				>A> CGT	Mar 30, 2019
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	001	10028995	Dec 18, 2034	U-2338	NCE	Dec 21, 2022
		9220745	Dec 18, 2034	U-2217		
		9220745	Dec 18, 2034	U-2218		
		9572856	Sep 20, 2030	U-2221		
		9867863	Dec 16, 2029	U-2231		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	002	10028995	Dec 18, 2034	U-2338	NCE	Dec 21, 2022
		9220745	Dec 18, 2034	U-2217		
		9220745	Dec 18, 2034	U-2218		
		9572856	Sep 20, 2030	U-2221		
		9867863	Dec 16, 2029	U-2231		
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	001 >A>	10052314	Sep 23, 2033	U-2381	NCE	Feb 14, 2023
	>A>	10052314	Sep 23, 2033	U-2382		
		8445507	Sep 15, 2030	DS DP U-2237		
		8802689	Mar 27, 2027	U-2237		
		9388159	Mar 27, 2027	DS DP		
		9481663	Jun 04, 2033	DS DP U-2237		
		9884054	Sep 23, 2033	U-2237		
<u>APREMILAST - OTEZLA</u>						
N 205437	001 >A>	10092541	May 29, 2034	U-2403		
		7427638	Feb 16, 2028	DS DP		
		9724330	Mar 19, 2023	U-1561		
		9724330	Mar 19, 2023	U-1595		
		9872854	May 29, 2034	U-2232		
		9872854	May 29, 2034	U-2233		
<u>APREMILAST - OTEZLA</u>						
N 205437	002 >A>	10092541	May 29, 2034	U-2403		
		7427638	Feb 16, 2028	DS DP		
		9724330	Mar 19, 2023	U-1561		
		9724330	Mar 19, 2023	U-1595		
		9872854	May 29, 2034	U-2232		
		9872854	May 29, 2034	U-2233		
<u>APREMILAST - OTEZLA</u>						
N 205437	003 >A>	10092541	May 29, 2034	U-2403		
		7427638	Feb 16, 2028	DS DP		
		9724330	Mar 19, 2023	U-1561		
		9724330	Mar 19, 2023	U-1595		
		9872854	May 29, 2034	U-2232		
		9872854	May 29, 2034	U-2233		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - CINVANTI</u>						
N 209296 001	9974742	Sep 18, 2035	DP			
	9974793	Sep 18, 2035	DP			
	9974794	Sep 18, 2035	DP U-2161			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001 >A>	9452131	Mar 19, 2035	U-2402			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002 >A>	9452131	Mar 19, 2035	U-2402			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003 >A>	9452131	Mar 19, 2035	U-2402			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004 >A>	9452131	Mar 19, 2035	U-2402			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	10016415	Sep 08, 2035	DP		NCE	Oct 05, 2020
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018	U-2204		ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6723351	Nov 10, 2018	U-573			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-617			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-617			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-651			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	6723351	Nov 10, 2018	U-2204		ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENUVU</u>						
N 209381 001	10016504	Sep 10, 2033	DP		NP	May 04, 2021
	8999313	Sep 10, 2033	DP			
	9326969	Sep 10, 2033	U-2310			
	9592252	Aug 11, 2032	DP U-2310			
	9707297	Sep 10, 2033	DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001					M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002					M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9987231	Jan 02, 2033	U-2324			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9987231	Jan 02, 2033	U-2324			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	10039718	Oct 04, 2032	DP			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	May 05, 2025	DS DP		NCE	May 21, 2023
	8765764	Jan 15, 2023	U-2314			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-2244			
	7112592	Feb 24, 2022	DS DP U-282			
	8178554	Jul 24, 2021	DS DP U-2245			
	8178554	Jul 24, 2021	DS DP U-282			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9211259	Feb 28, 2029	U-1796			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 002	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9901585	Jun 13, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	Jun 08, 2030	DS DP		NCE	May 31, 2023
	8420629	Mar 10, 2029	U-247			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2019	DS DP U-594			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDAMUSTINE HYDROCHLORIDE</u>						
N 205580 001	10010533	Jan 28, 2031	DP			
	8609707	Aug 11, 2031	DP U-1971			
	8609707	Aug 11, 2031	DP U-1972			
	8791270	Jan 12, 2026	DP U-1971			
	8791270	Jan 12, 2026	DP U-1972			
	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	10010533	Jan 28, 2031	DP		ODE-179	Dec 07, 2022
	10052385	Mar 15, 2033	U-1971			
	10052385	Mar 15, 2033	U-1972			
	8791270	Jan 12, 2026	DP U-1790			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9877974	Aug 31, 2030	DP U-1858			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	6642245	Nov 04, 2020	U-257		NCE	Feb 07, 2023
	6703396	Mar 09, 2021	DS DP			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	>A> 10005761	Aug 27, 2030	U-2331		NCE	Jun 27, 2023
	>A> 7777050	Mar 13, 2023	DS DP		ODE-194	Jun 27, 2025
	>A> 8178693	Mar 13, 2023	DS DP			
	>A> 8193229	Mar 13, 2023	U-2330			
	>A> 8513293	Mar 13, 2023	U-2331			
	>A> 9314464	Jul 04, 2031	U-2332			
	>A> 9562016	Oct 18, 2033	DS DP			
	>A> 9593100	Aug 27, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	>A> 9598376	Oct 18, 2033	U-2330			
	>A> 9850229	Aug 27, 2030	U-2333			
	>A> 9980944	Oct 18, 2033	U-2334			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003					ODE-163	Dec 19, 2024
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9687443	Jul 10, 2021	DP			
	9687443*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	9861631	Mar 25, 2031	U-1428			
	9861632	Mar 25, 2031	U-1428			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	8293742	Jul 14, 2030	U-2222			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9907801	Apr 19, 2022	DP U-2239			
	9907802	Apr 19, 2022	DP U-2240			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-2295			
	6911461	Feb 21, 2021	DS DP U-2295			
	8492416	Feb 21, 2021	U-2295			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9895422	Jun 07, 2030	U-2114			
	9895422	Jun 07, 2030	U-2116			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9895422	Jun 07, 2030	U-2281			
	9895422	Jun 07, 2030	U-2282			
	9895422	Jun 07, 2030	U-2283			
	9895422	Jun 07, 2030	U-2284			
	9895422	Jun 07, 2030	U-2285			
	9895422	Jun 07, 2030	U-2286			
	9895422	Jun 07, 2030	U-2287			
	>A> 9993474	Apr 30, 2032	U-2384			
	>A> 9993474	Apr 30, 2032	U-2385			
	>A> 9993474	Apr 30, 2032	U-2386			
	>A> 9993474	Apr 30, 2032	U-2387			
	>A> 9993474	Apr 30, 2032	U-2388			
	>A> 9993474	Apr 30, 2032	U-2389			
	>A> 9993474	Apr 30, 2032	U-2390			
	>A> 9993474	Apr 30, 2032	U-2391			
	>A> 9993474	Apr 30, 2032	U-2392			
	>A> 9993474	Apr 30, 2032	U-2393			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	>A> 10064878	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001					I-771	Apr 06, 2021
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002					I-771	Apr 06, 2021
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					NP	Nov 30, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					NP	Nov 30, 2020
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9901539	Dec 21, 2032	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9931305	Feb 14, 2022	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10039757	Jul 18, 2031	U-1480			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10039757	Jul 18, 2031	U-1480			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10039757	Jul 18, 2031	U-1480			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	8426391	Aug 27, 2028	U-1872			
	9861644	Mar 14, 2034	DP			
	9925147	Apr 25, 2028	DP U-2255			
	9925147	Apr 25, 2028	DP U-2256			
	9925147	Apr 25, 2028	DP U-2257			
	9925147	Apr 25, 2028	DP U-2258			
	9925147	Apr 25, 2028	DP U-2259			
	9943530	Feb 02, 2027	U-2274			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	8222219	Apr 11, 2025	U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	8222219	Apr 11, 2025	U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	8222219	Apr 11, 2025	U-493			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	10039780	Jul 10, 2035	U-2260			
	6114313	Dec 11, 2018	DP U-1715			
	6130208	Jun 29, 2019	DP U-1715			
	9925265	May 13, 2029	U-2260			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	7232818	Apr 14, 2025	DS DP			
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025	U-2319			
	7491704	Apr 14, 2025	U-2320			
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025	U-2319			
	8129346	Apr 14, 2025	U-2320			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-2319			
	8207127	Apr 14, 2025	U-2320			
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029	U-1924			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9872906	Mar 14, 2034	DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694 001	9993471	Mar 15, 2030	U-1680			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB</u>						
N 021524 001					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK</u>						
N 021524 002					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP</u>						
N 208288 001	>A> 8623935	Jul 26, 2029	DP U-1022		NP	Aug 08, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9603796	Apr 21, 2029	DS DP U-2252		I-770	Mar 02, 2021
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001					NPP	Aug 15, 2021
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	10010537	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	10010537	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	10010537	Oct 10, 2031	DP			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	10064875	Aug 31, 2030	DP U-1408			
	10064875	Aug 31, 2030	DP U-1858			
	10064875	Aug 31, 2030	DP U-193			
	10064875	Aug 31, 2030	DP U-742			
	10064875	Aug 31, 2030	DP U-88			
	9956231	Aug 31, 2030	DP U-1408			
	9956231	Aug 31, 2030	DP U-1761			
	9956231	Aug 31, 2030	DP U-1858			
	9956231	Aug 31, 2030	DP U-193			
	9956231	Aug 31, 2030	DP U-742			
	9956231	Aug 31, 2030	DP U-88			
<u>COBICISTAT - TYBOST</u>						
N 203094 001	10039718	Oct 04, 2032	DP			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	10039718	Oct 04, 2032	DP			
	8148374	Sep 03, 2029	DS DP U-1279			
	9889115	Jun 23, 2019	U-1660			
<u>COBICISTAT; DARUNAVIR ETHANOLATE; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	10039718	Oct 04, 2032	DP		NC	Jul 17, 2020
	6642245	Nov 04, 2020	U-2352		NCE	Nov 05, 2020
	6703396	Mar 09, 2021	DS DP			
	7390791	May 07, 2022	DS DP			
	7470506	Jun 23, 2019	U-2352			
	7700645	Dec 26, 2026	DS DP			
	7803788	Feb 02, 2022	U-2352			
	8148374	Sep 03, 2029	DS DP U-2353			
	8148374	Sep 03, 2029	DS DP U-2364			
	8148374	Sep 03, 2029	DS DP U-2365			
	8518987	Feb 16, 2024	DS DP			
	8597876	Jun 23, 2019	U-2352			
	8754065	Aug 15, 2032	DS DP U-2352			
	9296769	Aug 15, 2032	DS DP U-2352			
	9889115	Jun 23, 2019	U-2352			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	10039718	Oct 04, 2032	DP			
	9891239	Sep 03, 2029	DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	10039718	Oct 04, 2032	DP			
	9891239	Sep 03, 2029	DP U-257			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10016407	Feb 07, 2037	U-2329		NCE	Dec 14, 2022
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOPA</u>						
N 209936 001	RE46856	Oct 22, 2029	DS DP U-2124			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	8877245	Nov 14, 2023	U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	8877245	Nov 14, 2023	U-979			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	8980839	Aug 23, 2033	DP U-1483			
	9937225	Aug 23, 2033	DP U-1483			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Sep 29, 2034	DP U-2341			
	10028912	Sep 29, 2034	DP U-2342			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	9925174	Jun 14, 2023	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-778	Apr 30, 2021
	7994185	Jan 20, 2030	DS DP U-2031		I-781	May 04, 2021
	7994185	Jan 20, 2030	DS DP U-2032		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-183	May 04, 2025
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2297			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-2296			
	9233956	May 04, 2029	U-2297			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-778	Apr 30, 2021
	7994185	Jan 20, 2030	DS DP U-2031		I-781	May 04, 2021
	7994185	Jan 20, 2030	DS DP U-2032		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2296		ODE-183	May 04, 2025
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2297			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
	9233956	May 04, 2029	U-2297			
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	9918973	Dec 13, 2024	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	9884044	Jun 13, 2022	DP U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	>A> 6596746	Jun 28, 2020	DS DP U-748		ODE-164	Nov 09, 2024
	>A> 6596746	Jun 28, 2020	DS DP U-780			
	>A> 6596746*PED	Dec 28, 2020				
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875*PED	Oct 13, 2020				
	>A> 7153856	Apr 28, 2020	U-780			
	>A> 7153856*PED	Oct 28, 2020				
	>A> 7491725	Mar 28, 2026	DS DP			
	>A> 7491725*PED	Sep 28, 2026				
	>A> 8680103	Feb 04, 2025	DP			
	>A> 8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	>A> 6596746	Jun 28, 2020	DS DP U-748		ODE-164	Nov 09, 2024
	>A> 6596746	Jun 28, 2020	DS DP U-780			
	>A> 6596746*PED	Dec 28, 2020				
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875*PED	Oct 13, 2020				
	>A> 7153856	Apr 28, 2020	U-780			
	>A> 7153856*PED	Oct 28, 2020				
	>A> 7491725	Mar 28, 2026	DS DP			
	>A> 7491725*PED	Sep 28, 2026				
	>A> 8680103	Feb 04, 2025	DP			
	>A> 8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	>A> 6596746	Jun 28, 2020	DS DP U-748		ODE-164	Nov 09, 2024
	>A> 6596746	Jun 28, 2020	DS DP U-780			
	>A> 6596746*PED	Dec 28, 2020				
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875*PED	Oct 13, 2020				
	>A> 7153856	Apr 28, 2020	U-780			
	>A> 7153856*PED	Oct 28, 2020				
	>A> 7491725	Mar 28, 2026	DS DP			
	>A> 7491725*PED	Sep 28, 2026				
	>A> 8680103	Feb 04, 2025	DP			
	>A> 8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	>A> 6596746	Jun 28, 2020	DS DP U-748		ODE-164	Nov 09, 2024
	>A> 6596746	Jun 28, 2020	DS DP U-780			
	>A> 6596746*PED	Dec 28, 2020				
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875*PED	Oct 13, 2020				
	>A> 7153856	Apr 28, 2020	U-780			
	>A> 7153856*PED	Oct 28, 2020				
	>A> 7491725	Mar 28, 2026	DS DP			
	>A> 7491725*PED	Sep 28, 2026				
	>A> 8680103	Feb 04, 2025	DP			
	>A> 8680103*PED	Aug 04, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	>A> 6596746	Jun 28, 2020	DS DP U-748		ODE-164	Nov 09, 2024
	>A> 6596746	Jun 28, 2020	DS DP U-780			
	>A> 6596746*PED	Dec 28, 2020				
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875*PED	Oct 13, 2020				
	>A> 7153856	Apr 28, 2020	U-780			
	>A> 7153856*PED	Oct 28, 2020				
	>A> 7491725	Mar 28, 2026	DS DP			
	>A> 7491725*PED	Sep 28, 2026				
	>A> 8680103	Feb 04, 2025	DP			
	>A> 8680103*PED	Aug 04, 2025				
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	>A> 6596746	Jun 28, 2020	DS DP U-748		ODE-164	Nov 09, 2024
	>A> 6596746	Jun 28, 2020	DS DP U-780			
	>A> 6596746*PED	Dec 28, 2020				
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875*PED	Oct 13, 2020				
	>A> 7153856	Apr 28, 2020	U-780			
	>A> 7153856*PED	Oct 28, 2020				
	>A> 7491725	Mar 28, 2026	DS DP			
	>A> 7491725*PED	Sep 28, 2026				
	>A> 8680103	Feb 04, 2025	DP			
	>A> 8680103*PED	Aug 04, 2025				
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9949986	Feb 21, 2028	U-1940			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	7560429	Feb 02, 2024	DP U-2326		NP	Jun 21, 2021
	7947654	Dec 29, 2023	DP			
	8802624	Dec 29, 2023	U-2326			
	9220747	May 07, 2023	U-2326			
	9504647	May 07, 2023	DP U-2326			
	9919025	May 07, 2023	U-2326			
	9974826	Apr 13, 2030	U-2326			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	7560429	Feb 02, 2024	DP U-2326		NP	Jun 21, 2021
	7947654	Dec 29, 2023	DP			
	8802624	Dec 29, 2023	U-2326			
	9220747	May 07, 2023	U-2326			
	9504647	May 07, 2023	DP U-2326			
	9919025	May 07, 2023	U-2326			
	9974826	Apr 13, 2030	U-2327			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001					M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002					M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003					M-222	Feb 06, 2021
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10022502	Sep 12, 2020	U-2340		NP	Feb 09, 2021
	10028965	May 23, 2034	U-2340			
	6960346	Jul 03, 2023	DP			
	7560120	Sep 05, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	10016396	Jan 04, 2032	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	10016396	Jan 04, 2032	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628 003	9649296	Apr 20, 2036	DP			
	9717796	Apr 20, 2036	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628 004	9649296	Apr 20, 2036	DP			
	9717796	Apr 20, 2036	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Apr 01, 2019	DP			
	7320999	Oct 20, 2019			U-1384	
	7619001	Apr 01, 2019			U-1384	
	7803840	Apr 01, 2019			U-1385	
	8399514	Feb 07, 2028			U-1384	
	8759393	Jul 04, 2018	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Apr 01, 2019	DP			
	7320999	Oct 20, 2019			U-1384	
	7619001	Apr 01, 2019			U-1384	
	7803840	Apr 01, 2019			U-1385	
	8399514	Feb 07, 2028			U-1384	
	8759393	Jul 04, 2018	DP			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	>A> 8486975	Oct 07, 2031	DS DP U-2394		NCE	Aug 30, 2023
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	>A> 8486975	Oct 07, 2031	DS DP U-2395		NCE	Aug 30, 2023
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	>A> 10058564	Apr 05, 2022	DS DP U-1063			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	9937132	Feb 18, 2033	DP U-1382			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001					>A> NCE	Sep 24, 2023
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002					>A> NCE	Sep 24, 2023
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175 001	>A> 10071054	Aug 08, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 001					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 002					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 003					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 091471 001					PC	Feb 14, 2018
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9877955	Jan 03, 2028	U-1969			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
	7056927	Sep 10, 2024	DS DP			
	7176211	Jul 06, 2024		U-2360		
	7179815	Mar 07, 2021		U-2360		
	7419983	Jul 06, 2024	DS DP	U-2360		
	7462625	Jan 25, 2021	DS DP	U-2360		
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
	7056927	Sep 10, 2024	DS DP			
	7176211	Jul 06, 2024		U-2360		
	7179815	Mar 07, 2021		U-2360		
	7419983	Jul 06, 2024	DS DP	U-2360		
	7462625	Jan 25, 2021	DS DP	U-2360		
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	6916802	Apr 29, 2022	DS	U-1571		
	>A> 7196205	Jun 26, 2026	DS			
	7253185	Apr 29, 2022		DP		
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	9949997	May 17, 2034		U-2292		
	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	9949997	May 17, 2034		U-2292		
	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	9949998	Jun 11, 2034		U-2290		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	9949998	Jun 11, 2034		U-2290		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	9949998	Jun 11, 2034	U-2290			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	9968553	Nov 06, 2032	U-1723			
	9968553	Nov 06, 2032	U-185			
	9968553	Nov 06, 2032	U-1892			
	9968553	Nov 06, 2032	U-3			
	9968553	Nov 06, 2032	U-71			
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	10039745	Mar 25, 2036	DP			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001	10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
	8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
	8541575	Feb 26, 2030	DS DP	U-2335		
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9387208	Nov 21, 2032	DP			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		NCE	Jun 27, 2023
	8501758	Mar 04, 2031	DS DP		ODE-194	Jun 27, 2025
	8541575	Feb 26, 2030	DS DP	U-2335		
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9387208	Nov 21, 2032	DP			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281		I-786	Jul 13, 2021
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	10004700	Aug 14, 2034	DP U-2325			
	10039728	Aug 14, 2034	U-1828			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001					NCE GAIN	Aug 27, 2023 Aug 27, 2028
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	RE46965	Jan 08, 2027	DP			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920 001	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	9180091	Dec 20, 2033	DP U-2316		NP	May 29, 2021
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	9180091	Dec 20, 2033	DP U-2316		NP	May 29, 2021
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA</u>						
N 208612 001	6716814	Aug 16, 2021	DS DP			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001					NCE	Aug 10, 2023
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 001	6878717	Nov 05, 2019	U-1016		>A> NPP	Jul 16, 2021
	6878717	Nov 05, 2019	U-1237		>A> PED	Jan 16, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 001	6878717	Nov 05, 2019	U-2354			
	6878717	Nov 05, 2019	U-256			
	6878717*PED	May 05, 2020				
	7037917	Dec 13, 2020	DS DP U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-2354			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019	DP			
	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 002	6878717	Nov 05, 2019	U-1016		>A> NPP	Jul 16, 2021
	6878717	Nov 05, 2019	U-1237		>A> PED	Jan 16, 2022
	6878717	Nov 05, 2019	U-2354			
	6878717	Nov 05, 2019	U-256			
	6878717*PED	May 05, 2020				
	7037917	Dec 13, 2020	DS DP U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-2354			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019	DP			
	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 003	6878717	Nov 05, 2019	U-1016		>A> NPP	Jul 16, 2021
	6878717	Nov 05, 2019	U-1237		>A> PED	Jan 16, 2022
	6878717	Nov 05, 2019	U-2354			
	6878717	Nov 05, 2019	U-256			
	6878717*PED	May 05, 2020				
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-2354			
	7037917*PED	Jun 13, 2021				
	7887845	Mar 25, 2019	DP			
	7887845*PED	Sep 25, 2019				
	8003789	Nov 01, 2019	DS DP			
	8003789*PED	May 01, 2020				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8778962	Feb 18, 2022	U-1541		I-773	Apr 10, 2021
	8778962	Feb 18, 2022	U-2280		ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8778962	Feb 18, 2022	U-1541		I-773	Apr 10, 2021
	8778962	Feb 18, 2022	U-2280		ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8778962	Feb 18, 2022	U-1541		I-773	Apr 10, 2021
	8778962	Feb 18, 2022	U-2280		ODE-169	Apr 10, 2025
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6872700	Jan 14, 2020	U-2288		M-224	Apr 02, 2021
	6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6872700	Jan 14, 2020	U-2288		M-224	Apr 02, 2021
	6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	10016403	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	10016403	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9814705	Jan 08, 2024	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2019	DP U-1577			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001					I-767	Feb 02, 2021
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	5604229	Feb 18, 2019	DS U-1086		NPP	May 11, 2021
	5604229*PED	Aug 18, 2019			PED	Nov 11, 2021
	8324283	Mar 29, 2026	DP			
	8324283*PED	Sep 29, 2026				
	9187405	Jun 25, 2027	U-1086			
	9187405*PED	Dec 25, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 002	5604229	Feb 18, 2019	DS U-1086		NS	May 11, 2021
	5604229*PED	Aug 18, 2019			PED	Nov 11, 2021
	9592208	Mar 30, 2032	DP U-2315			
	9592208*PED	Sep 30, 2032				
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 001	>A> 9566260	Nov 12, 2023	DP U-2366		NCE	Jul 27, 2023
	>A> 9629821	Nov 12, 2023	DP U-2367		ODE-202	Jul 27, 2025
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 002	9566260	Nov 12, 2023	DP U-2366		NCE	Jul 27, 2023
	9629821	Nov 12, 2023	DP U-2367		ODE-202	Jul 27, 2025
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10010632	Nov 28, 2026	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	7915243	Sep 08, 2023	DP			
	7939516	Sep 08, 2023	DP			
	8247395	Oct 25, 2022	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	8534281	Mar 08, 2030	DP		NPP	May 17, 2021
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003	7101866	Aug 03, 2021	DS DP U-2349		NS	May 17, 2021
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	8534281	Mar 08, 2030	DP		I-775	Apr 24, 2021
	9750726	Nov 29, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10022510	May 18, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10022510	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10022510	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10022510	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10022510	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10022510	May 18, 2031	DP			
	9987229	Sep 01, 2024	DP			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	9730890	Jun 22, 2021	DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001	5691336	Mar 04, 2019	DS DP		NPP	Apr 03, 2021
	5691336*PED	Sep 04, 2019			PED	Oct 03, 2021
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002	5691336	Mar 04, 2019	DS DP U-2265		NPP	Apr 03, 2021
	5691336*PED	Sep 04, 2019			PED	Oct 03, 2021
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	8426450	May 23, 2032	DS DP		NCE	Apr 19, 2023
	8895586	May 23, 2032		U-2301		
	9186357	Nov 18, 2030		U-2301		
	9403772	May 23, 2032	DS	U-2301		
	9908907	May 23, 2032	DS DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS	U-2294	ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS	U-2294		
	8163902	Jun 17, 2026	DS	U-2294		
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030	DP			
	8445485	Jun 17, 2026	DP			
	8652492	Nov 06, 2028	DP			
	8771648	Jul 27, 2032	DP			
	8912170	Jun 17, 2026		U-2294		
	8951504	Jul 27, 2032		U-2294		
	9266912	Jan 19, 2026		U-2294		
	9283238	Jun 17, 2026		U-2294		
	9737554	Jan 19, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS	U-2294	ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS	U-2294		
	8163902	Jun 17, 2026	DS	U-2294		
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030	DP			
	8445485	Jun 17, 2026	DP			
	8652492	Nov 06, 2028	DP			
	8771648	Jul 27, 2032	DP			
	8912170	Jun 17, 2026	U-2294			
	8951504	Jul 27, 2032	U-2294			
	9266912	Jan 19, 2026	U-2294			
	9283238	Jun 17, 2026	U-2294			
	9737554	Jan 19, 2026	DP			
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002	6039931	Nov 13, 2021	U-1239			
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001	9375498	Aug 10, 2032	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 001	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 002	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 003	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 004	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 005	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 006	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 007	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 008	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 009	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 010	9241948	Jul 01, 2033	DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001 >A>	10028937	Jun 10, 2030	U-2141		M-230	Aug 06, 2021
	10039754	Jun 10, 2030	U-2141			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	10045958	Sep 22, 2030	U-1816			
	10045959	Sep 22, 2030	U-1816			
	9962359	Sep 22, 2030	U-1816			
	9999608	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	9931304	Jun 27, 2021	DP			
	9962338	Jun 27, 2021	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	9931304	Jun 27, 2021	DP			
	9962338	Jun 27, 2021	DP			
<u>GLYCOPYRRONIUM TOSYLATE - OBREXZA</u>						
N 210361 001	>A> 10004717	Feb 28, 2033	DP U-2398			
	>A> 10052267	Oct 17, 2028	DP U-2398			
	>A> 6433003	Apr 10, 2020	U-2398			
	>A> 8618160	Dec 10, 2029	DP U-2398			
	>A> 8859610	Feb 28, 2033	DP U-2398			
	>A> 9006462	Feb 28, 2033	DP			
	>A> 9259414	Feb 28, 2033	U-2398			
	>A> 9744105	Jul 18, 2030	DP U-2398			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	9913910	Sep 28, 2024	U-2253			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
N 210566 001					NDF	May 24, 2021
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP U-1087		M-220	Feb 15, 2021
	7348361	Nov 06, 2020	DP U-2250			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	10028946	Jul 25, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	10028946	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9872837	Dec 21, 2031	DP			
<u>HYDROCORTISONE BUTYRATE - HYDROCORTISONE BUTYRATE</u>						
A 209556 001					PC	Aug 11, 2018
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	9980983	Apr 21, 2035	U-2205			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9789257	Feb 11, 2034	DP			
	9844558	May 02, 2036	U-2236			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	RE44846	Aug 10, 2019	DP			
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 001					ODE-177	Dec 21, 2024
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 002					ODE-177	Dec 21, 2024
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10004746	Jun 03, 2031	U-1684			
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10016435	Jun 03, 2031	U-1650			
>A>	8563563	Apr 26, 2027	U-1491			
>A>	8563563	Apr 26, 2027	U-1650			
>A>	8563563	Apr 26, 2027	U-1946			
>A>	8563563	Apr 26, 2027	U-2219			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
>A>	8563563	Apr 26, 2027	U-1491			
>A>	8563563	Apr 26, 2027	U-1650			
>A>	8563563	Apr 26, 2027	U-1946			
>A>	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
>A>	8563563	Apr 26, 2027	U-1491			
>A>	8563563	Apr 26, 2027	U-1650			
>A>	8563563	Apr 26, 2027	U-1946			
>A>	8563563	Apr 26, 2027	U-2241			
>A>	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
>A>	8563563	Apr 26, 2027	U-1491			
>A>	8563563	Apr 26, 2027	U-1650			
>A>	8563563	Apr 26, 2027	U-1946			
>A>	8563563	Apr 26, 2027	U-2241			
>A>	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
>A>	8563563	Apr 26, 2027	U-1491			
>A>	8563563	Apr 26, 2027	U-1650			
>A>	8563563	Apr 26, 2027	U-1946			
>A>	8563563	Apr 26, 2027	U-2241			
>A>	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10004746	Jun 03, 2031	U-1684		NCE	Nov 13, 2018
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	7514444	Dec 28, 2026	DS DP			
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
>A>	8563563	Apr 26, 2027	U-1491			
>A>	8563563	Apr 26, 2027	U-1650			
>A>	8563563	Apr 26, 2027	U-1946			
>A>	8563563	Apr 26, 2027	U-2241			
>A>	8563563	Apr 26, 2027	U-2242			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026			U-1491	
	8703780	Dec 28, 2026			U-2242	
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031			U-1456	
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8952015	Dec 28, 2026			U-2241	
	8952015	Dec 28, 2026			U-2242	
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	
	8999999	Jun 03, 2031			U-2241	
	8999999	Jun 03, 2031			U-2242	
	9125889	Jun 03, 2031			U-1650	
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034			U-2150	
	9801881	Jun 03, 2031			U-1491	
	9801881	Jun 03, 2031			U-2242	
	9801883	Jun 03, 2031			U-2159	
	9801883	Jun 03, 2031			U-2243	
	9814721	Jun 03, 2031			U-1947	
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9072661	Mar 16, 2032			U-2264	
	9072710	Mar 16, 2032			U-2266	
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9861603	Dec 18, 2026			U-1440	
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	9861603	Dec 18, 2026			U-1440	
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001 >A>	7615532	Jun 28, 2029	DS DP			
	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
	9884094	May 01, 2033			U-2238	
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001 >A>	7615532	Jun 28, 2029	DS DP			
	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002 >A>	7615532	Jun 28, 2029	DS DP			
	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002 >A>	7615532	Jun 28, 2029	DS DP			
	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001 >A>	7615532	Jun 28, 2029	DS DP			
	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP U-1832			
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP U-1855			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP U-2146			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	10029011	Aug 02, 2032	DP			
	9717852	Apr 08, 2033	DP			
	9950039	Dec 10, 2035	U-2277			
	9950039	Dec 10, 2035	U-2278			
	9950039	Dec 10, 2035	U-2279			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9717852	Apr 08, 2033	DP			
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9717852	Apr 08, 2033	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 04, 2024	DP U-2146			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9717852	Apr 08, 2033	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 04, 2024	DP U-2146			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001 >A>	10046031	Aug 11, 2029	U-2383			
	9943571	Aug 11, 2029	U-1537			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002 >A>	10046031	Aug 11, 2029	U-2383			
	9943571	Aug 11, 2029	U-1537			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003 >A>	10046031	Aug 11, 2029	U-2383			
	9943571	Aug 11, 2029	U-1537			
<u>IOBENGUANE I-131 - AZEDRA</u>						
N 209607 001					NP ODE-204	Jul 30, 2021 Jul 30, 2025
<u>ITRACONAZOLE - ITRACONAZOLE</u>						
A 205573 001					>A> PC	Mar 17, 2019
<u>IVACAFITOR - KALYDECO</u>						
N 203188 001	8629162	Jun 24, 2025	U-2234		ODE-186 ODE-187 ODE-189 ODE-190 ODE-199	Feb 21, 2021 Dec 29, 2021 Jul 31, 2024 May 17, 2024 Aug 15, 2025
<u>IVACAFITOR - KALYDECO</u>						
N 207925 001	8629162	Jun 24, 2025	U-2234		ODE-188 ODE-189 ODE-190 ODE-199	Mar 17, 2022 Jul 31, 2024 May 17, 2024 Aug 15, 2025
<u>IVACAFITOR - KALYDECO</u>						
N 207925 002	8629162	Jun 24, 2025	U-2234		ODE-188 ODE-189 ODE-190 ODE-199	Mar 17, 2022 Jul 31, 2024 May 17, 2024 Aug 15, 2025
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	>A> 10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027		U-2246		
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027		U-2246		
	8598181	May 01, 2027		U-2246		
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025		U-2247		
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033		U-2248		
	9670163	Dec 28, 2026	DP	U-2246		
	9931334	Dec 28, 2026	DP	U-2275		
	9974781	Apr 09, 2027	DP	U-2318		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9931334	Dec 28, 2026	DP	U-2276	M-218	Jan 25, 2021
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	9931334	Dec 28, 2026	DP	U-2276	M-218	Jan 25, 2021
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	7973038	Nov 08, 2026		U-2374	NP	Aug 07, 2021
	8324242	Aug 05, 2027		U-2374	ODE-195	Aug 07, 2025
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
>A>	8716338	Sep 20, 2030	DP	U-2396		
	8741933	Nov 08, 2026		U-2374		
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028		U-2375		
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028		U-2375		
>A>	9192606	Sep 29, 2029	DP	U-2397		
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP	U-2376		
	9931334	Dec 28, 2026	DP	U-2376		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	7973038	Nov 08, 2026		U-2374	NP	Aug 07, 2021
	8324242	Aug 05, 2027		U-2374	ODE-195	Aug 07, 2025
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
>A>	8716338	Sep 20, 2030	DP	U-2396		
	8741933	Nov 08, 2026		U-2374		
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028		U-2375		
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028		U-2375		
>A>	9192606	Sep 29, 2029	DP	U-2397		
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP	U-2376		
	9931334	Dec 28, 2026	DP	U-2376		
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	9474779	Aug 19, 2033	DS DP	U-2350	NCE	Jul 20, 2023
	9850277	Jan 18, 2033	DS DP	U-2350	ODE-203	Jul 20, 2025
	9968595	Mar 13, 2035	DP	U-2351		
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	RE38551	Mar 17, 2022	DS DP	U-1567		
	RE38551	Mar 17, 2022	DS DP	U-2140		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	RE38551	Mar 17, 2022	DS DP U-1567			
	RE38551	Mar 17, 2022	DS DP U-2140			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	9901546	May 17, 2019	DP			
	9901546*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	9901546	May 17, 2019	DP			
	9901546*PED	Nov 17, 2019				
<u>LATANOPROST - XELPROS</u>						
N 206185 001	>A> 9539262	Apr 20, 2035	DP U-2400			
	>A> 9629852	Sep 12, 2029	DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369			
	10039779	Jan 30, 2034	DS DP U-2370			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-787 ODE-196	Aug 15, 2021 Aug 15, 2025
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-787 ODE-196	Aug 15, 2021 Aug 15, 2025
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	9956205	Dec 28, 2031	U-2311			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002					ODE-165	Nov 08, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	9868739	Nov 09, 2031	U-1981			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9914802	Nov 13, 2020	DS DP U-1666			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - LUTRATE DEPOT KIT</u>						
N 205054 001 >A>	9789064	Dec 15, 2020	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	10028858	Mar 22, 2034	DP U-2348			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
A 206163 001					PC	Sep 29, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
A 206163 002					PC	Sep 29, 2018
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 013	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	9283174	May 10, 2031	DP		NP	Feb 28, 2021
	9925264	May 10, 2031	DP U-2267			
	9931403	May 10, 2031	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	9890141	Oct 21, 2030	DS			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	10034877	Aug 05, 2029	U-2347			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	10022379	Apr 02, 2029	U-2339			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	10022379	Apr 02, 2029	U-2339			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	10022379	Apr 02, 2029	U-2339			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	10022379	Apr 02, 2029	U-2339			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	10022379	Apr 02, 2029	U-2339			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9968659	Jan 09, 2037	U-2313			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	10039800	Nov 06, 2035	U-1723			
	10039800	Nov 06, 2035	U-185			
	10039800	Nov 06, 2035	U-1864			
	10039800	Nov 06, 2035	U-1991			
	10039800	Nov 06, 2035	U-3			
	10039800	Nov 06, 2035	U-71			
	10039800	Nov 06, 2035	U-8			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	10028910	Nov 11, 2030	DP			
	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
	9981013	Aug 30, 2030	U-2297			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	10028910	Nov 11, 2030	DP			
	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
	9981013	Aug 30, 2030	U-2297			
<u>LOFEXIDINE HYDROCHLORIDE - LUCEMYRA</u>						
N 209229 001					NCE	May 16, 2023
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	10016404	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001					M-229	Jul 20, 2021
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001					NP	Aug 22, 2021
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001					M-225	Apr 26, 2021
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002					M-225	Apr 26, 2021
<u>LULICONAZOLE - LUZU</u>						
N 204153 001					NPP	Feb 20, 2021
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LUSUTROMBOPAG - MULPLETA</u>						
N 210923 001	7601746	Sep 05, 2024	DS DP U-2344		NCE	Jul 31, 2023
	8530668	Jan 21, 2030	DS DP			
	8889722	Jul 29, 2028	DS DP			
	9427402	Sep 29, 2031	DP			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001					NCE ODE-166	Jan 26, 2023 Jan 26, 2025
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	6861409	Aug 01, 2022	DS DP U-2220		ODE-170	Dec 20, 2024
	8192719	Oct 12, 2027	U-2220			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Dec 05, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	10040872	Jan 30, 2034	DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002	8323692	Mar 30, 2023	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9855215	Jan 02, 2033	DP			
<u>METHYLERGONOVINE MALEATE - METHYLERGONOVINE MALEATE</u>						
A 211483 001					>A> CGT	Mar 20, 2019
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	10039719	Dec 16, 2019	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	>A> 8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	>A> 9028868	Mar 23, 2032	U-2357			
	>A> 9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	>A> 9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	>A> 8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	>A> 9028868	Mar 23, 2032	U-2357			
	>A> 9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	>A> 9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	>A> 8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	>A> 9028868	Mar 23, 2032	U-2357			
	>A> 9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	>A> 9603809	Mar 23, 2032	U-2357			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	>A> 8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	>A> 9028868	Mar 23, 2032	U-2357			
	>A> 9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	>A> 9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	>A> 8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	>A> 9028868	Mar 23, 2032	U-2357			
	>A> 9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	>A> 9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	>A> 8916588	Mar 23, 2032	U-2357		NP	Aug 08, 2021
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	>A> 9028868	Mar 23, 2032	U-2357			
	>A> 9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	>A> 9603809	Mar 23, 2032	U-2357			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10006924	Aug 12, 2036	U-1643			
	9943526	Apr 20, 2036	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	>A> 8592362	Feb 12, 2029	U-2371		NCE	Aug 10, 2023
	>A> 9000011	May 16, 2027	U-2371		ODE-205	Aug 10, 2025
	>A> 9095584	Feb 12, 2029	U-2371			
	>A> 9480682	May 16, 2027	U-2371			
	>A> 9987263	May 16, 2027	U-2371			
	>A> 9999618	Apr 28, 2028	U-2372			
	>A> 9999618	Apr 28, 2028	U-2373			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	8772315	Oct 30, 2028	U-2300		I-777	Apr 27, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	8772315	Oct 30, 2028	U-2300		I-777	Apr 27, 2021
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001	7544192	Nov 29, 2026	U-2272			
	7662141	Mar 12, 2024	U-2272			
	7713255	Mar 12, 2024	U-2272			
	7951130	Mar 12, 2024	U-2272			
	7951131	Mar 12, 2024	U-2272			
	7951133	Mar 12, 2024	U-2272			
	8025635	Jun 12, 2027	DP U-2272			
	8109918	Mar 12, 2024	U-2272			
	8763222	Feb 08, 2032	DP			
	9585681	Apr 04, 2026	U-2272			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					NCE ODE-193	Jun 13, 2023 Jun 13, 2025
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001 >A>	10085937	Mar 16, 2035	U-1903			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	9907793	Apr 04, 2023	DP U-1556			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	10022344	Mar 03, 2026	DP U-1731			
	10022344	Mar 03, 2026	DP U-1732			
	10028925	Mar 03, 2026	DP U-1731			
	10028925	Mar 03, 2026	DP U-1732			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	10035788	Oct 15, 2028	U-2043			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	9931336	Mar 14, 2034	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8623826	Nov 18, 2030	U-2293			
	9186357	Nov 18, 2030	U-2293			
	9271975	Sep 09, 2031	U-2293			
	9943515	Nov 18, 2030	U-2293			
	9951016	Sep 25, 2035	DS DP			
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003	7169791	Jul 04, 2023	DS DP U-836		NPP	Mar 22, 2021
	7169791*PED	Jan 04, 2024			ODE-171	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		ODE-172	Mar 22, 2025
	8163904*PED	Feb 23, 2029			PED	Sep 22, 2021
	8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2025
	8389537	Jul 18, 2026	DS DP U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	9907756	Jun 07, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	9907756	Jun 07, 2029	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					M-167	Oct 09, 2018
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	9926559	Jan 09, 2034	U-1943		M-226	May 14, 2021
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		I-762	Jan 12, 2021
	8143241	Aug 12, 2027	U-2102		ODE-180	Aug 17, 2024
	8143241	Aug 12, 2027	U-2103		ODE-181	Aug 17, 2024
	8143241	Aug 12, 2027	U-2358			
	8143241	Aug 12, 2027	U-2359			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2102			
	8859562	Aug 04, 2031	U-2358			
	8859562	Aug 04, 2031	U-2359			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2102			
	8912187	Mar 12, 2024	U-2358			
	8912187	Mar 12, 2024	U-2359			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		I-762	Jan 12, 2021
	8143241	Aug 12, 2027	U-2102		ODE-180	Aug 17, 2024
	8143241	Aug 12, 2027	U-2103		ODE-181	Aug 17, 2024
	8143241	Aug 12, 2027	U-2358			
	8143241	Aug 12, 2027	U-2359			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2102			
	8859562	Aug 04, 2031	U-2358			
	8859562	Aug 04, 2031	U-2359			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2102			
	8912187	Mar 12, 2024	U-2358			
	8912187	Mar 12, 2024	U-2359			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2019	DP			
	5948818	May 13, 2019	DP			
<u>OMEPRazole - OMEPRazole</u>						
N 209400 001 >A>	10076494	Dec 08, 2036	DP			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2020	DS DP U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	8946235	Aug 08, 2032	DS DP U-1777		I-774	Apr 18, 2021
	8946235	Aug 08, 2032	DS DP U-2289		ODE-176	Apr 18, 2025
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	8946235	Aug 08, 2032	DS DP U-1777		I-774	Apr 18, 2021
	8946235	Aug 08, 2032	DS DP U-2289		ODE-176	Apr 18, 2025
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
<u>OSPemIFENE - OSPHENA</u>						
N 203505 001	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10004729	Dec 10, 2030	DP U-1556			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADe</u>						
N 208552 001	8815929	Jan 22, 2024	U-1959			
	9974773	Jun 11, 2035	U-2306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2019	DS			
	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 090713 002					PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 001					PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 002					PC	Sep 19, 2018
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 001					I-785	Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 002					I-785	Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 003					I-785	Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 004					I-785	Jun 29, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 005					I-785	Jun 29, 2021
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	9925212	Oct 08, 2033		U-1766		
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	9925212	Oct 08, 2033		U-1766		
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	9925212	Oct 08, 2033		U-1766		
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001	8058069	Apr 15, 2029	DP		NCE	Aug 10, 2023
	8158601	Nov 10, 2030	DP U-2378		ODE-197	Aug 10, 2025
	8168775	Oct 20, 2029	DS DP U-2378			
	8334373	May 27, 2025	DS DP			
	8362231	Mar 30, 2021	DS DP			
	8372968	Mar 30, 2021	DS DP			
	8492359	Apr 15, 2029	DP			
	8552171	Mar 30, 2021	DS DP			
	8642076	Oct 03, 2027	DP			
	8741866	Oct 20, 2029	U-2378			
	8778902	Mar 30, 2021	U-2378			
	8802644	Oct 21, 2030	DP U-2378			
	8822668	Apr 15, 2029	DP U-2378			
	8895718	Mar 30, 2021	DS DP			
	8895721	Mar 30, 2021	DS DP			
	9193753	Mar 30, 2021	U-2378			
	9234196	Oct 20, 2029	DP U-2378			
	9364435	Apr 15, 2029	DP U-2378			
	9567582	Mar 30, 2021	DS DP			
	9943538	Nov 04, 2023	DP			
	9943539	Nov 04, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10028944	Jan 15, 2024	U-1974			
	6756393	Mar 06, 2021	DS DP			
	6815458	Mar 06, 2021	DS DP		U-1843	
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			
	9296694	Mar 06, 2021	DS DP			
	9566271	Jan 15, 2024	U-1974			
	9765053	Jul 27, 2022	U-1974			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10028944	Jan 15, 2024			NCE	Apr 29, 2021
	6756393	Mar 06, 2021	DS DP			
	6815458	Mar 06, 2021	DS DP		U-1843	
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			
	9296694	Mar 06, 2021	DS DP			
	9566271	Jan 15, 2024				
	9765053	Jul 27, 2022	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	8383150	Sep 22, 2026	DP U-1607			
	8383150	Sep 22, 2026	DP U-2361			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001 >A>	8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	7566729	Apr 22, 2029	U-2269			
	7566729	Apr 22, 2029	U-2270			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2054			
	8084475	Jan 08, 2030	U-2268			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
>A>	8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003 >A>	8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
<u>PLAZOMICIN SULFATE - ZEMDRI</u>						
N 210303 001	8383596	Jun 02, 2031	DS U-2328		NCE	Jun 25, 2023
	8822424	Nov 21, 2028	DP		GAIN	Jun 25, 2028
	9266919	Nov 21, 2028	U-2328			
	9688711	Nov 21, 2028	DS U-2328			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	10011637	Jun 05, 2034	DS		I-764	Jan 24, 2021
	9610321	Sep 15, 2031	U-1999			
	9610321	Sep 15, 2031	U-2230			
	9919024	Sep 15, 2031	U-1999			
	9919024	Sep 15, 2031	U-2230			
	9925231	Sep 15, 2031	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8198262	Jun 17, 2025	U-1360			
	8198262	Jun 17, 2025	U-2254			
	8673939	May 15, 2023	U-1360			
	8673939	May 15, 2023	U-2254			
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	9993467	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8198262	Jun 17, 2025	U-1360			
	8198262	Jun 17, 2025	U-2254			
	8673939	May 15, 2023	U-1360			
	8673939	May 15, 2023	U-2254			
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	9993467	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8198262	Jun 17, 2025	U-1360			
	8198262	Jun 17, 2025	U-2254			
	8673939	May 15, 2023	U-1360			
	8673939	May 15, 2023	U-2254			
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	9993467	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8198262	Jun 17, 2025	U-1360			
	8198262	Jun 17, 2025	U-2254			
	8673939	May 15, 2023	U-1360			
	8673939	May 15, 2023	U-2254			
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	9993467	May 19, 2030	DP			
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
A 211067 001					CGT	Feb 25, 2019
<u>POTASSIUM CHLORIDE - POTASSIUM CHLORIDE</u>						
A 211067 002					CGT	Mar 06, 2019
<u>PREGABALIN - LYRICA</u>						
N 021446 001					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 002					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 003					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 004					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 005					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 006					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 007					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 021446 008					NPP	May 03, 2021
<u>PREGABALIN - LYRICA</u>						
N 022488 001					NPP	May 03, 2021
<u>PREGABALIN - LYRICA CR</u>						
N 209501 001	10022447	Nov 02, 2026	U-2136			
	10022447	Nov 02, 2026	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 002	10022447	Nov 02, 2026	U-2136			
	10022447	Nov 02, 2026	U-2137			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 003	10022447	Nov 02, 2026	U-2136			
	10022447	Nov 02, 2026	U-2137			
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Nov 17, 2022	U-2271			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	9957232	Jul 09, 2032	DS			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8962630	Dec 09, 2029	U-1981		I-783	Jul 18, 2021
	8962630	Dec 09, 2029	U-2355		I-784	Jul 18, 2021
	8962630	Dec 09, 2029	U-2356			
	9416136	Aug 20, 2029	U-1981			
	9416136	Aug 20, 2029	U-2355			
	9416136	Aug 20, 2029	U-2356			
	9868739	Nov 09, 2031	U-1981			
	9868739	Nov 09, 2031	U-2355			
	9868739	Nov 09, 2031	U-2356			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001					M-223	Feb 01, 2021
<u>RILUZOLE - TIGLUTIK KIT</u>						
N 209080 001 >A>	8765150	Mar 12, 2029	DP U-2401			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	7173037	Dec 04, 2026	DS DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
	10058554	Sep 26, 2026	U-2363			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	10010612	Feb 13, 2028	DP		NP	Jul 27, 2021
	10058554	Sep 26, 2026	U-2363			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
<u>RITONAVIR - RITONAVIR</u>						
A 202573 001					PC	Sep 16, 2018
<u>RITONAVIR - NORVIR</u>						
N 209512 001					ODE-184	Jun 07, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034	U-1953			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					D-171	Jan 23, 2021
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	5712298	Jan 27, 2020	DS DP U-1115		NS	Jan 23, 2021
	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	9925150	Mar 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	9925150	Mar 01, 2032	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	7351701	Jul 23, 2024	U-2012		I-772	Apr 06, 2021
	7351701	Jul 23, 2024	U-2101		ODE-168	Apr 06, 2025
	7351701	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2101			
	7531530	Jul 23, 2024	U-2273			
	8071579	Aug 12, 2027	U-2012			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2101			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9856265	Jul 28, 2026	DS DP U-1467			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	6332985	Mar 29, 2019	U-2312		NCE	May 18, 2023
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS	U-2312		
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	6332985	Mar 29, 2019	U-2312		NCE	May 18, 2023
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS	U-2312		
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	9868745	Nov 16, 2032	DS DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	9616180	Jan 20, 2026	DP			
	9861757	Jan 20, 2026	DP			
<u>SOYBEAN OIL - LIPOSYN III 30%</u>						
N 020181 001	9717852	Apr 08, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 001					NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709 002					NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 001					NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223 002					NCE ODE-198	Aug 20, 2023 Aug 20, 2025
<u>TADALAFIL - CIALIS</u>						
N 021368 001	6821975	Nov 19, 2020	DS DP U-1184	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-533	Y	PED	Aug 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y		
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP U-1184	Y		
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 002	6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 003	6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	6821975	Nov 19, 2020	DS DP U-533	Y	M-219	Feb 15, 2021
	6821975	Nov 19, 2020	DS DP U-614	Y	PED	Aug 15, 2021
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - ADCIRCA</u>						
N 022332 001	6821975	Nov 19, 2020	DS DP	Y		
	6821975*PED	May 19, 2021				
	7182958	Apr 26, 2020	DP	Y		
	7182958*PED	Oct 26, 2020				
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001					NCE NP	Jul 20, 2023 Aug 08, 2021
<u>TAFENOQUINE SUCCINATE - KRINTAFEL</u>						
N 210795 001					NCE ODE-201	Jul 20, 2023 Jul 20, 2025
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	9999593	May 28, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALC - STERITALC</u>						
N 205555	001				ODE-191	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555	002				ODE-191	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555	003				ODE-191	May 01, 2024
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	>A> 10071977	Feb 12, 2035	DS DP		
		>A> 5856529	Dec 09, 2022	DS DP	U-2149	
		9855241	Jan 25, 2033		U-2149	
<u>TAVABOROLE - KERYDIN</u>						
N 204427	001	7582621	May 26, 2027	U-2016	Y	
		7582621*PED	Nov 26, 2027			
		9549938	Feb 16, 2026	U-1951		
		9549938*PED	Aug 16, 2026			
		9566289	Feb 16, 2026	DP		
		9566289*PED	Aug 16, 2026			
		9566290	Feb 16, 2026	U-1970		
		9566290*PED	Aug 16, 2026			
		9572823	Feb 16, 2026	U-1970		
		9572823*PED	Aug 16, 2026			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627	001	7737168	May 03, 2027	U-2346	NCE	Jul 13, 2023
		8039504	Jul 23, 2027	DP	ODE-200	Jul 13, 2025
		8124643	Jun 18, 2024	DS DP		
		8530509	Jun 18, 2024	DP		
		8802714	Jun 18, 2024	U-2346		
		9339466	Mar 23, 2031	DS DP		
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441	001	9968655	Nov 01, 2025	U-2308		
		9968656	Nov 01, 2025	U-2308		
		9968658	Nov 01, 2025	U-1320		
		9974835	Nov 01, 2025	U-1320		
		9974837	Nov 01, 2025	U-1320		
		9981014	Nov 01, 2025	U-1320		
		9981016	Nov 01, 2025	U-1320		
		9987334	Nov 01, 2025	U-1320		
		9987335	Nov 01, 2025	U-1320		
		9993528	Nov 01, 2025	U-1320		
<u>TIGECYCLINE - TIGECYCLINE</u>						
N 211158	001	>A> 9855335	Apr 07, 2033	DP		
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820	001	7696178	Sep 22, 2022	DP		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	001	7842699	Dec 08, 2020	U-2322	I-780	May 30, 2021
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	002	6956041	Dec 08, 2020	DP	I-780	May 30, 2021
		6965027	Mar 25, 2023	DS		
		7265221	Dec 08, 2020	DS		
		7301023	May 23, 2022	DS		
		7842699	Dec 08, 2020	U-2322		
		RE41783	Dec 08, 2025	DS		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	9937181	Mar 14, 2034	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	5753677	May 19, 2020	U-2307		I-779	Apr 23, 2021
	5972882	Dec 14, 2018	U-2307		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TRABECTEDIN - YONDELIS</u>						
N 207953 001	8895557	Jan 07, 2028	DP		>A> M-232	Jun 29, 2021
	8895557*PED	Jul 07, 2028			NCE	Oct 23, 2020
					ODE-100	Oct 23, 2022
					PED	Apr 23, 2021
					>A> PED	Dec 29, 2021
					PED	Apr 23, 2023
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	May 29, 2027	DS DP		I-778	Apr 30, 2021
	8835443	Jun 10, 2025		U-1581	I-781	May 04, 2021
	8835443	Jun 10, 2025		U-1582	ODE-182	Apr 30, 2025
	8835443	Jun 10, 2025		U-2020	ODE-183	May 04, 2025
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	May 29, 2027	DS DP		I-778	Apr 30, 2021
	8835443	Jun 10, 2025		U-1581	I-781	May 04, 2021
	8835443	Jun 10, 2025		U-1582	ODE-182	Apr 30, 2025
	8835443	Jun 10, 2025		U-2020	ODE-183	May 04, 2025
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	May 29, 2027	DS DP		I-778	Apr 30, 2021
	8835443	Jun 10, 2025		U-1581	I-781	May 04, 2021
	8835443	Jun 10, 2025		U-1582	ODE-182	Apr 30, 2025
	8835443	Jun 10, 2025		U-2020	ODE-183	May 04, 2025
	8835443	Jun 10, 2025		U-2037		
	8835443	Jun 10, 2025		U-2302		
	8835443	Jun 10, 2025		U-2305		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001 >A>	10076505	Dec 16, 2024	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002 >A>	10076505	Dec 16, 2024	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003 >A>	10076505	Dec 16, 2024	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004 >A>	10076505	Dec 16, 2024	DP			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	8497393	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8497393	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8497393	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8497393	Dec 15, 2028	DS	Y		
<u>TRETINOIN - ALTRENO</u>						
N 209353 001					NDF	Aug 23, 2021
<u>TRYPAN BLUE - VISIONBLUE</u>						
N 021670 001	6367480	Oct 26, 2019	U-2321			
	6720314	May 07, 2019	U-2321			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	8534281	Mar 08, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8534281	Mar 08, 2030	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2019	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2019	DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001 >A>	10065952	Oct 28, 2036	DS DP U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002 >A>	10065952	Oct 28, 2036	DS DP U-1995			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	7173038	Aug 14, 2021	DS DP			
	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	7173038	Aug 14, 2021	DS DP			
	8642608	Feb 06, 2022	U-1490			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9937223	Jan 30, 2035	U-1857			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	9174982	May 26, 2030	U-2323		I-782 M-228 ODE-185	Jun 08, 2021 Jun 08, 2021 Jun 08, 2025
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	9174982	May 26, 2030	U-2323		I-782 M-228 ODE-185	Jun 08, 2021 Jun 08, 2021 Jun 08, 2025
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	9174982	May 26, 2030	U-2323		I-782 M-228 ODE-185	Jun 08, 2021 Jun 08, 2021 Jun 08, 2025
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7713999	May 30, 2024	DS DP U-2291			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9125908	Jun 15, 2027	U-2309		M-227	May 02, 2021
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9861630	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 38th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm